Biomarkers of neurological tissue injury and inflammation in paediatric tuberculous meningitis by Rohlwink, Ursula Karin
I 
 
Biomarkers of neurological tissue injury 





Thesis Presented for the Degree of 
 
DOCTOR OF PHILOSOPHY 
 
In the Division of Neurosurgery 
 






Candidate: Ursula Rohlwink 



















The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
 
Published by the University of Cape Town (UCT) in terms 

































…who is my first, and greatest teacher, and is of such an exceptional nature 
that I am continuously convinced that I have met one of the world’s most 
luminous beings in her. She is imbued in everything I am and in everything I do, 








No project is the work of an individual alone, and this was no exception. A large part of the learning 
and the growing over the last four years has taken place at the bedside, in the laboratory or in front of 
the computer screen; but I have also had the opportunity to profit from the wisdom, the expertise and 
the support of many. I take this opportunity to acknowledge those people. 
I wish to begin by acknowledging the patients who I had the privilege of studying for this project; 
their manner of managing their pain and illness with gentle surrender was utterly humbling. I thank 
their parents, who handed over their child’s wellbeing with such trust and were so supportive of my 
presence during their child’s treatment.   
The individual to whom I owe the deepest gratitude is my supervisor, Tony Figaji; he has taught me 
everything I know about the brain, about science and about research, and has instilled in me the drive 
to do research that is meaningful to the patient, and to do so with integrity and belief. I consider him 
one of the revolutionaries in brain research today, and I have been tremendously privileged to work 
with him these last 5 years. I thank him for going beyond the call of duty on this project; he has been 
invested in it from its inception to the very last chapter of the thesis. Without him this project would 
not have been possible! 
I also wish to thank  
 Our Head of Department, Professor Graham Fieggen, for running a department in which the 
growth of each member is sincerely nurtured, and their triumphs joyously celebrated. I have 
been the fortunate beneficiary of his excitement for neuroscience and thank him for his 
support. I also thank Llewellyn Padayachy, Nthe Mjoli, Edwin Mogere, Ncedile Mankahla, 
Nico Enslin, Johan Malan, Dave Roytowski, Mohammed Ben-Husein, Emmanuel Wegoye, 
Chris Young, Tiago Morgado, Vincent Pretorius, and Nqobile Thango - my colleagues in the 
Neurosurgery Division, who managed these patients and were the ones to place the biological 
samples, upon which the bulk of this project is based, into my hands. Their support for the 
project in their already busy work schedules was greatly appreciated. 
 My funders from the Clinical Infectious Diseases and Research Initiative and the Wellcome 
Trust who so generously supported this project and provided the laboratory space for sample 
analysis.  
 All the paediatricians who were involved in sample collection and patient management, their 
cooperation was vital to the success of this project. I thank the ward nursing staff for their 
patience with me and my monitoring equipment in the wards, and the S19 Outpatients staff 
who were such a help with patients attending follow-up clinics. 
VI 
 
 Lisa Ungerer who guided me through the logistics of sample processing and storage, and 
taught me my first laboratory techniques. The deep friendship that has emerged from our 
working relationship has been a gift. I am grateful to all the staff in the NHLS Chemistry lab 
for welcoming me into their working space and accommodating my work and consumables.  
 Katalin Wilkinson for conducting all the ELISA and Luminex analysis with me, I learnt a 
great deal from her vast experience in the lab. 
 The radiologists Tracy Kilborn, Nicole Wieselthaler and Ebrahim Banderker for the hours 
they spent reviewing and re-reviewing the imaging results of these patients. 
 Kirsty Donald, who mentored me through the Griffiths Mental Scales assessments and was 
my sounding board in determining how best to analyse such qualitatively complex data. I’d 
also like to acknowledge Rosy Khethelo who assessed all the Xhosa speaking children with 
me; her insight and sweet nature were such a pleasure.   
 Katya Mauff for her excellent statistical assistance with seemingly never-ending data. 
 My colleagues on the 6th Floor for being so supportive and encouraging; in particular John 
Lazarus for sharing his office with me, and Noorunisa Vollenhoven for being a constant pillar 
of strength. 
 Bronwyn Gavine for helping me gather and reformat some of the patient data, and for proof 
reading some of the final thesis chapters. 
 Jo Wilmshurst for her valuable comment on several chapters. 
 My beloved sister, Inge, for her unconditional love and support. And to her and my brother-
in-law Levent for the great gift of my two beloved little ones, Emre and Lale 
 My dear friends for their support and love, and for lending fresh eyes to several chapters of 
this thesis. 
I feel enormously privileged to be able to work at an institution like Red Cross Children’s Hospital, 
and I owe thanks to Professor Astrid Berg and Professor Heinz Rode for the instrumental role they 
played in paving my way to RXH. I thank them for their continued care and support of me in my work 
and in life – they are surrogate parents to me. 




Biomarkers of Neurological Injury and Inflammation in Children with 
Tuberculous Meningitis 
Candidate: Ursula Rohlwink, Supervisor: Professor Anthony Figaji 
ABSTRACT 
Background Tuberculous meningitis (TBM) in children has high mortality and neurological 
morbidity rates. The assessment of disease severity and prognostication are difficult because several 
factors influence initial presentation, and advanced tools for these are lacking. Biomarkers of 
neurological injury could help to assess severity and to prognosticate, but have not been assessed in 
paediatric TBM. This study examined serum and cerebrospinal fluid (CSF) biomarkers of 
neurological injury in paediatric TBM in association with clinical and physiological data, radiology, 
inflammatory markers, and outcome. 
Methods Serum and CSF (ventricular and lumbar) samples were taken on admission and over 3 
weeks in children with probable TBM and hydrocephalus. These were analysed with ELISA for 
neuromarkers S100B, neuron-specific enolase (NSE) and glial fibrillary acidic protein (GFAP), and 
with Luminex multianalyte array assay for a panel of inflammatory markers. Results were compared 
with 2 controls groups.  Computerized tomography was done on admission and magnetic resonance 
imaging (brain, spine and magnetic resonance angiography) at 3 weeks. Brain oxygenation was 
monitored invasively and non-invasively in selected patients. Clinical and neurodevelopmental 
outcomes were assessed at 6 months. Data were analysed with various statistical tools, including 
principal component analysis. 
Results Data were collected from 44 children. Of these, 16% died and 36% had disability (25% mild-
moderate, 11% severe). S100B, NSE, GFAP and inflammatory markers were elevated in CSF on 
admission and for up to 3 weeks, but not in serum. Elevated neuromarkers were significantly 
associated with poor outcome and increased over time in patients who died, although combined 
inflammatory biomarkers decreased. Cerebral infarcts occurred in 66% of patients and were 
associated with neuromarker elevation. Novel findings on spinal MRI were the high frequency of 
asymptomatic disease. Cerebral vascular pathology was documented frequently on imaging but did 
not predict infarcts. Low brain oxygenation was common and in keeping with physiological events 
and outcome. 
Conclusion CSF neuro- and inflammatory markers are elevated in TBM. Neuromarkers were 
prognostic of clinical and radiological outcome and an increasing trend suggested ongoing injury. 
This does not appear to be related to ongoing inflammation as measured by cytokines but may reflect 











List of Tables XI 
List of Figures XIII 
Abbreviations list XV 
List of Appendices XVII 
 
  Page no 
 Introduction to the thesis 
 
1 
 Section A: Background to TBM 
 
 
Chapter 1 Pathogenesis and pathophysiology of TBM 
 
7 
Chapter 2 TBM: Epidemiology and clinical considerations 
 





Chapter 3 The radiological features of TBM 
 
31 
Chapter 4 Ischaemia and brain oxygenation in TBM 
 
47 
 Section B: Introduction to Biomarkers  
Chapter 5 Biomarkers of neurological tissue injury in cerebral infection 
 
55 
Chapter 6 Biomarkers of inflammation in TBM: cytokines and 
chemokines 
75 
 Section C: Study Outline  
Chapter 7 Methodology 95 
 Working hypothesis and study objectives 95 
 Study design 95 
 Study funding 96 
Chapter 8 Patient selection 97 
X	  
	  
 TBM Cases 97 
 Controls 97 
 Sample size calculation 98 
 Subject recruitment 99 
 Patient management 99 
Section D: Study results  
Chapter 9 Patient and admission clinical characteristics  
 Chapter summary 103 
 Methods 105 
 Results 111 
  Discussion 125 
Chapter 10 Biomarker analysis  
  Chapter summary 133 
  Methods 135 
  Results 143 
  Discussion 183 
Chapter 11 The radiological features of the brain and spinal cord in 
paediatric TBM 
 
 Chapter summary 195 
 Methods 197 
 Results 203 
 Discussion 223 
Chapter 12 Monitoring brain oxygenation in TBM  
 Chapter summary 231 
 Methods 233 
 Results 239 
 Discussion 255 
Chapter 13 Summary and Conclusion 261 
Appendices   






List of Tables 
 
Tables are numbered according to the chapter to which they belong and the order with which 
they appear in the chapter. 
 
 
  Page no 
Chapter 2 TBM: Epidemiology and clinical considerations  
Table 2.1 MRC stages for classifying the severity of TBM 18 
Chapter 3 The radiological features of TBM  
Table 3.1 The frequency of radiological features of TBM 44 
Chapter 5 Biomarkers of neurological tissue injury in cerebral infection  
Table 5.1 S100B Reference Ranges 68 
Table 5.2 S100B data from clinical studies 69 
Table 5.3 NSE Reference Ranges 70 
Table 5.4 NSE data from clinical studies 71 
Table 5.5 GFAP Reference Ranges 72 
Table 5.6 GFAP data from clinical studies 73 
Chapter 6 Biomarkers of inflammation in TBM  
Table 6.1 Cytokine concentrations in TBM patients 91 
Table 6.2 Chemokine concentrations in TBM patients 92 
Chapter 8 Patient selection  
Table 8.1 Study inclusion and exclusion criteria 97 
Chapter 9 Patient and admission clinical characteristics  
Table 9.1 Admission demographic and clinical characteristics 113 
Table 9.2 Admission CSF chemistry and cell counts 115 
Table 9.3 Surgical HCP management 117 
Table 9.4 Clinical outcome at 6 months 119 
Table 9.5 Control and Case scores in relation to British normative age equivalents 121 
Table 9.6 Neurodevelopmental and clinical outcome scores 122 
Chapter 10 Biomarker analysis  
Table 10.1 ELISA Results: Lowest limits of detection 143 
Table 10.2 Luminex results: Lowest limits of detection 144 
Table 10.3 Descriptive statistics for neuromarkers in all sample types 145 
Table 10.4 Descriptive statistics for inflammatory markers in all sample types: 
TNF-α, IFN- , IL-6 
146 
 Descriptive statistics for inflammatory markers in all sample types: 147 
XII 
 
IL12p40, IL-1 , IL-1Ra 
 Descriptive statistics for inflammatory markers in all sample types: IL-
8, MCP-1, IL-10 
148 
 Descriptive statistics for inflammatory markers in all sample types: 
MIP-1α, GRO, IL-10 
149 
 Descriptive statistics for inflammatory markers in all sample types: 
VEGF, RANTES 
150 
Table 10.5 Percentage of elevated case samples in each sample type 152 
Table 10.6 Correlation matrix for S100B, NSE and GFAP 166 
Table 10.7 Summary of neuromarker univariate outcome analysis 174 
Chapter 11 The radiological features of the brain and spinal cord in paediatric 
TBM 
 
Table 11.1 Summary of radiology features overall 204 
Table 11.2 Anatomical location of infarcts 205 
Table 11.3 Vascular detail of infarcts on MRI 206 
Table 11.4 Infarcts overall by vessel 206 
Table 11.5 Tuberculoma location 211 
Table 11.6 Frequency of vascular pathology per vessel 213 
Table 11.7 MR characteristics of the spine accompanying TBM 214 
Table 11.8 Association between neuromarkers and admission radiology 219 
Table 11.9 Association between neuromarkers and overall radiology 221 
Table 11.10 Association between inflammatory markers and overall radiology 222 
Chapter 12 Monitoring brain oxygenation in TBM  
Table 12.1 Summary of monitored physiological variables for the duration of 
monitoring 
239 






List of Figures 
 
Figures are numbered according to the chapter to which they belong and the order with which they 
appear in the chapter. 
 
 
  Page no 
Chapter 1 Pathogenesis and pathophysiology of TBM  
Figure 1.1 Exudate in the basal cisterns in TBM 11 
Chapter 2 TBM: Epidemiology and clinical considerations  
Figure 2.1 Components of presumptive TBM diagnosis 19 
Chapter 9 Patient and admission clinical characteristics  
Figure 9.1 Flow chart for defining neurodevelopmental deficit in cases 109 
Figure 9.2 Flow diagram of patient selection 111 
Figure 9.3 HCP Management 117 
Chapter 10 Biomarker analysis  
Figure 10.1 PCA plots - cases vs controls: Neuromarkers: Initial lumbar CSF 153 
Figure 10.2 PCA plots - cases vs controls: Neuromarkers: Initial ventricular CSF 154 
Figure 10.3 PCA plots - cases vs controls: Neuromarkers: Initial serum 155 
Figure 10.4 PCA plots - cases vs controls: Inflammatory markers: Initial lumbar 
CSF 
156 
Figure 10.5 PCA plots - cases vs controls: Inflammatory markers: Initial 
ventricular CSF 
157 
Figure 10.6 PCA plots - cases vs controls: Inflammatory markers: Initial serum 158 
Figure 10.7 Box-plot over time: S100B 160 
Figure 10.8 Box-plot over time: NSE 160 
Figure 10.9 Box-plot over time: GFAP 161 
Figure 10.10 Box-plot over time: Inflammatory markers 162-165 
Figure 10.11 Pairs plots for correlations between sample type for neuromarkers 167-168 
Figure 10.12 PCA Plot: Neuromarkers in all sample types 170 
Figure 10.13 PCA Plot: Inflammatory markers in all sample types 171 
Figure 10.14 Cluster dendrogram: Neuromarkers and inflammatory markers 172 
Figure 10.15 PCA Plot: Combined neuro- and inflammatory marker data on 
admission 
176 
Figure 10.16 PCA Plot: Combined neuro- and inflammatory marker data for the 
trend over time 
177 
Figure 10.17 PCA plot: Temporal profile combined neuromarkers in lumbar CSF 179 




Chapter 11 Radiological features of the brain and spinal cord in paediatric 
TBM 
 
Figure 11.1 Hydrocephalus 207 
Figure 11.2 Hydrocephalus resolution 207 
Figure 11.3 Basal meningeal enhancement 208 
Figure 11.4 Evolution of pre-contrast hyperdensity 208 
Figure 11.5 Infarcts 209 
Figure 11.6 Luxury perfusion in infarcted areas 210 
Figure 11.7 Parenchymal tuberculoma 210 
Figure 11.8 Late onset tuberculomas 212 
Figure 11.9 Evolution of enhancement 212 
Figure 11.10 MRA abnormalities 215 
Figure 11.12 Spinal disease 216-217 
Chapter 12 Brain oxygen monitoring in TBM  
Figure 12.1 Temporal profile of PbtO2 and ICP 240 
Figure 12.2 Scatterplot of ICP and PbtO2 240 
Figure 12.3 PbtO2 in response to increasing ICP 241 
Figure 12.4 Fluctuations of ICP within the normal range may negatively impact on 
PbtO2 
242 
Figure 12.5 Median PbtO224 and the lowest PbtO2 for poor and good outcome 
groups 
243 
Figure 12.6 Time spent below critical thresholds of PbtO2 243 
Figure 12.7 Time spent below critical thresholds of NIRS for mortality and clinical 
outcome 
244 
Figure 12.8 NIRS recording showing declining brain oxygenation in the hours 
before death in one patient 
245 
Figure 12.9 NIRS improves after a lumbar puncture to treat raised ICP 246 
Figure 12.10 NIRS improves with resuscitation 246 
Figure 12.11 NIRS responds to ischaemia and luxury perfusion 247 
Figure 12.12 Bland-Altman plot for PbtO2 and NIRS standardised scores 248 
Figure 12.13 Temporal profile of PbtO2 and NIRS for the monitored cohort overall 249 
Figure 12.14 Temporal profile of PbtO2 and NIRS per patient 249 
Figure 12.15 NIRS mirrors the trend in PbtO2 250 
Figure 12.16 PbtO2 and NIRS in response to ICP and MAP 251 
Figure 12.17 PbtO2 and NIRS both increase in response to nasal prong oxygen 252 




List of abbreviations 
ACA Anterior cerebral artery 
AEG Air encephalogram 
AFB Acid fast bacilli 
AIDS Acquired immunodeficiency syndrome 
ART Anti-retroviral treatment 
AUC Area under the curve 
BBB Blood brain barrier 
BCG Bacillus Calmette–Guérin 
BCH Brooklyn Chest Hospital 
CBF Cerebral blood flow 
CI Confidence interval 
CHCP Communicating hydrocephalus 
CNS Central nervous system 
Coef Coefficient  
CPP Cerebral perfusion pressure 
CSF Cerebrospinal fluid 
CSW Cerebral salt wasting syndrome 
CT Computed tomography 
CXR Chest x-ray 
DWI Diffusion weighted imaging 
ELISA Enzyme-linked immunoassay 
EMB Ethambutol  
ETH Ethionamide  
ETV Endoscopic third ventriculostomy 
EVD External ventricular drain 
FLAIR Fluid-attenuated inversion-recovery 
FiO2 Inspired fraction of oxygen  
GCS Glasgow comas score 
GEE General estimating equation 
GFAP Glial fibrillary acidic protein 
GMDS-ER Griffiths Mental Development Scales – extended 
version 
GQ General quotient 
GRO Growth regulated oncogene 
Hb Haemoglobin 
HCP Hydrocephalus  
HIV Human immunodeficiency virus 
HLOD Highest limit of detection 
ICA Internal carotid artery 
ICP Intracranial pressure 
ICU Intensive care unit 
IFN-γ Interferon-gamma 
IL Interleukin  
INH Isoniazid 
IP-10 Interferon-inducible protein -10 





IRIS Immune reconstitution inflammatory syndrome 
XVI 
 
LLOD Lowest limit of detection 
LOC Level of consciousness 
LP Lumbar puncture 
MAP Mean arterial pressure 
MCA Middle cerebral artery 
MCP-1 Monocyte chemoattractant protein -1 
MIP-1α Macrophage inflammatory protein 1-α 
MRA Magnetic resonance angiogram 
MRC Medical research council 
MRI Magnetic resonance imaging 
Mtb Mycobacterium tuberculosis 
NCHCP Non-communicating hydrocephalus 
NHLS National health laboratory service 
NIRS Near-infrared spectroscopy 
NSE Neuron specific enolase 
NO Nitric oxide 
OP Opening pressure 
OR Odds ratio 
PbtO2 Brain tissue oxygen tension 
PC Principle component 
PCA Posterior cerebral artery 
PCA Principle component analysis 
Pcomm Posterior communicating artery 
PCPS Paediatric cerebral performance scale 
PCR Polymerase chain reaction 
pTB Pulmonary TB 
PZA Pyrazinamide  
RANTES  Regulated upon-activation, normal T-cell-
expressed and secreted 
RMP Rifampicin  
ROC Receiver operating curve 
RXH Red Cross War Memorial Children’s Hospital 
S100B S100 beta 
SaO2 Systemic saturation 
SAS Subarachnoid space 
SES Socio-economic status 
SIADH Syndrome of inappropriate anti-diuretic hormone 
SO2 NIRS saturation 
TB Tuberculosis 
TBH Tygerberg Hospital 
TBI Traumatic brain injury 
TBM Tuberculous meningitis 
TNF-α  Tumour necrosis factor- alpha 
TST Tuberculin skin test 
VEGF  Vascular endothelial growth factor 
VPS Ventriculoperitoneal shunt 




List of Appendices: Included at the end of main thesis text 
Appendix 1 TBM Case definition criteria  
Appendix 2 Ethics approval  
Appendix 3 HCP management protocol  
Appendix 4 PCPS  
Appendix 5 Griffiths Mental Scales test  
Appendix 6 TBM patients not eligible for study enrolment  
Appendix 7 What is Principal Component Analysis?  
Appendix 8 Neuro- and inflammatory marker box-and-whisker plots, including 
outliers 
 
Appendix 9 Confidence intervals for GEE coefficients for biomarker concentrations 
according to sample type 
 
 
Appendix 10 Correlations matrix: neuro- and inflammatory markers  
Appendix 11 Summary of neuromarker univariate outcome analysis, p-values  
Appendix 12 ROC curves: Analysis neuromarkers and mortality  
Appendix 13 p-values for the association between neuromarkers and admission 
radiology 
 
Appendix 14 p-values for the relationship between overall radiology features and 
neuromarker concentrations 
 






BIOMARKERS OF NEUROLOGICAL INJURY AND INFLAMMATION 
IN TBM 
THESIS SUMMARY 
Tuberculous meningitis (TBM) is the most lethal form of TB and is associated with unacceptably high 
rates of mortality and morbidity. It occurs commonly in children from high TB prevalence settings. 
However, TBM remains challenging for clinicians to discern early because of the nonspecific nature 
of its presentation and the lack of swift and definitive diagnostic tools. Consequently, treatment 
initiation is often delayed, which increases the risk of a poor outcome. The aetiology of neurological 
impairment in these patients is multifactorial – it may due to direct brain inflammation, vasculitis, 
hydrocephalus, hyponatremia, and seizures. Some factors may be reversible while others may lead to 
relentless deterioration. In keeping with this, some patients present in a poor condition and then 
improve, while others have a less severe presentation but then proceed to deteriorate and die. Clinical 
examination lacks the sensitivity and specificity to accurately assess injury severity and radiological 
examination only illustrates injury once it is irreversible. Advanced tools to assess cerebral injury 
severity, to direct limited resources to children at highest risk of poor outcomes, and prognosticate are 
lacking. 
Inflammatory markers have been studied in TBM; however, the extent of inflammation as detected by 
these markers may not correlate with the extent of cerebral tissue injury. To date direct markers of 
cerebral tissue injury have not been widely examined in this pathology. Reliable markers of 
neurological tissue injury may serve as a means of assessing injury severity, predicting deterioration, 
directing treatment, prognosticating, and developing new strategies for treatment in TBM.  
This project aimed to examine three markers of neurological tissue injury, S100B, neuron-specific 
enolase and glial-fibrillary acidic protein, as candidate biomarkers for assessing injury severity and 
predicting outcome in TBM. All children presenting to Red Cross War Memorial Children’s Hospital 
with probable TBM and hydrocephalus from October 2010 to August 2013 were enrolled in this 
study. Hydrocephalus was a prerequisite because serial cerebrospinal fluid (CSF) sampling is 
common in this group and afforded the opportunity to examine biomarker trends. Serum, lumbar and 
ventricular CSF taken on admission and for the next three weeks were analysed for neuromarkers 
S100B, neuron-specific enolase (NSE) and glial fibrillary acidic protein (GFAP) using enzyme-linked 
immunoassay (ELISA), and a panel of inflammatory markers analysed with Luminex multianalyte 
array assay. Results were compared with two controls groups: children with a fatty filum presenting 
for elective surgery (serum and CSF), and children with pulmonary TB (serum only). Data from brain 
computerized tomography scans at admission and magnetic resonance imaging (MRI - including 
spinal imaging and magnetic resonance angiography) at three weeks were collected, in addition to any 
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follow up imaging clinically indicated. Brain oxygenation was monitored invasively (brain tissue 
oxygenation, where clinically indicated) and non-invasively (near-infrared spectroscopy) in a subset 
of patients. Clinical outcome (according to the Paediatric Cerebral Performance Category Scale) and 
neurodevelopmental outcome (tested with the Griffiths Mental Scales) were assessed at six months. 
Data were analysed with various statistical tools, including principal component analysis. 
Data were collected from 44 patients (median age 3.33 years). Of these, 16 % died, 36.4% suffered 
disability and 47.7% had no discernible neurological deficits on clinical assessment; however, 
neurodevelopmental deficits were present in all children assessed. In part, poor neurodevelopmental 
outcomes may reflect socio-economic and hospitalisation circumstances, but also highlight the more 
subtle deficits that these children may have. Biomarker analysis demonstrated that CSF S100B, NSE, 
GFAP and inflammatory markers were elevated in TBM patients on admission and for up to three 
weeks compared with controls. Ventricular CSF concentrations of neuromarkers exceeded lumbar 
concentrations, whereas inflammatory markers were more elevated in lumbar CSF, suggesting that the 
two compartments are not directly comparable. CSF Neuro- and inflammatory markers were not 
elevated in serum. Elevated neuromarkers were significantly associated with poor outcome and 
principle component analysis combining all three neuromarkers over time demonstrated increasing 
concentrations in patients who died, although combined inflammatory biomarkers decreased. Cerebral 
infarcts occurred in 66% of patients and showed significant associations with neuromarkers.  Novel 
descriptions of findings on spinal MRI were the high frequency of asymptomatic disease, including 
arachnoiditis, intramedullary and extramedullary lesions, and thick exudates in the region of the cauda 
equina. Lumbar punctures on these children could not successfully draw CSF which has important 
clinical implications for diagnosis and differentiating between communicating and non-
communicating hydrocephalus with air encephalography. Cerebral vascular pathology was 
documented frequently on imaging; these were not predictive of infarcts overall, but worse vascular 
pathology was observed in patients with large infarcts. Brain oxygenation monitors detected episodes 
of low brain oxygenation in keeping with physiological events and clinical and radiological outcome. 
The main findings of this study indicate that CSF neuro- and inflammatory markers are elevated in 
TBM. Elevated neuromarkers are prognostic of poor clinical and radiological outcome, and an 
increasing temporal profile suggests ongoing cerebral injury despite treatment; this does not appear to 
be related to ongoing inflammation as measured by cytokines, but may be a consequence of the 
ongoing secondary injury processes initiated by inflammation. In addition to the biomarker results, 
several of our approaches in this study, including spinal and vascular imaging as well as brain oxygen 




This thesis presents the project findings and is structured to provide an introduction to TBM and 
biomarker analysis, followed by results of the analyses of neurological and inflammatory biomarkers 
and their association with clinical, radiological and physiological indicators of injury severity, as well 
as clinical and neurodevelopmental outcome: 
Section A: Background of TBM 
Chapter 1 discusses the dissemination of TB from the lung to the cranium and the pathophysiology of 
the meningitis disease that ensues. 
Chapter 2 introduces the epidemiological burden of TBM and highlights the challenges facing treating 
clinicians. A summary of the current climate of TBM in the Western Cape, where this project was 
conducted, is also provided. 
Chapter 3 outlines the radiological features associated with TBM, their role in diagnosis, evolution 
and contribution to outcome. 
Chapter 4 discusses ischaemia in TBM and introduces two methods of brain oxygenation, brain tissue 
oxygen tension and near-infrared spectroscopy, which are not currently being used in this disease. 
Section B: Introduction to Biomarkers 
Chapter 5 provides an introduction to neurological biomarker analysis in cerebral infections, with a 
particular focus on S100B, NSE and GFAP in terms of normal reference ranges, and pathological 
elevations in adult and paediatric cerebral infections. 
Chapter 6 summarises the inflammatory process underlying TBM with specific reference to 
inflammatory cytokines and chemokines which have been studied in this disease. This chapter 
concludes the introductory literature review of the thesis. 
Section C: Study Outline 
Chapter 7 defines the hypotheses and objectives of this project. 
Chapter 8 introduces the inclusion and exclusion criteria and methods of patient recruitment. 
Section D: Study Results 
Chapter 9 presents the study patient cohort in terms of their demographic, clinical and outcome 
profile. 
Chapter 10 is dedicated to biomarker analysis. The methods of sample collection and analysis are 
described, and the results are discussed in terms of comparisons with controls, temporal profile of 
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elevation, relationship between biomarkers, association with clinical characteristics and association 
with outcome. 
Chapter 11 discusses the findings of admission and follow up scans, and introduces novel descriptions 
of spinal disease and vascular pathology on magnetic resonance angiograms. The association between 
radiology and biomarkers as well as outcome are discussed. 
Chapter 12 provides a descriptive account of study findings with brain oxygenation monitors and 
discusses their potential utility in TBM. 
Chapter 13 finally concludes this thesis with a summary of the overall findings and recommendations 
for future work. 
The candidate was responsible for all aspects of this project, other than the clinical decisions made for 
patient management, including the recruitment of patients and controls, the gathering, storage and 
testing of samples in the laboratory, setting up and running the brain monitoring, collecting and 
analysing clinical, radiological and laboratory data, and liaising with the clinicians regarding patient 
follow-up and imaging. The candidate completed the necessary training and conducted the Griffiths 
Mental Scales neurodevelopmental assessments with the TBM patients and controls. Finally she was 






















CHAPTER 1: PATHOGENESIS OF TUBERCULOUS MENINGITIS 
 
The systemic immune response to tuberculous infection 
Tuberculosis (TB) is spread through the inhalation of infectious droplets of aerosolised mycobacteria 
tuberculosis (Mtb) which colonise the alveolar macrophages in the lungs constituting the primary site 
of TB infection. Infected macrophages present TB antigens on major histocompatibility complex 
(MHC) Class II to T-cells and stimulate T-cell activation through the release of interleukin (IL)-12. A 
T-helper cell I (Th1) response is initiated and several key cytokines are released, including tumour 
necrosis factor alpha (TNF-α), IL-17 and various chemokines which stimulate the recruitment of 
additional macrophages and neutrophils. Interferon gamma (IFN- ) is also released by Th1 cells in the 
lung and surrounding lymph nodes, resulting in activation of macrophages to kill the TB bacillus. The 
activated macrophages stimulate further T-cell activation and the initiation of an adaptive immune 
response to augment the functions of the innate immune macrophages. This inflammatory process 
results in the formation of a granuloma which encapsulates the infected cells. In healthy individuals 
this arrests the development of active TB disease. However, in the aged, immune compromised or 
very young, an on-going immune defensive may result in active disease associated with tissue 
destruction in the lung and dissemination of the TB bacillus to other organ systems 
1,2
.  
Dissemination to the central nervous system (CNS) 
Dissemination of TB commonly occurs hematogenously facilitating the seeding of Mtb to other sites 
including the liver, bones, kidney and CNS.  In some cases, and often in children, exacerbated 
hematogenous spread of TB to the brain may occur in the context of miliary TB particularly in young 
children less than 2 years suggesting that the weak immune system predisposes young children to 
dissemination 
3,4
.  Dissemination probably occurs early after primary infection before the adaptive 
immune response is able to control the infection 
3,5
. Several mechanisms by which the bacilli are able 
to migrate from the primary site of infection into the lymphatic or blood stream have been suggested. 
Mtb interact with epithelial cells in the alveoli and in vitro models have demonstrated that the bacilli 
are able to invade the epithelial cells, replicate intracellularly and initiate cell lysis and spread to 
neighbouring cells 
6
. Bacterial proteins early secretory antigenic target 6kDa (ESAT-6) and culture 
filtrate protein 10kDA (CFP-10) are involved in cell lysis while heparin binding haemagglutinin 
adhesion (HBHA) aids in Mtb translocation across the epithelium without lysis 
7
. Mtb may also 
invade and traverse vascular endothelial cells 
8
 and be trafficked to distant locations in phagocytes. 
Additionally mycobateria are able to survive in infected macrophages by preventing their fusion with 
lysosomes through the action of bacterial gene PknG 
9
 and dendritic cells, less efficient at destroying 
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bacilli, may also transport Mtb from the lungs to other organ systems and secondary lymphoid organs 
7
. Furthermore, factors relating to host immunity and Mtb strain influence the degree to which 
dissemination may occur. Polymorphisms in the genes encoding for antigen recognition and 
macrophage activation 
10-12
 or impaired pro-inflammatory cytokine release may weaken the ability of 
the initial innate response to control infection 
7
. Virulent TB strains, like the Beijing strain, which are 
able to compromise the innate immune response, promote survival, replication and more severe 
disease including TBM 
11,13
. The association between decreased hours of sunshine and increased 
incidence of TBM suggest that vitamin D may have a role in preventing bacterial dissemination 
14
. 
In order to maintain the crucial homeostasis of its microenvironment the CNS is protected from 
indiscriminate influx of potentially harmful blood-borne substances by 2 vascular barriers; the blood 
brain barrier (BBB) which forms the defence between the brain and the systemic circulation, and the 
blood –cerebrospinal fluid barrier (BCB) which separates the cerebrospinal fluid (CSF) from the 
systemic circulation at the level of the choroid plexus in the ventricles 
15
. These barriers are formed by 
brain microvascular endothelial cells which are characterised by intercellular tight junctions which 
restrict paracellular transport, a paucity of endocytotic vesicles and fenestrae which limit transcellular 
movement and dedicated transport mechanisms to regulate influx and efflux of substances between 
the CNS and the blood compartment 
15,16
. Despite these protective mechanisms Mtb bacilli are able to 
migrate across these barriers and enter the immune limited domain of the CNS. The mechanism by 
which the BBB is breached has been studied using in-vitro and animal models which demonstrate that 
Mtb is able to invade and traverse brain endothelial cells through rearrangement of the actin 
cytoskeleton of brain microvascular endothelial cells 
8,17
. A number of bacterial genes are upregulated 
during the interaction between Mtb and the brain endothelium 
8
; the gene Rv0931c (pknD) has been 
identified as a potential virulence factor responsible for promoting CNS infection in certain TB strains 
as it enables the bacilli to interact with extracellular factors on the brain endothelium facilitating 
bacillary endothelial adhesion 
17
. Another potential route of entry is the Trojan horse mechanism by 




In order to protect the minimally regenerative brain from the damage of inflammation, the baseline 
immune characteristics of the brain are weak; antigen presentation is poor as microglia have poor 
antigen presenting capabilities, there is a dearth of antigen-presenting dendritic cells and low 
expression of MHC Class II molecules 
15
. Traditionally it was believed that the CNS was an immune 
naïve domain but it is capable of mounting a local immune response manifested by the intrathecal 
production of inflammatory mediators. Unfortunately however, CNS inflammation is often ineffective 
in destroying the invading pathogen
18
. The presence of the BBB effectively reduces the access of 
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leukocytes and plasma components to the intracranial compartment and CNS inflammation is 
consequently dependent primarily on local production of inflammatory mediators although some 
systemically produced cytokines may gain access through specific transport systems on the BBB or 
through a leaky BBB 
18
.  
Once the TB bacilli gain access to the brain, the poor innate local immunity allows their survival and 
replication and likely the development of silent tuberculous lesions. These lesions undergo either 
immediate or delayed progression to caseate and discharge their bacilliary contents.  Based on post-
mortem studies, Rich and McCordock contended that TBM stems from the rupture of one of these 
established tuberculous lesions located under the cortical pia or adjacent to the meninges or ventricles, 
the Rich’s focus, which releases Mtb bacilli into the sub-arachnoid space resulting in a granulomatous 
infection of the meninges 
3,19-21
 may also result from the rupture of miliary tubercles of the brain 
22
, 
from a caseating focus in the choroid plexus 
23
 or rarely spread from the tuberculous infection of 
adjacent skull bones 
23,24
. The cause of foci rupture is not clearly understood but the release of 
bacterial wall components into the CSF triggers a prolific inflammatory response characterised by the 
production of cytokines and the recruitment of leukocytes
25-27
 (discussed in Chapter 6) and the 
formation of a thick inflammatory exudate. The inflammatory process is most prolific at the base of 
the brain, an important anatomical location that interfaces with the cerebral vasculature of the Circle 
of Willis, the pathways of CSF flow, and several cranial nerves, and that communicates inferiorly 
with the spine.    
ANATOMICAL PATHOLOGY OF TBM 
Exudate 
The characteristic feature of TBM in post-mortem studies is the presence of inflammatory exudate in 
the basal cisterns and subarachnoid spaces of the brain 
21,28,29
. It is described as thick and gelatinous 
28,29
 and is made up of lymphocytes, neutrophils, erythrocytes, monocytes, and epithelioid cells, which 
may merge to form Langhans’ giant cells, and as well as Mtb bacilli 19,21,29. The inflammatory exudate 
may organise into meningoencephalitis or progress to form intraparenchymal tuberculomas with 
caseous centres surrounded by cellular peripheries and associated generalised oedema and vascular 
congestion 
21
. Where the exudate comes in contact with the brain tissue it causes a borderzone 
reaction which results in tissue damage 
19
. Exudative material is seen primarily at the base of the brain 
but may also involve the cerebral convexity and cause ependymitis of the ventricle walls, and may 
extend downward to encase the spinal cord 
19,21
. The basal localisation of the exudate is hypothesised 
to be as a result of normal CSF flow; although Rich foci are not exclusively distributed at the base of 
the brain 
20
. The predominant location of exudate at the base of brain has a number of important 
implications; firstly, all the major cerebral vessels originate from the base of the brain and are at risk 
10 
 
of being encapsulated by the exudate. Secondly, the accumulation of exudate in the basal cisterns 
interferes with the circulation of CSF causing hydrocephalus. Thirdly, it envelopes and compresses 




Exudate fills the interpeduncular fossa covering the optic chiasm anteriorly and extending posteriorly 
to the antero-superior surface of the pons. It spreads along the lateral extensions of the 
interpeduncular cistern into the Sylvian fissures along which run the middle cerebral arteries (MCA), 
anteriorly into the cisterna lamina terminalis where the anterior cerebral arteries are located (ACA) 
and postero-superiorly into the ambient cisterns where it surrounds the midbrain and comes into 
contact with the origins of the posterior cerebral artery (PCA), superior cerebellar arteries and the 
optic tracts. The origins of all the major cerebral vessels lie therefore in this main subarachnoid lake at 
the base of the brain and as the exudate spreads along the cisternal extensions it coats the large 
arteries and their small perforators causing subacute-chronic arteritis and vasculitis 
28
. 
Vascular pathology includes infiltration of inflammation from the adventitia of arteries and veins 
inwards resulting in peri- or pan-arteritis involving segments or the full thickness of vascular wall 
tissue 
30
. Infiltrative processes involve mostly vessels located at the base of the brain where the 
exudate is most prolific. Tubercles may also directly impinge on vessel walls 
30
. Evolution of vascular 
inflammation may involve thickening of the vessel intima resulting in vessel stenosis or occlusion. 
This intimal proliferation is considered a feature of chronic or partially treated TBM at which juncture 
the exudate may have thickened and become more organised 
30
. Necrosis of the vessel wall may 
involve partial or complete destruction of the vascular wall and is fibrinoid in nature. Necrosis may 
more commonly affect small calibre vessels and is demonstrated in both treated and untreated TBM 
30
. Both cerebral and spinal vessels may be affected by any or all of these processes and this may 
reflect the duration of illness 
30
. The role of vasospasm in initiating structural vessel wall damage and 
precipitating necrosis remains unclear, however, it is considered to play an important role in 
predisposing the brain to ischemic damage 
30
. It has been suggested that TBM may be associated with 
a prothrombotic status which predisposes patients to an increased risk of infarction 
31
, however this 
too remains uncertain 
30
.  
Minor arteritis results in anoxia whereas severe cases lead to infarction of whole territories supplied 
by the afflicted vessel 
28
. The exudate has a predilection for extension into the Sylvian fissures and 
therefore the MCA and its perforators around the floor of the 3
rd
 ventricle are most commonly 
affected resulting in ischemic damage to the sub-thalamic nuclei and lower internal capsule 
21
. 
Involvement of small vessels supplying the mid-brain may lead to infarction 
28
 and exudate in the 
interpeduncular cistern can compromise the vessels supplying the hypothalamic region and precipitate 
11 
 
hypothalamic symptoms in these patients 
28
. Diffuse oedema is seen around the grey and white matter 
as a consequence of ischemia and borderzone encephalitis which often occurs in the brain tissue 
underlying vessels bathed in exudate 
21
. In autopsy studies acute infarcts are associated with swelling 
of the infarcted area. When occurring in the basal ganglia they may be accompanied by compensatory 
diminution in the size of the lateral ventricle. Chronic infarcts however show shrinkage of the 
infarcted area and may therefore be associated with ex-vacuo dilatation of the ventricles 
28
. Infarcts 
have been recorded in up to 41% of post-mortem TBM studies 
32
 and there is a correlation among 
neurological changes, antemortem angiography and post-mortem cerebral and vascular pathology 
21
. 
Further discussion on cerebral vascular pathology and infarction follows in Chapter 3 on brain 
imaging. 
Figure 1.1 below illustrates how the exudate fills the basal cisterns distorting normal anatomy and 
CSF flow, and coats the cerebral vessels. 
 
Figure 1.1: Exudate in the basal cisterns in TBM 
 
  
Endoscopic view of the interpeduncular 
cisterns of the brain in a non-IB 
infected patient, depicting clear 
subarachnoid space, visible vessels, free 
flow ofCSF 
Same endoscopic view of the 
interpeduncular cistern in a patient with 
IBM depicting thickened and inflamed 
ventricular walls, opaque cisterns 





Extension of exudative material into the basal cisterns including the ambient and pontine cistern 
results in a collar of exudate around the midbrain which blocks CSF flow around the upper brain 




 ventricles with resultant 
hydrocephalus (HCP). Rarely the occurrence of an intra-aqueductal tuberculoma may also precipitate 
HCP. Further discussion on communicating and non-communicating HCP follows in Chapter 2. The 
pressure of expanding ventricles and the opposing pressure of diffuse brain oedema as a result of 
pathological processes can negatively impact the grey and white matter leading to pallor and diffuse 




Tuberculous encephalitis may occur deep in the sulci of the cerebrum and cerebellum. This is 
observed as small foci of necrosis in chronic cases which are not visible on the surface and only 
observed on cutting the brain. Encephalitis may also manifest as parenchymal tuberculomas which are 
identified in various stages of activity and healing in post-mortem investigations 
28
. Tuberculomas 
may coexist with TBM or occur independently and are thought to originate from expanding tubercles 
in the parenchyma. These lesions are typically granulomatous consisting of a necrotic centre 
surrounded by epithelioid cells which may merge to form Langhans giant cells, lymphocytes and a 
reactive border containing astrocytes and associated surrounding oedema and vascular proliferation 
19,21
. The vessel walls are characterised by infiltration and destruction by inflammatory cells 
21
. 
Caseous necrosis may ensue resulting in liquefaction of the central caseous tissue and the formation of 
cysts containing a clear or straw-coloured liquid 
33
. With time the tubercles become discretely 
organised and bound by a rim of connective tissue of reticulin fibres. They may occur throughout the 
brain in the cerebrum, cerebellum and brainstem 
21
. 
Tuberculous brain abscess 
TB brain abscesses may follow TBM or develop independently of a meningitic process 
34,35
, however, 
they are reported to occur infrequently 
33
. Brain abscesses of tuberculous origin manifest as 
encapsulated collections of pus which contain tubercular bacilli in the absence of typical features of a 
TB granuloma including epithelioid and giant cells and mononuclear cell infiltrates 
33
. These lesions 
must be distinguished from tuberculomas with central necrosis and liquefaction and Ziehl-Nelson 
staining or culture on the pus of surgically treated abscesses are preferable in confirming the 
diagnosis, although the culture yield may be poor 
19,35
. The prolific exudative process promotes 
caseation which may soften and be associated with the infiltration of polymorphonuclear leukocytes 
and pus formation. The tuberculous abscess wall is typically thicker than that of pyogenic abscesses 
13 
 
and histological examination of the wall reveals predominantly vascular granulation tissue comprising 
a mix of acute and chronic inflammatory cells, particularly polymophonuclear leukocutes 
33
. These 
abscesses have been reported in the cerebrum 
33,34
 and posterior fossa 
34,36,37
 occurring rarely in the 
brain stem 
35
, and may be singular or multiple 
19
.   
Spinal TB 
Spinal TB may develop as a primary tuberculous lesion, from the downward extension of intracranial 
TBM or secondary to vertebral TB 
21,38,39
. It involves the cord, meninges and nerve roots and 
manifests as spinal arachnoiditis, intradural (extramedullary) tuberculomas or rarely as intramedullary 
tuberculomas 
40-42
. Tuberculous leptomenigitis, also referred to as tuberculous radiculomyelitis, 
frequently accompanies TBM and is characterised by the extension of basal exudate into the spinal 
canal where it encases the spinal cord expanding the space between the dura and the leptomeninges 
causing compression but not infiltration of the spinal cord. It may be associated with areas of caseous 
necrosis, thickening of the dura and borderzone encephalitis of the cord. The nerve roots may become 
entrapped and matted in exudate filling the subarachnoid space precipitating the eventual adherence 
between the spinal nerve roots and thecal sac 
21,24
.  Exudate involvement of the lower lumbar 
segments is associated with difficulty in performing lumbar punctures and a high CSF protein 
21
. The 
microscoscopic appearance of spinal exudate is identical to intracranial exudate, consisting of giant 
cells and caseous areas, and causing vasculitis of the spinal veins and arteries which may led to cord 













Tuberculosis continues to be a massive global health problem. According to the World Health 
Organisation (WHO) Global TB Report 2013 
44
 the year 2012 saw 8.6 million incident TB cases and 
1.3 million TB-related deaths. South Africa ranks as one of 2 countries with the highest incidence rate 
per capita with 1 new case of TB for every 100 people each year, and the Western Cape has the 
highest incidence in the country 
45
. Although global mortality rates have been on the decline, 
mortality trends in South Africa appear less promising and it is estimated that approximately 119 000 
South Africans died of TB in 2012. The global incidence of TB amongst children is estimated at 
530 000 cases (6% of the total incident cases) and childhood TB mortality accounts for 8% of the 
global burden amongst human immunodeficiency virus negative (HIV-) individuals 
44
. Long-standing 
challenges to the eradication of the disease include the lack of effective vaccination, poverty, lack of 
education, and poor access to early and effective health care. New challenges that have increased the 
global problem of TB include its association with HIV/ acquired immunodeficiency syndrome (AIDS) 
and the emergence of multidrug resistance.  
Extrapulmonary TB constituted 15% of total global TB notifications 
44
. TBM is the most severe form 
of extra-pulmonary tuberculosis and the most common form of neuro-tuberculosis 
14,21
 leading to 
death or severe disability in half of the affected individuals 
45-52
. It is reported to occur more 
frequently in children 
14,47
, particularly in countries with high TB prevalence whereas adult cases are 
relatively more common in low TB prevalence regions 
53
. The incidence in children is highest in the 
first 5 years, particularly between 1-3 years 
45,48,54,55
. It is rarely observed before 3 months of age, 
however, the co-incidence of miliary TB and TBM occurs more commonly in younger children than 
TBM alone, and suggests that the weak immunity in young children may predispose them to 
disseminated TB 
4
. TBM often develops in association with malnutrition, particularly protein-calorie 
malnutrition in children 
21
 and is most commonly seen in patients from rural or impoverished 
circumstances 
48,56,57
. Risk factors for adults include corticosteroid treatment, alcoholism, diabetes 
mellitus, malignancy and HIV, and TBM has become the commonest form of meningitis in HIV 
infected (HIV+) adults 
50,53
. In both adult and paediatric cohorts males are more commonly affected 
45,47-49,51,52,58
. The disease peaks in late Winter/early Spring partly due to a seasonal increase in 
pulmonary TB during winter months of over-crowding, poor ventilation and poor housing conditions 
followed by a 3-4 month incubation period. The role of low vitamin D levels due to decreased 
16 
 
sunshine hours has also been suggested as the vitamin D receptor on microglia may play a role in the 
production of pro-inflammatory cytokines and immune activation 
14
. The protective value of the 
Bacillus Calmette–Guérin (BCG) vaccination remains controversial, but it is reported to confer 
greater protection against severe forms of disseminated TB in children including miliary TB and TBM 
59
. The comparison between vaccinated and unvaccinated paediatric TBM patients has generated 
mixed results in terms of the severity of presentation and outcome 
60,61
 but what is noteworthy is the 
predominance of BCG vaccination amongst children presenting with TBM (over 90% in some studies 
45,62
). This raises important questions regarding the quality of vaccine administration and the 
composition of the BCG vaccine. Considerable effort has been dedicated to the development of more 




Diagnosis and clinical presentation 
TBM is considered a medical emergency requiring immediate treatment in all patients in whom it is 
suspected 
53
. Diagnosing TBM remains challenging due to the non-specific nature of its presentation 
and the lack of clinical, laboratory or radiological tools to enable a swift and definitive diagnosis. 
Early diagnosis and commencement of treatment are considered the most important determinants of 
outcome 
64
. Missed opportunities for timely diagnosis, late presentation, inaccessibility to medical 
care and poor health care seeking all contribute to delayed diagnosis 
48,57,65
. 
Most institutions treat patients on the presumed diagnosis of TBM based on a combination of clinical, 
laboratory and radiological criteria 
45,47,48,51
. However, there is considerable variability across these 
criteria and a lack of uniformity in defining TBM exists, particularly in defining probable versus 
possible TBM. A number of studies have attempted to develop diagnostic algorithms 
66-68
 but these 
have not been validated across different settings or patient age groups. A recent consensus statement 
set out to develop standardised diagnostic criteria to allow appropriate comparison between research 
studies. Relevant literature in both adult and paediatric TBM was reviewed by an international panel 
of experts from various disciplines involved with TBM management, and a case definition was 
derived that can be used independently of patient age, HIV status or clinical/research resources 
69
 
(Appendix 1). International validation of this consensus case definition is still required.  
Clinical presentation 
In the early phases of disease patients may present with non-specific sub-acute symptoms like cough, 
fever, vomiting, malaise, lethargy, a worsening headache and weight loss/poor weight gain 
5,47,48,50,51,69-72
.  Meningism may be absent early in the disease and it is challenging to differentiate 
these symptoms from those of benign conditions like an upper respiratory tract infection 
5,45
. This is 
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particularly the case in children in whom symptoms may be challenging to recognise; however, failure 
to thrive demonstrated by a declining percentile of mass for age relative to the original growth pattern 
recorded on the growth chart is one of the most sensitive early features of TBM in children 
73
. With 
disease progression more severe symptoms develop including a decreased level of consciousness 
(LOC), meningism, signs of raised intracranial pressure (ICP), seizures and focal neurological fall-
out, and it is often only at this point that the diagnosis of TBM is considered. Focal neurology may 
include paresis, pupillary abnormalities, aphasia and cranial nerve palsies. The cranial nerves may be 
compromised by nerve arachnoiditis, ischemia and hydrocephalus (HCP) and commonly involves 
cranial nerve II, as well as III and VI possibly due to their long subarachnoid course 
47,48,52,74
. 
Headache, vomiting, poor weight gain or weight loss, meningism and an altered sensorium have been 
described among the commonest presenting symptoms 
45,47-49,51,52,70-72
. Abnormal motor function is 
reported in over half of patients and cranial nerve palsies in one quarter 
45,47
. Although raised ICP is 
common in these patients papilloedema is not often recorded 
49,71
 but a bulging anterior fontanelle 
may be reported in up to 70% of infants 
75
. Presenting symptoms are not significantly related to sex 
47
. 
History taking may reveal a recent positive TB contact in 20-66% of cases 
45,48,71,72
 and a previous 
history of TB in 13-27% of cases 
71,72
. Patients are commonly symptomatic for more than 1 week 
before diagnosis but duration of symptoms may be over 1 month 
45,47-50,72
. TB infection in other 
organs have been reported in over 30-50% of patients, including pulmonary, disseminated, abdominal 
and lymph node 
47,52,71,72
. A number of studies have examined the clinical features most predictive of 
TBM; symptom duration of longer than 5 days 
5
 and recent poor weight gain 
73
 have shown strong 
predictive power. 
Severity 
Currently there is a deficit of tools to accurately assess injury severity and prognosticate. Clinical 
examination lacks the specificity to estimate disease severity as a number of factors not directly 
related to TBM may contribute to presenting symptoms. Radiological findings do not demonstrate 
evolving injury and brain damage is only evident once it is already irreversible. Currently the 
commonly used means of assessing the severity of disease on admission is the British Medical 
Council (BMC) TBM staging criteria 
76
. This system was modified after its initial description to 
include the Glasgow Coma Score (GCS) and scores patients as Stage I with a GCS of 15/15 and no 
focal neurology, as Stage II with a GCS 11-14 or 15 with focal neurology, and as Stage III with a 
GCS ≤ 10. Although widely used this grading system does not account for the fact that a number of 
treatable factors other than TBM may be responsible for a decreased level of consciousness on 
admission including seizures, electrolyte disturbances, raised ICP and anti-convulsive medication. 
Consequently other grading systems including the Acute Physiology and Chronic Health Evaluation II 
77
, the TBM Acute Neurological Score (TBAN) 
78




, and the Tygerberg Children’s Hospital scale (TBH) 81 have been applied. Additionally a refined 
version of the MRC system was proposed which divides Stage II into 2 separate categories (Stage 2a: 
GCS 15 with neurological deficit/ GCS13-14 with/without neurological deficit, and Stage 2b: GCS 
10-12 with/without focal neurological deficit) 
81
. A recent paediatric study demonstrated that all these 
various scales had adequate power in predicting outcome and that using the refined MRC staging one 
week after admission significantly enhanced its prognostic power 
81
. However, the MRC system 
applied at admission still remains the most widely used 
45,47,69
 and the majority of presenting cases fall 
within Stage II (≈50%) or Stage III (≈40%) 45,47-50,69-71,75.  A longer duration of symptoms is reported 
in patients with more severe disease spanning sometimes more than 3 weeks before admission and 
diagnosis 
48
. Table 2.1 summarises the MRC stages of TBM severity. 
 
Table 2.1: MRC stages for classifying the severity of TBM 
MRC staging  Refined MRC staging  
Stage I: mild GCS 15/15 
No focal neurology 
Stage I: mild GCS 15/15 
No focal neurology 
Stage II: moderate GCS 11-14 or GCS 15 
With focal neurology 





Stage III: severe GCS ≤ 10 Stage IIb: moderate GCS 10-12 
with/without focal 
neurological deficit 
  Stage III: severe GCS < 10 with/without 
neurological deficit 
This table includes the criteria for mild – severe stages of TBM using the MRC Staging and a refined version of 





The current gold-standard for TB diagnosis is the culture of Mtb or the visualisation of acid-fast 
bacilli (AFB) in cerebrospinal fluid (CSF). CSF culture positivity yields are notoriously poor ranging 
from 0-47% 
45,47-49,52,70,72,75
 and results can take longer than 40 days. Consequently treatment must be 
initiated based on clinical suspicion to mitigate the devastating outcomes associated with treatment 
delay. Factors that may improve culture yields include larger volumes of CSF (>6ml), repeated CSF 
investigation in patients undergoing multiple lumbar punctures (LPs) and liquid culture media 
82,83
.  
CSF smear is the most accurate rapid investigation but the visualisation of AFBs is variable (0- 50% 
of patients) 
47,48,51,70,71,75
 and highly dependent of the volume of CSF and the expertise with which it is 
examined 
53. The sensitivity may also be improved with larger volumes and repeated CSF’s and with 
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the use of fluorescent microscopy 
69
. A recent laboratory study found that modifying the laboratory 
procedure by crytospinning the CSF to collect the cells, fixing and staining them with TritonX-100 
dye and then staining them with Ziehl-Neelsen dye allowed for 100% AFB visualisation. The method 
allowed the visualisation of not only extracellular bacilli but also intracellular bacilli located in 
monocytes, neutrophils and lymphocytes 
84
. Further validation studies for this innovative technique 
are required. 
Molecular technologies involving nucleic acid amplification like real-time polymerase reaction (PCR) 
are being investigated for TBM diagnosis as they potentially offer tests which are rapid and highly 
sensitive and specific. Studies in the clinical setting have demonstrated high specificities but 
sensitivities have not been adequate for these to be used as rule-out tests, but they may confirm TBM 
in patients presenting with signs and symptoms suggestive of TBM 
85,86
. This is largely as a result of 
the small number of bacilli and the presence of endogenous amplification inhibitors in the CSF 
85
. A 
novel nested PCR assay which dramatically increases the sensitivity and specificity of DNA 
amplification is in development, but widespread routine use is not yet feasible due to the complex and 
laborious techniques involved and the risk of cross-contamination; research is ongoing 
85
. However, 
unlike culture and microscopy these molecular tests may remain sensitive for up to 1 month after the 
initiation of treatment 
83,87
. The Gene Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA, USA) which 
uses real time PCR to allow for rapid near-patient diagnosis and drug sensitivity testing has shown 
high sensitivities and specificities in the diagnosis of pulmonary TB from sputum samples 
88
 and can 
effectively be applied in resource-limited settings 
89
. Studies on CSF samples in HIV+ TBM patients 
have found this method to be 11 times more sensitive than fluorescent microscopy, although the 
technique is currently still expensive 
90
. A study investigating the potential of this test in paediatric 
extra-pulmonary TB including TBM is currently underway.  
Diagnostic techniques that detect Mtb antibodies and antigens have demonstrated poor sensitivities 
and specificities and are consequently still considered experimental 
69,91
. Adenosine deaminase levels 
are elevated in the CSF and serum of TBM patients 
92,93
 and offer a useful diagnostic test which can 
differentiate TBM from other meningitides in resource limited areas as the assay is quick, easy and 
inexpensive to perform. Cut-off values suggestive of TBM are however varied across studies making 
ADA levels challenging to interpret and this test is not routinely being used 
91
. 
The mantoux or tuberculin skin test (TST) is frequently carried out in paediatric cases and is positive 
in up to 60% of paediatric patients 
45,47, defined by an induration of  ≥ 10mm or ≥ 5mm in HIV-
infected or malnourished children. Repeat TST’s are recommended in children who test negative as 
improved nutrition may lead to improved results 
94
. The specificity of TST may be mitigated by BCG 





Similarly, interferon-gamma release assay (IGRA) may demonstrate higher accuracy in diagnosing 
latent TB 
95




CSF microscopy and chemistry are essential in the presumptive diagnosis of TBM.  
CSF white cell count: Elevated leukocytes (10 - 100 cells/μL) occur in the overwhelming majority of 
patients (>80%) 
45,48
; lymphocytic predominance of >50% is common 
47,48,51
 and may be > 90% 
47,49
. 




Atypical findings have been described in children and HIV+ adults in whom CSF may be acellular or 
demonstrate neutrophil predominance similar to bacterial meningitis. Glucose levels may be normal 
or elevated, and protein levels may be low 
51,96
.Therefore, while these investigations contribute to the 
presumptive diagnosis, they are not considered rule-out tests. 
Radiology 
Radiological findings indicative of TBM include hydrocephalus (HCP), basal and leptomeningeal 
enhancement, infarcts and tuberculomas. These features are a vital component in building a 
presumptive TBM diagnosis and are discussed in detail in Chapter 3. 
The combination of clinical, laboratory and radiological criteria upon which the presumptive 




Figure 2.1: Components of presumptive TBM diagnosis 
 




The WHO TB treatment guidelines for children recommend 12 months of antibiotic treatment 
consisting of a 2 month regimen of  isoniazid (INH), rifampicin (RMP), pyrazinamide (PZA) and 
ethambutol (EMB) followed by 10 months of INH and RMP. Hospitalisation for the initial 2 months 
is recommended 
97
. Treatment doses for adults are lower but 12 months is also the recommended 
duration of treatment 
53
. A systematic review and meta-analysis suggested that 6 months of treatment 
were sufficient although a formal study to compare 6 month with longer treatment regimens has not 
been conducted 
98
. Longer treatment durations are encouraged due to concerns regarding relapse, the 




In resource limited contexts like South Africa administering and controlling such a long duration of 
treatment may not be feasible and hospital stays are curtailed by limited beds and staffing. Short-
course intensive treatment regimens over 6 months are less expensive and less labour intensive and 
may improve patient compliance which is vital as treatment interruption is an independent risk factor 
for death in TBM 
46,58
. Consequently, health care institutions in the Western Cape have adopted the 6 
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month intensified short course regimen introduced at TBH, comprising INH (20 mg/kg), RMP 
(20mg/kg), PZA (40mg/kg) and ethionamide (ETH – 20mg/kg) for 6 months in HIV- children and 9 
months in HIV+ patients with drug-susceptible disease 
46,99. Studies evaluating this institution’s 
treatment outcomes using this regimen over the last 15 years have consistently reported the regimen to 
be safe, sufficient and well tolerated 
46,99
. This group has also demonstrated successful home-based 
care for the last 5 months  after hospital discharge with an absence of relapses in 90% of children 
treated at home 
46
. An adult study using high dose intravenous RMP and moxifloxacin for 2 weeks in 
conjunction with standard treatment for 6 months demonstrated higher drug exposure without 
increased adverse effects and a 50% reduction in 6 month mortality, although this study was not 
powered as an outcome study 
100
. 
There is some debate about the choice of fourth drug and there are a number of options. Ethambutol 
has poor CSF penetration in the absence of meningeal inflammation and is associated with side effects 
including optic neuropathy 
53,91
. Streptomycin is frequently associated with toxicities and resistance 
has become common 
5,91
. Ethionamide shows good CSF penetration under conditions of meningeal 
pathology and health but may cause nausea and is consequently administered at night. Studies with 
fluoroquinolones suggest that certain agents including levofloxacin and moxifloxacin penetrate the 
CSF adequately and contribute to antituberculosis activity and improved outcome 
5,100
. This group of 
antibiotics form an essential component of 2
nd
 line treatment for multidrug-resistant (MDR) TBM 
5
. 
They are, however, not recommended for women who are pregnant or lactating and may be associated 




A randomised controlled trial on adjunctive steroid use in paediatric TBM concluded that steroids 
significantly reduced mortality, tuberculoma incidence and meningeal enhancement on CT and 
improved cognitive outcome. They had no effect on infarct size or incidence or on permanent motor 
deficits 
101
. An adult study found similarly that steroids reduced the risk of death across all stages of 
TBM but had no mitigating effect on the proportion of patients who died or were left severely 
disabled by 9 months and the benefit to mortality in HIV+ individuals was less certain 
58
. A Cochrane 
Review on the subject found that overall corticosteroids reduce mortality and disabling residual 
neurological deficits 
102
. Steroids are recommended as part of the routine treatment for TBM for the 
first 4-6 weeks 
5,53
. The mechanism by which steroids work is still unclear; there is some evidence in 
animal and human studies to suggest a role for the polymorphism in LTA4H which encodes for 
leukotriene A4 hydrolase, an enzyme which controls the balance of pro- and anti-inflammatory 
eicosanoids and the expression of tumour necrosis factor α (TNF-α). Variability in the expression of 
LTA4H renders individuals prone to either a hypo- or hyper-inflammatory state; corticosteroids may 
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be suitable only for the latter phenotype suggesting that individualisation of treatment may be 
important.  
A safety and efficacy trial using thalidomide in paediatric TBM found that it demonstrated immuno-
modulating effects including a decrease in pro-inflammatory mediators, reduced enhancement on 
head CT scans, decreased incidence of tuberculomas and improved resolution of established 
tuberculomas 
103
. However, the occurrence of adverse effects in the treatment arm of the randomised 
controlled trial necessitated the premature termination of the study 
104
. Adjunctive aspirin use has 
been considered owing to its anti-thrombotic, anti-ischemic and anti-inflammatory action. A 
randomised controlled trial in adult TBM found that the combination of adjunctive steroids and 
aspirin led to a decreased frequency of death at 3 months and a 19% decreased risk of ischemic stroke 
105
. This was followed by a paediatric study which found that low and high dose aspirin were not 
associated with a significant decrease in mortality or motor disability. Their high dose aspirin group 
were, however, younger and had more severe disease; the fact that their outcomes were no different 
from the other treatment groups may suggest some benefit of high dose aspirin 
106
. Currently aspirin 
does not form part of formal treatment recommendations and further studies are required. 
Drug resistance 
Detecting drug resistance early so as to initiate an appropriate alternative line of therapy is key to 
preventing death and the spread of drug-resistant TB strains 
5,107
. CSF culture is currently the only 
standard way to establish drug susceptibility 
91
and results can take as long as 10 weeks, increasing the 
risk of severe disease, mortality and morbidity 
108
. PCR techniques which allow rapid drug sensitivity 
testing are urgently needed but are limited by poor sensitivities in CSF and uncertainty around which 
mutations denote resistance for some drugs 
5,91
. Diagnosis relies on suspicion, patient history and 
knowledge of the local drug resistance patterns. Mono-resistant TB demonstrates resistance to INH or 
RMP and MDR TB denotes resistance to both INH and RMP 
107
. Globally MDR TB accounted for 
3.6% of newly diagnosed cases and 20% of previously treated cases in 2012 
44
. South African studies 
found that 8-10 % of adult and paediatric TBM cases demonstrated MDR as well as resistance to 
second-line drugs and the authors suggest that this may be an underestimate due to the difficulty in 
culturing TB from CSF. Two of the adult patients were resistant to 7 of the available TB drugs 
4,108
. 
Studies from other locations have reported resistance (MDR and mono-resistance) in 11-15% of TBM 
patients 
52,70
. MDR TBM is associated with high mortality; delay in diagnosis and initiation of 
appropriate treatment likely contribute to poor outcomes 
108,109
. A general consensus on treatment 
regimens for drug-resistant TBM has not been established and regimens should be tailored according 
to the drug susceptibility profile of individual patients. Second-line drugs used to treat drug-resistant 
TB include 1) fluoroquinolones (moxifloxacin, gatifloxacin, oflofloxacin, levofloxacin, 
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ciprofloxacin), 2) injectable agents including aminoglycosides (amikacin, kanamycin and 
streptomycin) and the glycopolypeptide capreomycin, 3) oral bacteriostatic agents (ethionamide, 
protionamide, cycloserine, para-aminosalicyclic acid, thioacetazone) and 4) drugs with unclear 




Treatment for TBM patients co-infected with HIV is complicated by the risk of potential drug-drug 
interactions and paradoxical TB associated immune reconstitution inflammatory syndrome (IRIS) 
after the initiation of anti-retroviral therapy (ART) 
46
. This condition occurs in HIV+, ART-naive 
patients who respond well to anti-TB treatment until the introduction of ART. Patients present with 
recurrent, new or worsening symptoms or deterioration of radiological manifestations of TB disease. 
Risk factors for TB-IRIS include more advanced HIV disease with lower CD4 cell count, 
extrapulmonary TB, earlier initiation of ART, and a more vigorous viral response to ART 
110
. A 
recent adult study of HIV+ TBM patients found that TB-IRIS occurred in 47% of patients manifesting 
as worsening headache, confusion, meningism, seizures and other signs of focal neurology. CSF 
neutrophil counts were higher at admission and poor outcome was seen in 44% of TBM-IRIS cases 
111
. The recommended time to commence ART in adults is 2 weeks after the initiation of anti-TB 
treatment, recommendations for paediatric TBM have not been established but treatment may be 
delayed 2-4 weeks after the initiation of anti-TB medication 
46
. Paradoxical worsening of TBM after 
treatment initiation is also seen in HIV- individuals or HIV+ individuals not on ART and is attributed 
to a hypersensitivity reaction of the immune system to bacterial antigen release as a result of drug 
induced Mtb destruction 
24,91
. These reactions are however more severe and frequent in ART-




Supportive and surgical management 
Raised ICP 
Raised ICP may be owing to cerebral oedema, mass occupying tuberculomas or abscesses, and HCP. 
Treatment with hypertonic saline is recommended for brain swelling 
112
 and a combination of medical 
and surgical management for HCP, tuberculomas and abscesses. Invasive continuous ICP monitoring 
is not currently used in TBM and further research into protocols for monitoring and managing ICP 
which are appropriate to the pathophysiological processes of TBM are required 
112
. The benefits of 
ICP monitoring in meningitis have, however, been demonstrated in patients with bacterial meningitis 
113
. HCP occurs in as many as 80% of patients with TBM 
45,47,49,64,114-118
 and can be more common and 
more severe in children 
24,118
. It may evolve rapidly or progress slowly; however, when the 
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compensatory capacity for increased CSF volume is reached, even small additional increases in 
volume will lead to precipitous increases in ICP. Raised ICP compromises cerebral blood flow (CBF) 
and increases the risk of ischemia, left untreated raised ICP can result in brain herniation and death 
112
. Raised ICP and HCP are consequently significantly associated with poor outcome, but can be 
relatively effectively treated if appropriately diagnosed. HCP in TBM is unusual as it is of two forms; 
communicating HCP (CHCP) if the obstruction to CSF flow by the exudate occurs in the 
subarachnoid space, mostly at the level of basal cisterns, and non-communicating HCP (NCHCP) 
when the obstruction occurs at the outlet foramina of the 4
th
 ventricle at the cerebral aqueduct, caused 
by the circumferential compression of meningeal exudates, mesencephalic oedema, intraventricular 
exudate or the presence of a tuberculoma 
22,112
. Occasionally exudate occludes the foramen of Monro, 
which leads from the lateral ventricles to the third ventricle. Although NCHCP occurs less frequently 
(14-25%) 
45,64,101
 determining the nature of the HCP has important implications for the appropriate 
management of ICP. Accurately differentiating between the two forms of HCP is not usually possible 
by examining brain imaging. Red Cross War Memorial Children’s Hospital (RXH) and TBH follow a 
protocol of investigating the communicating nature of HCP by air encephalography (AEG) and/or 
column tests 
64,101,112,119,120
. As there have been no controlled trials to validate methods of treating 
HCP considerable variability across centres exists, with some centres advocating shunts in all patients 
with hydrocephalus 
80,121-125
. Paediatric studies report that up to 70% of TBM patients receive 
neurosurgical intervention for HCP 
48,49,75
. 
CHCP is either treated medically 
22,45,112,126
, or using venticuloperitoneal shunts (VPS) determined by 
the severity of HCP regardless of HCP communication on the assumption that early CSF diversion 
decreases the risk of brain damage and improves outcome 
47,127
. Medical treatment proposes the use of 
diuretics acetazolamide (50-100mg/kg/day) and furosemide (1mg/kg/day) in combination with serial 
LPs. The frequency of LPs is variable across different centres ranging from daily to weekly 
22,112
. It 
has been argued that weekly LPs are unable to assess the trend in ICP between LPs and may miss 
ongoing raised ICP, whereas daily LPs allow more regular ICP monitoring and reduction, as the ICP 
returns to baseline within 12-24 hours after an LP 
112
. If by 3-4 weeks ICP has not normalised as 
determined by an elevated LP opening pressure, clinical deterioration or progressive HCP on 
computed tomography (CT) brain scan, a VPS is inserted for these patients who have failed medical 
treatment 
22,112
. Medical treatment for CHCP is successful in 75-82% of patients 
22,45
 and patients who 
are shunted due to failed medical treatment may suffer poorer outcomes 
22
. In cases where patients 
demonstrate severe HCP and a very depressed level of consciousness an external ventricular drain 
(EVD) may be used as a temporising measure until the ICP comes sufficiently under control and 





NCHCP is always treated surgically as an LP in this context would create a pressure gradient across 
the foramen magnum and result in hindbrain herniation (coning) 
112
. Surgical options include a VPS 
which is generally a lifelong device and can be prone to repetitive complications in nearly one third of 
patients 
22,127
. These include shunt infections reported in 13-15% of patients 
22,127
 and shunt blockage 
in 13-40% of cases 
22,127
 often due to the high protein CSF content 
128
. Other complications may 
include over draining and wound breakdown 
22
. Multiple shunt revisions are required in almost 20% 
of patients 
127
. Variation in complication rates is a reflection of surgical expertise, shunts used, and 
patient variables including age, nutritional status, concomitant skin infections and immune 
compromise 
22




The alternative is an endoscopic third ventriculostomy (ETV), a procedure first described in the 
context of TBM 
120
. This minimally invasive procedure involves making a stoma in the floor of the 
third ventricle allowing communication between the ventricles and the SAS and bypassing the 
blockage of the ventricular system. ETVs may be challenging due to the presence of proteinacious 
exudate in the ventricles which mars visibility and renders the floor of the third ventricle thick and 
difficult to perforate. Unrecognisable anatomy of the third ventricle floor may occur in 20-30% of 
patients and consequently the rate of procedural abandonment is high 
127,129,130
. The long term success 
of ETVs may be compromised by exudate blockage in the SAS which may prevent egress and 
reabsorption of CSF over the cortical surface, and predispose closure of the stoma in the inflamed 
ventricular floor 
127,130,131
. ETV success rates for NCHCP in terms of technical completion are 
reported to be approximately 60% 
129
. Medical treatment is recommended after an ETV as cisternal 
obstruction and CSF malabsorption may still occur and the HCP has not been cured but converted 
from NCHCP to CHCP 
112,132
. ETVs are also performed in patients with CHCP 
133,134
. In these cases 
ETVs performed later in the disease course, even in chronic and burnt out cases, are reported to have 
higher success than those performed during the early acute phase 
131,133,135
. Due to the potential 
complications of operative procedures for HCP coupled with the high rate of success with medical 
treatment for CHCP some centres recommend avoiding ETVs and VPS unless absolutely required 
130
. 
Tuberculomas and TB abscesses may manifest with signs of raised ICP depending on their location 
33,35
. Neurosurgical resection is only required for tuberculomas with mass effect 
49
 or intramedullary 
lesions causing progressive neurological deficit 
136
. The role of steroids in the treatment of 
tuberculomas is inconclusive: dexamethasone did not alter their evolution in adults 
114
 but a trial on 
corticosteroids in children demonstrated enhanced tuberculoma resolution and reduced incidence of 
delayed tuberculoma development 
101
. It is suggested that the nature of the necrotic centre, whether 




. Abscesses often present acutely, they may respond poorly to standard medical treatment and can 
present months after the commencement of TBM management 
138
. A paediatric case series suggested 
clinical and radiological improvement with adjunctive use of thalidomide 
34
. In cases of neurological 
deterioration a combination of medical and neurosurgical treatment may be preferable, this may 
involve stereotactic aspiration of the pus or surgical excision and drainage of the lesion depending on 




Hyponatraemia is a common finding in TBM occurring in 60 -90% of patients 
112,139
 it is associated 
with poorer outcome 
140
 and may exacerbate cerebral oedema 
112
. Perturbations in sodium levels may 
be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH) or cerebral salt 
wasting (CSW). Elucidating the cause is important as the two syndromes require different treatment. 
SIADH is characterised by excessive release of antidiuretic hormone (ADH) which leads to increased 
water absorption in the renal tubules leaving patients euvolemic or fluid overloaded. Total body 
sodium levels are unaltered but fluid levels are increased. Treatment requires fluid restriction to 
counter inappropriate water retention 
112,141
. Inappropriate release of ADH may be due to ischemic or 
inflammatory damage to the hypothalamus 
112
. CSW involves increased secretion of atrial natriuretic 
peptide (ANP) which leads to increased loss of urine sodium and subsequent extracellular fluid loss 
due to the renal fluid loss. When urine loss outweighs fluid loss hyponatremia ensues and total body 
sodium is reduced 
141,142
. Treatment in this case requires salt and fluid replacement rather than fluid 
restriction which would exacerbate an already depleted intravascular volume in patients at risk of 
cerebral ischemia 
112
. It is therefore important to correctly ascertain the cause for hyponatremia; 
however, this is challenging and necessitates an accurate assessment of intravascular volume. 
Furthermore, CSW may result in secondary compensatory secretion of ADH 
112
. Both SIADH and 
CSW have been reported in TBM 
139,143
 yet uncertainty about the prevalence and diagnosis of each 
condition remains and it is recommended that fluid restriction be avoided and cautious treatment with 





Mortality rates range from 3.8 - 43% in children 
46-49,75
 and 17 - 79% in adults with higher mortality 
seen in HIV+  cohorts 
50-52,71,72
. MRC TBM stage demonstrates a significant relationship with 
mortality and morbidity with a high rate of death and disability seen with Stage II (≈ γ0%) and III (≈ 
80%) and little to no neurological morbidity seen with Stage I 
22,45,47,49,50,70,72
. Mortality may be higher 
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in younger children 
48
, in HIV+ individuals with lower CD4 counts 
50
 and may commonly occur 
during the acute phase of disease 
48-50,72
.  
Good outcomes are reported in 16 - 50 % of patients based on the severity of disease on admission 
and co-infection with HIV 
45,47,52,71,72
. The majority of patients are left with residual neurological 
deficit including visual impairment 
45,47,144
, motor deficits in 28 – 44 % 45,47 hearing loss in 16% 45 and 
cognitive deficits (75%). Motor and cognitive morbidities are as a result of cerebral infarction 
145
 and 
optochiasmatic arachnoiditis and optochiasmal tuberculomas give rise to visual deficits 
144
.  
Predictors of outcome are numerous and varied across studies and include a delayed initiation of 
treatment, old age, low admission GCS, race, TBM stage, convulsions, headaches, motor function, 
brainstem dysfunction, CD4 count, basal exudate, cerebral infarction and the presence of 
comorbidities on multivariate analysis 
45,47,52,70,72,146
. Poorer outcomes have been reported in patients 
with confirmed TBM in some 
4,70






PAEDIATRIC TBM IN THE WESTERN CAPE 
 
Three retrospective studies examining the profile of paediatric meningitis at one of the 2 major 
tertiary institutions in the Western Cape have revealed that over the period from 1981 to 2009 the 
incidence of TBM has continued to rise and this disease now accounts for the majority of cases of 
bacterial meningitis 
54,55,147
. Prior to 1995 TBM was not yet the forerunning causative agent, but rates 
have doubled from 10% to 22% of all paediatric meningitis cases in the recent decade 
54
. The 
increased presence of TBM may in part be attributed to the rising incidence of pulmonary TB 
throughout this province from 689 cases/100 000 population in 1997 to 1000 cases/100 000 
population in 2012 
44
; this augments the risk of primary infection in children vulnerable to CNS 
dissemination. Another contributing factor may be the increasing national HIV seropositivity from 
approximately 4.5% in 1995 to 10.3% total population in 2009 
148
.  Recently published studies have 
found relatively low rates of 3.8 - 14 % HIV co-infection in paediatric TBM cohorts 
14,45,46,54
; 
however, studies on children admitted for long-term hospitalisation due to severe TB or poor social 
circumstances have found an increase in HIV rates between 1998 and 2001 
94,149
. Notably, the 
frequency of HIV-testing is variable with some studies reporting testing in only 40-80% of cases 
14,45,46,54
. It is possible, therefore, that the rate of HIV infection in children with TBM may be 
underestimated, and the opportunity to commence appropriate antiretroviral treatment may be missed 
54
. The prevalence of HIV in the Western Cape is, however, the lowest nationally 
4
. 
Incidence rates of TBM in the Western Cape in 2006 were estimated to be 31.5 per 100 000 in 
children <1 year and 0.7 per 100 000 in children from 10 – 14 years 45. Studies spanning from 1985 to 
the present day demonstrate that the majority of cases continue to occur in children under the age of 5 
years and of indigenous African ancestry or mixed ancestry 
45,54,150
. The vast majority of these 
children stem from impoverished families who live in overcrowded dwellings lacking in basic 
amenities 
56,150
. Contact with adult pulmonary TB source cases is reported in almost 60% of children 
with pulmonary and extra-pulmonary TB and drug susceptibility patterns mirror those of adult 
contacts 
94
. Drug susceptibility testing is limited to culture positive CSF samples and has not always 
been routinely performed. Current estimates of overall childhood drug resistance at Tygerberg 
Hospital suggest 12% prevalence 
45
. In a selective cohort of children with severe TB admitted to 
Brooklyn Chest Hospital (BCH) 19% of cases (pTB and TBM) had confirmed drug resistance with an 
almost even spread between mono-INH and multi-drug resistant TB. A history of previous TB 
treatment was recorded in 22% of the study cohort; only half of these patients had been compliant, 
and 15% of defaulters had drug resistance suggesting acquired drug resistance 
94
. This finding 
parallels national results on MDR TB which confirm the significant association between previous 
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treatment and drug resistance 
151
. According to the WHO 2012 Global TB Report South Africa 
recorded only 77% treatment success rate and is one of the three countries with increasing rates of 
MDR which occurs in 1.8% of new cases and 6.7% of retreatment cases. Poor treatment completion is 
likely to contribute to future increases in MDR TB and TBM prevalence in adults and children, who 
are as likely as adults to develop MDR 
44
.  
Mortality rates reported for TBM in the last 5 years have been promisingly low (3.8-12%) 
45,46
 and 
this may be attributed to the better adherence to drug regimens, active treatment of HCP and raised 
ICP and a low rate of HIV co-infection and multi-drug resistant TB 
45,46
. The morbidity rates, 
however, remain high with only 16-20% of children returning to their pre-TBM baseline 
45,46
. Motor 
deficits, cognitive impairment and neurodevelopmental delay are among the commonest morbidities 
and almost 20% of children are left severely disabled 
45,145
.  
Although focussed care may be provided during the acute in-hospital period, in a resource limited 
country like South Africa access to adequate rehabilitation, outpatient follow-up and special schooling 
is poor. A study on the long term outcomes of children with TBM demonstrated that less than half of 
post-TBM children with moderate to severe sequelae had access to specialist follow-up and the 
majority of patients in rural settings relied on private general practitioners due to poor accessibility to 
state hospital services 
56
. The majority of children attended mainstream schooling and more than half 
of these school-going children had failed at least once. The acute and long-term repercussions of 
TBM afflict not only the child, but also their family. Up to 35% of mothers cease to work in order to 
care for disabled children and those who maintain employment lose income for days spent taking their 
children for medical treatment. Family earnings are further compromised by additional expenses 
incurred directly due to the illness and its consequences. Sadly, most children presenting with TBM 
come from impoverished households to begin with and there is little capacity for the additional 
burdens this disease poses 
56
. Over 15% of paediatric TB admissions for long-term hospitalisation are 
due to poor social circumstances where parents are unable to care for their children or comply with 
treatment 
94
. Poor access to clinics, difficulty finding supervision for other children and fear of losing 
income make regular clinic attendance challenging and contribute to poor compliance, potential 
relapse and acquired drug resistance 
94
. The cost to the country in the form of medical expenses for 
acute and outpatient care, welfare grants as well as the loss of economic productivity due to disability 




CHAPTER 3: RADIOLOGICAL FEATURES OF TUBERCULOUS 
MENINGITIS 
 
Due to the limitations inherent in CSF TB culture, the decision to initiate treatment rests on the 
presumptive diagnosis, which is based on a combination of history, clinical examination, CSF 
chemistry and radiography. Due to the risk of transtentorial herniation associated with lumbar 
punctures in patients with non-communicating HCP, imaging prior to a lumbar puncture is clinically 
prudent and may aid in safe patient management as well as diagnosis 
112
. The value of computed 
tomography (CT) brain scans and magnetic resonance imaging (MRI) in the diagnosis of TBM is well 
recognised 
49,64,69,152,153
 and a recent consensus document includes radiographic features of TBM as a 
key factor in the presumptive diagnosis 
69
. Several radiographic studies of TBM have identified 
features highly suggestive of the disease on CTB and MR imaging, including hydrocephalus (HCP), 
periventricular lucency, basal and leptomeningeal enhancement, infarcts, and tuberculomas. The 
presence of HCP, enhancement and infarcts is considered a diagnostic triad in this disease 
152
. The 
role of vasculitis in TBM has led to angiographic studies which detail pathology in the major vessels 
of the Circle of Willis and deep perforators that arise from these vessels. Dissemination of TB into the 
spinal canal also occurs in association with TBM and commonly reported radiological features 
include spinal arachnoiditis and tuberculomas.  Radiological follow up in the weeks and months after 
the initiation of treatment provides valuable information about the resolution or progression of this 
disease and the development of new complications that may require intervention.     
The definitions and severity of radiological features in TBM vary across studies and currently no 
uniform guidelines exist. Some groups have adopted detailed objective criteria while others have 
relied on the experience of the reviewing radiologists. Additionally, some groups have access to more 
sophisticated imaging technologies than others. While this makes the generalizability of specifics 
challenging across studies, the overwhelming presence of classic radiological features allows for an 
adequate overview of TBM radiology combining the available literature. Although this project 
focuses specifically on paediatric TBM, much of the literature on the radiology of TBM reports on 
combined adult and paediatric cohorts. Consequently, this review chapter covers both adult and 
paediatric data with an emphasis on children where possible. Table 3.1 outlines the frequency of key 
radiological features across studies discussed in this review. 
CT and MRI 
CT scans provide valuable information in TBM and are widely used in TBM diagnosis and in 
planning acute HCP management. In most centres it remains the first imaging modality in the clinical 
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management of patients. MRI has increasingly become part of routine care in many centres 
internationally for several reasons. Unlike CT, MRI does not involve radiation, and there is a growing 
body of literature that has raised concerns about the long term risk of inducing cancer and cognitive 
deficits after exposure to excessive CT-radiation in children 
154,155
. A study comparing CT and MRI 
scans in paediatric TBM found that MRI is more sensitive in detecting the number, location and 
temporal resolution of infarcts with DWI demonstrating the greatest sensitivity for acute infarcts 
156
. 
MRI also better detects enhancement involving the basal cisterns, leptomeninges and cranial nerves 
due to better contrast resolution, multiplanar imaging and the lack of bony artifact. More 
tuberculomas are also detected 
156,157
. Specialised MR sequences including fluid-attenuated inversion-
recovery (FLAIR), diffusion weighted imaging (DWI) and apparent diffusion coefficient (ADC) 
mapping add further value. For these reasons, MRI is the preferred imaging technique in these 
patients; however, limited access to MR technology as well as the need for sedation or anaesthesia in 
children limits access to this imaging modality. Therefore, CT scans remain an important tool, 
especially in resource-limited settings where TBM occurs most frequently. It performs equally well in 






HCP occurs in as many as 80% of patients with TBM 
45,47,49,64,114-118
 and can be more common and 
more severe in children 
24,118
. HCP is of two forms; communicating HCP (CHCP) if the obstruction to 
CSF flow by the exudate occurs in the subarachnoid space, mostly at the level of basal cisterns, and 
non-communicating HCP (NCHCP) when the obstruction occurs at the outlet foramina of the 4
th
 
ventricle at the cerebral aqueduct, caused by the circumferential compression of meningeal exudates, 
mesencephalic oedema, intraventricular exudate or the presence of a tuberculoma 
22,112
. Occasionally 
exudate occludes the foramen of Monro, which leads from the lateral ventricles to the third ventricle. 
Although NCHCP occurs less frequently (12-25%) 
45,64,158
, determining the nature of the HCP has 
important implications for the appropriate management of intracranial pressure (ICP): lumbar 
punctures (LPs) in the context of NCHCP can create a pressure gradient across the foramen magnum 
and result in hindbrain herniation (coning) 
112
. These patients cannot be treated medically with serial 
LPs and require neurosurgical intervention. Accurately differentiating between the two forms of HCP 
is not usually possible by examining brain imaging and requires further investigations including an air 
encephalogram or column test 
112,120,159
 and the ICP cannot be estimated based on ventricular size in 
childhood TBM 
64
. Periventricular lucency indicates interstitial oedema as a result of the 
transependymal movement of CSF in response to increased intraventricular pressure 
24
, and is 
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considered a marker of acute HCP. It occurs commonly in TBM 
160
, usually in association with severe 
HCP 
118
. Several definitions of HCP focus primarily on ventricular dilatation 
114,160
, others have 
incorporated periventricular lucency and surface sulcal effacement 
64
 as well as clinical signs of raised 
ICP 
161
, allowing for a broader characterisation of HCP severity. 
Evolution 
HCP in TBM is characterised by its progressive nature 
24
. At admission it may range from mild to 
severe 
47,118
 and is more commonly seen in patients with a long duration of symptoms before the onset 
of treatment 
118,160,161
. Medical treatment for CHCP has been shown to resolve HCP in approximately 
two thirds of cases but more than one third of patients may fail medical treatment and require 
ventriculoperitoneal shunting (VPS) by 1 month post-admission 
22,64,114,152
. HCP may persist or 
develop where there was no baseline HCP in up to 20% of patients for 6 months after treatment 
commencement 
160,161
. This highlights the importance of follow-up imaging to identify patients in 
need of surgical intervention to control HCP and raised intracranial pressure. Complete HCP 
resolution may take from 3-6 months or longer 
160,161
 and steroids do not significantly improve HCP in 




Markers of inflammation have shown mixed associations with HCP. In a study by Thwaites et al CSF 
protein, interferon-  (IFN- ), interleukin-6 (IL-6) and interleukin-10 (IL-10) concentrations were 
significantly associated with HCP after 60 days 
114
. However, in a study by Misra et al their panel of 
cytokines did not demonstrate a relationship with HCP at baseline or after 3 months, although the 
sample size of this study was small 
162
. HCP is associated with a longer duration of illness and 





contributes to a depressed level of consciousness due to raised ICP and is significantly associated with 
focal neurology and visual impairment 
160
. Unresolved HCP and raised ICP are also important causes 
of seizures in paediatric TBM 
163
. Radiologically it is associated with the presence of basal exudate, 




The association between HCP and outcome is mixed; several studies have concluded that no 
association exists 
47,64,158
. In part this may be explained by the varying descriptions of the severity of 
hydrocephalus, the difficulty in predicting ICP from ventricular size, and variable approaches in 
treating hydrocephalus. However,  two studies focused specifically on HCP have found that patients 





both these studies patients with HCP relative to those without HCP were characterised by a longer 
delay in the initiation of treatment and more severe disease including a greater number of infarcts. 
Neither study stratified outcomes as a function of the severity of HCP at admission or during the 
disease course. In a paediatric study covering 20 years of TBM admissions, HCP and periventricular 
lucency were associated with outcome in univariate but not multivariate analyses 
45
. In another study 
spanning 10 years, mortality was significantly higher in those patients for whom HCP was not 
successfully treated 
164
. The delay in presentation, severity of HCP, degree of success in HCP 
treatment 
22
 and the severity of illness including the concomitant presence of infarcts 
165
 likely all 
have some bearing on this relationship.  
Enhancement 
Enhancement is present in up to 93% of admission scans and may be visible in the basal cisterns, the 
Sylvian fissure, the tentorium, around the optic chiasm, over the cerebral convexity, and (with 
extension of disease into the ventricular system) in the ependyma and choroid plexus 
24,45,114,115,117,118,158,166,167
. Occasionally it affects the cerebellar sulci and cranial nerves 
166
. 
Enhancement is likely due to meningeal inflammation and the presence of an enhancing gelatinous 
exudate or granulation tissue in the subarachnoid space 
168
. Enhancement is best identified on 
contrast-enhanced CT and T1-weighted MR scans and the typical pattern is considered one of the 
most sensitive features of TBM 
153
. Pre-contrast hyperdensity in the basal cisterns is a highly specific 
feature of TBM and is identified as obliterated basal cisterns on non-contrast CT scans 
24,153
. To 
overcome the subjective variability in characterising basal enhancement objective criteria have been 
proposed by Przybojewski et al: the most useful criteria include enhancement at the suprasellar and 
middle cerebral artery (MCA) cistern, linear enhancement in the MCA cistern, obliteration of the 
basal cisterns and asymmetrical enhancement 
168
.  Enhancement in TBM is generally diffuse but may 
be focal in less than 10% of cases and involves the Sylvian fissure, cistern of the lateral fossa, ambient 




The evolution of enhancement is variable; some follow-up scans show improvement or no change but 
up to 28% of scans may demonstrate new or progressive enhancement after the first month of 
treatment 
64,152,158
 usually with resolution by 6 months 
64,158
. Early enhancement may be limited to the 
basal meninges while obliteration of the basal cisterns and extension into the Sylvian and hemispheric 
fissures and over the cortical surface of the brain may signify progressive disease 
153,168
. The presence 
and progression of enhancement is considered to add confidence to the diagnosis of TBM as this is 
such a characteristic feature of this illness 
152
. The beneficial effect of steroids on enhancement is 
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uncertain: a significant decrease has been reported in children 
101
 but no change in the degree or 
duration of enhancement has been found in adults 
114
. 
Associations and marker of prognosis 
Basal enhancement is seen more commonly in children 
118
 and is associated with a poorer response to 
medical treatment for raised ICP and more severe stage of TBM 
64
. Moderate to severe enhancement 
has been associated with more basal ganglia infarcts and poorer clinical (motor and visual) and 
cognitive outcome 
47,64,118,158
. It is suggested that basal enhancement may therefore reflect the 
underlying vasculitis which is the primary cause of poor outcome 
64
; however, the relationship 
between exudate and angiographic abnormalities is variable and may reflect timing in the disease 
course 
116,118,169
. Furthermore, the intensification of enhancement is contended to signify an ongoing 
inflammatory response 
64
; however, a significant association between exudate and inflammatory 
cytokines and chemokines has also not been demonstrated 
114,162
. Cytokine associations with various 





Infarcts are reported in 30 to 60% of adult and paediatric patients with TBM, ranging from small 




Ischemia resulting in infarcts is the major source of irreversible damage in TBM. Periarteritis of the 
cerebral vessels surrounded by exudate progresses to panarteritis and vascular occlusion, most 
commonly affecting the medial branches of the middle cerebral artery (MCA). This results in infarcts 
in the head of the caudate nucleus, anterior limb of the internal capsule and the anteromedial thalamus 
– considered the ‘tubercular zone’ 176 due to the high incidence of infarction in these areas 
24,49,64,114,116,118,166,169,173,174,177
. The large vascular distribution territories of the MCA and anterior 
cerebral artery (ACA) are less frequently affected but complete occlusion leads to grey and white 
matter infarcts 
64,166,169,178
. In both adult and paediatric studies most infarcts occur within the basal 
ganglia, although extension of infarcts to cortical and watershed areas is also seen. The posterior 
circulation is thought to be less affected by ischemia ; however, infarcts in the cerebellum and 
midbrain have been described in adults 
166,169,173,174
 and have been reported  in 37- 47% children with 
TBM in whom they occur in the cerebral peduncles, pons, brachium ponti and midbrain 
117,179
. These 
lesions are likely also due to exudate coating the basilar artery and its branches and appear to be 
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associated with more severe clinical presentation and poorer outcome 
117,179
. Infarcts may be single or 
multiple, unilateral or bilateral 
169,174,175,178
.  
DWI detects acute infarcts earlier and estimates infarct size with greater accuracy than conventional 
T2-weighted MRI. It is suggested that this technique is superior in detecting evolving ischemia within 
hours after the onset of the ischemic process 
167
. It has also been used to detect borderzone necrosis - 
areas of infarction immediately adjacent to or underlying areas of severe exudate or cisternal and 
meningeal inflammation 
180
. Acute and subacute infarcts appear hyper-intense on DWI and T2-
weighted imaging with possible hypointensity on T1-weighted images. They may be associated with 
peri-lesional oedema or mass effect. Chronic infarcts appear iso- to hypo-intense on DWI and T1-
weighted and hyperintense on T2-weighted imaging 
167
.  Fluid-attenuated inversion-recovery (FLAIR) 
imaging assists in characterising old infarcts which have a central hypointense area surrounded by a 
hyperintense rim 
24
. On CT old infarcts appear as hypodense lesions. Chronic infarcts are often 
associated with ipsilateral dilatation of the anterior horn of the lateral ventricle, due to tissue loss 
28,118
. 
Infarcts may undergo hemorrhagic transformation 
166,175
; however, this is less common and rarely seen 
in children. More commonly a pattern of luxury perfusion in the infarcted territory may be seen. 
Evolution 
Infarcts may be poorly demonstrated on admission scans 
114,152
, especially on CT; MRI and DWI may 
be more sensitive in this early phase 
152,176
. Infarcts not present on admission imaging are identified on 
follow- up scans in 22-48% of children and adults, suggesting that the disease process is ongoing 
despite treatment and that the injury is evolving 
64,114,152,152,158,175
. There are little data available on the 
temporal profile of infarct development in the acute phase when patients are at greatest risk. A 
paediatric study using CT showed infarct development within one week of the initial scan 
152
 and a 
DWI study in adults found that 90% of infarcts within the first 7 days were of the acute/subacute 
nature 
167
. In a study of imaging at 6 weeks, 3 months and 6 months after admission, new infarcts not 
present on initial imaging were detected on scans at 6 weeks with no further development observed on 
the 3 and 6 month scans 
158
 suggesting that patients are at greatest risk during the early weeks of 
illness. Trials with adjunctive steroids and aspirin in adults and children have not shown a statistically 




Infarcts have been associated with other radiological features of TBM including HCP 
175
 and exudate 
166,173,175
, although there is some variability across different studies 
174,177
. Infarcts have also shown 
mixed associations with markers of inflammation; significant associations are reported with a reduced 
CSF/blood glucose ratio, elevated IL-8 and IL-10 concentrations and greater impairment in the blood 
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brain barrier (BBB) 
114
; however, this is not consistent across studies 
162
. Among CSF findings only 
neutrophil levels demonstrate an association with infarction and it is suggested that this may be 
indicative of occult vascular thrombosis in the early stages of disease 
173
. They are associated with 
hypertension 
175
, and more severe disease on admission according to BMC staging 
167,173-176
, and 
raised intracranial pressure 
177
. The association with admission Glasgow Coma Score (GCS) is mixed 
174,177
. While infarcts are significantly associated with focal neurology 
174,177
 and may result in seizures 
and EEG abnormalities 
163
, they may in some patients be clinically silent 
117,169
. The association with 
age in adult and paediatric studies is mixed with some evidence supporting an increased risk with age 
>25 years 
174
 and other evidence finding no association at all 
173,177
. Infarcts and sex are not related in 




Infarcts have a strong association with poor outcome, including mortality, neurological deficits, 
cognitive impairment, and neurodevelopmental delay 
45,47,101,158,167,169,173,175,177,178145
. This relationship 
may vary based on regional infarct localisation (with poorer outcome seen with subcortical MCA and 
posterior circulation infarcts 
174,175,178
 and focal motor deficit correlating well with infarct location 
177
), 
infarct size (with lacunar infarcts correlating with better outcome than large lesions 
176
), infarct 
number (with multiple territory infarcts heralding a worse prognosis 
174,178
) and as a function of time 
(with some patients improving over the long term). Factors other than infarction, such as duration of 
illness, HCP and raised ICP also have significant roles to play in determining outcome 
175
. Infarcts, 
however, remain an important prognostic indicator in TBM.  
Vascular pathology 
The vessels of the Circle of Willis traversing the basal cisterns are at greatest risk of injury due to the 
accumulation of exudate at the base of the brain; the supraclinoid portion of the internal carotid (ICA), 
the MCA and ACA are commonly affected with the MCA and its lenticulostriate perforators being 
most compromised, likely due to the high prevalence of exudate in the basal cisterns and Sylvian 
fissure. Involvement of the posterior circulation, namely the posterior cerebral artery (PCA), 
cerebellar, basilar and vertebral arteries, occurs less frequently but may occur in conjunction with or 
independently of pathology in the anterior circulation 
116,166,169,177,178
. Vascular abnormalities detected 
on MR and CT angiograms include paucity of terminal branches, irregular beading and segmental 
attenuation of major vessels, complete vascular occlusion and very rarely aneurysms  
167,176,177
. This is 
as a consequence of the inflammatory exudate which subjects the arteries to evolving stages of 
arteritis of the vessel wall (infiltrative, proliferative and necrotising) followed by fibrinoid necrosis of 
the vascular endothelium and secondary thrombus formation or aneurysmal dilatation 
176,177
.  Infarcts 
are considered a result of cerebral hypoperfusion due to a variable combination of vasospasm, 
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proliferation of the vessel intima and thrombosis 
176
. HCP may further compromise vascular integrity 
by precipitating stretching of already compromised vessels 
116,169,176,181
. Abnormalities on MR and CT 




There is little available literature on follow up angiograms. A study by Sing et al demonstrated that 
angiographic abnormalities persisted for longer than 6 months in 82% of patients who had baseline 





Evidence of vascular pathology is present on the angiograms of 70-90% of TBM patients with infarcts 
169,182
. Therefore, approximately 10-30% of these patients with infarcts do not demonstrate vascular 
abnormality; this may due to limitations of angiography or highlights that other factors are also 
responsible for brain tissue injury, these are discussed in Chapter 4. Additionally, up to one third of 
abnormal angiograms are not associated with infarction. It has been suggested that vessel narrowing 
in these patients may be related to vasospasm early in the pathophysiology of the disease 
118
. Timely 
intervention to treat the vascular pathology in this group of patients could prevent the development of 
infarcts 
166,169,182
. However, although MR and CT angiography offer a non-invasive means of 
assessing vascular abnormalities they are not routinely performed in TBM. Furthermore, how these 
angiographically-detected pathologies should be treated is uncertain. 
MRA abnormalities are also associated with HCP 
116,169,182





and leptomeningeal enhancement 
116
. Variable associations have been demonstrated with exudate 
116,118,169
. Early vasospasm may not be associated with exudate but more progressive disease often 
involves increased accumulation of exudate and vasculitis 
118
. Associations with BMC stage have also 
been mixed 
116,169,182
; small vessels may be involved during the early phase of disease and larger 
vessels in later phases, although this requires further investigation 
169
. This variability may be due to 
patient heterogeneity and the diversity of factors which could precipitate vascular injury 
169
. In largely 
adult studies no associations have been demonstrated with age or sex, nor with admission GCS, CSF 
characteristics or duration of illness 
116,169,181
. Angiographic abnormalities have been reported more 









Angiographic abnormalities have not shown a significant relationship with outcome. The fact that not 
all infarcts are associated with angiographic abnormality and not all angiographic abnormalities are 
related to infarcts suggests that there are other factors responsible for infarction and an isolated 
angiographic abnormality is not necessarily indicative of a bad outcome. Where disturbed 
angiography is associated with poor outcome like motor impairment or focal neurology this is 
probably mediated by infarction. Neither infarcts nor vascular pathology on angiography are 
associated with admission GCS; this may be due to their evolving nature whereas a depressed level of 
consciousness on admission may more likely be a consequence of more immediate factors like raised 
ICP and electrolyte imbalance.  
Parenchymal Tuberculomas 
Cerebral tuberculomas are the most common extra-pulmonary tuberculous lesion that present 
clinically 
183. These may account for the genesis of TBM through the rupture of the Rich’s focus. 
These intracranial granulomas account for a large portion of intracranial non-neoplastic lesions in TB 
endemic areas and sometimes can be difficult to discern from brain tumours 
184
.   
Location 
Tuberculomas present as single or more frequently as multiple lesions of varying sizes 
163,185
. They are 
reported to most commonly arise supratentorially in adults and infratentorially in children 
163,185
 and 
may occur in the brain parenchyma, ventricular ependyma and frequently in association with areas of 
meningeal inflammation including the region of the basal cisterns, surrounding the vessels of the 
Circle of Willis and in the Sylvian fissures 
137
. A paediatric study found that all parenchymal 
tuberculomas present on admission were associated with a miliary TB pattern on chest x-ray which 
suggests seeding to the central nervous system, while the vascular distribution of tuberculomas 
supported hematogenous spread of TB bacilli to the brain  
137
. Their radiological appearance differs 
depending on whether they are solid, noncaseating or caseating with a solid or liquefied centre. Non-
caseating lesions appear hypo/isodense and enhance homogenously with contrast on CT and T1-
weighted imaging, and hyperintense on T2-weighted images. Solid, caseating tuberculomas are 
usually iso- to hypointense on CT and T1-weighted images, identified by ring enhancement with 
contrast or gadolinium MR and appear iso/hypointense on T2. Liquified centres demonstrate marked 
ring enhancement on contrasted CT and T1-weighted images and are hyperintense on T2-weighted 
images. Differentiating these tuberculomas from abscesses of tuberculous or pyogenic origin can be 
challenging, DWI has shown promise in differentiating between cerebral abscesses and tuberculomas 
42






The presence of tuberculomas on admission scans varies from 11-64% of adults and children with 
TBM 
45,49,64,101,114,137,158,160,185
. These may resolve within the first month of treatment 
64
 but 
tuberculomas are commonly observed several weeks and up to 6 months after the initiation of 
treatment, during which time established tuberculomas may enlarge and new tuberculomas develop 
49,114,137,183,185. These have been termed as ‘paradoxical’ tuberculomas and described as a phenomenon 
which may occur as a result of antimicrobial destruction of the mycobacteria and the consequent 
release of bacillary debris which precipitates a hypersensitivity reaction and an excessive ongoing 
inflammatory response as part of immune reconstitution
24,183
. They usually do not present 
symptomatically except in the rare circumstance where their size and location may precipitate CSF 
obstruction, localising signs or seizures, and are consequently often incidentally discovered during 
follow-up imaging 
64,114,137,163
. Tuberculomas may take  6 months 
64




Tuberculomas have been associated with IL-6 and IL-10 concentrations after 60 -90 days of treatment 
which may indicate enhanced immune reactivity 
114,185
. An association with elevations in CSF white 
cell count and protein has been reported but findings are mixed 
162,183
. Tuberculomas may precipitate 
seizures and abnormalities on EEG 
163,185
 and are associated with focal deficits 
185
. An association 
with the presence 
185
 and persistence of basal enhancement has been observed, suggesting that 
meningeal tuberculomas appear to develop in areas of meningeal inflammatory intensity 
137
. No 




Generally tuberculomas resolve without many significant residual signs on CT and little bearing on 
mortality after 6-9 months 
47,64,185
. An association with cognitive impairment and tuberculomas at 6 
months has been reported 
158
 and disability may be significantly worse when they are located in the 
frontal and temporal lobes, the brainstem or optic chiasm 
185
. 
Parenchymal TB abscesses 
TB abscesses are rare complications of CNS TB. They are radiologically very similar to caseating 
tuberculomas although they may be larger with thinner walls, tend to be singular, and follow a more 
rapid disease course. They often present acutely with symptoms of fever, headache and neurological 
signs and may require urgent neurosurgical intervention 
24,138
.  
A summary of intracranial radiological features reported in the literature is provided in Table 3.1 at 
the end of this chapter. 
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Spinal TB associated with TBM 
The literature on intradural spinal disease associated with TBM is sparse. Studies comprise 
predominantly case reports or small series of less than 10 patients and no data on spinal disease in 
paediatric TBM has been published 
186
. What data exists suggests spinal involvement accompanying 
TBM in 18-24% of cases 
40,187
. However, most studies have focused on patients presenting with 
neurological deficits and investigation of asymptomatic TBM patients has not been widely conducted 
although spinal disease may be clinically silent. The prevalence of spinal disease in TBM patients 
may therefore be under appreciated. Spinal arachnoiditis is optimally identified on MRI with 
gadolinium as nodular, thick or linear enhancement with obliteration of the subarachnoid space, loss 
of the cord outline and clumping of nerve roots in the lumbar region 
40
. Spinal lesions, like 
intracranial tuberculomas, typically appear isointense on T1 and iso- to hypointense on T2 MRI 
images, depending on the stage of tuberculoma formation, and frequently occur in the thoracic region 
42,186
.  
Evolution and prognosis 
Intradural spinal disease may develop weeks to years after the onset of TBM. Analogous to the 
appearance of ‘paradoxical’ intracranial tuberculomas, expansion of TBM to the spinal compartment 
may occur weeks after antimicrobial and steroid commencement and it is suggested that this too may 
be the result of a strengthened immune response and increased antigen release following treatment 
186
. 
Spinal arachnoiditis is often asymptomatic, possibly because the exudate does not always disturb cord 
and nerve root function 
40
. However, in some cases more severe spinal disease may progress to motor 
and sensory deficits: mass lesions may cause spinal cord compression 
42
, chronic arachnoiditis may 
result in axonal damage, peripheral nerve injury and neuropathies, and vasculitis may cause infarction 
188
. Response to treatment in these cases is often poor 
38,40
. Syringomyelia can develop as a 
consequence of focal scarring in the subarachnoid space which inhibits CSF flow and forces CSF into 
the central canal. Focal cystic dilatations may amalgamate to form a CSF-filled syrinx 
24,189
. These 
patients may present with limb weakness and sphincter dysfunction 
189
. The benefit of steroids for 
intradural spinal disease remains inconclusive and surgical intervention is only recommended under 




Chest x-rays are suggestive of TB in 29-72% of patients with TBM 
45,49,67,161,163,187,190
 and demonstrate 
mediastinal lymphadenopathy, consolidation, collapse, cavitation and pleural effusion 
45,49
. A miliary 
pattern has been reported in 12-60% of TBM patients 
4,45,49,187,191
 and occurs more commonly in young 





Effect of HIV status 
Studies in adults and children comparing the CT and MRI features of TBM patients based on their 
HIV status have found that basal enhancement, non-communicating HCP, and parenchymal 
tuberculomas occur more frequently in HIV-uninfected (HIV-) patients 
192-194
. HIV-infected (HIV+) 
patients demonstrated little exudate formation after the initiation of anti-TB medication and a greater 
frequency of ventricular dilatation secondary to cerebral atrophy, 
192-194
. The paucity of basal 
enhancement and parenchymal tuberculomas on imaging has been confirmed in post-mortem brain 
studies, and it has been suggested that the relative absence of these features in HIV+ individuals may 
represent an impaired granulomatous inflammatory response as a result of immune suppression 
193,195
. 
However, even in the context of no immune suppression (age-appropriate CD4 count) in HIV 
infection, basal enhancement may still be absent suggesting that other factors may exist 
194
. The 
influence of HIV status on the number of infarcts remains unclear 
193-196
. HIV presents the additional 
challenge of immune reconstitution syndrome (IRIS) whereby the recovery of the immune system 
after anti-retroviral treatment initiation results in paradoxical worsening of TB. Neuroradiological 
manifestations include tuberculomas, radiculomyeltits, and spondylitis; however, sample sizes studied 




Radiological features of TBM including HCP, basal enhancement, infarcts and tuberculomas occur 
commonly and aid in swifter diagnosis and initiation of appropriate management strategies. They also 
serve as indicators of injury severity. Common admission features include acute HCP with peri-
ventricular lucency and basal meningeal enhancement on contrasted scans. Imaging findings illustrate 
the evolving and chronic nature of TBM with baseline pathology persisting over time accompanied by 
the evolution of new signs of disease. Follow up scans within the weeks and months following 
admission are required by the frequent occurrence of new pathology and evolution of existing 
pathology. Even in the face of clinical improvement radiological pathology may persist. The value of 
radiology is, however, limited by temporal resolution and usually demonstrates parenchymal injury 
once it is already irreversible. 
Variability in the prevalence and severity of radiological features of TBM across the literature is a 
function of several factors: firstly, currently no widely accepted review criteria exist; secondly, the 
progressive nature of this disease and variable timing of imaging relative to the onset of disease 
makes comparisons across patients challenging; and thirdly, access to imaging techniques like MRI is 
limited and direct comparisons between CT and MRI findings are limited. While MR technologies 
offer greater sensitivity and specificity in recognising and quantifying the features of TBM, CT scans 
remain a valuable tool in the diagnosis and long term management of these patients, especially in 
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resource-limited settings. Similarly, the large variability in the prevalence of radiological features 
within adult and paediatric cohorts makes it difficult to highlight particular radiological differences 
between these two patient groups. Perhaps the most striking difference in contexts where HIV and TB 
are endemic is the substantially lower HIV infection rate in children in whom less radiological 
variability is seen as a result of differing levels of immune suppression and reconstitution. 
Potential radiological sequelae of TBM include encephalomalcia, syringomyelia and syringobulbia. It 
is challenging to identify the prognostic significance of individual radiological features as each feature 























    Adm 
 
FU Total Adm FU Total Adm FU Total Adm FU Total 
Paediatric 
cohort 
               
Schoeman et 
al (1988) 
27 MRI x   100   100   74   11 
Leiguarda et 
al (1988)* 
65 CT x   89   69   38   28 
Schoeman et 
al (1994) 
198 CT Variable 83 x  75 28A  31 22  11 2 13 
Patwari et al 
(1996) 
136 CT x   32      13   27 
Andronikou 
et al (2004)* 
37 CT x   68   89   62   13.5 
Farinha et al 
(2000) 
33 33 Not 
specified 
94 x 94 93 x 93 33 17 50 15 18† x 
Paganini et al 
(2000)* 
40 CT x   78   25   5   x 
Ravenscroft 
et al (2001)* 
202 CT             17 
Andronikou 
et al (2005) † 
50 CT 1 week x 25  88 10  60 40     
   1 month x 28  88 20  60 48     
Theron et al 
(2006)* 
130 CT x   73   x   x   x 
Przybojewski 
et al (2006) 
34               
Andronikou 
et al (2006)* 
118 CT x         57    
Van Well et 
al (2009)* 
553 CT x   70   75   32   13 
Van der 
Merwe et al 
(2009)* 
30 MRI x         47B    
Pienaar et al 
(2009)* 
30 CT x   77   70   70   17 
  MRI x   77   97   83   40 
Ramzan et al 
(2013)* 
65 CT x   72   60   29   9 
                
Mixed 
cohort 
               
Bhargava et 
al (1982) 
60 CT x   83   82   28   10 
Kinglsey 
(1987) 
25 CT Variable 72 12 84 64 32†C x 12 20D 32 16 12E 28 
Gupta et al 
(1994) 
26 MRI x 73   85   54   65   
Ranjan et al 
(2003) † 
31 CT 6 weeks 48 26  48 23  32 19  42 10  
   3 months 48 16  48 45  32 19  42 6  
   6 months 48 3  48 -23  32 19  42 -13  
Ahmadinejad 
et al (2004) 
96 CT x 80            
Kalita et al 
(2009) 
122 MRI x 39   26   45   49   
                
Adult cohort                




Koh et al 
(2007) 
43 CT/MRI x       21F      
Thwaites et 
al (2007) 
43 MRI 60 days 77 -10  82G x  9 32  64 10  




x   47   90   57   73 
Anuradha et 
al (2010) 
100 MRI Not 
specified 
31   94   27 3 30 38   
Anuradha et 
al (2011) 
110 MRI X 31   88   25   39   
Singh et al 
(2012) 
47 CT  77   96H 
62I 
  41   17   
Raut et al 
(2013) 
80 MR 6 months 65 28†  93H 
53I 
x  33 x  39 x  
                
                
Adm = admission scan, FU = follow-up scan, Total = combination of admission and FU scans where features on FU were 
new and not present on the admission scan. Data presented as percentages rounded up to the nearest whole number, follow-
up percentages calculated based on the number of patients with follow up scans. Adults defined as > 13 years. 
* Timing of scans not specified, † Follow up percentages reported as a combination of deterioration of baseline features and 
new feature development and are therefore a representation of change over time. Negative values indicate improvement 
A Only represents deterioration of baseline enhancement, no new enhancement reported, B Brainstem infarcts, C Follow up 1-
96 months, D Follow up at 2 weeks, E Follow up 5-7 months, F Within first week post-admission, G includes enhancement of 








CHAPTER 4: ISCHAEMIA AND BRAIN OXYGENATION IN TBM 
 
Ischaemia plays a pivotal role in the poor outcomes associated with TBM. Infarction is common in 
these patients and a strong prognostic indicator for poor outcomes including disability and death 
45,47,101,145,158,167,169,173,175,177,178
. Currently, no effective diagnosis or treatment of threatened infarction 
exists, and ongoing brain injury occurs despite full treatment with anti-TB medication and adjunctive 
steroids. Other cerebral pathologies like traumatic brain injury have incorporated monitors of brain 
oxygenation into patient management and have demonstrated the value of such monitors in detecting 
and potentially mitigating secondary ischaemic brain injury 
198-200
. This chapter outlines briefly the 
factors contributing to ischaemia and poor brain oxygenation in TBM and introduces two monitors of 
brain oxygenation which may have utility in diagnosing and monitoring brain oxygenation 
compromise in TBM. 
Factors precipitating ischaemia and poor brain oxygenation 
Ischaemia is the common end-point of two important complications resulting from TBM; HCP 
associated with raised ICP and cerebrovascular injury. Both of these complications are thought to 
result from the formation of a thick basal exudate which blocks the flow of CSF precipitating HCP, 
and coats the cerebral vessels resulting in vessel pathology (discussed in Chapter 1). Elevated ICP can 
cause brain herniation due to pressure gradients created within the cranial cavity and compromises 
cerebral perfusion 
201,202
. Brain oxygenation decreases as cerebral perfusion compromise leads to 
progressively reduced CBF (especially below 18mls/100g/min) and subsequent metabolic dysfunction 
203-205
. Exudative coating of the cerebral vessels causes a local inflammatory response in the vascular 
wall resulting in infiltrative, proliferative and necrotising vascular pathologies which may result in 
vasospasm in the early stages of disease and vascular occlusion in more advanced cases 
30
. The basal 
location of the exudate and predilection for the Sylvian fissures places the major vessels of the Circle 
of Willis, their branches and perforators at risk of vasculitis. Cerebrovascular injury is likely to result 
in either focal ischaemia, due to individual vessel involvement, or general ischemia as a result of 
decreased cerebral perfusion pressure respectively 
112
. 
Other factors which may also contribute to compromised CBF or poor brain oxygenation include 
hemodynamic disturbances like the loss of pressure autoregulation and vascular reactivity due to 
cerebral infection 
206
. When pressure autoregulation is intact, an increase in mean arterial pressure 
(MAP) within the autoregulatory range will result in cerebral vasoconstriction and maintenance of a 
relatively constant CBF. Conversely, cerebral vessels vasodilate in response to a drop in MAP thereby 
allowing for increased flow. However, when pressure autoregulation is impaired cerebral vessels fail 
48 
 
to adjust their calibre to changes in systemic blood pressure and passively distend with increase blood 
pressures, causing increased cerebral blood volume and therefore raised ICP. Cerebral cell death due 
to bacterial toxins, the accumulation of oxygen free radicals and inflammatory cytokines, and poor 
cerebral perfusion is associated with cytotoxic oedema 
18,26,27,207
. Additionally, cerebral inflammation 
may disrupt the BBB, allowing the influx of proteins and water thereby facilitating vasogenic oedema 
18
. Both cytotoxic and vasogenic oedema further contribute to raised ICP as well as compromised 
brain oxygenation as transport of oxygen from the vessels into tissues takes place through diffusion, 
driven by partial pressure gradients. Increases in the diffusion distance of oxygen between the vessels 
and tissues due to oedema may compromise the diffusion of oxygen into the cells and potentiate 
ischemia 
208
. Inflammatory cytokines alter CBF, cerebral oxygen uptake, cerebral metabolism and 
lead to the uncoupling of metabolic demand and CBF 
209,210
. These patients are also at risk of a 
hypercoagulable state which may increase the risk of thrombosis 
106,176
. 
Brain oxygenation monitoring 
Several techniques are available for monitoring various aspects of brain oxygenation, including 
‘snapshot’ imaging of the brain like positron emission tomography (PET) scanning, which is the gold-
standard for measuring brain perfusion, and continuous methods including brain tissue oxygen tension 
(PbtO2) and near-infrared spectroscopy (NIRS). The ideal brain oxygenation monitor would provide 
accurate real time data on brain oxygenation which allows clinicians to respond immediately to 
episodes of hypoxia or ischaemia, would be responsive to interventions and enable the tailoring of 
treatment to suit the individual patient’s needs, and demonstrate sensitivity to the dynamics of other 
physiological variables like ICP 
211
.  Available brain oxygenation monitors measure various aspects of 
brain oxygenation and have variable strengths and limitations, and none has achieved widespread 
acceptance as yet. PbtO2 and NIRS differ in the physiological variables they measure and the physical 
principles used to measure them, but both have been used in a number of domains of neurocritical 
care and will be briefly introduced here. 
Brain tissue oxygen tension (PbtO2) 
PbtO2 is frequently used in the management of cerebral ischaemia 
200,211
. It involves inserting a thin 
catheter into the parenchyma and is considered safe, efficient, and sensitive to cerebral ischaemia 
200,212
. There are various suggestions of what PbtO2 represents; however, it may be considered a 
measure of the factors that affect the perfusion and diffusion characteristics of oxygen in brain tissue 
211
. Consequently, it is influenced by a number of factors including: 1) the systemic partial pressure of 
oxygen (PaO2 – also a measure of oxygen tension) in that increases in PaO2 will lead to increases in 
PbtO2 even if blood is fully saturated; 2) tissue barriers to diffusion, like oedema; 3) raised ICP which 
compromises cerebral perfusion pressure (CPP) and exerts local tissue pressure effects; and 4) arterial 
49 
 




Normal and threshold values have not been established in healthy humans; however, animal studies 
demonstrating normal values ranging from 25-30 mmHg have been confirmed in patients with normal 
ICP and CPP, in normal tissue of patients with brain tumours, and in patients who underwent 
temporary clipping of cerebral vessels 
212-218
. The risk of poor outcome increases as PbtO2 falls below 
20 mmHg 
219
 and values between 15 and 20 mmHg may be indicative of oligemia or cell damage 
198
. 
A PbtO2 threshold of 10mmHg has demonstrated the strongest association with outcome 
198,212,220,221
 
and is associated with ischaemic CBF thresholds and perturbations in brain function 
222-226
. Low 
PbtO2 values are independent and strong prognosticators of poor outcome and death after adult and 
paediatric head trauma 
198,227
. Currently there are no formal guidelines detailing indications for PbtO2 
monitoring in either adults or children, however maintaining PbtO2 >10mmHg is recommended for 




PbtO2 has been used extensively in paediatric and adult TBI and is associated with reduced mortality 
in these patients 
198-200,229,230





. The only available literature on PbtO2 in meningitis includes a case report of PbtO2-guided 
decompressive craniectomy in a patient with bacterial meningitis 
235
, and a case report from our 
institution on PbtO2 monitoring in TBM 
236
. In this case report one of the two TBM patients presented 
with severe TBM on admission and demonstrated a dramatic decline in PbtO2 levels from >25mmHg 
to 0mmHg within 17 hours after admission and catheter insertion. This occurred in spite of ICP 
control with an EVD and full treatment, suggesting that vascular insults may continue despite 
adequate patient management. The second patient presented with less severe TBM and also 
experienced a decline in PbtO2; however, this responded to immediate interventions aimed at 
increasing oxygen delivery and diffusion. These included adjusting ventilator settings to increase the 
inspired fraction of oxygen (FiO2) and the arterial CO2, fluid resuscitation to augment the CPP and 
blood transfusion to improve haemoglobin (Hb). The PbtO2 recovered to levels above 20mmHg 
within 5-6 hours and the patient went on to make a good recovery with no evidence of infarction on 
follow-up CT brain scan. This study suggests a role for PbtO2 as a monitor of brain oxygenation and 
the response to interventions in TBM. Although PbtO2 is a focal monitor and focal ischaemia in other 
locations may not be detected, the diffuse distribution of exudate and the large territory infarcts in 
TBM suggest that ischaemia is likely diffuse rather than exclusive to discrete foci 
236
. Furthermore, 




. PbtO2 does not, however, only reflect the balance between the supply and demand of CBF 
and brain oxygenation as it is influenced by other factors, such as diffusion through tissues. These 
need to be considered in the interpretation of PbtO2 data. 
Near-infrared spectroscopy (NIRS) 
NIRS provides an attractive means of non-invasive continuous brain oxygenation assessment 
available at the bedside 
238,239,239
. It has been used for somatic monitoring, for monitoring the normal 
brain at risk of injury during cardiac surgery 
240
, and in neurocritical care 
241
. NIRS uses optical 
technology based on the transmission and absorption of near-infrared light of multiple wavelengths as 
it passes through tissues. Oxygenated and deoxygenated Hb have different absorptive capacities for 
near-infrared light and, therefore, their relative concentrations can be used to calculate brain 
oxygenation. The NIRS sensors are applied to the scalp and the near-infrared beam investigates an 
area of approximately 2cm below the skull. 
Threshold values 
Research with an animal model established that a NIRS saturation (SO2) of 35% for longer than 2-3 
hours was associated with permanent neurological deficits 
238,239
. Normal values in humans are 
thought to be between 60% and 80% 
238,242,243
, however, baseline variation is as high as 10%. This 
high variability may be due to the fact that thresholds of SO2 at which ischemia develop seem to be 
individual and disease specific 
238
.  However, little human data exists to support particular absolute 
values as treatment thresholds and, therefore, fluctuations within an established individual or 
population range as well as trend analysis have been used as measures of compromised SO2 
244
. 
Computed indices of cerebral oxygenation obtained using NIRS, like the tissue oxygen index (TOI - 
the ratio of oxygenated to total tissue hemoglobin) have been used as measures of intracranial 
oxygenation, with their own defined thresholds 
240
. Normal values for TOI are considered to be in the 
range of 65% to 85% in adults. Studies in patients undergoing elective carotid endarterectomies 
showed that a change in TOI of -13% reflected a threshold for cerebral ischemia with a high degree of 
sensitivity and specificity 
245
. However, findings pertaining to TOI still require validation in other 
clinical contexts. NIRS is also used intra-operatively, frequently with cardiac surgery, where 20% 
deviation from an established baseline SO2 alerts surgeons to impending cerebral injury 
246,247
. 
Clinical application  
NIRS has been used as a monitor of brain oxygenation and CBF in paediatric TBI 
248
, impending 
cerebral ischaemia during surgery 
245-247
, cerebral autoregulation 
241
, in functional studies 
249
, in 
neonates with birth asphyxia 
244,250
, in assessing CBF changes in response to reductions in raised ICP 
associated with HCP treatment 
251





.  There are no known published studies on the use of NIRS in meningitis in humans, 
however, research in experimental models of meningitis have found NIRS to be a useful tool to study 




Concerns regarding the validity of NIRS as a monitoring device center on technical limitations. Near-
infrared light appears to penetrate the cortex only superficially, suggesting that the tissue sampled 
does not extend beyond grey matter. Penetration of infrared light may be distorted by the skull and its 
interface with multiple underlying layers which may create an optic channel, by contamination from 
ambient light or extracranial tissue perfusion, by light scatter, CSF, brain swelling, and skull 
thickness, although this is less of a concern in children with thinner skull bones 
238,255,256
. Additionally, 
defining the relative contributions of the venous, arterial and capillary compartments is challenging. 
Spatial–resolved spectroscopy has been developed to accommodate for the contribution of multiple 
vascular compartments 
245,255
, and further advances in NIRS technology have demonstrated improved 
NIRS reliability, including frequency domain NIRS which allows the calculation of light absorption 
and scattering, and facilitates the determination of oxygenated and deoxygenated Hb in absolute 
concentrations excluding extracranial contamination 
257
. 
The potential utility of PbtO2 and NIRS as monitors of brain oxygenation in TBM was explored as 








































CHAPTER 5: BIOMARKERS OF NEUROLOGICAL TISSUE INJURY 
IN CEREBRAL INFECTION 
 
Central nervous system (CNS) infections, including TBM, are an important public health concern 
worldwide as they occur commonly and are associated with high rates of mortality and morbidity 
258,259
. The resulting cerebral tissue injury accounts for most deaths related to CNS infections and 
stems from direct bacterial toxicity and consequences of the host inflammatory response including 
ischaemia 
26,27
. However, several uncertainties about the disease process remain because the 
pathogenetic mechanisms of tissue injury are still not fully understood. Quantification of the degree of 
cerebral injury is inexact: disease severity is commonly evaluated by the clinical status of the patient 
and radiological manifestations. Yet several factors, both reversible and irreversible, may contribute 
to the presenting neurological status, and imaging findings manifest late in the disease course once the 
damage is usually already permanent. Biomarkers to diagnose disease, quantify injury, and monitor 
progress are used frequently for other organ systems but their use in CNS pathology is in its infancy. 
Several studies have examined biomarkers of neurological tissue injury in different CNS pathologies 
which shed light on the underlying pathophysiological processes while they are occurring; however, 
data are sparse. This chapter reviews the available literature on neuromarkers S100B, NSE and GFAP 
in cerebral infection in general, as there are only a handful of studies published on TBM. 
Role of Biomarkers in CNS pathology 
Biomarkers are measurable objective indicators of normal function or pathology. They provide 
information about dynamic processes and pathogen activity that assist diagnosis, prognostication, and 
evaluation of treatment safety and efficacy. They can also act as surrogate markers for clinical or 
research end-points, such as the effectiveness of novel treatments 
260
. Their quantification is user-




Biomarkers for CNS pathologies are gaining increasing attention and are being investigated across a 
spectrum of acute and chronic CNS diseases 
265
. CNS infection, trauma, hypoxia, inflammation or 
degeneration results in cell damage and a collection of breakdown products in the cerebral 
extracellular fluid as well as increased permeability of the BBB. Diffusing along concentration 
gradients into the CSF and through a leaky BBB into the blood stream, these products become 
accessible measurable indicators of brain injury. The degree to which these biomarker levels are 
elevated reflects the severity of injury, the cell-specificity hints at the nature and potentially the 
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location of injury, and sequential sampling provides information about the evolution of the damage 
260,266,267
.  
The ideal biomarker for brain injury should demonstrate high sensitivity and specificity for the brain, 
their release should be associated with irreversible brain injury and reflect the temporal profile of that 
injury, they should appear rapidly in serum, demonstrate limited variability based on age and sex, and 
should be easily and speedily quantified by reliable assays 
268
. However, finding such an ideal 
biomarker for the brain presents many challenges. The brain is a highly complex and heterogeneous 
organ with multiple cell types, and disease varies both in form and severity. CSF is better than serum 
in reflecting changes in the brain, but is not always accessible. The size and amount of the biomarker 
infiltrating the blood stream is limited by the blood brain barrier (BBB), and so serum values may be a 
function of cell injury as well as the degree of BBB disruption, which commonly occurs in brain 
injury 
261
. Even in CSF variability exists; biomarker levels may be influenced by the distance between 
the affected area and the CSF compartment, regional variability of biomarker proteins in the brain and 
degradation by proteinases in the parenchyma or CSF 
269
. In addition, biomarker analysis is purely a 
quantitative measure which cannot reflect both the qualitative and quantitative functions of the brain 
270
. One way of overcoming some of these limitations is by using a panel rather than individual 
biomarkers and by combining these with clinical and radiological tools 
261,271
.  
Studies in traumatic brain injury (TBI) 
270,272





Alzheimer’s disease 275, stroke 267, cardiac arrest 276 and various other pathologies have found that 
although biomarkers of CNS injury do not currently form part of regular clinical practice, they hold 
promise as diagnostic and prognostic markers. Their role in infections of the CNS has generated less 
research. From the available studies, however, three key biomarkers with potential have emerged, 
namely S100B, neuron-specific enolase (NSE) and glial fibrillary acidic protein (GFAP). This chapter 
will focus primarily on these proteins but also briefly summarise studies on other potential 
biomarkers. 
Limitations of biomarkers 
Biomarker analysis is prone to some methodological pitfalls. The technique with which samples are 
collected has implications for their suitability, for example, hemolysed blood samples may be 
contamination by biomarkers released from erythrocytes 
277
. The collection tube may influence 
biomarker concentrations and tubes appropriate to the biomarker of interest should be used 
278
. 
Samples should preferably be stored at -70 degrees Celsius as early as possible to prevent antigen 
degradation, however this varies as a function of biomarker stability.  Multiple freeze-thaw cycles and 
prolonged storage can also lead to biomarker breakdown 
279
. Currently the primary method to test for 
biomarkers is the immunoassay, which demonstrates good sensitivity, is simple and inexpensive to 
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administer, and for which various kits are commercially available. This technology exploits the high 
affinity and specificity with which antibodies bind to their antigens ensuring that only the target 
antigen in a sample will bind even when it is present in very low concentrations and in the presence of 
many other analytes. Immunoassay plates are coated with antibodies for the biomarker of interest; 
when test samples are added to the plate the target antigen (biomarker) binds to the antibody and the 
degree of binding provides a measure of the biomarker present.  Since the interaction of antibody and 
antigen is not associated with a quantifiable physical or chemical change, the binding event is 
measured by an auxiliary reaction in which one of the immunoreactants is labelled with a substance 
that can easily be detected by spectrophotometry 
280
. Platforms differ based on the antibody and label 
used to detect the antibody-antigen binding; commonly used options include enzymes (enzyme-linked 
immunosorbent assays [ELISAs]), radioisotopes (radioimmunoassays [RIA]), fluorophors 
(immunofluorometric assays), and chemiluminescent compounds (chemiluminescence immunoassay). 
Electrochemical immunoassays, which are label-free and rely on changes in charge densities or 
conductivities to detect antibody-antigen binding, are also becoming increasingly available 
280-282
. 
Upper and lower detection limits are variable for different assays and therefore comparison of 
reference values and pathology-related measurements across testing platforms is challenging, 
highlighting the need for the establishment of standardised operating and testing procedures. Large-
scale multi-centre trials would enable accumulation of sufficient samples for well-powered studies to 
establish standards, reference ranges and appropriate disease-specific cut-off values.  Much biomarker 
work is still confined to dedicated laboratories or projects; however, the true translation of biomarkers 
from bench to bedside requires the development of rapid, user-friendly, technologically undemanding 




S100B belongs to the larger S100 family of small acidic proteins approximately 10-12 kDa in size and 
composed of subunits A and B 
283
. These proteins regulate intracellular processes including cell 
growth, transcription and differentiation. The extracellular concentration of S100 proteins determine 
their activity; at nanomolar levels they have trophic effects while at micromolar levels they may cause 
cell damage and apoptosis. In the CNS, subunit B is found in highest concentration 
283
 and is 
synthesized by astrocytes, oligodendrocytes and Schwann cells 
284
  It is involved in cell to cell 
communication 
285
, cell growth and intracellular signal transduction as well as the development and 
maintenance of the CNS. Several S100B assays are available which detect both S100AB and BB, but 
currently a normal reference range for S100B remains uncertain. Labs conducting S100B assays are 
therefore required to generate reference ranges for their population and studies in patients should 
include a representative control group. Brain injury results in leakage of S100B into the CSF and 





S100B is metabolized by the kidneys and excreted in the urine. Levels usually normalize within 24 
hours after an acute injury; therefore, persistent elevation of S100B may reflect ongoing or secondary 
cellular injury 
286,287
. At elevated levels S100B may be neurotoxic by inducing apoptosis, causing the 
release of pro-inflammatory cytokines as well as nitric oxide from astroglial cells, and contributing to 
oxidative stress 
258,284,285,288
. Therefore, elevated levels do not only reflect tissue damage but may also 
exacerbate it 
288
. This protein is easily quantified in various biological samples including CSF, blood 
and urine. It remains stable over a wide range of temperatures (room temperature to -70°C) for up to 
48 hours after collection and does not degrade after freezing making it a suitable candidate for daily 
laboratory measurement and batch analysis in studies 
289,290
. 
 S100B is elevated in various CNS pathologies including TBI 




 and subarachnoid haemorrhage 
273
. Extracranial sources of S100B include white 
and brown fat, skin, skeletal muscle, melanocytes and adipocytes 
263,293-295
. Clinically, elevated blood 




S100B levels differ across various developmental phases from the fetal period through to old age 
296
. 
Stages of fetal development are associated with differential S100B levels in amniotic fluid and cord 
blood suggesting that elevated S100B within a physiological range may represent its neurotrophic role 
in brain maturation
297,298
. Age related S100B levels are, therefore, probably due to the role of S100B 
in the maturation of glial cells, formation of synapses and general brain morphogenesis which occur 
most frequently during early childhood 
299
. The pattern of age-related differences is however difficult 
to interpret in the existing literature. Portela et al 
299
 collected serum samples from three age groups of 
healthy donors; neonates, children (4-16 years) and adults (18-70 years). They found no differences 
based on sex, but age demonstrated a significant negative correlation with S100B with the highest 
values found in neonates. After the age of 20 years, the baseline levels seemed to stabilise. Gazzolo et 
al 
300
 also found that S100B levels in serum were associated with age in a detailed study of 1004 
children between the ages of 0 and 15 years. Highest values were recorded during the first year of life 
and then again between 7 and 13 years. The authors hypothesize that these epochs correspond to the 
greatest spurts of growth and maturation; infancy and early adolescence. Different peaks of S100B 
were also found based on sex, again a possible manifestation of the growth phenomenon which varies 
between the sexes. Bouvier et al 
301
 found that serum S100B levels decreased with age. Their results 
in an exclusively paediatric cohort showed that the highest levels of S100B were recorded before two 
years. The permeability of the BBB, higher protein turnover in neuronal cells, low renal secretion of 
S100B as well as dynamic CNS development in children under two years are possible explanations 
proposed for this finding. However, Spinella et al 
288
 found a positive correlation between age and 
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CSF S100B levels in their study on 107 paediatric patients ranging from three days to 17.8 years. 
Although a significant positive correlation was found between age and S100B levels, the degree of 
variance attributed to age was only 4%. These results have been mirrored in an adult study conducted 
by Nygaard et al 
302
, who found that S100B levels in the CSF increased with age with 43% of the 
variability attributed to age in men, and 30% in women. Overall S100B levels were also significantly 
higher in men. This study could not detect S100B in serum samples. Contrary to the above mentioned 
studies Wiesmann et al 
303
 selected 200 healthy blood donors which they divided equally in five age 
bands each of approximately nine years spanning from 18 to 65 years. Their study found no 
significant age- or sex-related differences.  
These seemingly opposing findings between studies may be a function of whether or not children are 
included in the study cohort as evidence suggests the largest influence of age early in life. 
Furthermore, the heterogeneity of normal cohorts selected to establish reference ranges is challenging 
because much of the inter-individual difference cannot be accounted for and sample sizes often are 
not large enough per age group to adequately compensate for this variability. The selection of so-
called ‘normal’ samples is also subject to interpretation - some studies have chosen individuals with 
symptoms which could indicate neurological disease and warrant invasive procedures like a lumbar 
puncture, while others have selected completely healthy individuals. These are important 
considerations when evaluating the role of S100B or any biomarker in conditions of pathology, 
defining reference values or matching controls and cases. A summary of reference values for S100B 
is included in Table5.1 at the end of this chapter. 
Studies in CNS infections 
Experimental studies 
Bertsch et al 
292
 measured serum S100B levels in a mouse model infected with CNS Candida 
Albicans. They found that levels were significantly elevated relative to control mice, and peaked 
within one day post-infection followed by a subsequent decline. The kinetics of S100B appear to 
reflect the infective process whereby pathogenic entry into the CNS leads to an immediate 
inflammatory response, cell destruction and BBB breakdown. When the infection is contained, tissue 
damage is halted and S100B levels return to baseline. In a sheep model Garnier et al found that sheep 
foetuses exposed to infection intra-uterine developed white matter injury. The degree of injury and 
mortality were positively associated with S100B levels in both the foetal and maternal circulation 
suggesting the value of S100B in the early detection of foetal white matter injury 
304
. Another 
experimental model reveals the role of S100B as a marker of hypoxic distress in fetal sheep. Elevated 
plasma S100B levels were associated with markers of metabolic acidosis, redistribution of blood flow 





Clinical studies in Adults 
Infante et al 
283
 examined S100B in the CSF of adult patients with various neurological pathologies 
including meningitis, dementia, hydrocephalus, acute cerebral infarction, multiple sclerosis, motor 
neuron disease and lymphatic leukemia. S100B levels were significantly elevated in the meningitis, 
dementia and acute cerebral infarction groups with the highest levels associated with dementia. The 
authors suggest that S100B in acute limited injury may peak early and clear the system swiftly, in 
which case accurate assessment is highly dependent on the timing of sampling relative to onset of 
injury. Continued elevation likely represents ongoing injury or the inflammatory activation of glial 
cells. Unden et al 
306
 found higher levels of serum S100B in adults with cerebral infections compared 
with extra-cerebral infections. Viral encephalitis patients demonstrated the highest levels, and 
bacterial meningitis patients recorded higher levels than those with viral meningitis which is 
congruous with the established cellular injury associated with these diseases. However, some of their 
encephalitis and meningitis patients did not demonstrate elevated values despite radiological and 
clinical abnormalities, suggesting that S100B may produce some false negative results when used as a 
marker of brain injury. Considering that S100B is a brain derived protein this may have been 
influenced by the fact that they sampled blood rather than CSF. Further, in one of these encephalitis 
patients sampling was done a few days later than in those patients with elevated levels; S100B has 
been shown to peak earlier in the disease process and so the peak may have been missed 
283,307
. The 
authors also suggest that S100B may demonstrate false positive results: some cases with extra-cranial 
infection and no evidence of cerebral involvement had elevated S100B. The exact extracranial sources 
of these elevated S100B levels is not known, however, in these instances S100B levels were mostly 
only marginally elevated and did not reach levels as high as in encephalitis. In general, CNS 
infections were the predominant source of elevated S100B. 
Clinical studies in Children 
Having examined reference values in infants, Spinella et al 
288
 compared CSF S100B levels between 
normal children and those with established meningitis and found the latter had significantly higher 
levels. Hamed et al 
258
 examined levels of S100B and markers of oxidative stress and antioxidative 
activity in 40 children with bacterial meningitis. S100B levels were elevated in both serum and CSF 
samples. They contend that brain injury resulting from bacterial meningitis is evidenced by the 
increased intrathecal production of S100B and markers of oxidative activity, and that the levels of 
these markers are related to injury severity. A study of infants with bacterial meningitis 
308
 found 
elevated levels of CSF S100B with the highest levels recorded in infants who developed encephalitis 
in addition to their meningitis. A receiver operating curve indicated that S100B levels above 1.0 ug/L 
were diagnostic for the early detection of bacterial meningitis-encephalitis with a sensitivity of 91% 
and a specificity of 82% with an area under the curve of 0.92. S100B also surpassed standard 
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monitoring techniques in identifying the development of encephalitis 
308
. Table 5.2 summarises 
concentrations reported for S100B in clinical studies. 
Neuron-specific enolase 
NSE ( -enolase) is a stable cell-specific isoenzyme of the glycolytic enzyme enolase, a dimer protein 
made up of α,  and  sub-units measuring 78 kDa. Although highly localised to neurons and 
neuroendocrine cells, NSE has also been found in erythrocytes, liver, smooth muscle and 
lymphocytes; however, this is often of the hybrid (αδ) enolase form and has low concentrations (less 
than 10 ng/mg) 
262,266
. In the brain NSE is concentrated exclusively in the cytoplasm of neurons 
262
. 
NSE demonstrates enzymatic activity and is a promising marker of general neuronal function. Normal 
serum levels range from 5-15 ng/ml. When neuronal membranes are injured, NSE easily diffuses into 
the extracellular space and CSF 
277
. Consequently, increased levels of NSE in the CSF and serum have 
been identified in several cerebral pathologies including encephalitis, cerebral infarction, Parkinson’s, 
amyotrophic lateral sclerosis, spinocerebellar degeneration, cervical spondylosis, polyradiculoneuritis 
and TBI 
274,309,310
. NSE is also elevated in small cell lung cancer 
266




Van Engelen et al 
311
 sought to establish reference values for NSE, S100B, and myelin basic protein 
(MBP). They collected CSF samples in 79 control patients ranging from 1 to 60 years of age. Their 
findings suggest a significant increase with age which was similar across all three markers, with a 
median increase of 1% per year. Possible explanations proposed for this finding relate to an increase 
in cell and myelin loss with age and/or a parallel reduction in CSF bulk flow. Nygaard et al 
312
 studied 
CSF and serum NSE levels in normal individuals ranging from 20-90 years of age. In the serum they 
found no differences based on sex and age, but in CSF there was a positive significant association 
with age and males had higher values. The authors suggest that the increase in NSE levels with age 
may be attributed to increased NSE concentration in the face of stable cell turnover, increased cell 
turnover with age, or an increased NSE half-life due to reduced CSF bulk flow. Sex dependency may 
be explained by similar mechanisms. In addition this study found no correlation between the NSE 
levels in the two biological fluids. However, the association with age is not a consistent finding. In a 
paediatric study Rodriguez-Nunez et al 
313
 examined NSE levels in the CSF of 37 children aged 1 
month to 13 years. Their findings did not suggest an association with age. Casmiro et al 
314
 studied 
both CSF and serum in an exclusively adult population of 108 individuals and also found no 
significant association with age, however their sample was skewed to patients over 60 years old. NSE 






This in conjunction with findings of Nygaard et al 
312
 suggests that serum cannot substitute CSF and 
that normal serum NSE does not necessarily exclude the presence of CNS injury, although this 
requires validation in a sample of patients with CNS disease. Studies on reference ranges in NSE are 
subject to the same limitations and cautionary interpretation as for S100B. Reference values for NSE 
are summarised in Table 5.3. 
Studies in CNS infections 
Experimental Studies 
The authors are unaware of any studies of NSE levels in experimental models of CNS infection. 
However, a study of NSE in an ischemic rate model is relevant as ischemia is an important 
determinant of poor outcome in CNS infections. Hardemark et al 
315
 correlated NSE levels in CSF 
with the development and size of infarcts in rats by sampling fluid pre- and post-MCA occlusion over 
several days. NSE levels peaked between 24 and 72 hours after occlusion with a subsequent return to 
baseline over six days. Infarct size was significantly correlated with NSE levels and the area under the 
NSE concentration curve. These findings suggest that sequential analysis of CSF NSE reflects the 
development as well as size of infarcts. The temporal variation of NSE reflects the dynamic nature of 
the ischemic process which may occur over several days and is subject to inter-individual variation. 
The timing of sampling as the injury evolves is therefore an important consideration. 
Clinical Studies in Adults 
Lima et al 
277
 examined whether NSE levels correlate with severity of neurological impairment. They 
sampled serum and CSF in 51 adults: 11 with meningitis, 7 with encephalic injuries, 25 with 
neurocysticercosis and eight controls.  They found no age or sex differences. NSE levels were 
elevated only for the group with encephalic injuries, and only in CSF. It is worth noting that none of 
the meningitis group was neurologically compromised and so the degree of neurological injury is 
debatable. Song et al 
316
 measured NSE in the CSF and serum of adult patients with tuberculous 
meningitis (TBM) (n=15) and aseptic meningitis (n=28) in comparison with controls. While serum 
and CSF NSE levels were not significantly different across the three groups, the CSF/serum NSE ratio 
was significantly higher in the TBM group. This ratio was significantly correlated with the diagnosis 
of TBM in univariate and multivariate analysis demonstrating its potential as a diagnostic marker. The 
sample size of this study was small and provides a limited picture of NSE levels in meningitis. 
Clinical studies in Children 
There is a dearth of literature available in children, with most of the research in TBI 
270,309,310,317
. 
Rodriguez-Nunez et al 
318
 examined CSF markers of cell hypoxia and NSE to discern the utility of 
these markers in the differential diagnosis of meningitis. They examined 160 control children and 100 
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children with bacterial, viral or TB meningitis and found that NSE levels in bacterial meningitis and 
TBM cases were not significantly higher than controls, did not differ based on sex, and were not 
different between meningitis groups. Only the viral meningitis group had significantly elevated levels; 
however, this was attributed to nine cases with mumps etiology in whom NSE levels were highest 
overall. Two limitations of this study are: first, their TBM group was very small, comprising only 
0.9% of the meningitis cases, and second, the CSF samples were collected very early in the disease 
course (1-16hrs post onset of symptoms). Experimental work in animal models suggested that NSE 
levels tend to increase beyond 24 hours post-injury 
315
, therefore sample may have been taken when 
hypoxia had not been sufficiently prolonged or intense to induce cell death and cause elevations in 
NSE. In a study of 20 comatose children suffering from acute encephalitis, acute encephalopathy and 
Reye’s Syndrome, Nara et al 319 found that both CSF and serum NSE levels were significantly 
elevated relative to controls. NSE was associated with neurological compromise and showed higher 
initial values and subsequent increase in patients with more severe brain damage and poorer outcome. 
Their findings support the variability of NSE levels at different disease stages and between patients. 
Contrary to other studies these authors found a good correlation between serum and CSF NSE. NSE 
concentrations from clinical studies are summarised in Table 5.4. 
Combining S100B and NSE 
Lins et al 
307
 performed sequential paired CSF and serum measurements of S100B and NSE in 
patients with bacterial and viral meningitis. Results from 32 adult patients revealed significantly 
elevated serum and CSF S100B in patients with bacterial meningitis only. Elevated S100B was 
associated with lesions on CT or MRI and a higher CSF/serum albumin ratio. In most patients S100B 
levels decreased after the initial samples, except in a patient with TBM in whom biomarker levels in 
CSF and serum continued to climb, peaking by day 27. NSE was not significantly elevated in this 
study. Mokuno et al 
274
 examined CSF S100B and NSE in patients with a range of neurological 
pathologies including encephalitis, meningitis, cerebral infarction, Parkinson’s disease, sclerosis and 
others. Levels of NSE and S100B were elevated in several of these conditions, but not always 
simultaneously suggesting that their presence may reflect the kind of tissue damage: glial versus 
neuronal. Levels were highest in encephalitis and cerebral infarction and S100B normalised earlier 
than NSE. 
Glial Fibrillary Acidic Protein 
Glial fibrillary acidic protein (GFAP) forms an integral part of cytoskeleton of astrocytes. The 
molecular mass is estimated to be between 50 and 53 kDa, and the soluble fragment released into CSF 
and the cerebral extracellular fluid is approximately 41 kDa 
320-322
. It is involved in modulating the 
motility of astrocytes and providing structural stability to astrocytic processes, and plays an important 
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role in maintaining myelin and white matter architecture as well as BBB integrity 
320,323
. Astrocytes 
respond rapidly to injury or inflammation by undergoing hypertrophy, proliferation and various 
enzymatic changes 
324
. Reactive astrogliosis is a prominent feature of cells in the penumbral zone 
surrounding tissue injury and is characterized by increased concentrations of GFAP 
320
. GFAP is also 
released in the event of cell death 
320,321,325
  and appears to be specific to central nervous system injury 




This marker is frequently investigated to detect gliosis by immunostaining in brain tissue samples 
327
 
or as a cell marker for damage due to infection 
328,329
. Various in-house assays to detect GFAP in the 
CSF and serum have been developed and have shown good sensitivity in detecting GFAP in both 
biological fluids 
322,330,331
. Commercially available assays are now easily available. The exact half-life 
of GFAP is uncertain; studies in TBI, stroke, intracerebral haemorrhage and subarachnoid 
haemorrhage demonstrate variability in the release kinetics of GFAP and its temporal profile of 
elevation ranges from 24 hours to 4 days 
321,326,332-335
, but few studies have systematically measured 
GFAP serially. It is suggested that while GFAP clears the bloodstream rapidly, persistent elevation 
may reflect ongoing secondary injury which contributes to poorer outcome 
325,332
. Elevated 
concentrations of GFAP in TBI have demonstrated high sensitivities and specificities as a marker of 
injury and predictor of outcome 
325,326,336
. Research in stroke patients has found serum GFAP 
concentrations to be a promising tool in differentiating stroke of ischemic and haemorrhagic origin 
335,337
. GFAP is significantly associated with head CT scan abnormalities, infarct volume and 
perturbations in other physiological variables like raised intracranial pressure and poor cerebral 
perfusion pressure 
332,338
. This neuromarker has also been examined in the diagnosis of brain tumours 
and assessment of tumour volume 
339,340




There is little available research defining normative values for age in GFAP. The relationship between 
age and GFAP concentrations is also contentious; a study examining GFAP in individuals from the 
paediatric to the adult age ranges found GFAP to be independent of age and elevations in the elderly 
were attributed to the increased prevalence of Alzheimer’s disease and dementia 341. A study in 
teenagers and adults found that GFAP was positively related to age and appeared to increase from the 
age of 50 years, reaching the highest concentrations at 75 years 
343
. The same group conducted a study 
in a patient sample ranging from 1.3-29 years, and recorded significantly lower concentrations in 
younger children 
344
. The increasing trend of GFAP during the life course is attributed to expansion of 
the fibrillary astrocytes in the maturing brain 
344
, and it is possible that early neurodegenerative 
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mechanisms may also influence concentrations in older subjects. GFAP reference ranges are outlines 
in Table 5.5.    
Studies in CNS infections 
Research on the diagnostic and prognostic value of GFAP has focussed largely on TBI and stroke; 
data on measurement of soluble GFAP in the CSF or serum of humans with cerebral infections is 
sparse and there are no experimental animal models to our knowledge. 
Clinical studies in adults 
A proteomics study aimed to identify proteins which could be used to differentiate between bacterial 
and viral meningitis. Their analyses in serum and CSF revealed that CSF GFAP was significantly 
more elevated in patients with bacterial meningitis, suggesting its value as a marker to discriminate 
between the two meningitides early, and to direct appropriate treatment 
345
. A study on Lyme 
neuroborreliosis demonstrated that GFAP concentrations were elevated in the CSF of affected 
individuals relative to control patients, suggesting that the disease process was not only limited to the 
meninges but affected the parenchyma as well. GFAP responded positively to antibiotic treatment 
346
. 
Further studies have looked at GFAP in combination with other neuromarkers.  In a cohort of patients 
with varicella-zoster virus CNS infections, Grahn et al 
347
 measured CSF S100B, GFAP and 
neurofilament protein light chain (NFL), a potential marker of neuronal injury. NFL showed the 
highest and most prolonged elevation, followed by GFAP whereas S100B levels were normal. This 
suggests that damage may have involved astrogliosis while the astrocyte cell membrane remained 
intact, and that persistent or secondary injury may be responsible for ongoing NFL elevation. A 
review by Bonneh-Barkay et al 
348
 summarises research into biomarkers for encephalitis in adults; 
CSF NSE, NFL, GFAP, S100B, a variety of proinflammatory cytokines, and soluble Fas (an apoptotic 
marker) were identified in herpes encephalitis.  
Clinical studies in children 
A multi-centre paediatric study combining a panel of biomarkers of neurological injury demonstrated 
that GFAP was elevated in the CSF of children with infectious or inflammatory cerebral disease and 
elevations in this neuromarker were attributed to astrogliosis. Contrary to reports on healthy controls, 
this study found that GFAP was negatively associated with age, and highest GFAP concentrations 
were observed in patients less than 5 years. This may reflect greater vulnerability of the immature 
brain to injury 
349
. Tsukahara et al 
350
 examined CSF S100B, GFAP and Tau protein (a microtubule-
associated protein found in neuronal axons) in children with acute encephalitis/encephalopathy. CSF 
biomarker levels were only elevated in patients with poor outcome and S100B had the best predictive 
accuracy with respect to outcome. GFAP showed poor sensitivity (40%) but was very specific 
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(100%). Tau protein had a sensitivity of 70% and specificity of 85%. Combining several markers 
allowed for the best predictive value for outcome. GFAP concentrations recorded from clinical studies 
are included in Table 5.6. 
Other Potential Biomarkers 
Advances in genomics, transcriptomics, proteomics and metabolomics offer opportunities for 
investigating various molecular aspects of the host-pathogen interaction in CNS infections. These 
include pathogen-specific molecular or metabolic signatures, pathogen-directed alteration to host gene 
expression patterns, genetic susceptibility to infections, inter-individual genetic variation in response 
to pathogen exposure, and the association between gene expression profiles and disease outcome. 
These technologies therefore have the potential to contribute biomarkers which could accurately 
diagnose the disease as well as the offending pathogen, allow early selection of appropriate treatment, 
identify patients at greater risk of severe disease and poor outcome, and allow treatment tailored to 
both host and pathogen characteristics. This field is still in a fledging state, however, especially with 
respect to CNS infections 
351
. In the field of proteomics, Goonetilleke et al 
352
 studied the CSF protein 
profile of patients with pneumococcal meningitis using two dimensional gel electrophoresis. Elevated 
proteins were associated with inflammation, cellular damage and metabolic derangement in non-
survivors and could provide insight into novel biomarkers and drug targets. In a proteomics study on 
the CSF of TBM patients, Kataria et al 
353
 found 18 differentially expressed proteins. Up-regulated 
proteins of human origin included: arachidonate 5-lipoxygenase, which contributes to the 
pathophysiology of TB by weakening the host’s immune responses; GFAP, a marker of tissue 
damage; and anti-thrombin-III which indicates the involvement of coagulation pathways. Down-
regulated human proteins included: apolipoprotein E and A-1, which are important for neural growth 
and repair, immune regulation and their anti-inflammatory properties, and transthyretin, which aids in 
reducing brain oedema, neuronal death and inflammation. Mycobacterial proteins identified in the 
CSF could present diagnostic markers for swift detection of the causative agent in patients with 
meningitis. Metabolomics is a high throughput technology which allows for a broad unbiased analysis 
of the full complement of metabolites present in biological samples. It is increasingly being used in 
disease diagnostics, therapeutics and drug development as it provides insight into the combined effect 
of metabolites from the infecting organism, inflammatory cells and cerebral cellular responses to 
pathogens and therapeutics
354
. In a study on patients with meningitis and ventriculitis, Coen et al
355
 
demonstrated that metabolomics of the CSF could rapidly diagnose these infections and showed 
improvement on routine CSF cell count and chemistry. Subramanian et al
356
 developed an expert 
system to aid in the differential diagnosis of meningitis using a unique combination of clinical 





More in depth studies looking at a broader panel of markers are required. Using a combination of 
neurological markers may also be useful in tracking injuries of various tissue types and may mitigate 
the influence of extracranial sources. Combining inflammatory and tissue injury markers has 
demonstrated improved prognostic power in TBI 
271
 and may prove beneficial in CNS infections as 
well. Few of the available studies in CNS infections examined biomarkers in relation to outcome. 
Several studies have confirmed significant associations between biomarker levels and radiological and 
clinical outcome in TBI 
272,357,358
 since these are the current tools available it is important to ascertain 
the strength of the associations with biomarkers in infectious injury. 
Conclusion 
Despite the limited number of studies on biomarker levels in CNS infections the literature available 
suggests that in both adults and children biomarkers of neurological injury have the potential to 
answer several important questions; 1) when presenting symptoms and history are non-specific, is 
there CNS involvement, 2) what is the nature of the pathological process, 3) what is the likely 
causative pathogen, 4) which cells of the CNS are affected, 5) how severe is the injury, and 6) is the 
disease process responding to intervention? Biomarkers of neurological injury carry promise as 
markers of diagnosis as well as prognosis and may serve as surrogate end-points for determining the 
response to novel interventions. Further studies on biomarkers in this field will add to our 
understanding of their utility. When conducting biomarker studies it is important to consider 
limitations presented by heterogeneity in the study cohort, the relative value of CSF versus serum and 




Table 5.1: S100B Reference Ranges (μg/L) 




 percentile unless otherwise stated, SD = standard deviation, CSF= 
cerebrospinal fluid, ♂ = male, ♀ = female 
a 
Additional age related data available in original articles 
b 
Sample sizes derived from article where possible
  
c
 Sample sizes not stated in article 
d








Authors Age group N Specimen Mean (SD) Median Range 
 
Paediatric cohort       
Bouvier et al (2011)
a
 0-2 years 139 serum 0.21 (0.12)  0.07-0.83 
 >2 years 97  0.11 (0.03)  0.07-0.2 
Gazzolo (2003)
a, b
 0-1 year 85 serum  0.95 0.44-2.55 
 2-7 years 461   0.73 0.44-1.06 
 9-11 years    1.65 0.91-1.74 
 11-12 years 32   0.45 0.39-0.45 
 13-14 years 35   1.23 1.12-2.01 
 14-15 years 18   0.78 0.5-0.87 
Spinella et al (2004) <1 months 16 CSF  0.79 0.52-1.32 
 1-2 months 29   0.6 0.44-0.84 
 2-3 months 11   0.61 0.4-0.81 
 3-12 months 20   0.58 0.46-0.73 
 1-5 years 10   0.96 0.77-1.33 
 5-10 years 8   0.87 0.65-1.07 
 10-15 years 7   1.3 0.87-1.8 
 15-18 years 6   1.2 0.66-1.8 
Mixed cohort       
Portela (2002) Neonates 19 serum  1.79 1.57-2.44 
 4-9 years 16   0.37 0.27-0.41 
 10-15 years 8   0.31 0.26-0.37 
 16-20 years 10   0.11 0.02-0.2 
 21-25 years 13   0.1 0.05-0.15 
 26-30 years 9   0.1 0.06-0.15 
 30-70 years 54   0.06 0.03-0.1 




1 year  CSF   0.9-2.6 
d
 
 20 years     1.1-3.3 
 40 years     1.3-4 
 60 years     1.6-5 
Adult cohort       
Wiesmann (1998) 18-65 years 200 plasma  0.05 0.02-0.1
 e
 
Nygaard et al (1997) 20-89 years 110 serum undetectable   
   CSF 1.9 (0.7) ♂ 




Table 5.2: S100B data from clinical studies (μg/L) 




        
Hamed et al 
(2009) 
< 15 years Controls 20 serum 0.13 (0.01)  0.11-0.16  
 <15 years Bacterial 
meningitis 
40 serum 0.22 (0.07)  0.13-0.57 ✓ 
    CSF 0.61 (0.03)  0.55-0.7  




Controls 107 CSF  0.71 0.48-1.07  
  Meningitis 34 CSF  1.1 0.91-1.4 ✓ 
Gazzolo (2004) 38 weeks Controls 44 CSF  0.16 0.11-0.33  
 38 weeks Bacterial 
meningitis 
44 CSF  1.34 0.84-1.78 ✓ 
Mixed cohort         
Infante (2003)
a
 1-79 years Controls 22 CSF 0.88 (0.08)    
  Lymphocytic 
meningitis 




10  5.06 (2.43)   ✓ 
  Dementia 6  2.09 (0.62)   ✓ 
  Acute cerebral 
infarction 
10  1.69 (0.26)   ✓ 
Adult cohort         








5 serum 0.58   ✓ 




Controls 13 serum 0.05 (0.03)    
    CSF 1.22 (0.49)    
  Bacterial 
meningitis 
11 serum >controls   ✓ 
    CSF >controls   ✓ 
  Viral 
meningitis 
13 serum <controls   X 
    CSF <controls   X 




 Controls 18 CSF 0.33 (0.09)  0.16-0.52  
  Encephalitis 6  1.9 (1.8)  0.34-5.1 ✓ 
  Meningitis 24  0.6 (0.48)  0.06-2.4 ✓ 
  Cerebral 
infarction 
10  1.4 (1.4)  0.12-4.1 ✓ 
  Parkinson’s 
disease 
18  0.58 (0.23)  0.21-0.96 ✓ 
  Cervical 
spondylosis 
9  0.51 (0.2)  0.24-0.84 ✓ 
  Acute P (R) N 5  0.83 (0.62)  0.2-1.8 ✓ 
  Chronic P (R) 
N 
6  1.5 (2.3)  0.34-6.6 ✓ 




 percentile, SD = standard deviation,’ >’ greater than, ‘<’ less than, CSF = 
cerebrospinal fluid, P(R)N = poly-(radiculo)neuritis, ✓ = cases> controls at p<0.05, X = case>controls p>0.05 
a
 Only pathologies with S100B levels significantly greater than controls included in table, further detail in 
original articles 
b
 Several other pathologies included in the study had elevated S100B levels, however, no 
descriptive statistics are reported in the paper 
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Table 5.γ: NSE Reference Ranges (μg/L) 
Authors Age group N Specimen Mean (SD) Median Range 
Paediatric cohort       
Rodriguez-Nunez et al 
(1999) 
1 month – 13 years 37 CSF 1.5 (1.01) 1.5 0-4.8 
Rodriguez-Nunez et al 
(2003) 
1 month – 13 years 160 CSF 1.5 (1.01)   
Mixed cohort       
Van Engelen et al (1992) 
a
 
1 year  CSF   2.2-10.2 
b
 
 20 years     2.7-12 
 40 years     3.1-13.8 
 60 years     3.8-16 
Adult cohort       
Casmiro et al (2005) 62.7 (16.7) years 108 serum 8.7 (3.9) 
c
   
   CSF 17.3 (4.6)   
Nygaard et al (1998) 20-89 years 87 serum 7.1 (3.6)  6.2-8.1 
d
 
   CSF 5.1 (1.6) ♂ 
4.1 (1.4) ♀ 
  




 percentile unless otherwise stated, SD = 
standard deviation, CSF = cerebrospinal fluid, ♂ = male, ♀ = female, a Sample sizes not stated in article, bRange 
reflects 5
th




Table 5.4: NSE data from clinical studies (μg/L) 






        
Rodriguez-




Controls 160 CSF 1.52 (1.01)    
  Viral meningitis 46  2.87 (1.21)   ✓ 
  Bacterial meningitis 45  2.47 (1.59)   X 
  Tuberculous 
meningitis 
9  2.25 (0.49)   X 
Mixed cohort         




Controls 8 Serum 4.7 (2.3) 4.9   
    CSF 6.3 (3.6) 6.1   
  Meningitis 11 Serum 5.8 (4.6) 5.4  X 
    CSF 4.9 (4.6) 4.4  X 
  Neurocysticerosis 25 Serum 6.6 (3.4) 7.1  X 
    CSF 3.9 (3.2) 3  X 
  Encephalitis 7 Serum 20.9 (19.2) 9.2  ✓ 
    CSF 35.8 (39.2) 29.7  ✓ 
Adult cohort         
Lins et al (2005) 41 (13) 
years 
Controls 13 Serum 5.82 (1.75)    
    CSF 6.78 (2.1)    
  Bacterial meningitis 11 Serum 5.1 (1.3)   X 
    CSF 8.38 (3.7)   X 
  Viral meningitis 13 Serum 5.73 (3.7)   X 
    CSF 8.23 (3.4)   X 




 Controls 18 CSF 4.5 (1.2)  1.3-7.2  
  Encephalitis 6  11.3 (12.9)  3.4-40 ✓ 
  ALS 10  6 (2.1)  2.5-10 ✓ 
  Cerebral infarction 10  9.9 (6.2)  3.3-25 ✓ 
  Parkinson’s disease 18  7 (3.6)  0.8-16 ✓ 
  Cervical 
spondylosis 
9  8.7 (3.4)  4.1-14.4 ✓ 
  Acute P (R) N 5  6.2 (2.3)  4-10 ✓ 
  Chronic P (R) N 6  2.5 (0.9)  1.2-4.2 ✓ 
  Spinocerebellar 
degeneration 
10  7.2 (2.5)  3.2-10.8 ✓ 
Song et al 
(2012) 
Adults Control 37 Serum 10.42 (6.06)    
    CSF 9.46 (5.76)    
  Tuberculous 
meningitis 
15 Serum 8 (2.17)   X 
    CSF 12.35 (3.52)   X 
  Aseptic meningitis 28 Serum 9.57 (7.16)   X 
    CSF 9.79 (6.1)   X 




 percentile unless otherwise stated, SD = 
standard deviation,’ >’ greater than, ‘<’ less than, CSF = cerebrospinal fluid, ✓ = cases> controls at p<0.05, X 
= case>controls p>0.05, 
a
 Only pathologies with S100B levels significantly greater than controls included in 




Table 5.5: GFAP Reference Ranges (μg/L) 
N = sample size, Range = minimum-maximum, SD = standard deviation, CSF = cerebrospinal fluid 
 
  
Authors Age group N Specimen Mean (SD) Median Range 
 
Mixed cohort       
Rosengren et al  
(1992) 
1.3-29 years 13 CSF 66.6 (17.2)   
Rosengren et al 
(1994) 
16-77 years 25 CSF   100-1300
 
 
Fukuyama et al 
 (2001)  
1-25 years 13 CSF 2.96 (1.04)   
 26-55 years 9 CSF 2.80 (1.46)   
 > 65 years 8 CSF 3.99 (1.55)   
Adult cohort       
Rosengren et al 
(1994) 
 
      
Vissers et al 
(2006) 
Not  specified 46 Serum   <0.014-0.066
 
 
Van Geel et al 
(2002) 
21-70 years 72 Serum  0.15 0.15-0.49 
Missler et al 
(1999) 
20-65 years 70 Serum  0.004 0.002-0.049
 
 
Dotevall et al 
(1996) 
20-61 years 24 CSF 121 (87)    
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Table 5.6: GFAP data from clinical studies (μg/L) 




        







101 CSF   0.5-100  






 CSF 24.53 (2.63)    
Adult cohort         








7 CSF 176.97 
(195.3) 
  ✓ 
    Serum 0.75 (1.23)   x 




21 CSF 22.53 
(32.37) 
  ✓ 






20 CSF 592 (596)   ✓ 
Grahn et al 
(2013) 
15-80 Varicella zoster 
virus 
20 CSF   0.34-2.67  
GFAP = glial fibrillary acidic protein, N = sample size, MDN= median, Range = minimum – maximum,  unless 
otherwise stated, SD = standard deviation,’ >’ greater than, ‘<’ less than, CSF = cerebrospinal fluid, ✓ = cases> 
controls at p<0.05, X = case>controls p>0.05. 
a 
Data reported from 2 study centres, patients from the second 







CHAPTER 6: BIOMARKERS OF INFLAMMATION IN TBM: 
CYTOKINES AND CHEMOKINES 
 
The prolific host inflammatory response is considered one of the most important determinants of poor 
outcome in TBM. Cerebral inflammation is responsible for the formation of the thick basal exudate 
which coats the major vessels of the brain and causes cerebral vasculitis, which obstructs the flow of 
CSF and precipitates HCP and raised ICP, and which ultimately puts the brain at risk of ischaemia. 
Understanding the cerebral inflammatory response to TBM, therefore, is key in understanding the 
pathophysiological consequences of the disease and in developing avenues for effective treatment. 
This chapter aims to review the current literature on the central nervous system (CNS) immune 
response to TBM, focussing on the role of cytokines. 
CNS INFLAMMATION 
Traditionally it was believed that the CNS was an immune naïve domain; however, the CNS is indeed 
capable of mounting a local immune response manifested by the intrathecal production of 
inflammatory mediators. Unfortunately CNS inflammation is often ineffective in destroying the 
invading pathogen 
18
. An important difference between the CNS and other bodily tissues is the 
presence of the blood brain barrier (BBB) which effectively reduces the access of leukocytes and 
plasma components to the intracranial compartment. Consequently, CNS inflammation is dependent 
primarily on local production of inflammatory mediators although some systemically produced 
cytokines may gain access through specific transport systems on the BBB or through a leaky BBB 
18
. 
Once bacteria gain access to the brain, the poor innate local immunity allows their survival and 
replication. The release of bacterial wall components in the CNS triggers an inflammatory response 




Cytokines are a network of proteins secreted by leukocytes and other non-immune cells which interact 
to stimulate, generate, and regulate an immune response through pro- and anti-inflammatory 
activities. These include the attraction of leukocytes and the transmigration of these cells from the 
circulation into the target tissue through the activation of adhesion molecules on the endothelial 
surface of blood vessels. Regulation of the immune response is governed by the anti-inflammatory 
activities of cytokines; the specific nature of the immune process, therefore, is dictated by the 







Chemokines are a group of cytokines which exhibit chemoattractant qualities that induce leukocyte 
migration. They are divided into two subfamilies, based on whether their cysteine residues are 
adjacent to each other (CC) or separated by an intervening amino acid (CXC). The CC subfamily 
attracts predominantly monocytes/macrophages, but also lymphocytes, basophils, eosinophils, natural 
killer (NK) cells and dendritic cells. They bind to receptors CCR-1 through to CCR-9, and play a key 
role in granuloma formation against TB. The CXC subfamily attracts mainly neutrophils and is further 
divided into the ELR-CXC and the non-ELR-CXC chemokines, depending on the presence of the 
ELR motif on the first cysteine of their amino acid sequence. Their receptors have been labelled 
CXCR1 through to 5. Most chemokines are induced by pro-inflammatory cytokines including IL-1, 
TNF-α and IFN- . Release at the site of infection generates a chemoattractant gradient that enables the 
navigation and homing of effector leukocytes. Chemokines act on the target cell’s membrane protein 
composition to facilitate the chemotaxis of leukocytes from the circulation into inflamed tissues. They 
also induce or inhibit angiogenesis, hematopoietic precursor cell development, embryogenesis, 
lymphogenesis and wound repair. Chemokine release initiates the activation of serine or threonine 
kinases which regulate chemokine activity by phosphorylating chemokine receptors and thereby 
down-regulating chemokine-mediated leukocyte responses 
18,360-362
. In the brain they play an 





Microglia and astrocytes are the resident immune cells of the CNS. Microglia act as CNS 
mononuclear phagocytes participating in the innate immune response. In their resting state microglia 
exhibit an immunologically quiescent phenotype that lack phagocytic activity. In comparison, active 
microglia are highly phagocytic and are involved in the induction of neuroinflammation and 
regulation of T-cells through antigen presentation 
364
. Astrocyte foot processes form a key part of the 
BBB and activated astrocytes consequently play an important role in controlling leukocyte infiltration 
into the CNS. Astrocytic and microglial release of proinflammatory cytokines initiates and regulates 
CNS inflammation. These immune mediators include TNF-α, IFN- , IL-1 , IL-6, IL-8, IL-12 and 
nitric oxide (NO) 
365
 as well as chemoattractant cytokines. Additional sources of cytokine release 
include ventricular ependyma and meninges 
18
. Upon release cytokines induce the rapid although 
transient expression of cell adhesion molecules on vascular endothelial cells. Leukocytes attracted to 
the site of inflammation adhere to these endothelial cells and migrate from the circulation into the 
CSF via diapedesis 
162
. Evidence suggests that some cytokines may perform dual roles exhibiting pro-
and anti-inflammatory actions depending on the disease course, their concentrations, and their 
synergistic interaction with other mediators. The consequences of these different distribution patterns 
77 
 
of pro and anti-inflammatory mediators on pathogen clearance and brain integrity is not yet fully 
understood 
365
. Several of these immune molecules may have both beneficial and deleterious effects 
on the CNS depending on their concentrations, at which point during the disease course they are 
released and the duration and nature of the inflammatory condition. Chronic activation has been 
implicated in cytotoxicity 
364
.  
A study of physiological levels of cytokines in the CSF found that the ratio of pro- to anti-
inflammatory cytokines was greater in the CSF than in serum. This may reflect a tendency in the CNS 
towards a pro-inflammatory immunologic pattern; however, several immune mediators also play an 
important role in embryogenesis and the maintenance of normal CNS function 
365
. There is a paucity 
of data on normal values for cytokines in the CSF. Maier et al 
365
 examined physiological levels of 
CSF cytokines in 113 adults. Their results report medians and ranges for IL-6 (6, 1-34 pg/ml), IL-8 
(39, 5-90 pg/ml) and IL-10 (0.9, 0-39 pg/ml). As part of a study on paediatric traumatic brain injury, 
Bell et al 
366
 established means and standard deviations for 20 healthy control children for IL-6 (20.6 
±5.8 pg/ml) and IL-10 (8.9 ±7.5 pg/ml).  An intrinsic challenge in establishing reference values is the 





, heterogeneity amongst sample individuals 
370




Cytokine effects on the brain 
Although inflammatory mediators are important in mounting a defence against the invading pathogen, 
the inflammatory process often precipitates substantial damage to the brain in several ways that are 
summarized below. 
BBB permeability. The BBB is integral to maintaining homeostasis in the brain, allowing the influx of 
required nutrients and the efflux of by products while preventing the movement of cytotoxic 
molecules into the CNS. This barrier is composed of specialised endothelial cells lining the lumen of 
cerebral vessels which are functionally and morphologically unique. Among their exclusive properties 
are intercellular tight junctions, selective transporters and the presence of enzymes which constitute a 
metabolic barrier 
371
. These properties effectively and tightly regulate access to the CNS. Increased 
permeability of the BBB is considered a hallmark of CNS infection 
18
 and is thought to be a 
consequence of tight junction opening, augmented pinocytotic activity and/or the formation of 
transendothelial channels 
371
. This facilitates the leakage of proteins and other molecules into the 
cerebral space which contribute to CNS inflammation, alterations to the neuronal microenvironment, 
and vasogenic oedema with increased intracranial pressure due to the protein-induced osmotic 
gradient. Experimental models of meningitis have implicated TNF-α, IL-6, IL-1  and cytokine-





MMP-9 has been implicated in BBB breakdown in TBM and the fact that it may remain elevated for 
up to 60 days after the initiation of treatment suggests that the BBB may be compromised months 
after the initiation of TB treatment
372
. Chemokines have also been implicated in BBB breakdown by 
way of chemotaxis-induced leukocyte migration into the brain 
363
. Neutrophils migrating into the CSF 
further contribute to BBB damage by the release of toxic oxygen species and vasoactive lipid 
autocoids such as platelet activating factor, leukotrienes and prostaglandins 
162
. This breakdown of the 
brain’s defences increases its vulnerability to further damage. 
Cerebral blood flow (CBF) and metabolism – The inflammatory exudate in the subarachnoid space 
coats the vessels of the Circle of Willis causing vasculitis, vasospasm and vascular occlusions with 
resulting ischemia. CBF is further compromised by the loss of cerebral pressure autoregulation which 
subjects the brain to fluctuations in systemic blood pressure and places it at risk of both hypertension 
(increased intracranial pressure and cerebral oedema) and hypotension (ischemia) 
206
. Uncoupling of 
metabolic demand and CBF increases this risk. Changes in CBF have been shown to correlate with 
cytokine concentrations. Elevated CSF IL-1 and IL-6 were associated with increased blood flow 
velocity in the middle cerebral artery recorded with transcranial Doppler in patients with bacterial 
meningitis 
210
. TNF-α has been implicated in reducing CBF by increasing the vascular reactivity of 
the capacitance vessels, and by decreasing cerebral oxygen uptake and cellular metabolic demand. It 
also appears to increase cerebral anaerobic metabolism manifested by an increase in CSF lactate. 
Several of these changes are mediated by TNF-induced NO activation 
209
. IL-1  may increase cerebral 




Effect on CNS and vascular cells. Endotoxins reduce metabolism and may alter astrocytic 
morphology. TNF-α may cause cell injury through the production of reactive oxygen free radicals207 
and may contribute to vascular injury by promoting thrombosis 
30
, and cytokines may have a direct 
effect on neurons 
18
. 
The classic hallmarks of CNS inflammation thus include BBB disruption, leukocyte infiltration from 
the circulation into the brain, cerebral oedema formation, activation of CNS resident immune cells, 
and release of immune mediators 
359,363
. 
CNS INFLAMMATION IN TBM 
Studies on inflammation in TBM have primarily focussed on a particular selection of cytokines. This 






In the inflamed CNS TNF-α is secreted by activated microglia and astrocytes. This pro-inflammatory 
mediator modifies the BBB, induces adhesion molecule expression on cerebral microvascular 
endothelial cells and activates infiltrating systemic immune cells as well as CNS glial cells. It also 
appears to play an important role in initiating meningeal inflammation 
374
. At high concentrations 
TNF-α can cause severe illness, including cachexia, septic shock and death 18,364. 
IFN-  
This is a characteristic cytokine of Th1 immune cells and a potent inducer of TNF-α and NO 
production. It is involved in endothelial cell activation and induction of class I and II MHC 
molecules
18,375
. It is also an important cytokine in the formation and maintenance of TB granulomas 
376
. Together with TNF-α and vitamin Dγ, IFN-  may induce an antimicrobial pathway that results in 
the inhibition or destruction of Mtb in macrophages, although the bacillus may impair the macrophage 
response to IFN- . It may exhibit anti-inflammatory properties by inhibiting pro-inflammatory 





IL-1  is secreted by activated microglia and astrocytes 18,364. It activates both resident and infiltrating 
immune cells thereby stimulating the production of further TNF-α and IL-6, chemokines and adhesion 
molecules. It also stimulates phagocytic functions and tissue repair. It is implicated in various CNS 
pathologies, is involved in the initial stages of meningeal inflammation and may have a detrimental 
effect on the brain 
374
. IL-1  may increase BBB permeability by recruiting neutrophils, impair 
diffusion in the brain and lead to an increased cerebral blood volume 
373
. Experimental data indicate 
that IL-1  stimulates astrocytic production of NO and that this is enhanced by the co-presence of 
TNF-α and IFN-  378. NO is an important inflammatory mediator as well as a free radical; over-
production may lead to tissue damage and further inflammation 
379
. IL-1 receptor agonist (IL-1Ra) is 
an important regulator of immunity released in response to IL-4, IL-10 and IFN- . It occupies the IL-1 
receptors and inhibits the binding of IL-1 . Large quantities of IL-1Ra are required to suppress IL-1  
and it has been suggested that IL-1Ra may limit the aggressiveness of the immune response and the 
extent of disease except when levels are inadequate in the face of a prolific pro-inflammatory process. 
The balance of IL-1  and IL-1Ra is, therefore, an important indicator of disease severity 171. IL-1  is 
further regulated by the IL-1 decoy receptor which binds IL-1  without producing any signal and IL-1 




IL-6 is secreted mostly by astrocytes and is involved in both acute and post-acute inflammation. It 
promotes inflammation by stimulating IFN-  release but also regulates immune responses by 
suppressing gene expression of pro-inflammatory cytokines, and promotes the proliferation of 




IL-10 is an anti-inflammatory cytokine produced by activated monocytes and T-cells that inhibits the 
production of pro-inflammatory cytokines TNF-α, IL-1α, IL-1 , IL-6 and IL-12 as well as some 
chemokines. It is, therefore, important in the controlling inflammation and conferring protection on 
the CNS from the potential harm of pro-inflammatory cytokines like TNF-α 18,382-384. 
IL-12 
Activated monocytes and dendritic cells are the predominant sources of IL-12, which activates 
cytolysis, induces IFN-  synthesis in NK cells and T-cells and bridges innate and adaptive immunity 
by stimulating the generation of Th1 cells 
18
. IL-12 is composed of 2 covalently linked chains, the 
constitutively expressed p40 and the induced p35 which form the bioactive IL12p70. IL12p70 is 




This low molecular weight cytokine is a potent chemoattractant and activator of neutrophils and 
lymphocytes 
25,170,361
. It promotes adherence to the vascular endothelium by enhancing the expression 
of 2-integrin, which allows the migration of neutrophils from the vascular space to the site of IL-8 
production 
25
. IL-8 also eliminates microorganisms by enhancing bactericidal activity through 
nonoxidative mechanisms. 
Interferon-inducible protein -10 (IP-10/CXCL-10)  
IP-10 is produced by astrocytes and astroglia in response to TNF-α, IL-1  and IFN- 385. In addition to 
attracting T lymphocytes, this chemokine also stimulates NK cells and promotes T cell migration 
361
.  
Growth regulated oncogene (GRO)  
GRO is secreted by neurons and astrocytes. It interacts with type 2 CXC receptor on neutrophils and 
is an important chemokine in the attraction of neutrophils to the CNS 
386,387
. It is also involved in 





Monocyte chemoattractant protein -1 (MCP-1/CCL-2) 
This is the most potent activator and chemotactic factor for monocyte recruitment and migration and 
also attracts CD4+ T cells. Elevated levels in the serum may indicate a strong gradient to recruit 
monocytes to a local site of infection 
361,389
. MCP-1 is present in the perivascular space of the BBB 
and is key in increasing BBB permeability by altering the tight junction complexes on the endothelial 
cells making up the BBB. It acts through the receptor CCR2 which is present on both endothelial cells 
and monocytes and it has been suggested that the MCP-1 induced recruitment of monocytes may 
further contribute to BBB breakdown. Targeting MCP-1/CCR2 may be an avenue to regulate CNS 
inflammation and reduce BBB breakdown 
362
. Elevated levels of this chemokine are also implicated in 
an increased susceptibility to TBM as it appears to down regulate human macrophage IL-12 
production, a cytokine integral to initiating the immune response to TB 
390
. TNF-α and IL-1  have 
been shown to induce MCP-1 
385
. 
Macrophage inflammatory protein 1-α (MIP-1α /CCL-3)  
MIP-1α induces activation and proliferation of T-cells and macrophages, recruits mononuclear cells 
and promotes Th-1 cell differentiation 
387,390,391
. 
Regulated upon-activation, normal T-cell-expressed and secreted (Rantes/CCL5)  
This chemokine is involved in chemotaxis and activation of mononuclear cells, it also induces 
activation and proliferation of T-cells. In the CNS it is secreted by astrocytes and microglia 
390,391
 in 
response to TNF-α and IL-1 385. 
Studies in TBM 
Animal models 
The earliest work describing the pathogenesis of TBM was done by Rich and McCordock using a 
guinea pig model of TBM. Infecting the animals hematogenously with TB did not cause direct 
meningeal inflammation but was associated with the development of a tubercle in the sub-pial tissue 




Although the guinea pig is a very sensitive model for TB, immunological reagents are not currently 
available to investigate the immune response and subsequent work has focussed on other animals 
392
. 
In a rabbit model of TBM, animals were infected with a non-virulent strain of mycobacteria that 
secreted murine TNF-α. Results indicated that the production of TNF-α rendered this non-virulent 
strain virulent as the TNF-α triggered an inflammatory cascade, stimulated the breakdown of the BBB 
82 
 
and an influx of leukocytes, precipitated cerebrovascular damage and blocked control of Mtb. These 
findings suggest that TNF-α may be a determinant in the pathogenicity of TBM 393. In subsequent 
studies with this model these authors studied the therapeutic effects of immune modulators on 
cytokine levels and outcome, their findings are discussed later in this paper 
394,395
.   
Although mice are not as sensitive to TB infection they have the advantage of generating an innate 
immune response which bears similarities to that in humans and genetically modified species allow 
the investigation of specific immune mediators
392
. Mazzolla et al 
396
 investigated the role of natural 
resistance-associated protein 1 (Nramp1) in murine resistance to TB infection. Nramp1 resistant and 
Nramp1 susceptible mice were intracranially infected with Mycobacterium bovis and the immune 
response was investigated. Results showed that the mice differed in microbial load and in the kinetics 
and concentrations of immune mediators MIP-2, IL-12, IL-1 , IFN- , IL-6 and TNF-α. This suggests 
that Nramp1 may alter cytokine expression and plays a role in whether host defences are able to 
contain the infection. In a murine model by Van Well et al 
397
 using intracerebral inoculation, cytokine 
levels were not elevated in brain homogenates relative to controls. MCP-1 and MIP-2 (an animal 
analogue for IL-8) were, however, elevated for up to 24 weeks post-infection demonstrating that 
while an acute inflammatory response was not discernible a chronic response had occurred. Be et al 
398
 developed a murine model focussed on hematogenous dissemination to the CNS through 
intravenous inoculation with Mtb. They found that although Mtb colonies were recovered from the 
brain, no inflammatory process was discernible. In comparison, the lung demonstrated significantly 
higher cytokine levels, leukocyte infiltration as well as gross TB pathology in the tissue. It is 
postulated that the inflammatory response in the CNS may be delayed by its poor immune baseline 
and that overt inflammation may have been detected if animals were sacrificed weeks or months later. 
Using intracerebral inoculation, Lee et al 
399
 compared peripheral and CNS immune responses to TB 
infection. They found that the CNS uniquely demonstrated the presence of IFN-  IL-17 double-
positive CD4 T-cells and that microglia were the primary source of intracranial TNF-α suggesting that 
resident CNS cells played an important role in the local immune response. Bolin et al 
400
 developed a 
swine model for disseminated TB by inoculating pigs through the blood, trachea or lymph nodes. 
Only a few animals developed meningitis, but none fulminant TBM. All of these animal models 
employed either intravenous or intrathecal inoculation as it is challenging to develop a model which 
accurately reflects human pathogenesis of TBM from a primary pulmonary infection. An attempt was 
made by Pando et al 
39
 whereby mice were intratracheally inoculated with Mtb strains isolated from 
the CSF of patients with TBM. The animals developed disseminated as well as cerebral TB, likely 
through hematogenous seeding as is presumed to occur in humans. Examination of the brain showed 
evidence of sub-pial lesions which had ruptured into the surrounding subarachnoid space and 
produced an inflammatory exudate, and immunohistochemistry was positive for IFN-  and TNF-α, as 
well as mycobacterial antigens in astrocytes, microglia, ependymal and meningothelial cells. Mice 
83 
 
infected with strains isolated from pulmonary TB did not result in remarkable cerebral pathology, 




Elevated CSF levels of TNF-α, IFN- , IL-1 , IL-10, IL-6, IL-8, IL-2, MCP-1 and MIP-1α have been 
reported in adult and paediatric TBM 
25,162,170,381,401-404
. TNF-α levels have sometimes been recorded at 
low levels 
372,381,401,404
. The interplay between TNF-α and its receptors may contribute to the biological 
activity of this cytokine based on its concentration 
372
. IL-12p70 was either undetectable in CSF or 
detected only at low levels 
170,381
. This may have been due to the inhibitory presence of IL-10 in the 
samples tested or may suggest that IL12 has a poor presence in the CSF. Cytokine levels may vary 
across studies, even when the same testing platform has been used, possibly as a function of the 
timing of sample collection, the synergistic interplay between pro- and anti-inflammatory cytokines, 
and variability in the strain of Mtb 
162
. To exemplify, IL-10 levels in adult CSF were 10-fold lower in 
a study by Kashyap et al
402
 relative to Mastroianni et al 
170
; however, the low levels of IL-10 in the 
former may indicate a developing rather than an established inflammatory cascade in which pro-
inflammatory cytokines were still dominant. Little data are available on children. Due to the large 
variability in cytokine levels within adult cohorts, it is difficult to determine age differences as 
paediatric values mirror values from some adult studies and diverge from others. In a study examining 
both adults and children age was not found to have a significant effect on cytokine levels 
25
. The 
ubiquitous finding across all studies is that cytokine levels are elevated in TBM with some decrease in 
levels after the initiation of treatment. The degree of the attenuating influence of treatment, however, 
varies between cytokines, and inflammation is continuous despite drug administration.  Table 6.1 and 
6.2 provide levels of cytokines and chemokines reported in the TBM literature.  
Differences between CSF and serum values 
Systemic levels of cytokines may not reflect the immune response at the site of disease. Increased 
serum levels may result from an overproduction of local CNS mediators that leak into the circulation, 
thereby generating a gradient for the recruitment and migration of leukocytes to the active site 
382
. 
Few studies have examined both CSF and serum cytokine levels simultaneously; in an adult TBM 
study Thwaites et al 
372
 showed that CSF far outstripped serum as a sample for the detection of TBM 
related cytokines. In serum TNF-α was undetectable, but IL-8, IFN-  and IL-10 had initial elevations 
followed by an immediate steep decline within the first few days or the first week, and serum values 
were up to 40 times lower than those found in CSF. In a study by Mastroianni et al 
360
 IL-8, MIP-1α 
84 
 
and MCP-1 were not detectable in serum. These findings suggest the compartmentalisation of the 
immune response to the site of infection. However, in a paediatric study Babu et al 
403
found that levels 
of TNF-α and IL-8 were elevated in both CSF and serum relative to controls. As a result of the sparse 
data and the poor detection of cytokines in serum, the remainder of this article focuses on CSF 
findings. 
Temporal profile 
Two experimental in vitro studies 
383,384
 of human monocytes and microglial cells stimulated with 
lipopolysaccharides demonstrated the acute release of pro-inflammatory markers including TNF-α, 
IL-1α, IL-1 , IL-6 and IL-8 by 4-8 hours followed by the delayed production of anti-inflammatory 
cytokine IL-10 at 7-8 hours. These kinetics are mirrored in patient studies; initial pro-inflammatory 
cytokine levels are highest followed by a subsequent decline over several weeks with cytokines only 
becoming undetectable months after the commencement of treatment. TNF-α peaks early and usually 
remains most chronically elevated with levels detectable for up to 16 months post-initiation of 
treatment 
170,401,404
.  Persistent elevation regardless of treatment suggests the importance of TNF-α in 
the chronic on-going inflammatory process in the CNS. Depletion of TNF-α during the chronic phase 
of pulmonary TB has been associated with granuloma destruction and exacerbation of infection 
405
. 
Extrapolated to the CNS, TNF-α may be involved in the immune reaction to TBM as well as 
protection against it 
170
. IFN- , IL-6 and IL-8 appear to have an initial peak followed by persistent 
elevation in TBM although not for as long as TNF-α 170,372,404. In a study examining the relationship 
between intracranial granuloma (IG) formation and IFN- , Mansour et al 376 found that admission 
CSF levels of IFN-  were not associated with the presence of IG’s on computed tomography (CT) 
brain scans but they were associated at 1 month post-admission in spite of IFN-  levels being highest 
at admission. The authors suggested that the on-going inflammatory process rather than the intensity 
of the initial response may be important for IG formation. IFN- , in conjunction with other immune 
factors, plays a role in this process. Initial levels of anti-inflammatory cytokines like IL-10 may be 
low if the samples are taken when the inflammatory cascade is still developing. The prolonged 
elevation of IL-10 in patients may down regulate continued inflammatory activity in TBM 
170,372,376,402
. 
Whether this preserves the CNS or hinders the immune clearance of the TB infection is unclear. IL-8 
appears to decrease most rapidly in TB meningitis; since IL-8 is predominantly a neutrophil attractant, 
this raises questions about differential immune cell attraction and activation in the inflammatory 
process over time 
25,360
. In an experimental study investigating the production of cytokines by 
microglia infected with different strains of Mtb, it was found that the virulence of a strain may be 
determined by the degree to which it is able to supress the immune response in the brain with more 
virulent strains inhibiting early release of TNF-α and IL-1  406. It is clear, therefore, that many factors 
relevant to the host as well as the pathogen may contribute to a heterogenenous temporal profile of 
85 
 
cytokines; however, the prolonged elevation of cytokines in the CSF of TBM patients is a common 
observation. 
Cytokine synergism 
In vitro studies have shown that microglial cell cultures treated with TNF-α and IL-6 resulted in a 
dose-dependent production of IL-10, which subsequently reduced the expression of class II MHC and 
inhibited the production of pro-inflammatory cytokines at a transcriptional level. Furthermore, IL-10 
exhibited autoregulatory control of its own mRNA synthesis in monocytes 
383,384
.  In human studies 
positive correlations have been found between TNF-α, IL-1 , IFN-  and IL-10 in adults 170,171 while in 
a paediatric cohort only IFN-  and IL-1  were significantly associated and not TNF-α and IL-1  401. 
Hasan et al 
382
 suggests that a positive correlation between the pro-inflammatory cytokine IFN-  and 
the anti-inflammatory cytokine IL-10 represents a balance between pro- and anti-inflammatory 
mediators which may be lost in cases of severe extrapulmonary TB disease. Akalin et al 
171
 found that 
the ratio between IL-1  and IL-1Ra indicates the aggressiveness of the inflammatory process and the 
severity of disease when skewed towards IL-1 . Similarly, the association between chemoattractants 
and anti-inflammatory cytokines may also indicate the degree of control exerted over the 
inflammatory process. Therefore, one possible mechanism for disease progression could be an 
imbalance of anti-inflammatory cytokines in the face of elevated proinflammatory mediators. In a 
comparative study across levels of TB disease severity, the balance between and levels of pro- and 
anti-inflammatory mediators varied 
382




Association with disease markers 
Cytokines demonstrate mixed associations with CSF markers of disease and data across studies are 
conflicting. In several studies TNF-α and IL-10 were not associated with CSF protein, glucose or 
white cell count but showed a correlation with CSF adenosine deaminase (a marker of local immune 
response) 
170,171,401
. The association between TNF-α and CSF lactate is mixed; some studies finding an 
association 
209,372
 while others found none
401
. Correlation results for IFN-  have not shown an 
association with any CSF markers except lactate and conflicting results have been found for its 
association with CSF protein 
170,401
. IL-1  was significantly correlated with CSF protein and lactate 
only in a paediatric study 
401
. Further evidence 
171,381
 demonstrates no association between cytokines 
and CSF white cell counts which supports the theory that resident CNS cells are responsible for 
generating inflammation in the CNS. Cytokine levels have also remained persistently elevated despite 
normalisation of these CSF markers.  It has also been suggested that the lack of an association 
between chemokine IL-8 and CSF leukocyte levels may denote that IL-8 has a role primarily in the 
early recruitment of leukocytes 
25,360




; however, factors other than cytokines are also important in leukocyte recruitment and maintaining 
CSF pleocytosis. 
Association with severity and outcome 
The association between cytokine levels and various markers of injury severity and outcome is also 
conflicting. The British Medical Research Council grading system 
76
 for TBM has shown a significant 
correlation with outcome 
58,372
 and so remains a widely used approach to quantifying disease severity 
on admission. Patients in Stage I present with a Glasgow Coma Score (GCS) of 15/15 and no focal 
neurology, in Stage II with a GCS 11-14 or 15 with focal neurology, and in Stage III with a GCS ≤ 
10. Several studies 
162,170,381,401,402,404
 have found no association between TBM stage and the levels of 
TNF-α, IL-10, IL-1- , IL-6 or IL-8. However, in a couple of studies a significant positive correlation 
was demonstrated between the levels of TNF-α and IFN-  and TBM stage 403 and for TNF-α and IL-
1  between Stage I and II 407, although the potential contribution of duration of illness cannot be 
excluded as a confounding factor. 
The association between cytokines and mortality and morbidity also is poor. TNF-α, IL-1  and IL-10 
have shown no association with the development of neurological sequelae 
170,171
. TNF-α, IL-6, IL-10, 
IL-1  and IL-8 do not show a correlation with 3 month clinical outcome and TNF-α, IL-2, IL-6, IL-
1 , IL-8, IL-10 and IFN-  levels have not been associated with mortality 25,171,360,372,381,402,404. Only in 
HIV infected (HIV+) patients were reduced levels of IFN-  associated with death 381. These results are 
surprising in light of the prevailing theory that the prolific host immune response is responsible for the 
poor outcome in TBM and suggest that other factors play a role in the pathophysiology and course of 
this disease while inflammatory markers serve to indicate an ongoing inflammatory process. The 
degree to which the host responds to an invading pathogen as manifested in the degree of cytokine 
production, recruitment of immune cells and inflammatory mediators may be determined by genetic 
factors. This genetic variability in conjunction with the compartment of inflammation and the 
progress of disease contribute to variations of severity and outcome in individual patients 
18
. 
A study examining magnetic resonance imaging (MRI) at 60 days found that hydrocephalus 
correlated positively with IFN- , IL-10 and IL-6; tuberculomas correlated positively with IL-6 and IL-
10 and infarcts with IL-8 and IL-10 
114
. In a more recent study 
162
 examining the relationship between 
CSF cytokines and MRI findings in TBM patients, cytokine levels on admission were not correlated 
with initial MRI findings (including the presence of exudate, tuberculomas, infarcts and 
hydrocephalus) or radiological findings seen after 3 months. This study was conducted on a small 
sample size and levels for individual cytokines demonstrated large variation across this cohort. These 
factors in combination may have contributed to the lack of correlation, or it is possible that the level 
of inflammation does not directly reflect the level of tissue damage occurring as a result of ischemic 
87 
 
processes. In the study on IFN-  and intracranial granuloma formation mentioned above 376, the 
authors found that it was not the level of initial IFN-  but rather the prolonged elevation that may 
have a role to play. Therefore, considering concentrations of cytokines as well as their chronicity may 
be important in elucidating the relationship between radiological findings and cytokines.  
Association with HIV 
In a study examining the cytokine profiles of HIV+ patients with TBM, Patel et al 
407
 found no 
difference between HIV+ and HIV uninfected (HIV-) individuals for TNF-α, IFN-  and IL-10. The 
CD4 counts between these 2 groups, however, were not significantly different and perhaps selection 
of a more immune compromised HIV cohort may have produced a different result. Results also 
indicated a poor correlation between CD4 count and cytokine levels suggesting that there may be 
other sources of cytokine release. The authors also contend that the immune response in the context of 
HIV may be neither Th1 nor Th2 but rather a non-differentiated response as would be seen early in 
immune activation. In a larger study by Simmons et al 
381
 only the levels of IL-10 differed 
significantly between HIV+ and HIV- TBM patients, with lower levels of IL-10 and a subsequently 
higher IFN- :IL-10 ratio found in the HIV+ cohort. The authors suggest that this finding may indicate 
a more pro-inflammatory immune response in HIV. It is noteworthy that this appears contrary to the 
suggestion that the HIV+ immune response to TBM is impaired, as evidenced by less basal 
enhancement seen on CT scans and less exudate in post-mortem studies
192,193
. Reduced IFN-  levels 
were significantly associated with mortality in the HIV+ patients and it is possible that IFN-  may 
confer some protective advantage. Further evidence suggests that TNF-α and IL-10 are not associated 
with HIV status 
170
. A recent study on adult paradoxical TBM-IRIS found that a combination of high 




The effect of immunomodulatory adjunctive chemotherapy 
Despite the fact that the inflammatory cascade has been identified as an important source of brain 
damage in TBM, very few therapeutic studies aimed at modulating the immune response have been 
conducted. One study in children 
101
 and a later study in adults 
172
 showed that adjunctive steroid 
therapy improved mortality, although the mechanism of action was unclear. An in vitro study of 
microglia 
408
 found that infected microglia released a range of cytokines including TNF- α, IL-6, IL-
1 , MCP-1, Rantes, IP-10 and IL-8. Upon treatment with dexamethasone either pre- or post-TB 
infection, there was a marked decrease in almost all these inflammatory mediators. An in vivo study 
394
 showed that treatment with thalidomide, a drug with immunomodulatory effects, decreased CSF 
TNF-α levels and leucocytosis, and that in combination with anti-TB antibiotics it improved survival 
to 100% from 50% achieved with antibiotics alone . 
88 
 
In a formal study on thalidomide in children, the safety and tolerability phase demonstrated that 
thalidomide decreased CSF levels of TNF-α, reduced basal enhancement on CT brain scans, and 
promoted the resolution of established tuberculomas while decreasing the incidence of new ones 
103
. 
These findings, however, were not replicated in the randomised controlled trial which had to be 
prematurely aborted due to adverse side effects in the thalidomide arm of the trial 
104
. Cytokine levels 
between treatment and placebo groups were not significantly different; however, there was an 
increase in plasma IL-12 in the thalidomide group, which may signal an enhanced Th1 response. The 
authors suggest that, in the context of an already exaggerated baseline immune response, this may 
have led to the worsening of vasculitis and ischemia in these children, contributing to their poor 
response to treatment. In a large randomised controlled trial in adults, dexamethasone improved 
mortality and decreased the incidence of hydrocephalus and infarction on MRI, but it did not 
significantly affect the levels or temporal profile of a large range of inflammatory mediators including 
IL-6, IL-10, IL-12p70, IL-1 , TNF-α and IL-8, IP-10, MCP-1, RANTES and MIG in CSF or blood172. 
The authors suggest that the benefit of steroids, therefore, may not be through immunosuppression but 
via mechanisms unrelated to inflammation. Furthermore, the question is raised as to whether immune 
mediators have as much of a causal role in the poor outcome of TBM disease as current thinking 
suggests. Several additional studies examining inflammatory mediators in TBM have found that the 
administration of steroids has not significantly altered cytokine levels or their temporal profile 
25,162,170,360,401
. In part this may be due to late presentation in which case much of the inflammatory 
response has already developed and the delivery of therapeutic molecules to the target site across the 
BBB may also be limited 
18
. 
There are a few case reports 
377,409-411
 in immune competent and compromised patients of the use of 
IFN-  to treat protracted CNS TB refractory to regular anti-TB drugs and steroids. These reports 
suggest that IFN-  aids in disease resolution. In the report by Coulter et al 377 gene analysis 
demonstrated a down-regulation of pro-inflammatory cytokine genes post-IFN-  administration, 
supporting the idea that IFN-  may also have an immunomodulatory role. Lee et al 411 suggest that 
IFN-  may enhance drug penetration through the BBB and thereby strengthen their activity 
intracranially. The domain of cytokine therapy in TB is still in evolution and further research is 
required. 
Comparison with bacterial meningitis 
Studies suggest that, relative to TBM, concentrations of pro- and anti-inflammatory markers in acute 
bacterial meningitis are detectable at higher levels, span a much larger range during disease onset, are 
more easily detected in CSF samples, and decrease rapidly post treatment initiation 
171,412,413
. In 
comparison with TB and viral meningitis, bacterial meningitis exhibits a more aggressive pro-
89 
 
inflammatory process characterised by high levels of pro-inflammatory cytokines like TNF-α and 
lower levels of immune regulators like IL-1Ra 
171
. The ongoing low level cytokine release in TBM 
appears indicative of chronic release in an on-going pathological process. A similar trend is seen for 
chemokines; in a study on CSF IL-8, MCP-1 and MIP-1α in patients with pyogenic and TB 
meningitis, the authors found that all three chemokines were elevated in meningitis cases on 
admission; however, pyogenic meningitis demonstrated the highest IL-8 and MCP-1 levels followed 
by a rapid decrease in the CSF over a 4 week period. In comparison TBM patients had more 
moderately elevated chemokine levels which remained chronically elevated and were detectable up to 
32 weeks post-admission. These findings matched those of 2 paediatric studies of CSF IL-8 levels in 
purulent, TB and aseptic meningitis 
25,414
. The differences in cytokine profiles may reflect differences 
in disease and the nature of immunity with pyogenic meningitis being characterised by an acute, 
neutrophil dominated, early resolving pattern relative to the chronic, mononuclear pattern of TBM. 
The role of IL-8 in pyogenic meningitis may be in the initiation of inflammation while in TBM it 
participates in the on-going inflammatory process. The mean duration of illness pre-admission was 
longer in TBM patients 
25
; it is possible, therefore, that an early acute rise in chemokine levels may 
already have been missed in the TBM cohort due to late presentation. Bacterial and TB meningitis 
further diverge with respect to cytokine associations with outcome; whereas the correlation between 
cytokines and outcome in TBM is tenuous, several studies have shown that levels of cytokines in 
bacterial meningitis are indicators of disease severity
415,416
 and predictors of outcome 
415,417,418
. 
Cytokines as diagnostic markers 
Several studies have examined specific cytokine levels across bacterial, viral, aseptic and TB 
meningitis. To date no single cytokine or combination of cytokines allows differential diagnosis with 
acceptably high sensitivity and specificity 
18
. The distinction between bacterial and TB meningitis 
relative to aseptic meningitis is easily made by comparing cytokine levels because aseptic meningitis 
shows much lower levels. However bacterial meningitis is better distinguished by the swift decline in 
levels versus the chronic elevation in TBM 
25,171,360,414,419
. The unique kinetics may reflect the 
differential attraction and activation of immune mediators, the inflammatory response and clinical 
course between these meningitides.  
IFN-  has shown greater sensitivity but less specificity than PCR for Mtb in the diagnosis of TBM 420. 
IFN-  levels are affected by anti-TB medication while PCR for Mtb is dependent on the bacillary load 
in the CSF; using both tests in combination has therefore been recommended. Although it was found 
that below a certain threshold of IFN-  TBM could be excluded, this test did not differentiate between 
TBM and other meningitides. Studies have found that IFN-  release assays (IGRA) are promising for 
the diagnosis of pulmonary TB, however they are not able to distinguish between latent and active 
TB. Combining IGRA with multiple cytokines and chemokines has shown that latent versus active TB 
90 
 
demonstrates different cytokine and chemokine correlations with IGRA. This research suggests that 
the diagnostic accuracy of IFN-  in TB may be enhanced when combined with a panel of other 
immune markers. The utility of inflammatory mediators as diagnostic markers is limited by costs and 
by the fact that they are currently not routinely measured 
18
 however, research is ongoing and results 
from extra-pulmonary TB samples including pleural fluid are uncovering the diagnostic potential of 





Cytokines are increased in TBM samples, especially in CSF. The inflammatory response in the CNS 
to TBM is distinct from other meningitides and appears to be acute initially followed by a low level 
but on-going chronic phase despite treatment. Conflicting data on elevation and cytokine associations 
between studies may result from variation in the frequency and duration of sampling, the timing of 
sampling relative to disease onset and treatment commencement, the synergism between cytokines, 
and the test platform used. Many of these factors are challenging to monitor and control and 
discrepancies between studies are consequently not likely to be easily resolved. The theory that poor 
outcome is a function of the prolific host immune response is perhaps too simplistic; poor outcome is 
not strongly associated with immune mediator levels and although steroids improve mortality they 
have no significant effect on cytokine levels and may provide benefit through channels other than 
mediating the inflammatory response. It is clear that other factors are also of importance, particularly 
the ischemic process which takes place as a result of raised intracranial pressure and cerebral blood 
vessel damage. Steroids may have limited benefit in TBM because they are unable to mitigate the 
vasculitis and infarction contributing to poor outcome. Markers of inflammation do not necessarily 
reflect the degree of cerebral tissue injury and the severity of the disease; therefore, assessing 
cytokines in combination with other markers of injury may improve the understanding of the 
pathophysiology, the disease course and outcome of TBM. Additionally, the interaction between host 
factors (such as nutrition, immune status, concomitant illness, age, genetics and anatomical site of 
infection) and pathogen factors (like strain, virulence and drug resistance) add to the complex picture 
of this disease. Treatment remains challenging and novel methods of intervention may benefit from an 




Table 6.1: Cytokine concentrations in TBM patients (pg/ml) 
Authors Sample TNF-α IFN-  IL-1  IL-6 IL-10 IL-12p70 
Donald et al 
(1995) 
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56.7 (<5-236)   46 (6.7-249) <5 
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CSF = cerebrospinal fluid, IL = interleukin, TNF-α= tumour necrosis factor alpha, IFN-  = interferon gamma, 
IL-1ra = interleukin 1 receptor agonist, HIV= human immunodeficiency virus. M= mean, Md = median. N= 
sample size. ¹ median and range, ² mean (standard deviation [SD]), ³ median, 
4 
mean (SD), range. * Values 




Table 6.2: Chemokine concentrations in TBM patients (pg/ml) 
Authors Sample IL-8 MCP-1 MIP-1α 
Mastroianni et al (1998) 





963(123-1236) 808(235-1375) 26.6(16.3-48) 
Yaramis et al (2001) 
























Thwaites et al (2003) 
>15 years 
N=21 
CSF4 8297 (9640), 
430-41298 
  
Yilmaz et al (2003) 
1 month – 14 years 
N=5 
CSF² 4112 (458)   
Simmons et al (2006)* 
Md = 38 (15-88) years 
N=408 HIV- 






















CSF = cerebrospinal fluid, IL = interleukin, MCP-1 = Monocyte chemoattractant protein – 1 alpha, MIP-1α = 
Macrophage inflammatory protein 1 α, HIV= human immunodeficiency virus. M= mean, Md = median. N= 
sample size. ¹ median and range, ² mean (standard deviation [SD]), ³ median, 
4 
mean (SD), range. * Values 






















CHAPTER 7: METHODOLOGY 
 
Working hypotheses and study objectives  
 
This study hypothesised that markers of neurological injury (singly and combined with inflammatory 
markers) are:  
1) elevated in TBM, and  
2) elevated concentrations are associated with injury severity and outcome. 
 
The primary objectives of this study were: 
1) to examine the profile of neurological and inflammatory biomarkers in acute paediatric TBM in 
lumbar CSF, ventricular CSF and serum, and 
2) to examine the relationship between biomarkers and 6 month clinical and neurodevelopmental 
outcome (assessed using the Paediatric Cerebral Performance Category Scale [PCPS] and Griffiths 
Mental Development Scales, extended version [GMDS-ER]) 
 
The secondary objectives were: 
1) to examine the association between biomarkers and measures of injury severity (clinical 
examination, radiology and physiological measures of brain ischaemia), 
2) to examine the association between biomarker concentrations and patient and clinical 
characteristics, and  
3) to examine novel approaches to detect brain ischaemia in TBM, using near-infrared spectroscopy 




This was a descriptive cross-sectional study that examined biomarkers of neurological injury and 
inflammation across different sample types in cases and controls, and a cohort study of the 
associations between biomarker concentrations and outcome and injury severity. 
 
Scientific and ethics approval 
 
Scientific and ethics approval for this study were granted by the local scientific research and human 
ethics review boards (ethics number 318/2010, Appendix 2). Hospital permission was obtained 





Funding for this project was generously provided by the Clinical Infectious Diseases and Research 











TBM cases were selected from children treated for definite or probable TBM with hydrocephalus at 
Red Cross War Memorial Children’s Hospital (RXH) between October β010 and August β01γ. The 
diagnosis of patients included in this study was evaluated according to criteria outlined in a recent 
consensus statement on diagnostic criteria for TBM 
69
. Definite cases were defined as patients in 
whom TB was cultured from the CSF or acid-fast bacilli were visualised in the CSF. The diagnosis of 
probable TBM was made based on a combination of clinical, bacteriological and radiological criteria 
as outlined in the Case Definitions chart (Appendix 1). Patients with other concomitant neural 
pathology or systemic infection were excluded. Inclusion and exclusion criteria are outline in Table 
8.1. 
 
Table 8.1: Study inclusion and exclusion criteria 
Inclusion Criteria Exclusion Criteria 
Diagnosed with definite or probable TBM Other neural pathology 
Diagnosed with hydrocephalus  Systemic infection other than TB 





Two groups of controls were selected: Group A served as controls for biomarker concentration 




This control group consisted of 2 patient categories: 
Category 1: This group of patients served as controls to establish normative biomarker concentrations 
and comprised children presenting to the Neurosurgery Unit at RXH for elective spinal surgery for a 
fatty filum – a congenital disorder characterized by an abnormal amount of fat in the filum terminale 
(non-neural structure) of the spinal cord. This is not a progressive disease, is not associated with 
ongoing acute neurological injury or inflammation and the operation is primarily prophylactic; 
therefore biomarker levels were not anticipated to be elevated.  
Category 2: To control for possible extra-cranial TB sources of S100B and NSE a second control 
group of children with pulmonary TB (pTB) was enrolled to validate the specificity of biomarkers for 
98 
 
neurological TB injury. As both these groups of patients were selected as convenience controls it was 
not possible to age-match them with TBM cases. 
 
Group B 
Studies on the development of children from low socio-economic status (SES) backgrounds in Cape 
Town demonstrated that low income, poor nutrition, family instability, and low levels of maternal 
education and childhood stimulation are significantly associated with poor baseline development, 
particularly after the age of 1 year 
422,423
. By virtue of it being a state institution most children 
admitted to RXH stem from these impoverished backgrounds and it is likely that pre-morbidly these 
patients would perform poorly on a developmental test developed in a first world setting like the 
United Kingdom.  Therefore, in an attempt to isolate the association between development and TBM 
specifically, a control group of children from similar social circumstances was included. Children 
from a similar SES, language and culture group as TBM cases coming from seemingly stable homes 
and without a recent history of illness or developmental delay were sourced from siblings, family, 
friends and neighbours of TBM cases. Controls and cases were age-matched as best as possible. 
 
Sample size calculation  
 
Estimation of the number of cases was powered by the sample size required for outcome analysis. 
Studies which have compared neuromarker concentrations between good and poor outcome groups in 
TBI demonstrate meaningful differences 
272,332,336,424
. It is reasonable to hypothesise that biomarker 
levels will be higher in unfavourable versus favourable outcome; therefore, we estimated the sample 
size using a one-sided test with an alpha level of 0.05. The smallest reported standardised mean 
difference noted in biomarker studies in paediatric TBI was for S100B and therefore sample size 
calculation was based on these data. The standardised mean difference between favourable and 
unfavourable outcome groups was 0.82, which is considered a large effect size (mean [standard 
deviation] unfavourable = 1.6[1.6] and favourable = 0.6[0.4]). This suggested a required sample size 
of approximately 42 patients for an adequately powered study (80%). One limitation of this sample 
estimation was that multiple comparisons were not accounted for. However, considering budget 
constraints, the time for patient accrual, and the fact that this was a pilot study aimed at collecting 
preliminary data, this sample size was selected.  
 
There is little research on cytokines in children with TBM, and none on markers of neurological 
injury such as S100B, NSE and GFAP. Research on neuro- and inflammatory markers in paediatric 
head injury has shown effect sizes ranging from 1.1-9.6 
272,425
 and inflammatory markers in TBM 
have shown effect sizes of 17-24 
403
 when comparing cases with controls. These effect sizes and the 
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very low biomarker levels and little variability seen in controls suggested that a small sample size 
would be sufficient to demonstrate a significant difference in biomarker levels due to TBM. 
Therefore, 11fatty filum controls undergoing elective spinal surgery and 9 controls with pTB were 
included.  
 
Subject Recruitment  
 
Patients meeting the inclusion criteria were identified from referrals or admissions to the casualty, 
paediatric and neurosurgical wards of RXH. On admission, parents were approached for consent after 
the study had been fully explained in their preferred language - English, Afrikaans or Xhosa with the 




Antimicrobial medication and steroids 
 
All patients were treated with the standard 4 drug regimen of rifampicin, isoniazid, pyrazinamide and 
ethambutol for 2 months followed by 4 months continuation of rifampicin and isoniazid at weight-
dependent doses. Prednisone was given adjunctively for the first 3 weeks as per standard of care. 
Anti-retroviral treatment (ART) was administered in HIV+ patients; the timing of ART initiation was 
determined by the infectious diseases consultants. 
 
Management of Hydrocephalus (HCP) 
 
All patients had an admission CT brain scan once TBM was suspected and patients with radiological 
evidence of HCP were referred to the neurosurgery unit. Tuberculous HCP is an unusual form of HCP 
which may be communicating or non-communicating. Successful medical treatment of the former has 
been demonstrated, obviating the need for surgery 
126
. As outlined in Chapter 1 there are variable 
protocols reported for treating tuberculous HCP, each with advantages and disadvantages. Our 
protocol is based on the work of Schoeman et al 
126
. Establishing the communicating nature of HCP 
involved performing an AEG according to described procedure 
119
; briefly 5-10 ml of air was injected 
into the lumbar subarachnoid space (SAS) after which the patient was sat in an upright position for 30 
minutes to allow the air to move up the spinal canal into the cranium. Air in the ventricular system 
suggests CHCP (positive test) and air in the basal cisterns or over the convexity of the brain but not in 
the ventricular system suggests NCHCP (negative test). Occasionally, no air is visible within the 
cranium, which may be due to a technical problem or impaired passage of air in the spinal canal due 
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to spinal exudates and arachnoiditis. If results were inconclusive on the first attempt, the AEG was 
repeated to exclude the possibility of technical errors. If necessary, an EVD was placed first to ensure 
safe continuation of the procedure in patients who may have had NCHCP. The procedure is safe and 
was performed either by the paediatrician or neurosurgeon treating the patient, but a neurosurgeon 
was always informed and able to take the child to theatre for an EVD or shunt immediately should 
non-communication have been diagnosed. Patients who were considered clinically too unstable or had 
a very depressed LOC on admission immediately received an EVD as a temporizing measure to 
control raised ICP. Thereafter, HCP in these children was investigated using an AEG and /or column 
test. Baseline skull X-rays were performed in all children after EVD insertion to exclude the presence 
of air in the ventricles as a result of surgery and the drain was clamped while the child sat upright 
after the AEG was performed. Column tests have been described 
120
 and briefly involved clamping the 
EVD distally to the drainage system and connecting a manometer to the proximal port. An LP was 
performed with the patient lying in the lateral position with a manometer connected to the LP needle. 
The lumbar and ventricular opening pressure (OP) readings were recorded before and after the release 
of CSF. CHCP was suggested by similar initial values and an equal change after CSF release. When 
readings did not correlate NCHCP was assumed. Column test results were considered in combination 
with AEG results were possible.  NCHCP was treated with a VPS or ETV 
120,426
. Patients with CHCP 
or who had undergone an ETV were medically treated with acetazolamide and Lasix in conjunction 
with serial LPs 
126
. The OP was recorded during serial LPs as a temporal measure of ICP. Cessation of 
serial LPs occurred once the ICP had normalised and remained low over a minimum of 2 LPs 
performed at least 1 week apart.  In general, medical treatment continued for 3 weeks or until the OP 
settled. A VPS was inserted if medical therapy failed to control HCP (defined by resolution of 
hydrocephalus on follow up brain imaging and normalised OP on LP). The protocol for patient 




Hyponatremia was slowly corrected, mostly using fluid resuscitation with normotonic or hypertonic 
fluids. The distinction between CSW and SIADH is not easily made 
112
 and we were guided in large 
part by patient volume status and laboratory urine results. Perturbations in any other organ systems 




















All analyses in this project were conducted with the assistance of a qualified statistician using the 
statistical software programs STATA (StataCorp. 2013. Stata Statistical Software: Release 13. 
College Station, TX: StataCorp LP) and R (R Development Core Team (2013). R: A language and 
environment for statistical computing. R Foundation for Statistical Computing,Vienna, Austria. ISBN 
3-900051-07-0, URL http://www.R-project.org.). Data are presented as median (range or interquartile 
range) due to the non-parametric distribution. Statistical tools used for the various analyses are 
outlined in the relevant methods sections. The significance level for all analyses in this project was set 
at the 0.05 level.  
 







CHAPTER 9 SUMMARY 
Patient and admission clinical characteristics 
 
 
This chapter aimed to provide a profile of the study patients in terms of their clinical admission and 
demographic characteristics, CSF diagnostic and chemistry results, treatment and outcome. A brief 
summary of TBM patients who were ineligible for study inclusion was also included. 
 
Data were collected from patient records and laboratory databases at RXH. Clinical outcome was 
assessed at routine 3 and 6 month outpatient hospital follow up and included mortality at 6 months, 
dichotomised clinical outcome (good or poor) and morbidity in survivors according to the Paediatric 
Cerebral Performance Category Scale. Neurodevelopmental outcome was assessed at 6 months using 
the Griffiths Mental Scales extended version (GMDS-ER).  
 
The main results were as follows: 
1. From October 2010 to August 2013 RXH admitted 74 children with probable or possible 
TBM. HCP was diagnosed in 71.6% of these patients.  HIV co-infection was recorded in 8% 
of patients, and the mortality rate was 13.5%. 
2. The 44 patients included in this study were young (≤5 years, n=γ7, 84.1%) and presented with 
the typically reported clinical signs and symptoms of TBM. Only 2 patients (5%) were co-
infected with HIV. 
3. Lumbar and ventricular CSF chemistry results were significantly different in terms of protein, 
glucose, chloride and lymphocytes.  
4. The culture positivity yield was 53.8%, which is an improvement on historical rates and those 
reported in the literature, and is possibly due to the larger volumes of CSF sent for culture. No 
cases of drug resistance were reported in the study cohort, although 2 cases of drug resistance 
occurred in the patients not eligible for study inclusion 
5. CHCP was more common than NCHCP (n=3, 8%). Medical treatment was successful in 57% 
of patients with CHCP. NCHCP was treated with a VPS or ETV.  
6. The mortality rate by 6 months was 16% (n=7). Four of these patients died within the first 10 
days after admission. Almost half (n=21) of the full cohort made a full clinical recovery; 11 
patients (25%) suffered mild-moderate disability, 2 patients were severely disabled (4.5%) 
and 3 patients (6.8%) were considered vegetative.  
7. TBM cases demonstrated neurodevelopmental deficits in all developmental domains assessed 
and the impact of TBM on development was multidimensional; the impact of socio-economic 










Admission clinical and demographic data 
 
General demographic and clinical data for TBM cases were prospectively collected, including gender, 
age, sex, immunization history, TB contacts, previous medical history and underlying disease 
including HIV. Clinical data included presenting symptoms, duration of symptoms before admission, 
clinical and neurological signs. TBM severity was determined using the refined British Medical 
Research Council criteria 
81
 on admission and after 1 week: Stage I: GCS 15 without focal neurology, 
Stage IIa: GCS 15 with neurological deficit/ GCS13-14 with/without neurological deficit, Stage IIb: 





Clinical data collected during hospital admission included neurosurgical interventions (EVDs, VPSs 
and ETVs), lumbar punctures (OP), Mantoux results (where performed), and medication. 
 
Laboratory data from CSF included glucose, protein, chloride, white cell count and differential, TB 
culture, Ziehl-Neelsen staining for AFBs, TB PCR and drug sensitivity as well as culture for other 
bacteria. TB culture results from tracheal aspirate, gastric wash and sputum were documented. 
Haematological data included blood sodium levels and HIV reactivity.  
 
Radiology findings: All imaging was reviewed by experienced paediatric radiologists, including chest 
x-rays (CXR), computed tomography (CT) brain scans, magnetic resonance imaging (MRI) of the 













Outcome was assessed at 6 months after initiation of treatment. For survivors, clinical outcome was 
assessed at 3 and 6 months post-diagnosis by a senior neurosurgeon who was blinded to the biomarker 
results. A second senior neurosurgeon scored the follow-up notes according to the Paediatric Cerebral 
Performance Category Scale (PCPS - Appendix 4) which has been validated in hospitalised paediatric 
patients for the assessment of physical and cognitive disability 
427
. Outcome scores were examined as 
follows: for the cohort overall scores were dichotomised at 6 months as 1-3 (good outcome) and 4-6 
(poor outcome which included death). For survivors, scores were categorised into 3 groups; 1 (normal 




At 6 months developmental outcome was assessed using the GMDS-ER (Appendix 5) which has been 
validated for a South African paediatric cohort using all three major languages, English, Afrikaans 
and Xhosa 
428
, and which has been used in a number of studies of development after TBM 
106,145
. This 
test battery is the internationally accepted gold-standard assessment of development in children aged 
0-8 years old and comprises 6 sub-scales: 
1. Locomotor – tests physical development in young children including the ability to sit, walk, 
run, jump, balance and master stairs. 
2. Personal-social - assesses personal and social development including the ability to respond 
socially to interactions, independence in eating, dressing and bathroom activities, and 
knowledge of personal details, such as birthday and address. 
3. Hearing and Language – examines the growth and development of language through tasks 
which test vocabulary, sophistication of speech and language expression as well as 
comprehension. 
4. Eye and hand coordination – assesses the handwork and visual ability of the child with tasks 
involving building blocks, drawing and manipulation of objects. 
5. Performance - tests skill in manipulation, speed of working, precision, pattern recognition 
through form boards, model construction and pattern-making. 
6. Practical reasoning – focuses on numerical reasoning and simple problem solving with tasks 
involving counting, memory and reasoning. 
 
Scores are assigned for the number of items passed in each sub-scale. The raw scores for each 
subscale as well as the general quotient (GQ - mean of all the raw scores) are then compared against 
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established British norms for age providing an estimate of the age-equivalence of the patient’s 
performance. 
 
The Baby Scales version of the test battery is designed for children aged 0-2 years; it assesses only 
sub-scales 1-5 and is therefore scored according to a separate system of normative values. TBM cases 
were scored according to the age appropriate scoring system and those patients who crossed between 
the Baby Scale and the 3-8 year version had to be scored on the 3-8 year system while compensating 
for the additional Scale 6. To allow for unified reporting across the 2 versions of the test battery, 
analysis focussed only on age equivalents as these are comparable across the Baby Scale and the 3-8 
years, sub-quotients are not reported. Children older than 8 years did not undergo developmental 
assessment. 
 
TBM cases underwent GMDS-ER testing as part of their routine 6 month outpatients follow up. The 
candidate was trained in administering the test battery and personally tested all English and Afrikaans 
speaking children (cases and controls). Xhosa-speaking children were assessed with the assistance of 
a Xhosa-speaking colleague trained and experienced in conducting GMDS-ER assessments in Xhosa. 
Mothers were requested to be present when possible and maternal level of education was ascertained. 
All patients were assessed for hearing difficulties either at RXH or at BCH prior to the developmental 




Group A (biomarker controls): Category 1: Data collected from fatty filum control patients included 
age, sex and previous medical history. 
Category 2: Data collected from pTB controls included age, sex, previous medical history and sputum 
TB investigation results.  
These data were extracted from patient medical records and the NHLS database. 
 
Group B (Neurodevelopment controls): Data collected included age, sex, previous medical history 
and maternal level of education. 
 
TBM patients not eligible for study enrolment 
 
The study had strict inclusion and exclusion criteria, the most important of which were the presence of 
hydrocephalus and the timing of treatment initiation. To place the findings of this selected study 
cohort in the general context of TBM at RXH, some basic demographic, radiological and laboratory 
data were also collected for patients who were treated for suspected TBM at RXH during the duration 
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of the study but were not eligible for study inclusion. These patients were evaluated according to the 
consensus diagnostic criteria and patients meeting the definite, probable or possible TBM diagnoses 
were included. 
 
General demographic and clinical data collected from hospital records included gender, age, sex, 
immunization history, TB contacts and underlying disease including HIV (when available). Clinical 
data included admission GCS and MRC stage on admission, and outcome data when recorded. From 
the NHLS database CSF diagnostic (culture, staining for AFBs, PCR and drug sensitivity) and 
chemistry results for the initial LP (glucose, chloride, protein, cell count) were also recorded as well 
as the results of TB investigations from other specimens. Imaging findings on admission CT brain and 
CXR were obtained from the RXH radiology database. Outcome data collected from patient folders 
only included in-hospital mortality as most of these patients are discharged to secondary hospitals and 






To ascertain if there was a rostro-caudal gradient in CSF chemistry time-linked lumbar and 
ventricular CSF chemistry results taken on admission were compared using the Wilcoxon signed rank 
test. In patients who did not have both lumbar and ventricular CSF taken initially, the first available 
combination of the two sample types was used for analysis. 
 
Association with clinical outcome 
 
The association between patient and admission characteristics and outcome (mortality, 6 month 
clinical outcome and survivor morbidity at 6 months) was analysed using the Chi-square or Fisher’s 
exact tests. The association between CSF chemistry and 6 month outcome was investigated using 




First, TBM case and control results were compared to the British norms in terms of age-equivalents; 
the distribution of scores above and below the age-equivalence was calculated. Next, cases were 
compared to controls using a general estimating equation (GEE) which incorporated subscale 
(locomotor, personal-social, language, eye-hand coordination, performance, reasoning, GQ) and 
group (case/control). As the term ‘neurodevelopmental delay’ has a very specific definition which is 
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not fully applicable to this patient cohort, the term ‘neurodevelopmental deficit’ was adopted to 
indicate that TBM cases were developmentally behind relative to the controls. The median raw score 
for each sub-scale and the GQ were calculated for the control group. This was done in age bands of 0-
24, 25-48, 49-96 months to accommodate for age-related function. The raw scores per sub-scale and 
for the GQ of the TBM cases were compared to these medians; if the raw score fell below the control 
median the TBM case was defined as having neurodevelopmental deficit on that sub-scale or the GQ. 
The median was selected as the threshold for comparison because the distribution of scores below the 
control median most closely matched the distribution of scores below the age-equivalents of the 
British norms. A flow diagram of this method is outlined in Figure 9.1. 
The relationship between clinical and neurodevelopmental outcomes were analysed to ascertain 
whether the two outcome measures were aligned. As the GMDS-ER testing was limited only to 
children who were physically and cognitively able to participate in testing, clinical outcome for this 
analysis was dichotomised as normal (PCPS 1) or mild-moderate disability (PCPS 2-3). Each 
patient’s neurodevelopmental score (deficit or no deficit) for the GQ and each sub-scale were 
examined in association with their clinical score using the Chi-square or Fisher’s exact test.  
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Seventy-four patients who met the consensus criteria for definite, probable or possible TBM were 
treated at RXH from 01 October 2010 to 29 August 2013. Among these patients HCP was diagnosed 
in 53 patients (71.6%); 44 (83%) of the HCP patients were enrolled in this study and 9 (17%) were 
excluded. Reasons for exclusion included having been started on TB treatment >72 hours before 
admission to RXH (n=3), HCP had not been diagnosed on admission when treatment was started 
(n=1), initial misdiagnosis as viral or bacterial meningitis (n=2), HCP was treated before the diagnosis 
of TBM was made (n=1), spinal TB had been treated before the diagnosis of TBM was made (n=1), 
and HCP was due to obstruction caused by multiple posterior fossa tuberculomas which accompanied 
TBM (n=1) – a flow diagram of patient selection is provided in Figure 9.2.  





Complete TBM cohort 
The median age for the 74 patients admitted to RXH was 3.9 (0.25– 13) years and 42 (56.8%) were 
boys. Definite TBM was confirmed on CSF culture in 31 (42%) patients and 2 had drug resistance. 
Most patients presented with MRC Stage II TBM (n=41, 55.4%), the HIV positivity rate was 8% 
(n=6) and the mortality rate was 13.5% (n=10). Details on patients ineligible for study enrolment are 
included in Appendix 6. 
TBM Study population 
Patient Admission Characteristics 
TBM Cases 
The median age for cases was 3.3 years, most children were < 5 years old (68.2%) and boys were 
more common (63.6%). Ninety percent of patients presented with Stage II or III TBM. By 1 week 
after admission clinical staging had improved in 21 (47.7%) patients and worsened in 20.5% (n=9). 
None of these patients had previous documented TB or had taken TB medication. A positive TB 
contact was reported in less than half the patients; known contacts included parents, care givers and 
close family members or friends. The median duration of symptoms was 7.5 days and the median 
number of admissions to health care facilities or practitioners before presenting to RXH was 2 per 
patient (maximum 5). Symptoms of pulmonary TB (pTB) including persistent cough and night sweats 
were not commonly reported, but weight loss and failure to thrive were noted in half the cohort. The 
most commonly recorded signs and symptoms were an altered level of consciousness (n=40, 90.1%), 
meningism (n=34, 77.2%), fever (n=30, 68.2%) and loss of appetite (n=27, 61.4%). Focal neurology 
included unilaterally non-reactive pupils (n=6, 13.6%), cranial nerve palsies (n=10, 22.7%), paresis 
(n=12, 27.3%) and aphasia (n=8, 18.2%). Papilloedema was infrequently reported, however the fundi 
were not examined in all admissions and may be difficult to assess accurately. Photophobia was 
recorded in 4 patients. Over 80% (n=26) of patients had been vaccinated against TB and almost 70% 
(n=20) who were tested demonstrated a positive TST. HIV status was tested in 43 patients (97%) and 
was positive in 2 children (5%). Where maternal HIV history was obtained (n=31), 8 patients (25.8%) 
were recorded as having been exposed to HIV; 6 patients (75%) had not sero-converted. Demographic 
and admission characteristics and their association with outcome are outlined in Table 9.1. 
Controls 
The median age was 2.75 (0.75-8) years for fatty filum controls (n=11) and 3.67 (1.25 – 11.83) years 
for pTB controls (n=9). Both groups were divided evenly between boys and girls. All pTB controls 
were treated according to the standard medical regimen; only 2 patients (22.2%) were sputum smear 




Table 9.1: Admission demographic and clinical characteristics 
Characteristic Value Outcome association 
Demographic characteristics   
Age 3.3 (0.3 – 13.1) years p=0.96 
 0-2 years 19 (43.2)  
 3- 5 years 18 (40.9)  
 > 5 years 7 (15.9)  
Gender 
 
Male       28 (63.6)  
Female   16 (36.4) 
p=0.1 
Admission characteristics   
MRC Staging  Admission Week 1 p=0.01* p<0.001* 
 1 4 (9) 18 (40.9)  
 2a 17 (38.6) 8 (18.2)  
 2b 14 (31.8) 5 (11.4)  
 3 9 (20.5) 11 (25)  
  Dead  0 2 (4.5)  
Symptom duration 7.5 (1 – 90) days p=0.05* 
Weight loss/failure to thrive 22 (50) p=0.74 
Night sweats 4 (9) p=0.56 
Cough > 2 weeks 8 (18.2) p=0.08 
Focal neurology 
a
 21 (47.7) p=0.32 
Altered level of consciousness 40 (90.1) p=0.56 
Lethargy and sleepiness 36 (81.8) p=0.66 
Meningism  34 (77.2) p=0.1 
Fever 30 (68.2) p=0.52 
Loss of appetite  27 (61.4) p=0.49 
Bulging fontanelle (n=9) 
b
 5 (55.6)  
Vomiting 24 (54.5) p=0.1 
Seizures 14 (31.2) p=0.11 
Headache (n=37) 
c
 15 (40.1) p=0.02* 
Papilloedema 9 (20.1) p=0.68 
Irritability 11 (25) p=0.02* 
Recent TB contact 21 (47.7)  
   
Vaccination (n=33)
 d
 26 (78.8)  
TST (n=29) 20 (69)  
HIV infection (n=43) 2 (4.7) p=0.02* 
HIV exposure (n=31) 7 (22.6) p=0.48 
   
Diagnostics   
CSF TB culture (n= 39)   p=0.56 
 positive 21 (53.8)  
 negative 18 (46.2)  
Values reported as median and range or number (percentage), Outcome is dichotomised (good and poor) at 6 
months. * = statistically significant result 
a
 Focal neurology includes pupillary response, paresis, cranial nerve palsies and aphasia, 
b
 For children with 
open fontanelles, 
c
 Pre-verbal children under the age of 1.5 years excluded, 
d 
Parent or guardian not present or 






Forty-one patients had CSF sent for TB diagnostic investigation; for 2 patients CSF TB investigations 
were not requested by the treating clinician and in one patient the only CSF sample obtained was 
insufficient for TB culture - these patients fulfilled the remaining diagnostic criteria for probable 
TBM. An additional 2 patients had CSF sent for culture more than 7 days after the initiation of 
treatment. Definite TBM was confirmed in 22 of the 39 remaining patients (56.4%); 21 had positive 
CSF TB cultures and/or visible AFBs and in 1 patient only AFBs were visualised. All culture positive 
patients were positive on PCR and none had drug resistant TB. Although two thirds of these cultures 
were confirmed on the initial CSF sample, culture positive results were also obtained from subsequent 
samples up until the 5
th
 sample sent. Of the initial samples sent for culture, 31 were lumbar CSF and 
13 were ventricular CSF (some patients had both lumbar and ventricular CSF sent); 16 (51.6%) of the 
lumbar and 8 (61.2%) of the ventricular CSF samples tested culture positive. One patient had 
disseminated TB confirmed on ultrasound and abdominal imaging, 3 patients had positive TB culture 
on tracheal aspirate, 1 on gastric wash and 1 on sputum. No bacteria other than Mtb were cultured on 
CSF during the sample collection phase of this study. 
 
CSF chemistry and white cell count 
 
Admission CSF chemistry and cell counts are summarised in Table 9.2. Eight patients (21%) had 
normal admission lumbar CSF glucose; however, 2 among them developed abnormally low glucose in 
subsequent samples. Only 2 patients (5.3%) had normal admission lumbar CSF protein values and a 
total white cell count (WCC) < 10/cu mm; however, these were all elevated by the second sample. 
Three patients (8.3%) had initially normal lumbar CSF chloride values, these decreased below the 
reference range in subsequent samples. Lymphocytic predominance >50% was seen in the majority of 
lumbar (84%) and ventricular CSF (90%) samples. CSF/blood glucose ratios could not be calculated 
as blood glucose tests are not routinely done at RXH. Analysis with outcome revealed that elevated 
polymorphonuclear cells in the lumbar CSF trended towards an association with better outcome at 6 
months (p=0.06). Lumbar CSF glucose and chloride were significantly lower than ventricular CSF 
(p<0.001 and p=0.04 respectively), and lumbar CSF protein and white cells were higher (p<0.001). 
The average CSF/serum albumin ratio was elevated in lumbar and ventricular CSF samples for TBM 
cases relative to controls (p<0.001). Lumbar ratios were elevated above the 95
th
 percentile of control 
values (6.1) in 31 patients (97%) and ventricular ratios in 18 patients (85.7%). Ratios were 
significantly higher in lumbar than ventricular CSF (p=0.002). Elevated CSF/serum albumin ratios 




Table 9.2: Admission CSF chemistry and cell counts 












Glucose (mmol/l) 1.6 (0.3-4.8) 3.25 (1.2-4.3) p<0.001* p=0.4 
Normal (2.3-3.9) 8 (21) 18 (90)   
Abnormal (< 2.3) 30 (78.9) 2 (10)   
Chloride (mmol/l) 
a
 106.5 (93.0-131.0) 110 (94.0-126.0) p=0.04* p=0.78 
Normal (120-130) 3 (8.3) 4 (20)   
Abnormal (< 120) 33 (91.7) 16 (80)   
Protein g/l  1.98 (0.34-40.88) 0.52 (0.15-1.47) p<0.001* p=0.2 
Normal (0.2-0.8/ 0.15-0.45) 2 (5.3) 9 (45)   
Abnormal (> 0.45/ >0.8)
 b
 36 (94.7) 11 (55)   
Polymorphonuclear 
Cells (/cu mm) 
18.5 (0-280.0) 2.5 (0-74.0) p=0.01* p=0.06* 
Lymphocytes (/cu mm) 144 (6.0-715.0) 19.5 (0-85.0) p<0.001* p=0.25 
Total white cell count 169 (0 – 901.0) 22.5 (0 -139.0)   
Normal (< 10)  2 (5.3) 4 (20)   
Abnormal (> 10) 36 (94.7) 16 (80)   
Lymphocyte predominance     
>50% 32 (84) 18 (90)   
>90% 14 (36.8) 12 (60)   
CSF/serum albumin ratio     
 29.68 (0.3-588.6) 10.3 (2.5-288.5) p=0.002* p=0.12 
Normal 1 (3.1) 5 (21.7)   
Abnormal 31 (97) 18 (85.7)   
Data presented as median (range), number (%), association with outcome analysed with lumbar CSF, 
a
admission 
chloride values were only available for 36 patients, 
b 
Protein references ranges are age dependent: >1 year and 




Serum hyponatremia was present on admission in 38 patients (86.4%). The average sodium value was 






All patients were treated with the standard anti-TB regimen and adjunctive steroids. Patients with 








AEGs and columns tests were performed in 43 patients, the 44
th
 patient was initially thought to have 
bacterial meningitis and underwent an immediate shunt procedure without an AEG; TBM was 
subsequently diagnosed. CHCP was diagnosed by a positive AEG and/or column test in 34 patients 
(79.1%) and NCHCP by a negative test in 3 patients (7%). In 6 patients AEGs were attempted but a 
result could not be obtained; 4 patients failed LP (LP needle was in the subarachnoid space but no 
CSF could be collected - likely due to the presence of spinal arachnoid exudate) and the AEGs could 
not be definitively performed, and 2 patients with an EVD in situ died before a clear result on AEG 
could be obtained. The median opening pressure on LP was 24 cmH2O (1-51 cmH2O). 
 
Patients with CHCP (n= 34) – Twenty-eight of these patients were treated medically. Sixteen among 
them (57.1 %) successfully completed medical treatment; ICP was controlled by 3 weeks and did not 
deteriorate. Twelve patients failed medical treatment; for 7 patients this was evident during their 
hospital stay (acute failure), and 5 patients had late deterioration after discharge to a rehabilitation or 
secondary level care centre (delayed failure). For the group with acute failure raised ICP had not 
normalised by 3 weeks (n=4), deteriorated acutely and necessitated a VPS (n=1) or deteriorated after 
normalising (n=2). Average time to VPS was 3.1 ± 1.2 weeks. Patients with delayed failure 
experienced ICP deterioration a median of 10 weeks post admission at which time they were shunted. 
Four patients with CHCP were considered too ill on admission to undergo a trial of medical treatment 
and were shunted soon after admission as the imperative was to definitively control ICP early. One 
patient failed LP and had to be shunted, and in 1 patient the results of the AEG were misinterpreted as 
NCHCP leading to a VPS when medical treatment would have been appropriate. A flow diagram of 
HCP management is outlined in Figure 9.3. 
Patients with NCHCP (n= 3) – VPSs were inserted in 2 patients, the third patient had an ETV 4 days 
post-admission but re-presented after 7 weeks with raised ICP. She was subsequently shunted. 
Uncertain – AEG result unclear or no AEG performed (n= 7) – five of these cases (71%) were treated 
with a VPS, one patient had an EVD and died before a shunt could be inserted, one patient had an 
ETV with no subsequent deterioration in ICP. 
 
Surgical procedures- EVDs were used as a temporising measure to treat high ICP in 31 patients 
(70.5%) and a total of 25 patients (56.8%) had a VPS inserted. Shunt complications included 
malfunction (n=3), over-drainage (n=1), infection (n=1) and wound dehiscence (n=1 patient with a 

























Table 9.3: Surgical HCP management 
Neurosurgical Intervention Value 
Initial EVD  
 CHCP 21 (61.8) 
 NCHCP 3 (100) 
 Uncertain 6 (100) 
 Total 
a
 31 (70.5) 
Shunt  
 CHCP (n=34) 18 (52.9) 
 NCHCP (n=3) 3 (100) 
 Uncertain (n=7) 4 (57.1) 
 Total (n=44) 25 (56.8) 
ETV 
b
 2 (4.5) 
This table details the frequency of surgical procedures for treatment of HCP in patients with CHCP, NCHCP 
and in whom the nature of HCP was uncertain. 
a
 This total includes all patients who had an EVD– the 31st 
patient was initially treated for bacterial meningitis and did not have an AEG to establishing the nature of HCP, 
b 









































Figure 9.2 demonstrates how HCP was managed in patients with CHCP, NCHCP and in whom the 
nature of HCP was uncertain. Percentages for CHCP, NCHP and uncertain HCP were calculated based 
on the total cohort number of 44 patients – when patients with uncertain HCP are excluded, CHCP was 
diagnosed in 92% of patients and NCHCP in 8%. Mdn=median 
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Patient Clinical Outcome 
Mortality - Overall mortality by 6 months was 16% (n=7). Four of these patients died within the first 
10 days after admission (median 4 days), 2 patients died after 7 weeks and 1 patient died by 6 months. 
All deaths were the direct result of TBM. Six patients (13.6%) continued to improve after 3 months 
and 1 patient who was vegetative at 3 months had died by 6 months.  
Six month dichotomised clinical outcome - According to the PCPS by 6 months good outcomes (PCPS 
1-3: normal –mild/moderate disability) were recorded in 32 patients (72.7%) and 12 patients (27.2%) 
suffered a poor outcome (PCPS 4-6: severe disability-died). Almost half of the full cohort (n=21) 
made a full clinical recovery with no neurological morbidity; 16 patients (36.6%) suffered some form 
of disability including one or more of the following: motor weakness (n=7), motor deficit (n=4), 
visual deficit (n=4), hearing deficit (n=2), memory deficit (n=1), cranial nerve palsy (n=1), and 3 
patients (6.8%) were considered vegetative. 
 
Six month survivor morbidity - Amongst the 37 survivors at 6 months, 21 patients (56.8%) had no 
neurological fall-out, 11 (29.7%) had mild-moderate disability, and 5 (13.5%) patients were severely 
disabled or vegetative.  
 
There was no loss to follow-up. Outcome data categorised by MRC stage are presented in Table 9.4. 
Associations with mortality 
MRC staging at admission trended towards significance in association with mortality as more deaths 
occurred in severe categories IIb and III (p = 0.06). MRC staging at 1 week was similarly predictive 
of mortality (p<0.001). Mortality was significantly higher among females (p=0.05). 
Associations with 6 month dichotomised outcome  
Admission or patient characteristics which were significantly predictive of poor outcome (PCPS 4-6) 
at 6 months included: MRC staging on admission (p=0.01) and at week 1 (p<0.001) with poorer 
outcomes occurring with severe stages IIb and III and a shorter duration of symptoms (p=0.05- 
measured as a continuous variable). A higher incidence of headaches and irritability were reported 
amongst patients who survived. A full list of variables assessed with outcome is provided in Table 
9.1. Age was not significantly associated with 6 month outcome and the 5 infant patients all survived; 
1 had a normal outcome, 3 demonstrated mild disability (motor weakness) and 1 had moderate 
disability (motor weakness and cranial nerve VI palsy). They did not differ from the cohort as a whole 





Associations with morbidity 
Morbidity at 3 and 6 months did not differ in their relationship with outcome; consequently results at 
6 months are reported. Only MRC staging at week 1 was a significant predictor of morbidity 
(p<0.001); poorer outcomes were seen in children with Stages IIb and III and children who presented 
in Stage I all made good recoveries. For survivors, children less than 2.5 years tended to be at greater 
risk of disability (p=0.06).  
Table 9.4: Clinical outcome at 6 months 
 Admission Total 
Stage I IIa IIb III N=44 
Full recovery 
(PCPS 1) 
3 (6.8) 12 (27.3) 6 (13.6) 0 21 (47.7) 
Mild disability 
(PCPS 2) 
1 (2.3) 2 (4.5) 3 (6.8) 2 (4.5) 8 (18.2) 
Moderate disability 
(PCPS 3) 
0 1 (2.3) 1 (2.3) 1 (2.3) 3 (6.8) 
Severe disability 
(PCPS 4) 
0 0 2  (4.5) 0 2 (4.5) 
Vegetative 
(PCPS 5) 
0 1 (2.3) 0 2(4.5) 3 (6.8) 
Died 
(PCPS 6) 
0 1 (2.3) 2 (4.5) 4 (9.1) 7 (15.9) 
 Week 1 Total 
Stage I IIa IIb III N=42 
Full recovery 
(PCPS 1) 
15 (35.7) 5 (11.9) 1 (2.4) 0 21 (50) 
Mild disability 
(PCPS 2) 
3 (7.1) 2  (4.8) 1 (2.4) 2 (4.8) 8 (19) 
Moderate disability 
(PCPS 3) 
0 1 (2.4) 2 (4.8) 0 3 (7.1) 
Severe disability 
(PCPS 4) 
0 0 0 2 (4.8) 2 (4.8) 
Vegetative 
(PCPS 5) 
   3 (7.1) 3 (7.1) 
Died 
(PCPS 6) 
0 0 1 (2.4) 4 (9.5) 5 (11.9) 
This table presents clinical outcome data according to MRC Staging on admission and at week 1. Data are 










TBM cases - Twenty-six TBM cases (69% boys) between the ages of 12 and 76 months (median 37 
months) underwent neurodevelopmental assessment using the GMDS-ER. Patients who exceeded the 
age limit of the test (> 8 years, n=5), with severe clinical disability (n=5) and who had died (n=7) 
could not be evaluated. One patient was excluded due to documented baseline neurodevelopmental 
delay from alcohol and cigarette exposure in-utero. Auditory assessments were normal in all children 
and one patient suffered from visual deficits requiring special schooling for the visual impairment. 
The majority of mothers (90%) had not completed high school, 5% had completed high school and 
5% were pursuing tertiary education. 
 
Control Group - This group comprised 25 children with a median age of 41 months (10 – 81 months), 
15 were boys (60%) and 10 were girls (40%). None of these children had a previous history of illness 
or TB and none had established developmental delay. Half of the mothers had completed high school, 
36% had not and 16% had tertiary education. 
 
In comparison to established norms 
 
The raw scores for each subscale and the overall general quotient (GQ) for the TBM cases and 
controls were compared to British norms. The control group performed at an age appropriate level for 
the locomotor and personal-social subscales but 40% of children performed below their age 
equivalent on the eye-hand coordination, performance and reasoning subscales. The GQ scores fell 
within the first standard deviation of the equivalent GQ for age. Most of the TBM cases performed at 
a level below their age equivalent on all subscales and scored a median of 3 standard deviations below 





Table 9.5: Control and Case scores in relation to British normative age equivalents 
 Normal Controls TBM Cases 
Locomotor   
 < age equiv 2 (8%) 24 (92.3%) 
 ≥ age equiv 23 (92%) 2 (7.7%) 
Personal-Social   
 < age equiv 2 (8%) 20 (76.9%) 
 ≥ age equiv 23 (92%) 6 (23.1%) 
Language   
 < age equiv 19 (76%) 24 (92.3%) 
 ≥ age equiv 6 (24%) 2 (7.7%) 
Eye-Hand Coordination   
 < age equiv 17 (68%) 26 (100%) 
 ≥ age equiv 8 (32%) 0 (0) 
Performance   
 < age equiv 14 (56%) 25 (96.2%) 
 ≥ age equiv 11 (44%) 1 (3.8%) 
Reasoning
a
   
 < age equiv 13 (76.5%) 14 (100%) 
 ≥ age equiv 4 (23.5%) 0 (0) 
GQ   
 < age equiv 12 (48%) 26 (100%) 
 ≥ age equiv 13 (52%) 0 (0) 
Data reported as number (percent), 
a
 only children > 2 years could be assessed on this sub-scale 
 
Cases versus controls 
 
A GEE to investigate the differences between TBM cases and controls revealed that TBM cases were 
significantly less likely to perform at an age-appropriate level than controls across all sub-scales (OR 
0.7, CI: 0.03-0.14, p<0.001).  The number of TBM patients who scored below the median control 
value on each sub-scale and the GQ was as follows: 22 (84.6%) on the Locomotor sub-scale, 23 
(88.5%) on Personal-Social, 18 (69.2%) on Language, 19 (73.1%) on Eye-Hand co-ordination, 20 
(76.9%) on Performance, 11 (78.6% - only 14 patients were old enough to be tested on this scale, >2 
years) on the Reasoning sub-scale and 21 (80.8%) on the GQ. 
 
No association was demonstrated between the clinical and neurodevelopmental scores for the sub-




Table 9.6: Neurodevelopmental and clinical outcome scores 
Neurodevelopmental sub-scale Clinical outcome  
 Normal Mild-moderate 
disability 
Total 
Locomotor    
 Developmental deficit 9 (34.6) 2 (7.7) 11 (42.3) 
 No deficit 7 (26.9) 8 (30.7) 15 (57.7) 
Personal Social    
 Developmental deficit 10 (38.5) 2 (7.7) 12 (46.2) 
 No deficit 6 (23.1) 8 (30.7) 14 (53.8) 
Language    
 Developmental deficit 9 (34.6) 3 (11.5) 12 (46.2) 
 No deficit 7 (26.9) 7 (26.9) 14 (53.8) 
Eye hand co-ordination    
 Developmental deficit 10 (38.5) 2 (7.7) 12 (46.2) 
 No deficit 6 (23.1) 8 (30.7) 14 (53.8) 
Performance    
 Developmental deficit 10 (38.5) 2 (7.7) 12 (46.2) 
 No deficit 6 (23.1) 8 (30.7) 14 (53.8) 
Reasoning
a
    
 Developmental deficit 4 (15.3) 1 (3.8) 5 (35.7) 
 No deficit 7 (26.9) 2 (7.7) 9 (64.2) 
GQ     
 Developmental deficit 8 (30.7) 5 (19.2) 13 (50) 
 No deficit 8 (30.7) 5 (19.2) 13 (50) 
This table displays the frequency of neurodevelopmental deficits in categories of clinical outcome 
a
 Only 14 




Only 2 patients were co-infected with HIV, both of whom had been diagnosed before admission to 
RXH for TBM. Patient 1 was a 4 year old male with definite TBM who presented in Stage IIb and 
progressed to Stage III after 1 week. He had defaulted on ART and had an admission CD4 count of 34 
cells/μL. CSF investigations revealed low glucose, high protein and a predominance of lymphocytes. 
His CXR was suggestive of TB. His admission CTB demonstrated moderate diffuse basal 
enhancement and right basal ganglia infarcts had developed by his 3 week MRI. He was treated with 
standard medical TB and CHCP treatment and started on ART after 1 week. His ICP had normalised 
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by the time he was discharged with a GCS of 15. He was readmitted after 6 weeks for severe HCP 
which was treated with a VPS. Two weeks later he represented with extensive basal meningeal 
enhancement and a new streptococcus pneumonia meningitis, a very uncommon pathogen in shunt 
infections. He was treated with antibiotics and his shunt was revised. At this point his condition 
deteriorated and on discharge 4 weeks later he had a GCS of 12 and suffered from visual and speech 
deficits. His shunt was revised once again due to blockage one month after insertion. He was severely 
disabled at 3 and 6 months (PCPS 4).  
 
Patient 2 was a 12 year female with probable TBM who presented in Stage IIa with a history of 
having defaulted on ART and a CD4 count of β8 cells/μL on admission. Her OP on LP was 17cmH20, 
she was diagnosed with CHCP on AEG and started on medical treatment for TB and HCP as well as 
ART from day 1. Her CXR was normal and CSF chemistry demonstrated low glucose and high 
protein. CSF lymphocytes and neutrophils were equal initially but lymphocytes were predominant by 
the second CSF sample on day 3. Her admission CTB showed moderate HCP with mild focal 
enhancement. Later on the day of admission her GCS deteriorated from 13 to 7 and she was 
immediately taken to theatre for an EVD. Post-operatively her GCS remained 5T and her pupils were 
fixed and dilated. Over the next 5 days her scans showed evolving global infarction and she passed 
away on the 9
th
 day likely as a result of progressive cerebral ischemia and infarction. 
 











From October 2010 to August 2013 RXH admitted approximately 24 patients with possible, probable 
or definite TBM per year, comprising mostly young children < 5 years old presenting with moderate 
TBM according to the MRC staging criteria. HCP was diagnosed in 71.6% of these TBM patients, 
HIV co-infection was recorded in 8% and the mortality rate was 13.5%. The RXH patient profile 
mirrored that of paediatric patients admitted over the last 2 decades to our neighbouring institution in 
the Western Cape, Tygerberg Hospital (TBH) who reported similar outcomes (mortality 12.9%) 
22,45
. 
The HIV co-infection rate in patients from RXH was higher than recorded by the TBH group (8% vs 
3.8%) and this likely reflects the increasing national prevalence of HIV over the last 20 years 
148
. 
TBM study population 
This study enrolled a select group of patients with HCP who were younger and presented with more 
severe stage TBM than the group of patients ineligible for enrolment. The study cohort reflected the 
general patient profile reported by TBH in terms of the socio-economic group, age (majority < 5 
years), delayed presentation and predominance of moderate-severe stage TBM on admission 
45
. 
Delayed presentation is likely due to the limited access to effective early health care, poverty and poor 
education which are so ubiquitous to the population which TBH and RXH serve. Most patients 
presented with the typically reported symptoms of a low level of consciousness, meningism, fever and 
loss of appetite or failure to thrive 
45,48,49
. Although commonly reported, these symptoms are not 
specific to TBM and there may be no previous or family TB history to support the presumptive TBM 
diagnosis. The delay in presentation and frequent health care seeking at medical facilities prior to 
RXH admission highlight the continued difficulty of diagnosis.  
Almost 50% of patients demonstrated an improvement in their MRC staging after 1 week in hospital. 
This is likely as a consequence of treating HCP and hyponatremia which improve the GCS and focal 
neurology and reduce seizure activity due to ICP control and the correction of electrolyte imbalances. 
This suggests that the MRC staging on admission is influenced by factors other than the parenchymal 
injury associated with TBM. Therefore, new tools are required to specifically detect and assess the 
severity of intracranial injury so as to facilitate prompt and appropriate management and the prudent 
direction of limited resources to patients in greatest need. The rate of HIV was low in this cohort and 
testing occurred in almost all patients allowing the opportunity for timeous ART initiation. The 
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Western Cape has one of the lowest rates of paediatric HIV infection and the reduction of mother-to-
child HIV transmission has been a national goal for over a decade 
429
, although challenges to 
achieving wide coverage of preventing mother-to-child transmission are still being addressed. 
Laboratory results 
The CSF TB culture positivity yield of 53% for the study population was a marked improvement on 
historical RXH rates (≈γ0%, unpublished data from a retrospective study conducted in anticipation of 
this project) and rates for the cohort of patients not eligible for study inclusion (33.3%). This was also 
higher than the 11.7% culture yield reported over 20 years from TBH 
45
. This may be attributed to the 
greater number of samples and the larger volumes of CSF sent for microbiology. There is evidence to 
suggest that larger volumes of CSF increase the culture yield 
430
, consequently, this prospective study 
aimed to increase the volumes of CSF sent for culture and clinicians were encouraged to take up to 10 
ml of CSF when performing AEGs or during therapeutic LPs. However, culture results took up to 44 
days to be reported; presumptive diagnosis continues to be the basis for treatment initiation but 
sensitive, specific and rapid diagnostic tests are urgently required. Evidence of TB from biological 
samples other than CSF was rare (11.4%). It is encouraging to observe the very low rate of drug 
resistance recorded, although this may be an underestimate due to the limited rate of culture positivity. 
The higher rate of drug resistance reported from BCH 
94
 discussed in the Chapter 2 is a skewed 
reflection from the more severe spectrum of patients as that institution specifically admits patients 
with complicated or drug resistant TB, but serves as an important reminder of the importance of 
treatment compliance and the risk of resistance present in the community.  
Laboratory findings demonstrated typically low glucose, high protein and lymphocytic predominance 
due to the adaptive immune response to TB. In the few samples in which this was not initially the 
case, most of the subsequent samples revealed these patterns; this highlights the value of repeated 
CSF testing in presumptive TBM diagnosis. Lumbar CSF protein and lymphocyte counts were higher 
than in ventricular CSF which in turn exhibited higher levels of glucose and chloride. The rostro-
caudal gradient of higher protein in the lumbar than ventricular CSF is observed under both normal 
and pathological conditions. In the healthy brain the successive addition of serum proteins as the CSF 
flows from the ventricles to the thecal sac is responsible for the observed gradient 
431
. In the context of 
cerebral infection lumbar CSF protein concentrations may be further augmented as more blood-
derived proteins influx into the CSF along its course from the ventricles to the lumbar space due to 
BBB injury (indicated by an elevated CSF/serum albumin ratio) and reduced flow rate (due to 
inflammatory exudate obstructing CSF flow) 
431
. Additionally, in TBM most of the inflammatory 
process occurs in the SAS and this would precipitate higher protein and lymphocytes in the lumbar 
CSF. It has also been contended that the lumbar meninges may be more permeable to the diffusion of 
serum proteins, and that immunoglobulins produced by the local inflammatory response add 
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cumulatively to the protein concentration as the CSF flows caudally 
432-434
. Glucose enters the CSF 
through the choroid plexus in the lateral ventricles and through carrier mediated transport into the 
extracellular fluid of the brain and spine. Decreased lumbar glucose may be attributed to cumulative 
bacterial glucose consumption along the rostro-caudal axis and impaired lumbar meningeal glucose 
transport due to inflammation 
431-433. This study’s findings suggest that lumbar CSF content cannot be 
inferred from ventricular CSF and vice versa. The typically anticipated low glucose, high protein and 
high lymphocytes in TBM apply to lumbar CSF and it is important to be cognisant of this when 
examining ventricular CSF in the absence of lumbar CSF so as to avoid missing the TBM diagnosis.  
Patient management 
NCHCP was diagnosed in only 8% of patients in whom an AEG result could be obtained; a much 
lower rate than reported in the literature (14-25%) 
45,64,101
. However, uncertainty about the nature of 
HCP existed in 16% of patients which could have reduced the reported frequency of both CHCP and 
NCHCP. Spinal imaging demonstrated that spinal arachnoiditis was present in 72% of patients 
(Chapter 11); spinal adhesions and exudate may create a barrier to the flow of CSF or the movement 
of air up the spinal canal resulting in unsuccessful AEGs; indeed more severe spinal arachnoiditis was 
associated with failure to LP (p=0.01). As spinal disease has not been described in paediatric TBM, 
the frequency of spinal arachnoiditis may not have been appreciated and failed AEGs due to spinal 
disease may have been incorrectly categorised as NCHCP. Additionally it is our institutional practice 
to investigate HCP fully with AEGs and column tests before making the diagnosis of NCHCP so as to 
avoid unnecessary shunts where possible. In spite of this approach, over half of this cohort received a 
VPS. This is more frequent than studies published from TBH (30-40%), the only other institution 
which, to our knowledge, routinely investigates the communicating nature of HCP 
22,45,64,101,126
. This 
may be attributed firstly, to the high rate of failed medical treatment observed; 53% versus 25% 
reported from TBH 
22,45
. The definition of failed medical treatment is however variable. At our 
institution the definition is quite strict - the ICP had to be normal on at least 2 consecutive LPs 
conducted 1 week apart with an absence of delayed ICP deterioration in conjunction with CT follow-
up confirming HCP resolution before medical treatment was considered successful. Secondly, this 
may be attributable to institutional concern about the risks of chronic uncontrolled raised ICP on an 
already ischaemic brain which has been demonstrated by continuous ICP and brain oxygen 
monitoring in TBM patients (discussed in Chapter 12). Shunt complications were low, documented in 
6 patients (24%) over the last 3 years, and in 2 of these patients the VPS was complicated by HIV and 
poor nutrition. Despite the high rate of shunting this is an improvement on complication rates of 32-
60% reported over 6-12 month follow-up in the literature 
22,127
. Due to the challenges inherent in 





Although the overall mortality rate at RXH was similar to TBH, the mortality for the study cohort was 
slightly higher than reported for TBH (16% vs 13%). However, this patient cohort represented a very 
particular selection of patients with HCP who represent the more severe spectrum of TBM disease. 
Indeed the study group was composed of the more severely infected patients treated at RXH as 
demonstrated by more severe presentation, greater CSF perturbations and higher mortality relative to 
patient ineligible for study inclusion (16% vs 10%). 
It is a reassuring finding that more than 70% of this cohort demonstrated good outcomes at 6 months; 
almost half made a complete recovery and disabilities were mostly mild. This reflects positively on 
the acute in-hospital care. However, 80 % of the patients who underwent neurodevelopmental follow-
up performed poorly; this demonstrates that although these children may appear grossly normal, they 
are left with deficits which will present them with very real challenges as they develop, most 
importantly the difficulty of completing their education successfully. Most of these children stem 
from impoverished homes which have limited finances and child caring options. Their communities 
generally have a baseline deficit of schools which can provide adequate support and stimulating 
environments to nurture development, especially for children requiring special attention. Adding 
disability, whether it be motor, cognitive, speech or sensory to already disadvantaged circumstances 
makes for real challenges in the short and long term. The 12 patients who suffered poor outcome 
(death or severe disability) presented with moderate - severe stage TBM and demonstrated clinical 
deterioration within the first week, whereas all patients who presented with mild TBM made a good 
recovery. These findings highlight the importance of early diagnosis before the window of 
opportunity to halt disease progression has closed, and demonstrate the acute progression of TBM 
disease in children who suffer poor outcomes. It is tempting to suggest that an earlier presentation 
would improve outcomes; however, the signs and symptoms of TBM are non-specific and diagnosis 
and treatment initiation may still be delayed. 
It is noteworthy that 2 patients made unexpectedly good recoveries. One young boy (2.8 years) 
presented with Stage 4 TBM; his cerebral imaging showed cerebral oedema and moderate HCP which 
was treated with a VPS. He suffered a prolonged depressed LOC (GCS<8), had multiple daily 
seizures for more than a month after admission and was not considered for resuscitation. By 6 months 
he had made a remarkable recovery; he was mobile, interactive and functioning well (PCPS 2) 
although his performance on the Griffiths demonstrated neurodevelopmental deficit. A second young 
boy (4.1 years) presented with severe TBM and HIV co-infection, demonstrated infarction in his right 
basal ganglia on his admission scan and experienced a difficult hospital course including multiple 
admissions, concomitant streptococcus pneumonia meningitis and multiple shunt revisions. At 6 
months he was unable to sit unsupported, to stand or feed himself and did not interact with his 
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environment (PCPS 4), he was too disabled to be assessed with the Griffiths. After 1.5 years, 
however, he had made a marked recovery and presented to the outpatients department as a happy, 
mobile, interactive and functioning child. He was then functionally able to engage in the Griffiths test 
although his performance was weak. These two cases demonstrate that recovery may be possible in 
some children in whom the early clinical picture would suggest otherwise. 
Associations with outcome 
The associations between admission characteristics and clinical outcome were weak; this may in part 
be a function of the low mortality seen in this group. It was an unexpected finding that a shorter 
duration of symptoms was associated with poor outcome at 6 months. This may reflect the aggressive 
nature of the disease in the patients who died as opposed to a low-level chronic disease process 
playing out over weeks in children who survived. This is also manifest in the acute deterioration 
within the first week after hospitalisation in patients who died or suffered severe disability. 
Alternatively, the duration of symptoms may have been poorly reported - the non-specific nature of 
TBM symptoms may have masked their relevance to parents, and β patient’s mothers had recently 
died and histories taken from relatives were sparse. Children under the age of 2.5 years were at a 
higher risk of a poor outcome, however, this association did not hold for infants as none of the infants 
in this study died and all made good recoveries by 6 months. A greater number of deaths were seen 
amongst female patients. Males and females did not differ significantly on any admission or clinical 
variables and with such a small number of deaths (n=7) it is possible that this may be a chance 
finding.  
Among the laboratory CSF findings only higher polymorphonuclear cell counts appeared to be 
associated with outcome. There are data to suggest that neutrophils contribute to the early defence 
against Mtb and that the recruitment of these white cells to the site of disease improves outcome 
435
. It 
is possible therefore, that patients who had higher neutrophil counts were admitted at an earlier stage 
of TBM disease, and were consequently more likely to have a good outcome.  
Neurodevelopmental outcome 
Assessments with the GMDS-ER demonstrated that TBM cases performed poorly in comparison to 
peers drawn from similar backgrounds. This would suggest that, having attempted to take the 
influence of socio-economic status and culture into account, TBM was associated with compromised 
development. Infarcts are significantly associated with poor development after TBM, particularly in 
locomotor performance 
145
. While there is certainly an organic component to developmental deficits, 
the impact of TBM extends to the outpatient period as well. Many of these patients were hospitalised 
at BCH for 6-9 months. Although the doctors and support staff at that institution provide the best care 
their limited resources allow, these children are exposed to a number of factors that may further 
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compromise their development. Firstly, normal procedure dictates that children are dressed, fed and 
washed by the nursing staff. Consequently, these children do not develop independence in these tasks, 
and this is reflected in their poor test scores on the personal-social subscale with up to 70% of TBM 
patients demonstrating deficits in this area. Secondly, BCH staff comprise English, Afrikaans and 
Xhosa speaking individuals who often speak a mixture of languages to the children. This may have 
contributed to their poor language scores (90% performing below controls) as communication takes 
place in languages other than the mother-tongue and the language foundation of these young children 
remains weak. Thirdly, these children are not often exposed to environments external to the hospital 
ward and playground. Consequently, their locomotor development was limited by their environment. 
For example, BCH does not have any stairs and poor stair climbing was ubiquitous among TBM cases 
at BCH, likely due to the lack of exposure rather than motor impairment. Fourthly, teaching at BCH is 
limited by human and material resource constraints. Certain skills like drawing, writing and 
recognising body parts were poor in all BCH children and this may be attributed, at least in part, to 
their limited exposure to tasks that build these skills or knowledge. Fifthly, these children live 
predominantly at BCH during their hospitalisation and may only see their parents on occasional 
weekends. Parents often live far from the hospital and need to work and care for other children 
limiting their opportunities to visit and fetch their children from BCH. The impact of maternal or 
family separation and the absence of maternal input may have a very real impact on the wellbeing and 
development of these children.  
As part of this study GMDS-ER assessments were also conducted with the non-TBM children 
admitted to BCH in an attempt to control for the impact of 6 month hospitalisation at BCH on 
development. However, apart from complicated TB, poor social circumstances are one of the 
admission criteria to BCH and 4 out of the 8 children assessed came from difficult home 
environments. It is well established in the literature that poor social circumstances can significantly 
negatively impact a child’s development 423,436 rendering 50% of this potential control cohort 
developmentally compromised at baseline. Additionally 2 children had established speech delay. Due 
to the developmental disadvantages intrinsic to this group they were not considered an optimal control 
group and recruitment for GMSD-ER assessment ceased. 
The 10 children who were not admitted to BCH were either admitted to other institutions with similar 
limitations (n=2) or discharged home (n=8). Children cared for at home were subject to the financial, 
schooling and care-giver limitations inherent to their poor SES. Several mothers struggled to care for 
their children as a result of commitments to work or other children and crèche was financially 
inaccessible for several families. The impact of TBM on development is therefore multidimensional 
comprising the organic injury, as well as the environmental, social and educational limitations 
imposed by their disease and prolonged treatment in both the short and long term.  
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The absence of an association between neurodevelopmental outcome and clinical outcome may be 
due to differences inherent in the nature of the outcome being assessed by the 2 tools.  Clinical 
outcome assessment was based on the overall neurological picture of the child thereby assessing 
outcome on a very general level with a focus on neurological deficits discernable on physical 
examination. The GMDS-ER assessed outcome in specific functional categories which covered motor 
and sensory performance as well as cognitive and social performance. Furthermore, the GMDS-ER 
assessed not only whether an activity could be performed but also the quality with which the activity 
was performed; therefore, it detected both gross and subtle deficits over a broad range of function, 
many of which may not be apparent on physical examination. Additionally, clinical outcome is 
determined largely by pathology, whereas neurodevelopmental outcome is influenced by pathology in 
combination with social, educational and psychological factors. 
HIV co-infection 
The small number of HIV+ patients did not allow formal analysis across the infected and un-infected 
patients groups; however, these 2 patients demonstrated admission characteristics and CSF findings 
similar to those of HIV- patients. Both children fell into the poor outcome group (1 died and the other 
had severe disabilities after 6 months); however, they had both defaulted on ART a number of months 
before their TBM admission and with the small sample size it is not possible to conclude whether 
appropriately treated HIV co-infection would also expose children to a greater risk of poor outcome. 
The patient who survived demonstrated worsening basal enhancement 10 weeks after ART initiation 
(drug-sensitivity had been confirmed). This may represent a TBM-IRIS response or represent ongoing 
TBM disease as seen in one of the HIV- patients who re-presented with worsening tuberculomas and 
enhancement 7 weeks after anti-TB treatment initiation. Although TB culture and drug-sensitivity 
could not be confirmed on the latter patient, the very low overall rate of resistance at RXH would 
suggest that his deterioration was not likely due to drug resistance. HIV exposure was not associated 
with outcome. 
Limitations 
Data on admission and demographic characteristics were drawn from patient folders and from 
interviews with parents when possible. The data were therefore subject to variable qualities of history 
taking and the accuracy or fullness of parental reporting may have been limited by language and the 
subjectivity with which parents experienced and recalled their child’s illness. A number of these 
patients presented to RXH without a parent or guardian present and the accompanying information 
from the referral hospital, often sparse, had to be used in lieu of a proper history. Other children were 
brought in by family members, other than the mother, who had limited knowledge of the child’s 
previous medical history. The frequency of admission characteristics may therefore have been 
underestimated. TSTs are usually performed on admission to the medical wards; when patients were 
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admitted directly to the neurosurgical ward or ICU or transferred there soon after admission these 
tests often were not performed as they did not form part of the routine ward procedures. Placing 
outcome of this HCP study group in the context of overall TBM outcomes at RXH was curtailed by 
the limited follow-up for non-HCP patients as these patients are generally not assessed in the 
Outpatients Departments of RXH. An accurate assessment of RXH’s TBM outcomes would require a 
prospective study which tracks children as they are discharged to secondary and primary level 
services. 
For the neurodevelopmental outcome it was not possible to exactly match cases and controls for age 
and gender, and several of the control children’s mothers were more educated. However, the average 
age of the children with mothers who had tertiary education was 13.5 months. Molteno et al’s study in 
Cape Town found that child development was similar across all SES groups till approximately 12 
months of age; only after infancy did the association between the deceleration in development and 
maternal education/SES become more apparent 
422
.  Therefore, some of the discrepancy between 
maternal levels of education may have been mitigated in this group. It remains possible, however, that 
the control group performed superiorly due to better home stimulation and that this may have falsely 
augmented developmental deficits associated with TBM. Establishing an appropriate control group is 
challenging, and although the GMDS-ER has been used for several local TBM studies they have 
focussed on within group comparisons and none have included comparisons to a control group 
106,145
. 
Future projects will continue to build an appropriate control group against which to compare the 





CHAPTER 10 SUMMARY 
Biomarkers of neurological injury and inflammation 
 
In this chapter, analysis aimed to establish if neuromarkers S100B, NSE and GFAP were elevated in 
TBM, associated with patient clinical characteristics and prognostic of clinical and 
neurodevelopmental outcome. A panel of inflammatory markers was also analysed. 
Biomarkers were analysed in serum, lumbar CSF and ventricular CSF on admission and for the next 3 
weeks using ELISA for neuromarkers and Luminex multibead array assay for inflammatory markers. 
Biomarker concentrations in patients were compared against control patients and their temporal 
profile was examined. Various neuromarker indices were analysed in association with outcome 
(clinical and neurodevelopmental) including initial and highest concentrations as well as the trend 
over time. PCA combining neuro- and inflammatory markers over time was examined in association 
with outcome. 
The main findings were as follows: 
1. Neuro- and inflammatory markers were elevated in the lumbar and ventricular CSF of TBM 
cases relative to controls on admission and for up to 3 weeks, however, serum concentrations 
were not. This suggests that CSF S100B, NSE and GFAP are indicators of cerebral injury in 
TBM and that the immune response in TBM is compartmentalised to the brain. 
2. Neuromarker concentrations were higher in the ventricular than lumbar CSF, likely reflecting 
the largely cerebral origin of neuromarkers. Inflammatory concentrations were higher in 
lumbar than ventricular CSF, probably reflecting the predominantly subarachnoid location of 
much of the inflammatory response.  
3. Neuromarkers were poorly associated with patient and admission clinical characteristics 
suggesting that they provide additional information about brain injury that is not reflected in 
the history and clinical examination. 
4. Elevated neuromarker concentrations within the first week and overall were prognostic of 
poor outcome. The strongest predictor of outcome was an increasing trend in neuromarker 
concentrations over time.  
5. PCA combining all 3 neuromarkers over time demonstrated that concentrations continued to 
increase in patients who died, while combined inflammatory concentrations decreased. This 
suggests that it is not the ongoing immune response which is responsible for the progressive 
brain injury associated with TBM, but rather secondary pathological processes that are 
initiated by the inflammatory process. 
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6. Associations between inflammatory markers and outcome were poor and combining neuro- 









Samples for biomarker examination included lumbar CSF, ventricular CSF and serum. A volume of 3 
ml of CSF and 3 ml of blood were collected (where possible) for study purposes. CSF was collected 
in sterile tubes and blood in SSTII tubes for serum collection (BD Vacutainer, Plymouth, UK). All 
CSF and serum samples were collected at the time of clinically indicated lumbar punctures, 




Admission samples: Lumbar CSF samples were collected from routine diagnostic LPs. In patients 
who were too unstable for an LP an EVD was placed, from which ventricular CSF was collected at 
insertion. In some cases a lumbar CSF specimen was also collected at the same time (immediately 
pre-EVD insertion).  Blood samples were collected at the time of LP or in the operating theatre if 
blood had not already been drawn for clinical purposes. If blood had already been drawn, a study 
sample was taken with the next planned phlebotomy. Where possible, samples were taken before the 
commencement of anti-TB treatment and steroids. Samples from patients started on treatment for 
more than 3 days were excluded. 
 
Serial samples: Additional CSF and blood samples were collected once per week during weeks 1-3. 
In patients with CHCP lumbar CSF was collected at the time of clinically planned serial LPs. 
Ventricular samples for these patients were taken during planned neurosurgical procedures including 
EVD insertion and removal or shunt insertion if these patients failed medical treatment. For patients 
with NCHCP ventricular CSF was collected during EVD insertion and removal, shunt insertion and/or 
ETV. Any lumbar CSF samples for these patients were collected during AEGs or column tests to 
establish that the HCP was non-communicating. Blood samples were time-linked with CSF samples 




For the fatty filum controls blood was drawn after the patient was anaesthetised at the time of 
checking haemoglobin/arterial blood gas and before the operation began to minimise the risk of 
possible extracranial sources of neurological biomarkers released in response to surgical procedures to 
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skin and bone. Lumbar CSF samples were taken before the dura was opened as part of the operative 
procedure. For pTB controls samples were taken at the time of clinically indicated phlebotomy. All 




Within the constraints of a busy 24 hour clinical service, sample processing occurred immediately 
after sample collection. When this was not possible, samples were refrigerated at 5
°
C for < 5 hours or 
frozen at -20 to -70
ᵒ
C overnight. Frozen blood samples were not used due to the potential for 
contamination from intracellular proteins released from blood cells. In the laboratory samples were 
centrifuged at 4000 rotations per minute for 5 minutes (1780 relative centrifugal force), the 
supernatants were preserved and the cells discarded. Samples were examined for serum hemolysis and 
CSF xanthochromia and affected samples were excluded from NSE analysis due to the contribution of 
NSE of erythrocyte origin. Samples were aliquotted into smaller volumes for ELISA and Luminex 
testing and frozen at -70
ᵒ
C for batch analysis. Multiple freeze thaw cycles were avoided. Serum 
albumin testing was run immediately in the in-house National Health Laboratory Service (NHLS) 







Commercially available enzyme-linked immunoassays (ELISA) were used to analyse S100B (Merck 
Millipore, Billerica, USA), NSE (DRG Diagnostics, Marburg, Germany) and GFAP (Merck 
Millipore, Billerica, USA). Batch analysis was performed thrice during the 3 years of patient 
enrolment based on the accumulation rate of samples. Testing procedures and ELISA kits were 
standard across the γ analysis episodes. The full complement of each patient’s samples (serum and 
CSF) were analysed on the same plate; samples were not analysed in duplicate. All assays were 
carried out according to manufacturer instructions. Briefly, the ELISA testing procedure was carried 
out using 96 well plates coated with monocolonal antibodies directed at the target analyte. Patient 
samples were incubated in the coated wells with an enzyme conjugate made up of anti-analyte 
antibodies conjugated with horseradish peroxidase. This facilitated binding of the enzyme to captured 
target analyte molecules. Free enzyme conjugate was washed away and the quantification of 
immobilized antibody-enzyme conjugate was measured spectrophotometrically at an absorbence of 
450nm. The amount of bound peroxidase was proportional to the concentration of the target analyte in 
patient samples and analyte concentrations were derived by interpolation using a standard curve 
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generated from reference standards of known concentration. Testing kits for S100B and GFAP were 
validated for both serum and CSF. The NSE assay was validated for serum; however, since no NSE 
assays validated for CSF are available in South Africa, both sample types were analysed on this test 




The panel of cytokines and chemokines examined included IL-1 , IL-1Ra, IL-6, IL-10, Il-12p40, 
TNF-α, IFN- , IL-8, GRO, MCP-1, IP-10, MIP -1α, VEGF and RANTES. These were analysed on 
the Bio-Plex platform (Bio-Rad Laboratories, Hercules, CA, USA), using customised 14-plex 
MilliplexTM kits (Millipore, St Charles, MO, USA), according to the manufacturer’s instructions. 
This technique uses fluorescent labels to uniquely colour-code beads which are each coated in a 
specific capture antibody. When patient samples are added to the bead-containing wells individual 
analytes are captured by the beads specific to that analyte. Steptavidin PE is added and acts as the 
reporter molecule to complete the interaction on the surface of each bead. The beads pass rapidly 
through a laser which excites the dyes coating them while a second laser excites the fluorescent label 
PE on the reporter molecule. This enables the identification of individual beads and quantification of 
the fluorescent signal of their reporter molecules from which analyte concentrations may be derived 
using a standard curve of known concentrations. The luminex plates were validated for serum and 




Biomarker values that fell below the lowest limit of detection (LLOD) of the testing kit were assigned 
the value 0.01. Neuromarker values that exceeded the highest limit of detection (HLOD) and were 
extrapolated from the standard curve were accepted if the standard curve was linear, variability 
around the curve was very low (R
2 
= 0.98-0.99) and quality control values fell within the expected 
ranges. For cytokine concentrations which were so elevated that the luminex software did not 
extrapolate a value, the highest value measured for that analyte by that testing kit was assigned + 1. 
Unfortunately, limited samples did not allow repeat experiments with diluted samples. 
 
Biomarker data were reviewed in the clinical context of each patient. Samples taken within 24-48 
hours after procedures like EVDs, ETVs, CSF shunts and AEGs were identified and excluded to avoid 
the contribution of invasive procedures to inflammatory and injury marker concentrations. Samples 
that were not immediately refrigerated or not processed and frozen within 12 hours of collection were 






Neuromarker data were analysed according to marker type (S100B, NSE, GFAP [neuromarkers] or 
inflammatory markers) and sample type (lumbar CSF, ventricular CSF and serum) over time. The 
primary focus of this analysis was to describe the profile of neuromarkers and their association with 
clinical and neurodevelopmental outcome as potential indicators of brain tissue injury in TBM. 
Inflammatory markers were introduced in the outcome analyses as complements to the neuromarkers 
to ascertain whether adding inflammatory markers to the neurological markers enhanced prognostic 
power.  
Analysis was, to some extent, curtailed by the large number of tests inherent in analyzing up to 17 
analytes in 3 sample types over multiple time points in a small sample size; this was particularly 
relevant to the 14 inflammatory markers. Univariate and multivariate analysis were used for 
neuromarkers where possible, but multivariate analysis is limited as the number of variables which 
can be analysed is restricted by the sample size and the level of significance requires adjustment for 
multiple testing. Principal component analysis (PCA) is a data reduction technique which overcomes 
the limiting factors of multivariate analysis by allowing complex data sets with multiple data points 
over multiple variables and time points to be analysed simultaneously within a small sample size 
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. 
It allows the major sources of variation in a multidimensional data set to be identified and classified 
according to overarching principal components (PC). It is an unbiased approach as it makes no 
assumptions as to which biomarkers are of importance. It does not, therefore, explain the biology of 
the relationships between variables but rather how biomarkers contribute to variability between 
patients and over time. Consequently, PCA was adopted to analyse the full data set, or large parts 
thereof. PCA involves transforming the data set from having multiple variables to having fewer 
variables, or PCs, which are combinations of the original variables that explain as much of the 
variability in the data as possible. The covariance among the original variables is reduced into a set of 
PCs which are not correlated with each other but which are common to all variables by calculating a 
weighted average for each data point for each biomarker type included in the analysis. The first 
principal component (PC1) represents as much of the variation as possible, the second PC represents 
as much of the remaining variation and so forth. The quality of the PCA fit is determined by the 
amount of variability the analysis accounts for in the smallest number of PCs. Therefore, a strong 
PCA would account for the majority of variability in the data set with the first 2 PCs. PC scores are 
represented as Z-scores which can be plotted on a 2-dimensional plane to represent the sample points. 
The plot can be composed of multiple axes which represent the original variables and each point is 
interpreted in terms of its distance relative to the axes 
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Descriptive statistics including median and interquartile range, and minimum and maximum for the 
17 analytes of interest in the 3 sample types of interest (lumbar CSF, ventricular CSF and serum) were 
calculated. 
 
Neuro- and inflammatory marker elevation 
 
Neuro- and inflammatory marker concentrations of TBM cases were compared to those of controls 
using Mann Whitney’s U with a Holm p-value adjustment to control for multiple testing. Elevated 
concentrations were defined as being > 95
th
 percentile of control values.Ventricular CSF could not be 
sampled from the fatty filum control patients. In absence of cerebral injury or infection it is unlikely 
that biomarkers of neurological injury or inflammation would be elevated in any CSF compartment 
and ventricular biomarker concentrations should theoretically be similar to lumbar CSF. 
Consequently, ventricular and lumbar CSF drawn from TBM cases were compared to fatty filum 
lumbar CSF. TBM serum values were compared to the serum values of both the fatty filum and pTB 
control groups. The serum concentrations of the two control groups were also compared to each other. 
PCA bi-plots were generated to depict the distribution of data for both cases and controls in the 17 
biomarkers and 3 sample types.  
 
Temporal profile 
Temporal profiles were evaluated graphically using box-and-whisker plots. Neuromarker 
concentrations were compared against control values at each time point. This temporal comparison 
could not be conducted for the inflammatory markers due to multiple testing with 14 analytes; 
therefore, only admission samples were compared with controls. 
 
Inter-biomarker associations 
Concentrations of the 17 neuro- and inflammatory markers at admission were correlated using 
Spearman’s R. Cluster analysis was used to examine the similarities among the biomarkers by 
calculating the distances between a patient’s data points. The smallest differences between biomarkers 
indicated the greatest similarity between them and these biomarkers were clustered together. The 
distances between cluster groups were calculated and the clusters exhibiting the smallest difference 
were connected. This was represented in a cluster dendrogram.  
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Additional correlations amongst the neuromarkers included overall median concentration for the 
sampling period and median concentration at each time point during the sampling period for the 3 
sample types. To examine the interaction between neuromarker type (S100B, NSE, GFAP), sample 
type (lumbar CSF, ventricular CSF and blood) and time a GEE model was constructed which 
accommodated for intra-individual variability. Additionally time-linked lumbar and ventricular CSF 
neuromarker concentrations were compared to further explore the differential between the 2 CSF 
compartments; the presence of spinal arachnoiditis (discussed further in Chapter 11) was included in 
this analysis using a GEE. 
PCA plots were constructed to depict the distribution of admission lumbar CSF, ventricular CSF and 
serum values on the same graph for all the neuromarkers, and on a separate graph for all the 
inflammatory markers.  
Association with admission and patient characteristics 
The association between initial neuromarker concentrations (admission or week 1 concentration when 
no admission concentration was available), and patient/admission characteristics (Chapter 9) was 
evaluated using the Chi-squared or Fisher’s exact test. The last recorded S100B, NSE and GFAP 
concentrations in lumbar and ventricular CSF were analysed in association with failed medical 
treatment and ICP deterioration to ascertain whether neuromarker concentrations may predict these 
events. 
 
Clinical outcome analysis 
Outcome variables analysed included mortality at 6 months, dichotomized clinical outcome at 6 
months (poor outcome [PCSP 4-6: severe disability- death] vs good outcome [PCPS1-3: normal – 
mild/moderate disability]), and survivor morbidity at 3 and 6 months (normal [PCPS 1], mild-
moderate disability [PCPS2-3], severe disability [PCPS 4-5]).  
Univariate analysis 
 
The relationship between neuromarker concentrations and outcome was examined using Mann-
Whitney’s U (mortality and 6 month outcome), the Kruskal-Wallis for survivor morbidity categorized 
across 3 levels, and Chi-square for categorical data. Neuromarker indices investigated in association 
with outcome included the initial concentration (admission or week 1 concentration when no 
admission concentration was available), highest in week 1 (highest from among admission and week 1 
values), and highest overall (across the sampling period).  As a measure of the trend over time, the 
absolute change (Δ) in the neuromarker concentration was calculated (change from initial to 2nd week 
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sample – the last available sample after admission was used for patients who were not sampled for as 
long as 2 weeks, or the week 3 sample was used in patients who did not have a sample at week 2). 
This last index could only be calculated for lumbar CSF as ventricular samples were too few. 
 
Outcome analysis with inflammatory markers was limited to avoid multiple testing with 14 analytes; 
however, the predictive value of individual admission cytokine concentrations could be of relevance 
in clinical practice, where available testing may be limited to a few key analytes. Therefore, univariate 
outcome analysis for each cytokine was conducted and the p-values were not adjusted for multiple 
testing as part of hypothesis testing to observe whether any cytokines demonstrated potential as 
prognostic markers in TBM. 
 
Principal Component Analysis (PCA) 
 
PCA was used to derive Z-scores combining all 3 neuromarkers or all 14 inflammatory markers for 
each patient, these z-scores combining multiple analytes were used as a statistical approximation of a 
single index for neurological injury which incorporates the contributions of multiple biomarkers and a 
single index for inflammatory markers. These were calculated for initial concentrations of lumbar 
CSF (Z-Neuro Initial LP, Z-Inflam Initial LP) and ventricular CSF (Z-Neuro Initial V, Z-Inflam 
Initial V), and for the absolute change (Z-NeuroΔ, Z-InflamΔ). The association between these 
variables and outcome was analysed using Mann-Whitney’s U. PCA plots for mortality were 
constructed for Z-Neuro Initial LP and Z-Inflam Initial LP and Z-NeuroΔ and Z-InflamΔ to ascertain 
whether the combination of neuro- and inflammatory markers demonstrated an association with 
outcome. Variables which were not significantly associated with outcome were not carried forward 
into further outcome analyses. Statistical tools to assess the association between the temporal profile 
of neuro- or inflammatory markers and outcome are limited by a single outcome variable in the face 
of multiple biomarker data points. Consequently, PCA was used to derive 3-dimensional plots for the 
combined neuromarkers over time and the combined inflammatory markers over time using the Z-
scores at each time point; the temporal profiles of patients who died were highlighted. 
 
Receiver operating characteristic (ROC) analysis 
 
ROCs were constructed to identify the thresholds of highest S100B, NSE and GFAP as well as 
ΔS100B, ΔNSE, ΔGFAP and Z-NeuroΔ which best predicted mortality and 6 month clinical outcome 
with the optimal combination of sensitivity and specificity. The efficacy of these variables in 
predicting poor outcome is indicated by the area under the curve (AUC), where the perfect curve 





Logistic regression models for mortality and morbidity were constructed for ΔS100B, ΔNSE, ΔGFAP 
and Z-NeuroΔ since these neuromarker indices demonstrated the strongest association with outcome 
on univariate analysis. Covariates were added to these models to determine whether their inclusion 
altered the relationship between the neuromarkers and outcome. Covariates were drawn from patient 
admission characteristics (Chapter 9) and radiology variables (Chapter 11) which were significantly 
associated with clinical outcome or biomarker concentrations on univariate analyses.  
 
Developmental outcome analysis 
 
The association between developmental outcomes and neuromarker concentrations was analysed by 
examining the association between the developmental score (deficit/no deficit) for the GQ and the 6 
sub-scales and neuromarker indices including: highest S100B, NSE and GFAP (lumbar and 
ventricular), ΔS100B, ΔNSE, ΔGFAP as well as Z-NeuroΔ. These analyses were conducted using the 




CHAPTER 10: BIOMARKER ANALYSIS 
Results 
 
A total of 301 samples from 44 TBM cases were collected for analysis: 131 lumbar CSF, 108 serum 
and 46 ventricular CSF samples. The average number of samples collected per patient was 7.3, with a 
minimum of 2 and a maximum of 15. Seventeen samples were excluded: 7 lumbar CSF samples (5 
were post-EVD/shunt/AEG, 2 were not frozen within 12 hours), 6 serum samples (4 post-
EVD/shunt/AEG, 2 were not frozen within 12 hours) and 4 ventricular CSF samples (3 post-
EVD/shunt/AEG, 1 was not frozen within 12 hours). For NSE analysis a further 15 hemolysed serum 
samples were excluded. For Luminex analysis an additional lumbar and serum sample were excluded 
as the plate reader was unable to detect any analyte beads in those samples, likely due to a technical 
error. Sample collection continued for up to 5 weeks depending on the HCP management of each 
patient. 
 
For the fatty filum controls, 11 lumbar CSF and 11 serum samples were collected, of which 1 pair was 
excluded from NSE analysis due to hemolysis. Nine serum samples were collected from TB controls, 




All quality control values in the ELISA and Luminex assays fell within the expected ranges.  All 
standard curves generated in the ELISA results had R
2
 values between 0.98 and 0.99. Details of the 
LLOD for each test kit are outlined in Table 10.1. For GFAP, serum samples accounted for most of 
the results <LLOD. 
 
Table 10.1: ELISA Results: Lowest limits of detection 
Analyte S100B NSE GFAP 
Limit of detection LLOD LLOD LLOD 
Plate 1 0.02 6.56 1.5 
Plate 2 0.02 6.53 1.5 
Plate 3 0.02 4.67 1.3 
Plate 4 0.01 4.09 0.4 
Plate 5 0.04 2.48 1.6 
Plate 6 - - 1.6 
% samples < LLOD 9.78 8.95 35.97 
This table demonstrates the lower limit of detection (LLOD) for each of the ELISA plates used to assay 
neuromarkers S100B, NSE and GFAP, as well as the percentage of the total samples which fell below these 




Table 10.2: Luminex results: Lowest limits of detection 
Analyte Plate 1 Plate 2 Plate 3 Plate 4 Plate 5 
 LLOD % LLOD % LLOD % LLOD % LLOD % 
GRO 15.9 2.6 17.1 2.6 16 12.8 16.4 2.6 16 12.7 
IL-Ra 2.5 20.5 12.1 5.1 8 30.8 16 6.4 16 26.8 
IL-12p40 2.8 26.9 2.4 6.4 16 34.6 3.19 11.5 16 19.7 
IP-10 3.1 0 3.8 0 3.2 25.6 16 0 3.2 38 
MCP-1 3.1 0 3 0 16 0 3.2 0 3.2 1.4 
MIP-1α 4.1 16.7 4.1 23 3.2 34.6 3.2 10.3 3.2 15.5 
TNF-α 3.1 1.3 3.1 0 3.2 1.3 3.2 0 3.2 5.6 
VEGF 80.1 3.8 84.3 8.9 80 12.8 80 25 80 29.6 
IFN-  3.1 5.1 3.1 11.5 16 8.9 3.2 1.3 3.2 9.9 
IL-10 3.1 3.8 3.5 2.6 3.2 10.3 3.2 0 3.2 9.9 
IL-1  2.9 57.7 3.1 38.5 3.2 41 3.2 41 3.2 29.6 
IL-6 3.1 7.7 3.1 10.3 3.2 0 3.2 11.5 3.2 19.7 
IL-8 3.3 0 3.2 0 3.2 1.3 3.2 0 3.2 1.4 
RANTES 16.6 51.3 2.5 50 3.2 55.1 3.2 52.5 3.2 52.1 
This table details the lower limit of detection (LLOD) of the inflammatory cytokines assayed using Luminex 




Tables 10.3 and 10.4 outline the descriptive statistics for all biomarkers for the 2 control groups and 
the TBM cases for the duration of sampling (patients treated for longer than 3 weeks had samples 




Table 10.3: Descriptive statistics for neuromarkers in all sample types (μg/L) 
Marker  S100B NSE GFAP 
Sample   LP V S LP V S LP V S 
Admission  n=36 n=23 n=36 n=36 n=23 n=30 n=36 n=23 n=36 
 Median 1.37 3.24 0.08 17.62 29.07 16.74 8.92 93.31 0.01 
 Min 0.01 0.91 0.01 0.01 0.01 0.01 0.01 2.73 0.01 
 Max 8.57 9.82 0.59 89.49 104.86 73.75 181.09 269.96 20.25 
 p25 0.7 1.34 0.02 8.48 20.53 11.36 3.25 33.86 0.02 
 p75 3.07 5.30 0.14 38.12 48.89 27.08 24.16 172.37 1.77 
Week 1  n=29 n=9 n=26 n=29 n=9 n=21 n=29 n=9 n=26 
 Median 1.37 5.37 0.11 24.67 39.61 16.09 6.06 168.64 0.01 
 Min 0.16 1.07 0.01 0.01 17.38 0.01 0.01 8.23 0.01 
 Max 9.13 16.25 1.00 94.97 154.86 42.60 298.66 344.40 16.29 
 p25 0.57 1.13 0.02 14.32 34.61 8.8 2.1 13.37 0.01 
 p75 3.46 9.12 0.23 46.42 91.97 24.21 21.84 331.87 0.01 
Week 2  n=31 n=6 n=24 n=31 n=6 n=23 n=31 n=6 n=24 
 Median 0.77 1.05 0.04 14.44 19.42 12.86 3.38 66.30 0.01 
 Min 0.16 0.29 0.01 0.01 0.01 0.01 0.01 0.01 0.01 
 Max 10.53 2.53 1.06 78.92 80.64 104.67 164.43 270.50 15.88 
 p25 0.4 0.62 0.03 8.21 10.82 7.99 0.03 17.09 0.01 
 p75 1.84 2.47 0.22 28.8 46.01 19.88 9.38 100.01 2.72 
Week 3  n=21 n=5 n=14 n=21 n=5 n=13 n=21 n=5 n=14 
 Median 0.48 1.10 0.06 10.52 29.20 12.74 3.26 196.12 0.89 
 Min 0.01 0.12 0.01 0.01 0.01 5.82 0.01 18.55 0.01 
 Max 16.9 11.86 0.44 101.92 44.64 50.08 257.8 281.20 20.79 
 p25 0.22 0.86 0.03 8.75 13.86 7.66 0.67 62.29 0.01 
 p75 1.01 3.81 0.11 20.08 34.52 18.62 10.27 271.99 2.21 
Week 4  n=11 n=2 
a
 n=7 n=11 n=2 
a
 n=5 n=11 n=2 
a
 n=7 
 Median 0.62 4.26 0.07 7.54 55.40 16.28 3.46 18.98 0.01 
 Min 0.01 0.90 0.03 0.01 35.47 0.01 0.01 15.74 0.01 
 Max 1.41 7.63 0.15 44.34 75.33 32.70 30.64 22.23 31.72 
 p25 0.03 0.90 0.05 6.51 35.47 14.07 1.62 15.74 0.01 
 p75 0.83 7.63 0.12 18.34 75.33 22.45 9.4 22.23 1.4 
Week 5  n=2 n=0 n=0 n=2 n=0 n=0 n=2 n=0 n=0 
 Median 0.1   3.78   8.12   
 Min 0.1   0.01   0.67   
 Max 0.1   7.54   15.57   
 p25 0.1   0.01   0.67   
 p75 0.1   7.54   15.57   




















Median  0.36 0.05 0.1 6.88 13.4 28.12 0.03 0.76 1.17 
Min  0.01 0.03 0.01 2.87 8.2 10.42 0 0.01 0.01 
Max  0.44 0.15 0.5 12.46 26.23 50.82 1.19 5.90 5.90 
p25  0.21 0.04 0.07 4.51 10.9 13.39 0 0.24 0.01 
p75  0.39 0.1 0.11 10.42 20.9 29.34 0.62 2.51 1.79 
p5  0.01 0.03 0.01 2.87 8.2 10.42 0.01 0.01 0.01 
p95  0.44 0.15 0.5 12.46 26.23 50.82 1.19 5.9 5.79 
LP = lumbar CSF, V = ventricular CSF, S = serum, p= percentile, min = minimum, max = maximum, 
a increase 




Table 10.4: Descriptive statistics for inflammatory markers in all sample types (pg/mL) 
Marker  TNF-α IFN-  IL-6 
Sample  LP V S LP V S LP V S 
Admission  n=36 n=23 n=36 n=36 n=23 n=30 n=36 n=23 n=36 
 Median 266.32 109 15.46 1095.67 684.79 9.66 1700.91 873.54 7.61 
 Min 76.97 20.63 0.01 140.99 118.89 0.01 218.79 38.35 49.95 
 Max 1604.31 1010.17 50.88 8541.02 3888.62 48.9 18448.02 13643.62 10.20 
 p25 180.14 75.49 8.42 619.97 307.39 4.12 1101.84 415.62 1.96 
 p75 493.68 171.6 19.11 2809.42 1080.8 19.58 4863.87 2272.35 12.35 
Week 1  n=29 n=9 n=26 n=29 n=9 n=26 n=29 n=9 n=26 
 Median 160.16 39.89 13.48 278.44 239.02 6.07 595.86 377.59 4.73 
 Min 34.63 12.09 3.36 48.44 57.14 0.01 0.01 43.08 0.01 
 Max 1329.57 712.6 52.55 10275.4 1055.49 75.84 10464.67 5174.25 392.83 
 p25 83.49 32.65 8.86 149.23 112.76 0.01 328.33 58.56 0.01 
 p75 295.86 74.18 17.94 793.26 259.64 13.05 2066.4 791.99 12.43 
Week 2  n=30 n=6 n=23 n=30 n=6 n=23 n=30 n=6 n=23 
 Median 95.15 67.55 11.45 244.51 271.32 4.43 373.81 343.71 0.01 
 Min 25.48 15.8 3.99 0.01 25.92 0.01 21.68 18.89 0.01 
 Max 402.75 141.27 25.31 2197.81 787.56 44.78 5175.25 1210.65 46.97 
 p25 48.62 50.58 7.19 80.71 108.88 0.01 91.83 170.51 0.01 
 p75 138.29 137.06 14.94 465.49 507.03 13.57 604.53 500.6 5.73 
Week 3  n=21 n=5 n=14 n=21 n=5 n=14 n=21 n=5 n=14 
 Median 56.84 90.7 11.7 126.68 93.92 0.01 351.6 244.88 2.78 
 Min 8.49 17.74 4.12 0.01 31.33 0.01 5.65 5.22 0.01 
 Max 216.71 118.5 50.26 757.17 315.17 268.25 1586.25 21146.37 67.69 
 p25 26.16 29.96 5.52 66.08 67.74 0.01 120.81 59.89 0.01 
 p75 84 110.26 16.64 154.25 184.12 7.04 482.87 561.8 4.74 
Week 4  n=11 n=2 n=7 n=11 n=2 n=7 n=11 n=2 n=7 
 Median 56.05 63.76 13.8 69.71 62.31 0.01 216.2 412.64 0.01 
 Min 20.5 58.08 5.35 21.1 45.61 0.01 12.87 23.32 0.01 
 Max 299.88 69.44 39.14 715.18 79.01 116.18 1117.09 801.96 35.62 
 p25 34.94 58.08 6.48 49.34 45.61 0.01 62.02 23.32 0.01 
 p75 129.88 69.44 29.52 209.65 79.01 9.15 678.55 801.96 6.8 
Week 5  n=2 n=0 n=0 n=2 n=0 n=0 n=2 n=0 n=0 
 Median 83.63   199.71   745.76   
 Min 52.6   84.3   110.24   
 Max 114.65   315.11   1381.28   
 p25 52.6   84.3   110.24   
 p75 114.65   315.11   1381.28   
Controls  Fatty filum pTB Fatty filum pTB Fatty filum pTB 



















 Median 0.01 12.09 27.4 0.01 0.01 13.1 0.01 0.01 34.39 
 Min 0.01 7.7 11.84 0.01 0.01 7.97 0.01 0.01 3.82 
 Max 0.01 27.82 135.02 0.01 261.3 196.87 0.01 47.63 458.64 
 p25 0.01 9.75 23.16 0.01 0.01 11.42 0.01 0.01 7.21 
 p75 0.01 20.84 33.06 0.01 6.24 20.9 0.01 0.01 40.48 
 p5 0.01 7.7 11.84 0.01 0.01 7.97 0.01 0.01 3.82 
 p95 0.01 27.82 135.02 0.01 261.3 196.87 0.01 47.63 458.64 
LP = lumbar CSF, V = ventricular CSF, S = serum, p= percentile, min = minimum, max = maximum, LP and 
serum samples in week 2 have 1 less sample relative to neuromarkers as this pair of samples was excluded due 




Marker  IL-12p40 IL-1  IL-Ra 
Sample  LP V S LP V S LP V S 
Admission  n=36 n=23 n=36 n=36 n=23 n=36 n=36 n=23 n=36 
 Median 43.34 4.85 10.69 6.7 0.01 0.01 456.2 72.65 33.31 
 Min 0.01 0.01 0.01 0.01 0.01 0.01 19.02 0.01 0.01 
 Max 279.46 63.99 126.18 58.76 27.14 16.37 1572.11 699.77 223.29 
 p25 20.25 0.01 0.01 0.01 0.01 0.01 204.17 28.42 0.01 
 p75 62.8 32.03 45.2 15.04 6.89 3.31 810.35 195.84 84.48 
Week 1  n=29 n=9 n=26 n=29 n=9 n=26 n=29 n=9 n=26 
 Median 44.96 2.39 17.29 0.01 0.01 0.01 182.06 62.91 31.18 
 Min 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 
 Max 330.96 114.41 114.21 99.39 50.68 13.62 2074.47 252.14 619.99 
 p25 25.2 0.01 0.01 0.01 0.01 0.01 47.26 0.01 0.01 
 p75 79.95 12.54 38.13 3.7 8.86 1.01 736.48 88.53 68.73 
Week 2  n=30 n=6 n=23 n=30 n=6 n=23 n=30 n=6 n=23 
 Median 50.99 23.7 21.47 0.01 0.01 0.01 71.99 46.68 19.02 
 Min 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 
 Max 356.42 133.38 92.16 12.31 18 14.6 2060.31 154.38 184.79 
 p25 30.99 16.74 0.01 0.01 0.01 0.01 2.53 0.01 0.01 
 p75 100.02 35.15 44.04 4.1 13.79 1.52 210.34 89.94 69.48 
Week 3  n=21 n=5 n=14 n=21 n=5 n=14 n=21 n=5 n=14 
 Median 41.37 64.48 13.99 0.01 0.01 0.01 2.53 31.57 38.74 
 Min 0.01 8.08 0.01 0.01 0.01 0.01 0.01 0.01 0.01 
 Max 217.54 146.87 236.27 8.47 5.58 50.42 293.77 1492.95 384.11 
 p25 4.87 12.89 0.01 0.01 0.01 0.01 0.01 0.01 0.01 
 p75 65.95 87.23 23.44 0.01 3.8 0.01 59.28 51.87 52.69 
Week 4  n=11 n=2 n=7 n=11 n=2 n=7 n=11 n=2 n=7 
 Median 30.99 65.28 0.01 0.01 0.01 0.01 0.01 1.27 37.8 
 Min 0.01 45.53 0.01 0.01 0.01 0.01 0.01 0.01 0.01 
 Max 273.4 85.02 176.57 3.7 0.01 33.5 618.6 2.53 261.35 
 p25 25.2 45.53 0.01 0.01 0.01 0.01 0.01 0.01 0.01 
 p75 59.27 85.02 52.47 3.41 0.01 0.01 130.97 2.53 66.3 
Week 5  n=2 n=0 n=0 n=2 n=0 n=0 n=2 n=0 n=0 
 Median 64.37   0.01   22.09   
 Min 52.47   0.01   0.01   
 Max 75.62   0.01   44.17   
 p25 52.47   0.01   0.01   
 p75 75.62   0.01   44.17   




















 Median 0.01 29.25 25.69 0.01 0.01 0.01 0.01 16.53 69.36 
 Min 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 
 Max 0.01 99.76 74.31 0.01 6.89 9.95 0.01 80.09 279.49 
 p25 0.01 5.74 6.51 0.01 0.01 0.01 0.01 0.01 23.65 
 p75 0.01 41.58 35.11 0.01 0.01 0.01 0.01 30.74 72.85 
 p5 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 
 p95 0.01 99.76 74.31 0.01 6.89 9.95 0.01 80.09 279.49 




Marker  IL-8 MCP-1 IP-10 
Sample  LP V S LP V S LP V S 
Admission  n=36 n=23 n=36 n=36 n=23 n=36 n=36 n=23 n=36 
 Median 1981.46 490.57 20.14 1947.4 4597.47 143.21 35505.4 24924.98 550.97 
 Min 487.48 23.41 4.31 507.8 1627.85 20.22 5919.14 970.83 165.43 
 Max 6539.84 1370.34 280.93 6257.75 15327.69 684.11 77800.54 77800.54 3654.24 
 p25 1122.93 177.8 16.68 1510.62 2678.13 78.21 25618.52 7422.5 395.26 
 p75 3396.45 806.4 36.2 2954.85 9227.79 225.95 69388.13 74447.62 1080.1 
Week 1  n=29 n=9 n=26 n=29 n=9 n=26 n=29 n=9 n=26 
 Median 1115.03 706.78 26.27 1280.36 2581.72 207.33 25618.52 15672.62 463.92 
 Min 197.78 35.16 5.73 421.86 500.45 34.4 1959.68 488.21 146.81 
 Max 7766.9 3399.34 236.15 6799.66 9936.64 792.72 78500.87 74531.67 4861.21 
 p25 467.65 94.41 17.43 906.29 2238.52 164.24 8734.63 1217.97 226.1 
 p75 2307.95 906.85 40.62 1702.15 3655.25 348.78 58255.83 69676.58 704.59 
Week 2  n=30 n=6 n=23 n=30 n=6 n=23 n=30 n=6 n=23 
 Median 804.1 323.85 21.77 1466.31 4045.46 225.1 25357.92 12102.38 324 
 Min 126.07 48.82 0.01 467.46 1894.41 45.62 1847.29 2804.47 162.49 
 Max 2424.95 749.45 969.47 9046.45 11696.31 740.67 76541.2 74447.62 1582.56 
 p25 407.35 182.55 13.82 892.7 2395.89 143.34 8481.32 4147.57 194.98 
 p75 1291.6 608.44 40.12 2295.7 6962.93 326.09 63333.72 35471.74 507.72 
Week 3  n=21 n=5 n=14 n=21 n=5 n=14 n=21 n=5 n=14 
 Median 651.52 244.96 17.42 1866.22 1821.05 263.32 14252.21 27490.36 312.1 
 Min 37.35 57.55 6.72 245.94 336.85 71.19 445.64 396.94 113.99 
 Max 3329.57 805.35 108.11 5474.77 4258.12 878.79 74447.62 74447.62 3768.51 
 p25 301.26 187.91 13.91 1006.69 1796.2 159.45 3284.14 20746.36 205.44 
 p75 1355.66 354.89 28.05 2455.82 2537.43 791.14 25618.52 69382.67 969.06 
Week 4  n=11 n=2 n=7 n=11 n=2 n=7 n=11 n=2 n=7 
 Median 635.77 498.95 25.91 1506.78 1816.67 331.02 14017.15 35227.77 532.95 
 Min 133.58 399.7 10.84 648.07 1784.44 95.63 980.38 7950.87 84.56 
 Max 4602.41 598.2 69.42 2938.7 1848.89 866.52 74447.62 62504.67 1002.57 
 p25 253.15 399.7 22.19 1016.79 1784.44 232.79 2476.6 7950.87 358.18 
 p75 1099.52 598.2 39.96 2539.85 1848.89 428.2 51893.2 62504.67 782.34 
Week 5  n=2 n=0 n=0 n=2 n=0 n=0 n=2 n=0 n=0 
 Median 1237.83   3270.23   37109.9   
 Min 366.18   1741.39   12431.57   
 Max 2109.48   4799.07   61788.22   
 p25 366.18   1741.39   12431.57   
 p75 2109.48   4799.07   61788.22   




















 Median 6.58 9.93 15.37 651.38 246.54 418.17 43.42 272.16 1931.02 
 Min 3.26 3.47 7.41 412.88 198.02 160.26 7.76 91.43 807.44 
 Max 30.11 42.59 300.62 1475.21 610.11 1543.51 364.18 1012.02 19318.78 
 p25 5.07 6.28 12.52 533.75 216.59 339.71 14.44 186.21 996.4 
 p75 13.65 18.75 30.44 1175.25 365.65 1084.61 106.29 470.15 2188.88 
 p5 3.26 3.47 7.41 412.88 198.02 160.26 7.76 91.43 807.44 
 p95 30.11 42.59 300.62 1475.21 610.11 1543.51 364.18 1012.02 19318.78 





Marker  MIP-1α GRO IL-10 
Sample  LP V S LP V S LP V S 
Admission  n=36 n=23 n=36 n=36 n=23 n=36 n=36 n=23 n=36 
 Median 57.79 35.2 3.26 1431.18 166.77 2165.63 420.32 97.22 8.54 
 Min 26.48 9.54 0.01 250.17 0.01 873 107.18 41.61 0.01 
 Max 256.37 113.17 1694.16 3207.74 819.52 4696.52 1209.5 536.41 78.76 
 p25 41.39 24.38 0.01 1010.29 43.9 1793 252.45 61.66 1.78 
 p75 78.92 46.58 17.34 1852.98 358.33 2779.23 653.04 255.17 17.86 
Week 1  n=29 n=9 n=26 n=29 n=9 n=26 n=29 n=9 n=26 
 Median 48.46 31.27 2.49 819.18 109.88 2155.46 140.29 50.24 14.04 
 Min 0.01 10.08 0.01 130.51 0.01 127.94 46.45 11.47 0.01 
 Max 91.08 140.46 1516.58 4067.42 3269.84 3651.44 873.74 603.21 85.51 
 p25 21.5 24.62 0.01 429.08 0.01 1274.39 108.71 29.09 5.47 
 p75 62.71 64.35 19.59 1589.94 415.05 2859.11 234.29 153.16 27.43 
Week 2  n=30 n=6 n=23 n=30 n=6 n=23 n=30 n=6 n=23 
 Median 37.4 37.94 9.54 696.18 179.1 2385.49 156.3 55.89 16.69 
 Min 0.01 14.01 0.01 62.24 0.01 1030.95 9.73 34.79 0.01 
 Max 92 49.28 864.09 2194.12 502.87 4252.57 439.5 605.45 132.23 
 p25 23.3 30.09 0.01 320.24 38.72 1909.51 84.18 35.62 4.92 
 p75 53.81 45.13 20.3 1267.34 290.01 3237.48 251.34 518.97 36.53 
Week 3  n=21 n=5 n=14 n=21 n=5 n=14 n=21 n=5 n=14 
 Median 32.61 22.18 2.44 508.08 107.09 2530.25 156.41 108.99 5.87 
 Min 11.87 15.49 0.01 0.01 0.01 956.73 22.22 27.07 0.01 
 Max 68.5 66.05 82.85 2898.23 180.76 5093.25 291.39 267.55 159.74 
 p25 22.59 21.07 0.01 348.11 73.41 1834.52 95.38 64.57 0.01 
 p75 36.28 24.27 19 1351.99 160.21 2984.26 215.3 154.01 25.74 
Week 4  n=11 n=2 n=7 n=11 n=2 n=7 n=11 n=2 n=7 
 Median 23.06 20.84 8.81 931.36 834.46 2609.84 216.77 163.4 16.88 
 Min 8.49 15.19 0.01 77.43 297.65 1334.27 74.58 109.84 8.41 
 Max 65.32 26.48 86.67 2425.63 1371.35 3242.75 275.68 216.96 68.74 
 p25 17.5 15.19 0.01 277.25 297.56 1597.04 125.43 109.84 12.38 
 p75 46.58 26.48 30.89 1785.63 1371.35 2948.99 254.48 216.96 38.48 
Week 5  n=2 n=0 n=0 n=2 n=0 n=0 n=2 n=0 n=0 
 Median 26.48   1376.51   191.21   
 Min 15.86   228.54   76.78   
 Max 37.09   2524.48   305.63   
 p25 15.86   228.54   76.78   
 p75 37.06   2524.48   305.63   




















 Median 0.01 6.63 0.01 0.01 2273.49 2414.41 0.01 8.01 19.31 
 Min 0.01 0.01 0.01 0.01 328.69 1254.55 0.01 0.01 4.08 
 Max 10.61 63.47 78.87 0.01 3272.34 3062.44 0.01 31.98 44.67 
 p25 0.01 0.01 0.01 0.01 1149.74 1538.76 0.01 3.4 7.58 
 p75 7.41 13.14 15.49 0.01 2560.79 2816.48 0.01 18.93 32.26 
 p5 0.01 0.01 0.01 0.01 328.69 1254.55 0.01 0.01 4.08 
 p95 10.61 63.47 78.87 0.01 3272.34 3062.44 0.01 31.98 44.67 





Marker  VEGF RANTES 
Sample  LP V S LP V S 
Admission  n=36 n=23 n=36 n=36 n=23 n=36 
 Median 145.33 136.15 220.27 0.01 0.01 4375.69 
 Min 0.01 0.01 0.01 0.01 0.01 1356.4 
 Max 836.7 424.78 1442.94 1022.21 0.01 13288.76 
 p25 108 0.01 152.5 0.01 0.01 3680.88 
 p75 269.13 220.27 382.75 0.01 0.01 7155.71 
Week 1  n=29 n=9 n=26 n=29 n=9 n=26 
 Median 141.88 67.17 236.19 0.01 0.01 4970.54 
 Min 0.01 0.01 0.01 0.01 0.01 0.01 
 Max 558.81 376.55 729.24 412.04 0.01 12984.16 
 p25 97.28 0.01 130.44 0.01 0.01 4164.56 
 p75 194.76 166.22 358.31 0.01 0.01 8418.42 
Week 2  n=30 n=6 n=23 n=30 n=6 n=23 
 Median 139.7 142.49 247.01 0.01 0.01 5026.29 
 Min 0.01 0.01 0.01 0.01 0.01 862.17 
 Max 504.41 399.71 973.74 314.6 0.01 11374.73 
 p25 0.01 56.6 162.47 0.01 0.01 3800.18 
 p75 206.25 309 383.57 0.01 0.01 8559.62 
Week 3  n=21 n=5 n=14 n=21 n=5 n=14 
 Median 0.01
a 238.68 180.6 0.01 0.01 4851.89 
 Min 0.01 97.28 0.01 0.01 0.01 1615.88 
 Max 558.81 327.99 819.39 0.01 0.01 11787.36 
 p25 0.01 221.98 150.43 0.01 0.01 4037.31 
 p75 184.11 271.79 265.75 0.01 0.01 7747.56 
Week 4  n=11 n=2 n=7 n=11 n=2 n=7 
 Median 90.24 115.2 166.22 0.01 0.01 4403.37 
 Min 0.01 56.6 0.01 0.01 0.01 2381.16 
 Max 399.71 173.8 970.41 0.01 0.01 13632.33 
 p25 0.01 56.6 135.06 0.01 0.01 3670.28 
 p75 127.84 173.8 534.92 0.01 0.01 9796.18 
Week 5  n=2 n=0 n=0 n=2 n=0 n=0 
 Median 267.93   0.01   
 Min 136.15   0.01   
 Max 399.71   0.01   
 p25 136.15   0.01   
 p75 399.71   0.01   














 Median 0.01 327.99 383.57 0.01 7270.56 9843.51 
 Min 0.01 0.01 0.01 0.01 3511.32 4984.65 
 Max 0.01 816.74 1950.31 0.01 12311.36 12977.91 
 p25 0.01 90.24 220.27 0.01 4008.91 7407.29 
 p75 0.01 546.56 681.05 0.01 9864.55 11179.14 
 p5 0.01 0.01 0.01 0.01 3511.32 4984.65 
 p95 0.01 816.74 1950.31 0.01 12311.36 12977.91 
LP = lumbar CSF, V = ventricular CSF, S = serum, p= percentile, min = minimum, max = maximum, 
a 
The 
LLOD for VEGF was 80, therefore values <80 were assigned 0.01; week 3 concentrations were predominantly 




Cases versus Controls 
Neuro-markers 
S100B - In TBM cases, S100B concentrations in lumbar and ventricular CSF samples were elevated 
compared to controls from admission to week 2 (p<0.05). Serum values were not significantly 
different from fatty filum or pTB controls.  
NSE - NSE lumbar CSF values were elevated for the first 2 weeks and ventricular CSF until week 1 
(p<0.05). Serum NSE concentrations were not elevated.  
GFAP - Lumbar CSF concentrations were elevated until week 4 and ventricular CSF until week 3 
(p<0.05); serum concentrations were not significantly elevated at any time point.  
Inflammatory markers 
Admission lumbar and ventricular CSF cytokine concentrations were significantly higher in TBM 
cases relative to control CSF. Only RANTES did not differ between the 2 groups. Serum 
concentrations for IP-10, IFN- , IL-6 and IL-8 were significantly higher than the fatty filum controls, 
and MCP-1 concentrations were significantly lower; the remaining cytokines did not differ 
statistically. In comparison to pTB controls, IP-10, MCP-1, TNF-α and RANTES were lower in case 
serum, and no differences were demonstrated across the other cytokines. 
The number of case samples elevated above the 95
th
 percentile of control values is tabulated for the 17 
markers in Table 10.5. 
PCA plots demonstrate that concentrations of all 17 biomarkers were greater in TBM cases compared 
to controls in lumbar (Figure 10.1 and 10.4) and ventricular CSF (Figure 10.2 and 10.5), but were not 
different in serum samples (Figure 10.3 and 10.6). 
Fatty filum controls vs pTB controls 
There were no significant differences in serum concentrations of the 3 neuromarkers between the fatty 
filum and pTB controls. Several of the inflammatory markers were significantly higher in the pTB 




Table 10.5: Percentage of elevated case samples in each sample type 
 Sample 
Type 
TBM LP vs 
Fatty filum LP 
TBM V vs  
Fatty filum LP 
TBM S vs  
Fatty filum S 
TBM S vs 
pTB S 
Biomarker  % > p95 % > p95 % > p95 % > p95 
S100B Admission 86.11 100 22.22 2.78 
 Highest 89.7 96.9 40.5 9.5 
NSE Admission 66.67 91.3 26.67 6.67 
 Highest 92.3 90.6 32.5 5 
GFAP Admission 91.67 100 2.78 2.78 
 Highest 92.3 100 9.5 9.5 
TNF-α Admission 99.23 100 10.28 0 
IFN-  Admission 99.23 100 2.78 2.78 
IL-6 Admission 99.23 100 2.80 0 
IL-12p40 Admission 99.23 100 3.74 6.54 
IL-1  Admission 99.23 100 9.35 7.48 
IL-Ra Admission 99.23 100 23.36 1.87 
IP-10 Admission 99.23 100 19.63 0 
MIP-1α Admission 95.38 95.65 8.41 8.41 
IL-8 Admission 99.23 95.65 19.63 2.78 
MCP-1 Admission 50.77 93.48 8.41 0 
GRO Admission 99.23 100 12.15 20.56 
IL-10 Admission 99.23 100 19.63 14.02 
VEGF Admission 99.23 100 6.54 0 
RANTES Admission 99.23 100 2.80 2.80 
This table details the percentage of TBM samples (admission and highest overall) which were elevated above 
the 95
th
 percentile of the CSF and serum concentrations of the control groups – TBM concentrations in lumbar 
CSF are compared to fatty filum lumbar CSF, TBM case ventricular CSF are compared to fatty filum lumbar 
CSF, and TBM case serum are compared to serum of fatty filum and pTb control groups. LP= lumbar CSF, V = 
ventricular CSF, S = serum. % > p95 represents the percentage of case concentrations which fell above the 95
th
 
percentile of control values. Admission LP samples (n=36), V (n=23), S (n=36); Highest LP samples (n=39), V 




Neuromarkers: PCA plots - cases versus controls 







This plot demonstrates lumbar S100B, NSE and GFAP concentrations simultaneously. The weighted 
average of initial S100B, NSE and GFAP concentrations for each patient were used to calculate a z-
score per patient which reflects their concentrations in all 3 neuromarkers simultaneously. Pink 
markers represent the z-scores of individual patients and the concentration of S100B, NSE and GFAP 
for an individual patient is indicated by their relative distance from the 3 axes. Blue markers indicate 
fatty filum controls and demonstrate that control patients had low concentrations on all 3 
neuromarkers. TBM cases had higher concentrations relative to controls on all 3 neuromarkers. 
 TBM Cases         
 Fatty filum controls 
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This plot demonstrates admission ventricular S100B, NSE and GFAP concentrations simultaneously using z-
scores as described for Figure 10.1 above. Green markers represent the z-scores of TBM patients, and blue 
markers indicate fatty filum controls - controls had low concentrations on all 3 neuromarkers. TBM cases had 
higher concentrations relative to controls on all 3 neuromarkers. 
TBM Cases          
Fatty filum controls 
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This plot demonstrates admission serum S100B, NSE and GFAP concentrations simultaneously using z-
scores as described for Figure 10.1 above. Orange markers represent the z-scores of TBM patients, dark 
blue markers indicate fatty filum controls, and light blue markers indicate pTB controls - control and TBM 
case concentrations on all 3 neuromarkers overlapped, this provides a graphical depiction of the finding 
that TBM serum neuromarker concentrations were not significantly different from control concentrations  
TBM Cases      




Inflammatory markers: PCA Plots - cases versus controls 
 






        TBM Cases  
        Fatty filum controls 
 
This plot demonstrates admission lumbar inflammatory marker concentrations simultaneously using z-
scores as described for Figure 10.1 above. Pink markers represent the z-scores of TBM patients, and blue 
markers indicate fatty filum controls - controls had low concentrations on all inflammatory markers, 
TBM cases had higher concentrations relative to controls on all markers 
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This plot demonstrates admission ventricular inflammatory marker concentrations simultaneously using 
z-scores as described for Figure 10.1 above. Green markers represent the z-scores of TBM patients, and 
blue markers indicate fatty filum controls - controls had low concentrations on all inflammatory markers, 
TBM cases had higher concentrations relative to controls on all markers 
TBM Cases         
Fatty filum controls 
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This plot demonstrates admission serum inflammatory marker concentrations simultaneously using z-scores as 
described for Figure 10.1 above. Orange markers represent the z-scores of TBM patients, dark blue markers 
indicate fatty filum controls, and light blue markers indicate pTB controls – TBM and control serum 
concentrations overlapped suggesting that they were not different across the groups.  
TBM Cases     





Graphical representations of the neuro- and inflammatory marker temporal profiles are shown in 





 percentile. In order to maximize the visual demonstration of biomarker temporal profiles, 
outliers (values >2 times the interquartile range above the median) and ventricular samples from week 
4 (n=2 - elevated concentrations belonged to a patient who had failed medical treatment and required 
a VPS) were excluded from the box-plots. Box-plots with outliers are included in Appendix 8.  
Neuromarkers 
S100B - The median concentration of lumbar CSF S100B peaked in week 1, although median values 
between admission and week 1 samples were almost equal. Concentrations decreased thereafter and 
had normalized by week 3.  Ventricular CSF concentrations peaked in week 1 and then declined.  
Serum S100B concentrations were highest on admission followed by a general downward trajectory. 
NSE – Median lumbar and ventricular CSF concentrations peaked in week 1 followed by a gradual 
downward trajectory thereafter, and normalized by week 3. Median serum NSE was highest on 
admission and in week 1. The increase in ventricular concentrations in week 4 is from the same 2 
patients described for S100B; these values were also not significantly different from controls. 
GFAP – Median lumbar CSF concentrations peaked at admission, and thereafter decreased. The 
increase in median concentrations in week 4 is attributable to the 2 patients described above and these 
samples were not significantly different from controls. Serum GFAP concentrations remained low 
throughout sampling.  
Inflammatory markers 
Overall, lumbar CSF inflammatory marker concentrations were highest on admission, followed by a 
decline thereafter, although they remained higher than controls until week 4. Only GRO levels 
increased in week 4. Similarly, ventricular CSF markers declined over time. Elevations in IP-10, IL-8, 
GRO, IL-10, IL-12p40, VEGF and TNF-α in week 4 are attributable to the same β patients described 





Box-and-whisker plots over time: Neuromarkers 
















 percentile, fatty filum control CSF values are represented in light grey on the lumbar and ventricular plots, and fatty 
filum control serum values (light grey) and pTB control serum values (dark grey) are represented on the serum plots. TBM 
case data are presented in colour. Only 1 patient had samples at week 6 (ventricular CSF and serum) 
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 percentile, fatty filum control CSF values are represented in light grey on the lumbar and ventricular plots, and fatty 
filum control serum values (light grey) and pTB control serum values (dark grey) are represented on the serum plots. TBM 












 percentile, Fatty filum control CSF values are represented in light grey on the lumbar and ventricular plots, and 
fatty filum control serum values (light grey) and pTB control serum values (dark grey) are represented on the serum plots. 












 percentile, Fatty filum control CSF values are represented in light grey on the lumbar and ventricular plots, and 
fatty filum control serum values (light grey) and pTB control serum values (dark grey) are represented on the serum plots. 













 percentile, Fatty filum control CSF values are represented in light grey on the lumbar and ventricular plots, and 
fatty filum control serum values (light grey) and pTB control serum values (dark grey) are represented on the serum plots. 


















 percentile, Fatty filum control CSF values are represented in light grey on the lumbar and ventricular plots, and 
fatty filum control serum values (light grey) and pTB control serum values (dark grey) are represented on the serum plots. 
TBM case data are presented in colour. Only 1 patient had samples at week 6 (ventricular CSF and serum). 
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Inter-biomarker associations  
Initial and overall median neuromarker concentrations per patient were positively correlated in 
S100B, NSE and GFAP for lumbar and ventricular CSF (Table 10.6, Figure 10.11). Overall median 
serum values per patient for NSE and S100B were positively associated (r = 0.65, p < 0.001). 
Correlations of the median S100B, NSE and GFAP concentrations at each time point over sample 
collection revealed that S100B and NSE were positively associated in both lumbar and ventricular 
CSF (r = 0.88, p=0.01 and r =0.8, p = 0.04 respectively). GFAP was not associated with S100B 
(p=0.3) or NSE (p=0.6).   
 
 
Table 10.6: Correlation matrices for S100B, NSE and GFAP 
 
Lumbar CSF Initial S100B Initial NSE  Median 
S100B 
Median NSE 
Initial NSE r=0.65* 
(p<0.001) 





















Initial S100B Initial NSE  Median 
S100B 
Median NSE 
Initial NSE r=0.64* 
(p<0.001) 
 Median NSE r=0.45* 
(p=0.01) 
 











Serum Initial S100B Initial NSE  Median 
S100B 
Median NSE 
Initial NSE r=0.6* 
(p<0.001) 
 Median NSE r=0.65* 
(p<0.001) 
 











This table depicts results for correlations between initial as well as overall median per patient 
















































Markers within V Sample: Initial Sample
Pairs plots demonstrate scatterplots for the correlation between S100B, NSE and GFAP for the 
initial lumbar CSF (LP) and ventricular CSF (V) samples  
























































Markers within V Sample: Median per Patient
 Correlation S100B and NSE                                 Correlation S100B and GFAP                           Correlation NSE and GFAP 
Pairs plots demonstrate scatterplots for the correlation between S100B, NSE and GFAP for the 
the overall median per patient in lumbar CSF (LP) and ventricular CSF (V) samples 
169 
 
The GEE model demonstrated ventricular CSF concentrations were greater than lumbar CSF 
concentrations, which was greater than serum concentrations across all time points for S100B, NSE 
and GFAP. At any time point, ventricular CSF S100B was estimated to be β.β μg/L greater than 
lumbar CSF S100B, ventricular NSE 1γ.55 μg/L greater than lumbar NSE, and ventricular GFAP 
91.18 μg/L greater than lumbar GFAP. Serum S100B was estimated to be 1.59 μg/L lower than 
lumbar CSF S100B, serum NSE 1β.8γ μg/L lower than lumbar NSE and serum GFAP β1.59 μg/L 
lower than lumbar GFAP. Since spinal arachnoiditis and adhesions potentially may influence the 
rostro-caudal gradient of biomarker concentrations, spinal arachnoiditis was added to the model. In 
patients with spinal arachnoiditis ventricular S100B remained higher than lumbar S100B but to a 
lesser degree than seen in patients without arachnoiditis, NSE concentrations were no longer 
significantly different across the ventricular and lumbar CSF, and ventricular GFAP remained higher 
than lumbar GFAP irrespective of arachnoiditis. The coefficients and confidence intervals (CI) for the 
GEE are presented in Appendix 9. 
PCA plots visually demonstrate the GEE findings that ventricular CSF concentrations were more 
elevated than lumbar CSF, which were more elevated than serum across all neuromarkers, as 
indicated by their position higher along the S100B, NSE and GFAP axes (Figure 10.12). For 
inflammatory markers overall lumbar CSF concentrations were greater than ventricular CSF, which 
were greater than serum. MCP-1 and IP-10 demonstrated higher values in ventricular CSF; and GRO, 
RANTES and VEGF were more elevated in the serum than CSF samples.  Similarly, serum 














This plot demonstrates admission lumbar CSF, ventricular CSF, and serum S100B, NSE and GFAP 
concentrations simultaneously using z-scores as described for Figures 10.1-10.3 above. Green markers 
represent ventricular z-scores, pink markers represent lumbar z-scores and orange markers represent serum 
z-scores. This plot illustrates that for all 3 neuromarkers ventricular CSF concentrations were greater than 





















This plot demonstrates admission lumbar CSF, ventricular CSF, and serum inflammatory marker 
concentrations simultaneously using z-scores as described for Figures 10.4-10.6 above. Green markers 
represent ventricular z-scores, pink markers represent lumbar z-scores and orange markers represent 
serum z-scores. This plot illustrates that lumbar and ventricular CSF concentrations exceeded serum 
concentrations on all 14 inflammatory markers, and lumbar CSF concentrations were greater than 






Correlations between neuro- and inflammatory markers and within inflammatory markers are 
tabulated in Appendix 10. S100B was correlated with IL-Ra, IL-6 and VEGF; NSE was correlated 
with IL-Ra, TNF-α, VEGF and IL-10; only GRO was correlated with GFAP. Significant correlations 
were observed between numerous cytokines. Cluster analysis demonstrated that neuromarkers 
clustered with cytokines GRO, IL-8, IL-6 and IL-Ra.  
 







The dendrogram represents the results of the cluster analysis – biomarkers which demonstrated the smallest 
distance between patient data points were clustered together, and clusters exhibiting the smallest difference 
between each other were connected  
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Association with patient and admission characteristics 
 
Lumbar NSE trended towards being higher in children < 2 years (p=0.07). Lumbar GFAP was 
significantly more elevated in TB culture positive patients, but this was not replicated in the 
ventricular CSF. Initial lumbar and ventricular S100B were not associated with admission or patient 
characteristics. 
 
Association with clinical outcome 
 




S100B - Absolute Δ in lumbar S100B was significantly predictive of mortality and 6 month 
dichotomized PCPS outcome (p<0.001 and p=0.02 respectively), demonstrating that in patients who 
died or who had a poor functional outcome, S100B tended to increase. The highest concentration 
recorded in week 1 and overall predicted clinical outcome at 6 months (p=0.04 and p=0.03 
respectively). All indices of ventricular S100B was associated with mortality and 6 month outcome as 
detailed in Table 10.7. 
 
NSE - Initial lumbar NSE was a significant predictor of morbidity in survivors at 3 and 6 months 
(p=0.02 and p=0.03 respectively). Highest NSE overall was predictive of mortality and survivor 
disability and highest in week 1 was associated with 6 month clinical outcome. Absolute Δ was 
predictive of both mortality (p=0.01) and clinical 6 month outcome (p=0.02). Initial and highest 
ventricular NSE were strong predictors of mortality and clinical 6 month outcome. 
 
GFAP - Highest lumbar GFAP overall and in week 1 and the absolute Δ were associated with 
mortality (p<0.05). Only highest overall trended towards predicting survivor morbidity at 3 and 6 
months. Ventricular GFAP was not a predictor of mortality or survivor morbidity.  
 
Neuromarkers combined- Z-Neuro Initial LP was not predictive of mortality (p=0.3) or clinical 
outcome (p=0.2), however, Z-Neuro Initial V was predictive of both (p=0.03 and p=0.04 
respectively), suggesting that combined initial S100B, NSE and GFAP lumbar neuromarker 
concentrations were not prognostic; whereas combined concentrations in ventricular CSF were.  Z-
Neuro Δ significantly predicted mortality (p<0.001) and outcome at 6 months (p<0.01), indicating 




In summary, results for neuromarkers, singly or in combination, suggest that elevated neuromarker 
concentrations (as represented by their highest recorded concentrations) and an increasing trend over 
time were prognostic of poor outcome. Outcome associations for neuromarker indices are summarized 
in Table 10.7 and p-values in Appendix 11. 
 
 
Table 10.7: Summary of neuromarker univariate outcome analysis 
 Neuromarker Mortality Outcome Morbidity 
 Index   3 month 6 months 
S100B      
Lumbar Initial x x  x 
Ventricular     p=0.08 x 
Lumbar Highest in week 1 x   x 
Ventricular     p=0.08 x 
Lumbar Highest overall x   x 
Ventricular    p=0.06 x x 
Lumbar Absolute Δ   x x 
NSE      
Lumbar Initial x p=0.07   
Ventricular     x x 
Lumbar Highest in week 1 x p=0.08   
Ventricular     x x 
Lumbar Highest overall     
Ventricular     x x 
Lumbar Absolute Δ   x x 
GFAP      
Lumbar Initial x x p=0.06 x 
Ventricular   x x x x 
Lumbar Highest in week 1 p=0.07 x p=0.07 x 
Ventricular   p=0.08 x x x 
Lumbar Highest overall  p = 0.07  p = 0.06 
Ventricular   x x x x 
Lumbar Absolute Δ  p=0.08 x x 
This table represents results of univariate analysis of various neuromarker indices with mortality, clinical 
outcome at 6 months, and morbidity in survivors at 3 and 6 months. Initial concentrations represent admission 
or week 1 concentration when no admission concentration was available (n= 39 lumbar CSF and 26 ventricular 
CSF samples), highest overall represents the highest concentration recorded during the duration of sampling, 
and absolute Δ represents the change in concentration from admission to week 2 (calculated as week 2-
admission),  = significant at p<0.05, x = not significant, indices trending towards significance are indicated by 




Inflammatory markers  
Univariate analysis demonstrated that none of the admission CSF cytokines were predictive of 
mortality or 6 month clinical outcome, except ventricular IL-6 was more elevated in patients with 
poor clinical outcomes (p=0.05).  
Inflammatory markers combined - Z-Inflam Initial LP was not significantly associated with mortality 
(p=0.93) or 6 month outcome (p=0.95), neither was Z-Inflam Initial V (p=0.16 and p=0.12 
respectively), or Z-Inflam Δ (p=0.8 and p=0.6 respectively).  
 
Therefore, the initial concentrations (singly or combined) and the change over time in inflammatory 
markers (combined) were not predictive of outcome. 
 
Combined neuro- and inflammatory markers 
Results from PCA combining Z-scores for neuro- and inflammatory markers were weak.  PCA for 
combined initial neuro- and inflammatory marker concentrations (Z-Neuro Initial LP and Z-Inflam 
Initial LP) demonstrated that PC1 accounted for 36% variability and PC1+PC2 accounted for only 
48% variability. Analysis of the trend in combined neuro- and inflammatory marker concentrations 
over time (Z-Neuro Δ and Z-Inflam Δ) revealed that PC1 accounted for 32% variability and 
PC1+PC2 accounted for 47%. This suggests that the combined neuro- and inflammatory data 
demonstrate a high degree of variability which cannot be explained by only β PC’s. When the 
combined data were plotted, patterns associated with mortality were not discernable. In comparison to 
the PCA results for neuromarkers alone (described above), these results suggest that combining 
neuro- and inflammatory markers creates more variability in the data and does not add prognostic 










This PCA plot demonstrates the combination of neuro- and inflammatory marker concentrations on admission using z-
scores. Patients who died are indicated in black, and patients who survived in pink. The distribution of the data suggests 












  This PCA plot demonstrates the combination of the trend in  neuro- and inflammatory marker concentrations over time 
using z-scores. Patients who died are indicated in black, and patients who survived in pink. The distribution of the data 





Temporal profile and mortality 
 
PCA plots of the temporal profile of combined neuromarkers illustrated that neuromarker 
concentrations in the lumbar CSF decreased over time, but that an increasing trend was observed in 
patients who died.  The analysis showed that for the neuromarkers in lumbar CSF, PC1 accounted for 
67.58% of the variability in the data, and PC2 accounted for 19.03%. Cumulatively the 2 principle 
components explained 86.61% of variability in the data over time. In ventricular CSF PC1 and PC2 
explained 92.49% of the variability over time (PC= 71.75%, PC2= 20.74%).  This demonstrates a 
good quality PCA fit for the neuromarkers. S100B contributed most to this variability. The PCA plot 
for combined lumbar CSF neuromarkers is depicted in Figure 10.17. 
The increasing temporal neuromarker profile in patients who died was not replicated in the PCA plots 
of the combined inflammatory markers over time; patients who died followed a similar downward 
trajectory to those who survived, as illustrated in Figure 10.18. For the combined inflammatory 
analysis over time only 52.52% of the variability was described by the first 2 PCs in lumbar CSF 




Figure 10.17: PCA plot: Temporal profile of combined neuromarkers in lumbar CSF 
 
  
This 3-dimensional PCA plot depicts the z-scores for combined neuromarkers in lumbar CSF over the 
duration of sampling (admission – week 5). Each pink mark represents a patient’s z-score at that time 
point, and the blue marks represent the fatty filum control patients for whom only 1 sample was 
collected. The axes represent principle component 1 (PC1), principle component 2 (PC2) and time. 
This plot demonstrates that patients who died (indicated by black marks) had increasing neuromarker 
trends, whereas survivors demonstrated a decline in concentrations over time. 
Control samples 





Figure 10.18: PCA plot: Temporal profile of combined inflammatory markers in 







This 3-dimensional PCA plot depicts the z-scores for combined inflammatory markers in lumbar CSF 
over the duration of sampling (admission – week 5). Each pink mark represents a patient’s z-score at 
that time point, and the blue marks represent the control patients for whom only 1 sample was 
collected. The axes represent principle component 1 (PC1), principle component 2 (PC2) and time. 
This plot demonstrates that, overall, patients who died (indicated by black marks) had decreasing 
neuromarker trends, similar to survivors 
Control samples 






Neuromarkers and mortality – ROC’s for mortality demonstrated that concentrations of S100B >β.75 
μg/L predicted death with a sensitivity of 71.4γ% and specificity of 70.97%, (area under the curve 
[AUC] 0.69, CI:0.4-0.97); NSE > 56.84 μg/L with a sensitivity of 77.42% and specificity of 78.95% 
(AUC 0.81, CI: 0.63-0.99); and GFAP elevations >β7.β5 μg/L with a sensitivity of 85.71% and 
specificity of 73.68% (AUC 0.84, CI: 0.71-0.98).  ROC analysis using the change in neuromarker 
concentrations from admission to week β demonstrated that ΔS100B > 0.06 μg/L predicted death with 
a sensitivity of 100% and specificity of 93.1% (AUC 0.97, CI: 0.92-1); ΔNSE > β.07 μg/L with a 
sensitivity of 85.71% and a specificity of 65.52% (AUC 0.81, CI: 0.56-1); ΔGFAP > 1β.54 μg/L with 
a sensitivity of 85.7% and specificity of 96.5% (AUC 0.87, CI: 0.64-1); and Z-Neuro Δ > 0.48 with a 
sensitivity of 85.71% and a specificity of 93.33% (AUC 0.93, CI: 0.8-1). Curves are shown in 
Appendix 12. 
 
Neuromarkers and clinical outcome - Analysis for 6 month dichotomized clinical outcome showed 
that S100B concentrations >β μg/L predicted poor outcome with a sensitivity of 8γ.γγ% and 
specificity of 61.54% (AUC 0.72, CI:0.53-0.9); NSE > γ8.86 μg/L with a sensitivity of 75% and 
specificity of 65.38% (AUC 0.77, CI: 0.62-0.9β); and GFAP > β7.β5 μg/L with a sensitivity of 50% 
and specificity of 65.38% (AUC 0.69, CI: 0.51-0.86).  ROC analysis using the change in neuromarker 
concentrations from admission to week β demonstrated that ΔS100B >0.06 μg/L predicted poor 
outcome with a sensitivity of 66.67% and specificity of 95.83% (AUC 0.73, CI:0.51-0.96); ΔNSE 
>8.67 μg/L with a sensitivity of 58.γγ% and a specificity of 91.67% (AUC 0.75, CI: 0.54-0.95); 
ΔGFAP > 1β.54 μg/L with a sensitivity of 85.7% and specificity of 96.5% (AUC 0.68, CI:0.48-0.88), 
and Z-Neuro Δ >0.01 with a sensitivity of 66.67% and a specificity of 84% (AUC 0.79, CI: 0.6β-
0.97).  




Z-Neuro Δ, S100B, NSE and GFAP all demonstrated an independent association with outcome on 
multivariate analysis. The strongest logistic regression model for predicting mortality and 6 month 
outcome included Z-Neuro Δ. The odds of death were 22 times greater with a 1 unit increase in Z-
Neuro Δ (CI: 1.57-324.66, p=0.02). Covariates added to this model included MRC staging, symptom 
duration, age, gender, HIV status, fever, seizures, culture positivity and radiology characteristics HCP, 
HCP severity and tuberculomas. Infarcts could not be added to the models as all patients who died or 
suffered a poor outcome had infarcts, and no patients without infarcts died or had a poor outcome; 
therefore infarcts perfectly predicted outcome. Only seizures altered the model, its inclusion 
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strengthened the predictive power of Z-Neuro Δ and the odds of death increased to β6 times per unit 
change (CI: 1.8 – 383.05, p=0.02). The next best model was for Δ S100B which was associated with 
9 times greater odds of death per unit increase in the absolute change in S100B (CI: 1.9-42.1, 
p=0.005), this relationship with mortality was independent of admission, clinical or radiology 
covariates. Patients with a 1 unit increase in ΔNSE or ΔGFAP had equal odds of death or survival 
(CI: 1-1.1, p=0.02 and CI: 1-1.2, p=0.01 respectively).  Significant covariates in the relationship 
between ΔNSE and death included HCP severity as patients with more severe HCP had greater odds 
of death, and tuberculomas, with the odds of death decreasing with tuberculoma incidence (CI: 1.01-
1.27,  p=0.02). The addition of seizures increased the prognostic strength of the model for ΔGFAP 
(CI: 1.02-1.21, p= 0.01) and the odds of death decreased in association with tuberculomas (CI: 1.01-
1.2, p=0.02). 
 
These models were also predictive of dichotomized outcome at 6 months; the odds of a poor outcome 
were 4 times greater per unit increase in Z-Neuro Δ (CI: 1.γ1-13.04, p=0.02) and 2 times greater per 
unit increase in Δ S100B (CI: 0.96-3.65, p=0.06). Patients with a 1 unit increase in ΔNSE (CI: 1.0-
1.11) or ΔGFAP (CI: 0.1-1.09, p=0.06) had equal odds of a poor or good outcome. These 
relationships were independent of clinical, admission and radiology characteristics. 
 
Developmental outcome analysis 
Twenty-six children were included in this analysis; 16 (61.5%) of these children made a full clinical 
recovery and 10 children (62.5%) suffered from mild-moderate disability. More than half of these 
patients were delayed relative to controls on all the sub-scales and the GQ (Chapter 9).  Biomarker 
concentrations were not significantly associated with developmental outcome for highest S100B, NSE 







CHAPTER 10: BIOMARKER ANALYSIS 
Discussion 
This study examined markers of neurological injury and inflammation in 44 paediatric patients with 
TBM. The main findings were as follows: Analysis using ELISAs demonstrated that neuromarkers 
S100B, NSE and GFAP were elevated in the CSF of TBM patients relative to controls. Across all 
time points and all neuromarkers, ventricular CSF concentrations were highest, followed by lumbar 
CSF, and then serum. Neuromarker association with outcome was examined in several ways; results 
indicated that elevated ventricular CSF S100B and NSE concentrations were strong predictors of 
mortality and 6 month clinical outcome. Highest lumbar S100B, NSE and GFAP were predictive of 
poor outcome but the most prognostic index of all neuromarkers was an increasing trend in 
concentrations. ROC analysis demonstrated that an increase of > 0.06 μg/L in S100B, of >β.07 μg/L 
in NSE and >1β.54 μg/L in GFAP were predictive of mortality with high sensitivities and 
specificities; S100B was the most sensitive and specific. A combined score of the change in all 3 
neuromarkers over time using PCA demonstrated an increasing temporal profile of neuromarker 
concentrations in patients who died, whereas the temporal profile decreased in patients who survived. 
Combining neuromarkers with inflammatory markers did not improve their association with outcome.   
Inflammatory markers, analysed with Luminex technology, were also elevated in the lumbar and 
ventricular CSF of TBM patients, however, this was not the case for the serum concentrations of most 
cytokines. Concentrations were highest on admission and declined thereafter. Associations between 
inflammatory markers and outcome were poor and the temporal profile of combined inflammatory 
markers demonstrated a downward trajectory for all patients, including those who died. 
Biomarker elevations in TBM cases 
Neuromarkers S100B, NSE and GFAP were significantly increased in lumbar and ventricular CSF 
relative to controls and demonstrated prolonged elevation for up to 3 weeks after hospital admission. 
This suggests that these markers may be sensitive indicators of ongoing cerebral injury in TBM. As 
such, they have potential to be used as surrogate markers of injury severity and outcome in clinical 
and research work and may help reduce sample sizes in preliminary studies. 
Serum concentrations were not elevated for any of the neuromarkers relative to the 2 control groups, 
which suggests that either serum S100B, NSE and GFAP concentrations are not sensitive to brain 
injury due to TBM, or that our fatty filum control group was not suitable for comparison. It is not 
clear through which channels brain-derived proteins like S100B, NSE and GFAP enter the peripheral 
circulation. It is contended that they diffuse passively along their concentration gradient across the 
blood-brain or blood-CSF barrier 
431,439
. Factors which determine the degree to which brain-derived 
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proteins may be detected in the blood include its intrathecal concentration, the change in its 
concentration in response to pathology, its molecular weight, and its half-life in the blood. It is 
suggested that brain-derived proteins diffuse into the blood regardless of BBB disruption 
431,439
, but 
that diffusion into the blood may be augmented in the presence of BBB break-down 
335
. The serum 
concentration is further influenced by the dilution of CSF due to the continuous production of CSF 
and by the flow of approximately 500 mL of CSF into 5 L of blood per day 
431
. Consequently, serum 
concentrations reflect only a fraction of CSF levels and only transiently.  
S100B is detectable in the blood early after injury 
258,306,307
, however, the half-life is estimated to be as 
short as 30 minutes, and consequently, elevated serum levels may decline swiftly. 
440
. NSE is known 
to be plentiful in the brain and increases rapidly in response to neuronal membrane damage. At 78 
kDa it is the largest of the 3 neuromarkers but it is detected well in the serum and appears early after 
TBI and stroke 
309,310,317
. The half-life is approximately 24 hours, suggesting that the timing of 
sampling is imperative to detection and quantification of this protein. Similarly, GFAP concentrations 
are elevated in response to cell injury as well as astrogliosis, and serum concentrations are considered 
promising indicators of stroke and TBI
321,325,332,337,338
.The exact half-life of GFAP is uncertain; 
however, serum concentrations after ischemic stroke may normalise within 6-48 hours after injury 
337
.  
The timing of sampling relative to the onset of injury is clearly an important factor in determining 
whether biomarker concentrations will be detected in serum and to what degree. The temporal nature 
of injury in TBM is not clear; due to the chronic nature of the disease the onset of injury cannot be 
identified, as in the case of traumatic or vascular head injury, and may not be a single discrete event. 
Disease processes may build up to a peak in tissue injury or injury may follow a fluctuating pattern 
influenced by multiple dynamic variables like raised ICP, CPP, brain oxygenation and treatment. 
Sampling in this study was determined by the timing of clinically indicated procedures. It is possible, 
therefore, that the frequency of sampling may have allowed episodes of ischemia and peaks in serum 
concentrations to be missed.  
Regarding the suitability of the control group, serum S100B and GFAP concentrations were low in 
the 2 control groups and the similarity of the fatty filum and pTB control groups suggests they were 
reasonable controls. Serum NSE concentrations for the fatty filum and pTB controls exceeded their 
CSF concentrations and were equal to or greater than TBM case serum concentrations. The serum 
control concentrations for this study were also substantially higher than reported normal values and 
the normal ranges suggested by the kit manufacturer (Tables 5.3). Although all visibly hemolysed 
samples were excluded, it remains possible that NSE of erythrocyte origin may still have contributed 
to the serum concentrations due to hemolysis occurring at phlebotomy, during storage or at sample 
processing. In particular, more of these children had blood drawn when placing an intravenous 
cannula, which may have caused more hemolysis due to the blood being drawn with negative 
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pressure. This suggests that serum NSE concentrations need to be interpreted with caution and that 
sample collection and processing need to be conducted with meticulous care. The sensitivity of NSE 
to hemolysis is well known, and means of accommodating for the role of hemolysis in NSE serum 
concentrations have been suggested 
441
 but are currently too laborious to be used routinely. This 
susceptibility to the effects of hemolysis may limit the clinical use of NSE as a serum biomarker for 
cerebral injury in TBM. Overall, these data suggest that S100B, NSE and GFAP are strong markers of 
TBM-induced injury in the CSF, but are not useful in serum. A serum marker would be useful but not 
critical because in these patients CSF sampling is routine. 
The inflammatory process generated by the CNS in response to TBM was reflected by the elevated 
concentrations of cytokines in lumbar and ventricular CSF, and the differential between CSF and 
serum concentrations. Concentrations in CSF were much greater than in serum, which suggests that 
the inflammatory response is compartmentalised to the site of disease, and that serum is not ideal to 
measure immunological markers in TBM patients.  The pattern of serum cytokines is also worth 
considering: it has been suggested that elevated serum cytokines in TBM may originate from the CSF 
and create a gradient to recruit leukocytes to the CNS 
382
. The higher serum concentration of GRO and 
RANTES relative to CSF may be as a result of their role in leukocyte recruitment as both cytokines 
are involved in chemotaxis. The pTB controls demonstrated the highest concentration of serum 
cytokines, likely reflective of the active pTB disease process. Cytokine elevations in the serum of 
fatty filum controls may have been influenced by subtle systemic factors or by the anaesthetic. The 
low concentrations in their CSF supports the notion that this condition is not associated with 
inflammation in the CNS. 
CSF S100B, NSE and GFAP concentrations in TBM cases were higher than reported for other 
cerebral infections. Serum values, however, were less impressive and only NSE values were elevated 
relative to reported pathological and normative values. Overall, CSF inflammatory marker 
concentrations for this study group were considerably higher and serum values lower than reported in 
other paediatric and adult TBM studies (Tables 6.1 and 6.2). These differences may be due to the 
different testing platforms used as well as variability in the timing of sampling and disease course. 
Biomarker Temporal profile 
S100B and GFAP values were highest initially and NSE peaked in the week 1 sample after admission; 
thereafter all neuromarkers decreased, likely in response to treatment, however, increasing trends 
were seen in patients who died early. Inflammatory markers also demonstrated an early downward 
trajectory over time, suggesting that the inflammatory response was subsiding; however, 
concentrations remained elevated above normal for a prolonged period. The concentrations of 
cytokines are dependent on the timing of their release relative to the initiation of the inflammatory 
186 
 
response and, therefore, the timing of sampling is important in assessing the degree of elevation and 
the temporal profile. As most patients presented late with moderate-severe MRC stage TBM, it is 
likely that the initial stages of the immune response and the peaks in cytokine concentrations were 
missed. This may explain the low concentrations of IL-1  which is usually involved in the initial 
stages of meningeal inflammation, although technical shortcomings of the assay cannot be excluded. 
Additionally, as discussed above for serum biomarker concentrations, sampling may not have been 
frequent enough to capture the response of cytokines to the dynamic nature of cerebral injury and 
inflammation, particularly in the first few days after the initiation of treatment. In one patient who 
failed medical treatment and required a VPS in week 4, the late increase in neurological and 
inflammatory markers may suggest that chronically raised ICP is accompanied by neurological injury 
and ongoing inflammation. Although overall there was no relationship between late elevations in 
neuro- and inflammatory markers and failed medical treatment, analysis was limited by a small 
sample size (n=1β) and likely heterogeneity in the patient’s degree of raised ICP. 
Relationship between biomarkers 
CSF S100B, NSE and GFAP concentrations correlated with each other, suggesting all 3 markers 
indicate brain tissue injury occurring in paediatric TBM patients. Several cytokines demonstrated 
correlations, but these are challenging to interpret. The synergistic or antagonistic relationships 
between cytokines may depend on the timing of their release relative to injury. It is challenging, 
therefore, to discern the functional significance of correlations between markers when the timing of 
injury is uncertain. However, cluster analysis demonstrated grouping of functionally related 
cytokines: pro-inflammatory cytokines (TNF-α and IFN- , IL-12p40 and IP-10), chemoattractants 
(MCP-1 and MIP-1α) and antagonistic anti- and pro-inflammatory cytokines (IL-10 and TNF-α). 
VEGF, RANTES and IL-1  likely clustered because their concentrations were low in CSF; VEGF 
and RANTES appear to be more elevated in the serum and IL-1  concentrations were low possibly 
because the early phase of meningeal inflammation had passed. A possible mechanism behind the 
clustering of neuromarkers with GRO and IL-8 may involve the neutrophil attractant function of these 
chemokines. During the early response to disease high levels of neutrophils are protective against 
infection. However, it has been found that during active TB disease the degree of neutrophilia is 
associated with the severity of disease and that the recruitment of neutrophils to damaged tissue may 
augment the damage through the release of cytotoxic substances
435
. Although this research was 
conducted in the context of pTB, it is possible that a similar mechanism may apply in the brain 
whereby recruitment of neutrophils during the active stage of TBM disease leads to increased tissue 
damage manifest by higher neuromarker concentrations. The peak of the inflammatory cascade may 
have been missed by the time sampling began, however, neurological tissue injury was still ongoing. 
This might explain why neuromarkers clustered with IL6 and IL-1ra, which function as immune 
regulators, rather than pro-inflammatory cytokines like TNF-α and IFN- .  
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Examination of the temporal profile of S100B and NSE and their correlation over time suggests a 
similar profile of neuronal and astroglial injury characterised by increasing concentrations from 
admission through week 1. Lumbar CSF GFAP concentrations began to decrease immediately after 
admission; this may account for the poor temporal correlation with lumbar S100B and NSE and 
suggests that injury to the astroglial cytoskeleton may precede astroglial and neuronal cell destruction. 
Alternatively, there is evidence to suggest that GFAP may be more sensitive than S100B and NSE to 
injury due to the mechanical effect of dilating ventricles on the parenchyma and periventricular white 
matter 
442,443
. A paediatric study on acute HCP found that CSF concentrations of GFAP were higher 
than S100B or NSE 
443
. Histopathology studies have shown that astrogliosis occurs in the 
periventricular white matter in response to HCP; GFAP is a marker of astrogliosis and is a sensitive 
marker of periventricular white matter injury 
443-445
. Neuronal or astrocyte damage in response to HCP 
may be more subtle, leading to lower NSE and S100B concentrations 
443
. This damage is transient if 
the HCP is effectively treated 
443
. Therefore, the decline in lumbar GFAP after peaking at admission 
may be attributed to the immediate treatment of HCP and raised ICP in these children. Furthermore, 
ventricular CSF GFAP demonstrated a more labile pattern and larger fluctuations in concentration 
relative to ventricular S100B and NSE. Considering that ventricular samples were collected from 
patients who required ventricular access for poorly controlled ICP this could reflect GFAP’s 
sensitivity to fluctuations in ICP. 
The highest CSF neuromarker concentrations were observed in the ventricular CSF for all biomarkers 
at all time points. This would be consistent with their cerebral origin and a rostro-caudal gradient 
along the brain-spine axis 
439,446
. Lumbar neuromarker concentrations are less elevated, likely due to 
degradation by proteinases in the CSF over time 
266
. In patients with spinal arachnoid lesions, 
however, the differential between ventricular and lumbar concentrations may be less as the diseased 
spine may contribute neuromarkers to the spinal SAS. Cytokine concentrations were greater in lumbar 
than ventricular CSF, likely due to the fact that most of the inflammatory process is occurring in the 
subarachnoid space.  
Association with patient admission characteristics 
Only NSE approached an association with age and none of the neuromarkers were associated with 
gender. This reflects the mixed age and gender-related findings in the literature and the absence of an 
association with age in this study may be due to the fact that this was an exclusively paediatric cohort 
whereas age-dependent studies have included adults (discussed in Chapter 5). Additionally, within 
this paediatric cohort the patient numbers in individual age categories were too small to assess 
significant differences. The fact that NSE was higher in younger children may be reflective of the 
relative vulnerability of developing neurons to damage. The relationship between biomarker 
concentrations and HIV co-infection could not be meaningfully studied as the sample size of HIV+ 
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children was too small (n=2). Neuromarker concentrations on admission were not associated with 
MRC staging which is the current means of assessing injury severity. This potentially highlights one 
of the limitations of clinical assessment, i.e. there is little certainty whether the decreased level of 
consciousness is due to cerebral tissue injury, raised ICP, seizures, or hyponatremia. The overall 
improvement in staging from admission to week 1 was likely due to the treatment of raised ICP, fluid 
resuscitation and correction of electrolyte disturbances; therefore, the MRC staging may be affected 
by potentially reversible pathophysiology in addition to actual brain tissue injury. The absence of 
strong associations between neuromarkers and clinical characteristics suggests that neuromarkers 
provide information about brain injury that may not be reflected in the clinical picture of the patient as 
gathered from history and clinical examination.  
GFAP concentrations were significantly higher in culture positive patients in lumbar CSF only. It is 
unclear why this may be the case; perhaps a higher bacterial load was associated with a more vigorous 
reaction and consequently more astrocyte cytoskelton damage. However, it is expected that this would 
be replicated in the ventricular CSF and in the other neuromarkers. GFAP appears to be sensitive to 
HCP and it is possible that children with more severe HCP may have had greater volumes of CSF 
drained and sent for culture. Larger CSF volumes are known to increase the culture positivity rate and 
therefore it is possible that culture positivity is merely a proxy for HCP in relation to GFAP. This 
would however apply to ventricular CSF too as larger CSF volumes were often drained during the 
insertion of EVDs relative to LPs. It may be that the ventricular sample size was too small (46 versus 
131 lumbar samples) to allow statistical identification of a relationship with culture positivity. 
Alternatively, it may be a chance finding.  
Association with clinical outcome 
NSE was the most prognostic neuromarker on admission as elevated concentrations significantly 
predicted disability at 6 months. Admission S100B and GFAP were not significantly associated with 
outcome; however, the highest concentration of lumbar CSF GFAP, S100B and NSE in week 1 
appeared to demonstrate and association with poor outcome. This was likely due to the evolution of 
the disease even after the initiation of treatment and patients who died demonstrated a continued rise 
in neuromarkers.  Potentially, this reflects progressive disease during the first week of treatment 
initiation that may yet be reversible, i.e. the degree of injury severity on admission suggests the likely 
outcome, but it is the evolution of the disease after admission that is the stronger determinant. The 
highest concentrations overall in both lumbar and ventricular CSF were predictive of mortality and 
morbidity, except highest lumbar CSF S100B was not associated with mortality.  
An increasing trend in neuromarker concentrations was a strong prognostic marker of poor outcome 
on univariate analysis and logistic regression. This was best demonstrated with combined 
neuromarker Z-scores suggesting that TBM involves complex brain injury of more than one cell type 
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that evolves over several weeks despite the initiation of anti-TB and steroid treatment. Combined 
neuromarker Z-scores are of interest as they provide a broader picture of what is likely heterogenous 
brain injury by combining injury markers from various cell types. Assessing several neuromarkers 
simultaneously may arguable provide greater insight into injury than a single neuromarker which is 
limited to a single injury type. However, in the resource and time-limited clinical context cerebral 
injury assessment and prognostication may rely on only a single marker. S100B concentrations were 
mostly low; from this relatively low baseline, an increase of as little as 0.06 μg/L predicted death with 
a very high degree of sensitivity and specificity. Change in NSE over time was less sensitive and 
specific likely because a larger range of NSE concentrations was observed across outcome groups. 
This was similar for GFAP, likely because this neuromarker is elevated in patients with transient 
damage, due to raised ICP, as well as irreversible damage. Seizures were significant covariates in the 
relationship with mortality for the trend in GFAP and the combined neuromarker z-score and 
increased the odds of death. This may reflect greater severity of injury or seizures may result from 
raised ICP of which GFAP appears to be a more sensitive marker than NSE and S100B. However, 
severe admission HCP was a significant covariate strengthening the relationship between NSE trend 
and mortality; this may reflect the fact that NSE is less sensitive to HCP-induced damage except 
under circumstances of severe HCP when neuronal damage may be more pronounced. Both severe 
HCP and increasing NSE likely represent the more injured brain at higher risk of poor outcome. For 
the trend in NSE and the trend in GFAP the odds of death or survival were equal; however, in patients 
with tuberculomas the risk of death was lower; this may suggest that the rise of neuromarkers with 
tuberculoma injury is less significant in predicting outcome than a similar magnitude rise in 
neuromarkers due to infarction. Alternatively, it may be a chance finding. 
Ventricular CSF was a stronger predictor of mortality and 6 month outcome for both S100B, NSE and 
the combined neuro-Z score, possibly because the rostro-caudal gradient of neuromarkers reduces the 
predictive power of lumbar CSF samples. GFAP ventricular concentrations were not predictive of 
death and showed elevated concentrations in patients with both good and poor outcomes, again 
possibly because of GFAP’s sensitivity to transient effects. Ventricular GFAP, therefore, may be 
more sensitive to injury than specific to the nature of that injury. 
Cytokines behave synergistically or antagonistically depending on the timing of their release relative 
to the onset of injury and the associated cytokine mileu 
437
. Consequently, considerable variability 
exists across cytokine data sets especially when the timing of injury cannot be identified or 
standardised across the patient cohort. This was demonstrated by the PCA for combined inflammatory 
biomarkers which only accounted for half the variability of the data set with the first 2 PCs. To 
determine the functional consequences of the cytokine profile and the association with outcome is, 
therefore, challenging. Univariate analysis with CSF revealed significant outcome associations with 
IL-6. The mechanisms for this relationship are uncertain. However, IL-6 concentrations may have 
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been elevated in patients with a poor outcome as a function of the advanced temporal course of 
inflammation in these patients. In the post-acute phase IL-6 modulates the immune response and since 
patients with severe disease may be at a later stage in the inflammatory process than patients with 
good outcome this may explain the association with elevated IL-6. Combined initial inflammatory 
biomarker concentrations did not predict outcome, but the peak of inflammation may have been 
missed. It is possible that the chronicity of cytokine elevation rather than the initial degree of 
elevation may be more relevant; the long term profile cannot be commented on because sampling in 
this study did not extend beyond the 4
th
 week after admission for most patients However, all cytokine 
concentrations decreased markedly from admission to week 4, although even at week 4 many 
cytokines remained above the normal range.  
The increasing trend of combined neuromarkers and decreasing trend of combined inflammatory 
markers in patients who died suggests that it may be less an ongoing immune response which is 
responsible for the progressive brain injury associated with TBM, and more secondary pathological 
processes that are initiated by the inflammatory process that then continue to cause and perpetuate 
tissue injury via secondary mechanisms. These may include several biochemical, metabolic and 
vascular consequences of the inflammation. The best recognized consequence is the thick exudate 
which obstructs CSF flow precipitating raised ICP and causes vascular damage, thereby placing the 
brain at risk of cerebral ischemia. Other mechanisms may include the loss of pressure autoregulation 
due to cerebral inflammation and vessel damage which makes the brain vulnerable to fluctuations in 
CBF; the uncoupling of metabolism and CBF which places the brain at risk of ischemia as well as 
hyperaemia and raised ICP; cerebral metabolic derangement which may lead to cell death, cytotoxic 
oedema and further raised ICP; the accumulation of oxygen free radicals associated with elevated 
cytokine concentrations which may damage brain tissue and contribute to cytotoxic oedema; and BBB 
destruction by inflammatory mediators predisposing the brain to vasogenic oedema, raised ICP and 
consequent ischemia. Tissue infarction increases the risk of cerebral electrophysiological disturbances 
in the form of clinical and subclinical seizures and possibly spreading depolarisation and their 
detrimental consequences on the developing brain.  
Association with developmental outcome 
Neuromarker concentrations did not reflect neurodevelopmental outcome scores. This may be due to 
several reasons. Firstly, only patients who had a relatively good outcome (normal, mild-moderate 
disability) were able to undergo neurodevelopmental follow-up. Therefore, the more severe spectrum 
of neuromarker concentrations would not have been represented in this analysis. Secondly, the 
neurodevelopmental assessment tests broad constructs which require global cerebral function. 
Differences in neuromarker concentrations within a limited range, and often indicative of focal injury 
in this patient sub-set, may have been too subtle to be reflected in the performance of these children.  
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Thirdly, neuromarker concentrations were measured during the acute phase of injury whereas 
neurodevelopmental outcome was assessed after 6 months. The temporal resolution of the association 
between the neuromarkers and neurodevelopmental outcome is severely compromised by the scope 
for healing and the plasticity of the young brain to overcome damage in the intervening 6 months. 
Fourthly, as discussed in Chapter 9, neurodevelopmental compromise after TBM is not only a 
function of organic injury, but also of the social, environmental and educational limitations inherent in 
long-term hospitalisation and poor home caring environments after discharge from hospital. 
Therefore, while neuromarkers may provide a valuable quantitative measure of brain tissue injury, 
they may not reflect the qualitative aspects of brain injury or predict the long-term functional 
outcomes of children who survive TBM. 
Limitations 
Samples were processed as soon after collection as possible and degraded samples were not included 
in the analysis. Yet, it is possible that those samples which were not immediately processed and 
frozen may have been exposed to cell breakdown and sample contamination. However, the robustness 
of biomarkers to the often unpredictable dynamics of the hospital environment is an important 
indicator of their appropriateness for wide-spread clinical use. In general S100B, NSE and GFAP 
concentrations appeared robust in the CSF but serum was very sensitive to cell breakdown and 
hemolysis and samples not processed swiftly had to be discarded. 
Some variability in the LLOD existed across Luminex plates; while some degree of human error is 
expected in the laboratory environment, this may have been influenced by variability in the Luminex 
plate reader as 2 plates were read on a different reader. IL-1  concentrations were low in CSF and 
serum. While this may have reflected physiology it is possible that this cytokine was poorly detected 
with Luminex testing. Re-running the samples with an ELISA would have clarified whether the low 
concentrations were real or artefactual. Additionally, for those cytokines which frequently exceeded 
the HLOD, retesting with diluted samples on ELISA plates would have been beneficial. Unfortunately 
samples and funds were limited; however, these are preliminary data and future testing protocols will 
be informed by these results.  
The sample size was too small and the age range too large to adequately compare cases with age-
matched control patients; however, the role of age in normative biomarker values remains contentious 
and there is no clear indication of how age influences normal ranges. Raised serum neuromarker and 
cytokine concentrations in fatty filum controls may be reflective of the general anaesthesia these 
children were under when the samples were taken. Their CSF neuromarker values were similar to the 
normal ranges reported in the literature and so they likely represent a reasonable control group. We 
considered several other possibilities as control patients, but options were limited by the invasive 
procedures required to obtain CSF. Most children in whom these invasive procedures are warranted 
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have some form of cerebral pathology or a potential confounder. Patients suspected of meningitis in 
whom the CSF was normal were considered; however, the signs and symptoms which warranted the 
investigative LP, such as pyrexia and headache, may be associated with some perturbation in normal 
physiology. Patients presenting for shunt replacements not associated with an infective process were 
also considered; however, there is evidence that chronic HCP, even under conditions of normal ICP, 
is associated with brain tissue injury 
442
 and the inflammatory response generated by foreign material 
(the shunt) in the CNS cannot be excluded. We also considered patients who present with seizures and 
in whom a LP was done revealing normal CSF results; however, seizures likely increase biomarkers. 
Ideally ventricular CSF from TBM cases should have been compared to ventricular CSF of control 
patients. However, for reasons mentioned above it would be very unlikely to obtain access to 
ventricular CSF in healthy patients and ventricular CSF concentrations were so elevated relative to 
control lumbar CSF as well as case lumbar CSF that it is unlikely they would not have exceeded 
normal ventricular CSF values. 
More frequent sampling at shorter time intervals during the acute phase (admission-week 2) may have 
provided greater insight into the dynamic nature of disease evolution. Interpreting the temporal profile 
of biomarkers in TBM is tricky because the timing and pattern of injury is unclear; it is possible that 
injury does not all occur at a single time point but may rather undergo fluctuations dependent on 
various dynamic factors like ICP, CBF, systemic blood pressure and saturation, treatment and so 
forth. Currently there are no tools to identify these patterns in real-time; frequent biomarker sampling 
could contribute some insight; however, frequent access to the CSF is not ethically possible. More 
regular blood sampling is also not ethically permissible in young children in whom the blood volume 
is already low and normal clinical investigations take preference. The fact that CSF neuromarker 
concentrations remained elevated over time does, however, provide valuable information about 
ongoing injury. Similarly, the temporal resolution of cytokine sampling was limited by infrequent 
sampling as well as delayed patient presentation. Insight into the functional role of cytokines was 
consequently limited. However, the primary aim of this study was to evaluate novel neuromarkers in 
TBM and describe their profile and association with outcome. Inflammatory markers were analysed 
complementary to the neuromarkers. 
The complexity of the data set significantly limited the statistical tools which could be applied in 
examining the association with outcome. PCA was a means of combining the multiple biomarkers 
over time; yet, it does not provide insight into the biology of the disease process being measured and 
only identifies patterns across the data. However, this study was directed at collecting pilot data and 
building hypotheses for future research on neuromarkers in TBM. 
Cytokines did not demonstrate a strong association with injury severity or outcome. It may be that 
cytokine quantification is not the ideal means by which to examine the immune response in TBM, and 
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that more unbiased techniques like transcriptomics which take into account the genetic determinants 
of the immune response and the heterogeneity amongst individuals would generate a better 
understanding of how the immune response is associated with outcome. Additionally, this study did 
not consider the virulence of the Mtb pathogen and its ability to suppress the immune response. 
Examining discrete aspects of the disease process may be somewhat artificial as it is the baseline 
characteristics of the host, the baseline characteristics of the pathogen and the interaction between 
them which determine the response pattern to disease. 
Conclusion 
Neuromarkers are elevated in the CSF of patients with TBM and provide additional insight into 
existing and ongoing cerebral injury. Elevated admission NSE concentrations may be of value as an 
early prognostic indicator. Repeat testing within the first week of admission can provide important 
prognostic information as patients at risk of a poor outcome demonstrate increasing neuromarker 
concentrations, this is most marked in S100B for which small increases may predict a poor outcome. 
Elevated GFAP concentrations may reflect transient damage due to HCP as well as permanent 
ischemic damage and should, therefore, be interpreted in the context of clinical and radiological signs 
of raised ICP. Individual neuromarkers reflect brain injury of different types and combining several 
neuromarkers may reflect heterogeneous brain injury; however, this may not be feasible. The most 
sensitive sample for neuromarker testing is ventricular CSF and lumbar CSF samples should be 
interpreted with the awareness that they do not reflect the full extent of brain tissue injury; treatment 
or injury thresholds should ideally be established separately for the 2 CSF compartments. The 
sensitivity of CSF neuromarkers to injury over time may render them valuable surrogate markers for 
testing novel interventions. Serum does not appear to be a sensitive sample for neuromarker 
measurement. The immune response to TBM is compartmentalised to the site of disease in the CNS 
and inflammatory cytokines are elevated in the CSF but only partly in the serum. The peak of 
inflammation likely occurs early in the infective process and appears to decrease fairly rapidly after 
treatment is initiated. Measuring inflammatory markers may not provide prognostic insights, but 
further examination of the secondary injury processes initiated by the inflammatory process would be 






CHAPTER 11 SUMMARY 
Radiology features of TBM 
 
This chapter aimed to describe the radiological findings of this cohort of children with TBM and 
hydrocephalus. It included novel descriptions of spinal pathology on MRI and vascular pathology on 
MRA, and examined their associations with neuro- and inflammatory markers as well as outcome. 
Data were gathered from admission CT brain scans, and MRIs (brain and spine) and MRAs at 3 
weeks. Radiology features were examined in association with clinical variables, neuro- and 
inflammatory markers (initial and highest), and clinical and neurodevelopmental outcome. 
The main findings were as follows: 
1. Most patients presented with moderate and severe HCP (n=33, 75%) and almost all had 
evidence of diffuse enhancement (95.5%). Infarcts and tuberculomas were uncommon on the 
admission head CT. 
2. MRI scans after 3 weeks demonstrated infarcts in 64% of patients, mostly in the MCA 
territory (92%). Multiple or large infarcts involving both hemispheres were prognostic of a 
poor clinical outcome. 
3. Tuberculomas were visualised in 59% of patients (n=23) by 3 week MRI and 
delayed/paradoxical development after the acute phase was observed in 10% (n=4) of patients 
a median of 78 days after treatment initiation.  
4. Attenuation and occlusion of the major cerebral vessels (particularly the MCA) occurred in 
55.2% of patients (n=16). Infarcts and MRA abnormalities were not statistically associated, 
suggesting either that some cerebrovascular pathology, such as vasospasm, occurred early and 
resolved before 3 week imaging, or that there are other factors which cause infarcts. 
Additionally, all infarcts were documented, including small lacunar infarcts, the vascular 
origin of which may be too small to see on MRA. 
5. Intradural spinal pathology occurred in more than 75% of patients (n=25) and was mostly 
asymptomatic. It involved arachnoiditis of the cord and nerve roots, exudates, and spinal 
tuberculomas. All patients who failed LP had moderate-severe spinal arachnoiditis which was 
associated with increased lumbar CSF protein; this has important clinical implications for the 
diagnosis of TBM and the establishment of CHCP or NCHCP on AEG.  
6. Elevated concentrations of S100B and GFAP were associated with the severity of HCP on 
admissions suggesting that these neuromarkers may be sensitive to damage induced by raised 
ICP and/or distended ventricles. 
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7. GFAP concentrations were elevated in patients with infarcts and tuberculomas and were 
positively associated with their size, suggesting that GFAP is sensitive to brain damage from 
various injurious processes and across the spectrum of severity. S100B and NSE were 
elevated in patients with multiple or large infarcts and likely reflect severe tissue injury. 




CHAPTER 11: THE RADIOLOGICAL FEATURES OF THE BRAIN 
AND SPINAL CORD IN PAEDIATRIC TBM 
Methods 
 
Radiology plays an essential role in TBM: firstly, it contributes to the diagnosis; secondly, it assists 
with long-term management to guide the treatment of ICP and other surgical complications; thirdly, it 
provides information on disease resolution or deterioration; fourthly, it aids the assessment of injury 
severity and prediction of outcome; and finally, it adds valuable insight into the pathophysiology of 
TBM. 
Aim 
The objectives of this part of the study were to prospectively describe the following in a cohort of 
children with TBM and HCP: 
1. Radiological features on admission and after 3 weeks  
2. The involvement of the spinal cord and nerves 
3. Vascular pathology as seen on MRA 
4. The relationship between biomarkers (neurological and inflammatory) and radiology features 
on admission and follow-up imaging  
 
Study Imaging protocol 
As part of routine care all patients received a contrast-enhanced CT brain scan on admission when 
TBM with raised ICP or HCP was suspected. Further CT scans were requested when indicated for 
deteriorating clinical status or to inform surgical management. All patients were scheduled for an MRI 
of the brain and spine at approximately 3-4 weeks post-admission, as the Radiology Department’s 
schedule allowed, or earlier if clinically required. MRI scans are not standard of care for patients with 
TBM at RXH due to resource constraints and the need for a general anaesthetic in younger children. 
This project was able to fund one MRI per study patient. The decision to conduct MRI scanning at 3 
weeks rather than admission was taken to maximise the detection of evolving pathology. Follow up 
CT scans after discharge were performed where clinically indicated to follow-up HCP and the 
progress of intracranial or spinal pathology. All data were analysed as part of this study. Results for 






CT brain scans were performed using a 64 slice Phillips Brilliance scanner. Admission CT scans were 
performed pre- and post- administration of intravenous non-ionic contrast (Ultravist- 1ml/kg). Follow 
up scans to assess ventricular size were not routinely done with contrast unless required for 
tuberculoma investigation.  
MRI Scans 
The Philips Achieva 1.5 Tesla MRI scanner was used for MR imaging. Patients who were less than 20 
kg and stable were sedated orally using Chloral Hydrate. All children for whom sedation was not 
considered safe had a general anaesthetic. Children (generally > 6 years) who would cooperate with 
the MRI procedure without requiring sedation or an anaesthetic did not receive any. 
Brain imaging included: Axial T2-weighted, axial FLAIR, and 3 DWI (acquired sagitally and 
reformatted in 3 planes),  MRA diffusion and axial T1 post-contrast (Magnevist –gadopentetic acid). 
Spinal imaging included: Sagittal T1 and T2, sagittal T1 post-contrast, and axial T2 and T1 post-
contrast imaging through the lesion if pathology was detected. 
Data collected 
Scans were reviewed by three senior paediatric radiologists and a senior paediatric neurosurgeon all 
experienced in evaluating CT and MRI scans in paediatric TBM. Each radiological feature was 
assigned to one primary reviewer who examined that feature across all scans included for analysis. 
Thereafter the scans were all reviewed for a second time by second reviewer from amongst the team 
to ensure uniformity. Results were compared to the original radiology and neurosurgery reports. 
Where discrepancies in reporting were noted, scans were re-evaluated by the team until consensus 
was reached. Due to the paucity of formal standardised criteria for characterising features of TBM, 
scans were evaluated according to the following criteria set by the reviewers. 
Brain imaging 
The following features were recorded from brain imaging on CT and MRI 
HCP:  mild- visible temporal horns, rounding of the third ventricle (V3) 
 moderate – all ventricles dilated, no transependymal fluid shift 





Basal enhancement: focal – localised enhancement 
   diffuse–enhancement not limited to a focal region 
 
Pre-contrast hyperdensity: obliterated hyperdense basal cisterns or Sylvian fissures on non-contrasted 
CT scan 
Infarcts: Acute/sub-acute – acute infarcts demonstrated restricted diffusivity on DWI evaluated in 
conjunction with the actual diffusion coefficient (ADC) map – infarcts positive on DWI were 
estimated to be < 10 days old, sub-acute infarcts were between 10-14 days old, and established 
infarcts which were not positive on DWI were >14 days old 
Size –small (lacunar), medium (multiple or large infarcts) and global (encompassing all vascular 
territories) 
Location - categorised accordingly to the number of vascular territories as well as anatomical 
locations – vascular territories were assigned as follows: 
Vessel L hemisphere R hemisphere Total 
MCA 1 1 2 
ACA 1 1 2 
PCA 1 1 2 
Vertebrobasilar   1 
   7 
Global infarction included infarcts in all 7 major vascular territories 
Tuberculomas and TB abscess: number, anatomical location as well as unilateral or bilateral location 
Spinal imaging (MRI with contrast) 
Arachnoiditis: visualised as enhancement of the cord or roots; defined as nodules, exudate and 
clumping of nerve roots; presence of plaques (extra or intra-dural collections of exudate). Spinal 
arachnoiditis was defined as mild (thin coating of exudate on the cord or nerve roots), moderate 
(clumping of nerve roots, presence of intra- or extra-dural exudate plaques) or severe (extensive 
exudate on neural structures and in the subarachnoid space). 
Tuberculoma or TB abscess: surface or intramedullary. 
MR Angiography 
Attenuation and occlusion of the ICA, MCA, ACA, PCA and posterior communicating artery 





Features suggestive of TB on CXR included adenopathy, airway compression, bronchogenic 
pathology, airspace disease and effusion. The presence of a miliary pattern on CXR was also noted. 
Analysis 
Statistical tests for categorical data included the Chi-square or Fisher’s exact tests for binary variables 
and Kruskal-Wallis for variables with >2 levels. This analysis aimed to explore whether relationships 
exist between radiology and clinical/biomarker characteristics rather than determining prognostic 
markers per se. Therefore, univariate analysis was conducted as part of hypothesis generation and p-
values were not adjusted for multiple testing. 
Associations between radiological features 
The relationships between radiological features recorded on admission and overall were examined. 
Association with admission, patient and laboratory characteristics 
Relationships between the following were examined:  
- Various radiology features: HCP, admission enhancement, infarcts, tuberculomas, spinal disease, 
vascular abnormality,  
- CXR findings,  
- Patient characteristics (age, HIV status, MRC staging on admission, culture result, seizures, 
symptom duration, failed medical treatment and ICP deterioration), 
- Admission CSF chemistry (glucose, protein, chloride, polymorphonuclear cells and lymphocytes 
measured in lumbar and ventricular CSF as well as the differential between the 2 CSF compartments 
to accommodate for the rostro-caudal gradient), 
- The relationship between opening pressure on LP and the severity of HCP was also investigated.  
Association with outcome 
Analysis between radiological features and outcome included mortality at 6 months and dichotomized 
clinical outcome at 6 months (poor outcome [PCSP 4-6: severe disability- death] vs good outcome 
[PCPS1-3: normal – mild/moderate disability]). Radiology features included admission enhancement 
(including severity), infarcts (including number of vessels involved, size, unilateral/bilateral location, 
single/multiple), vascular pathology on MRA, tuberculomas (including single/multiple) and spinal 
disease (spinal arachnoiditis and severity, and spinal tuberculoma).The association between infarcts 
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(number of vessels involved, size, unilateral/bilateral location, single/multiple) and 
neurodevelopmental outcome for the GQ and each sub-scale was assessed. 
Association with biomarkers 
Admission CT scan features were analysed in association with initial lumbar and ventricular CSF 
S100B, NSE, GFAP and combined initial neuromarker concentrations (Z-Neuro Initial). Analysis was 
also conducted with initial lumbar and ventricular CSF inflammatory markers and combined initial 
inflammatory concentrations (Z-Inflam Initial). Radiology features included HCP communication 
(CHCP or NCHCP), HCP severity (mild, moderate and severe), admission enhancement and 
enhancement severity, and the presence of tuberculomas and infarcts. 
Radiology features overall (including admission, MRI or final CT scans for patients who died before 
MRI scanning could be performed) were examined in association with highest overall concentrations 
of the γ neuromarkers and the 14 inflammatory markers.  Additionally lumbar CSF Δ S100B, Δ NSE, 
Δ GFAP, and the combined change in neuromarkers (Z-NeuroΔ) and inflammatory markers (Z-
InflamΔ) were also examined.  Radiology features analysed included severity of HCP, infarcts 
(including number of vessels involved, size, unilateral/bilateral location, single/multiple), vascular 
pathology on MRA (including the number of vessels involved), tuberculomas (including 







CHAPTER 11: RADIOLOGICAL FEATURES OF THE BRAIN AND 
SPINAL CORD IN PAEDIATRIC TBM 
Results 
Admission CT scans 
All 44 TBM cases had admission CT brain scans with and without contrast. HCP was present in all 
patients and HCP severity was scored as moderate in more than half the patients (n=24, 54.5%). The 
inter-observer agreement in grading HCP severity was 88.1% (Kappa, p<0.001). Enhancement was 
present on 95.5% of admission scans (n=41) and involved the basal cisterns in almost all cases (n=40, 
97.6%). Enhancement was more commonly diffuse (n=39, 95.1%) than focal (n=2, 4.9%). Pre-
contrast hyperdensity was visible in two thirds of the scans which demonstrated enhancement post-
contrast (n=27, 65.9%) and in none without enhancement. Seven patients (15.9%) presented with 
infarcts on their admission scan, largely involving the MCA territory. Tuberculomas were only 
reported in 3 admission CT scans (6.8%). No TB abscesses were observed. Details of admission 
imaging features are provided in Table 11.1, and details of tuberculoma location in Table 11.5.  
MRI Brain Scans 
MRI scans were conducted in 39 patients at an average of 26 ±11 days post-admission. Four of the 44 
study patients died before an MRI could be performed and 1 patient was not scanned due to 
complications with transport from the facility to which she was transferred. Persistent 
ventriculomegaly was reported in 24 patients (61.5%); in 12 patients (30.8%) HCP was treated with 
an EVD or VPS at the time of the scan, and in 3 patients (7.7%) HCP had resolved. Enhancement was 
present in all 38 patients who received contrast; one patient awoke before contrast could be 
administered. The pattern of enhancement was predominantly basal (92.1%) and diffuse (89.5%). 
Infarcts were reported in 25 patients (64.1%) and were limited to 1 or 2 vascular territories in most 
(n=18, 72%). The most common site for infarction was the basal ganglia (n=20, 80%, Table 11.2). 
The MCA was the vessel most affected (n=23, 92%), involving MCA perforators (n=22), branches 
(n= 6) and the major artery (n=1), singly or in combination. Infarcts occurred in the ACA branch 
territories in 3 patients with infarction (12%) and the major ACA artery in 2 cases (8% - Table 11.3). 
Only 8 of these 25 infarcted patients (24.1%) demonstrated infarcts on their admission scans; and by 
the time of DW imaging almost 90% of infarcts were already more than 2 weeks old, the remaining 
infarcts were acute or a mixture of acute and established. Luxury perfusion was observed in 4 patients 
(16%) with large infarcts. Tuberculomas were observed in 23 patients (59%), most of which were 
multiple (56.5%) and occurred bilaterally (47.8%). Summary imaging details are outlined in Table 
11.1-11.5. and Figures 11.1-11.7 depict various MRI features. 
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Table 11.1: Summary of radiology features overall 












HCP  n = 44 (100) n = 24 (61.5) Treated 
b
   
 Severity     p=0.7 
 Mild  11 (25) 18 (75)    
 Moderate 24 (54.5) 6 (25)    
 Severe  9 (20.5) 2 (8.3)    
 Periventricular 
lucency 
32 (72.7) 9 (37.5)    
Enhancement  n = 41 (95.5) n =38 (100) 
c
 No contrast  p=0.6 
 Severity     p=0.05* 
 Mild 21 (51.2) 15 (39.5)    
 Moderate 19 (46.3) 10 (26.3)    
 Severe  1 (2.4) 13 (34.2)    
 Focal 2 (4.9) 4 (10.5)    
 Diffuse 39 (95.1) 34 (89.5)    
 Basal 40 (97.6) 35 (92.1)    
 Pre-contrast 
hyperdensity 
27 (65.9)    p=0.18 
Infarcts 9 (20.5) 25 (64.1) 4 (100) 29 (65.9) p=0.01* 
 No. of vascular 
territories 
    p<0.001* 
 1 6 (66.7) 12 (48) 0 12 (41.4)  
 2 3 (33.3) 6 (24) 0 6 (20.7)  
 3 0 4 (16) 0 4 (13.8)  
 4 0 1 (4) 0 1 (3.4)  
 5 0 1 (4) 0 1 (3.4)  
 6 0 0 0 1 (3.4)  
 7 0 1 (4) 4 (100) 4 (13.8)  
 MCA 7 (77.8) 23(92) 4 (100)   
 ACA 1 (11.1) 5 (20) 4 (100)   
 PCA 0 3 (12) 4 (100)   
 Vertebrobasilar 1 (1.11) 6 (24) 4 (100)   
 Unilateral 6 (66.7) 14 (56)  14 (48.3)  
 Bilateral 3 (33.3) 11 (44) 4 (100) 15 (51.2) p<0.001* 
 Single 5 (55.6) 9 (36)  11 (37.9)  
 Multiple 4 (44.4) 14 (56) 4 (100) 18 (62.1) p=0.003* 
 Infarct size     p<0.001* 
 Small 3 (33.3) 10 (40) 0 10 (34.5)  
 Moderate  6 (66.7) 15 (60) 0 16 (55.2)  
 Large 0 0 4 (100) 3 (10.3)  
 DWI infarct 
evolution 
 n= 23   p=0.08 
 Acute 
d
  1 (4.3)  1 (4.3)  
 Old 
e
  20 (87)  20 (87)  
 Mixed 
f
  2 (8.7)  2 (8.7)  
Tuberculoma 3 (6.8) 23 (59) No contrast  p=0.04* 
 Single 1 (33.3) 10 (43.5)   p=0.98 
 Multiple 2 (66.7) 13 (56.5)    
This table summarises the frequency of radiology features reported on admission CT scans, final CT scans of 
the 4 patients who died before 3 week MRI (Early deaths), and on 3 week MRI. The associations between 
radiology features and 6 month clinical outcome are indicated. Data are presented as number (percent). 
a 
Overall 
represents all 43 patients with follow up imaging during their hospital stay (4 deceased and 39 with MRI), 
b 
HCP 
was treated with EVDs or VPS 
c 
Only 38 patients received contrast, 
d 
infarcts < 10 days old, 
e 









Four patients died within 10 days of admission (median 4 days) and could not undergo MR imaging 
but CT scans (average 2.5 ±0.6 scans per patient) were performed in order to monitor their 
deterioration and direct clinical management. In order to include them in the analyses, the findings of 
their final CT scans were recorded. These findings are reported separately from MRI findings in Table 
11.1 as features from the 2 imaging modalities are not directly comparable due to differences in 
sensitivities. The admission scans of these 4 patients demonstrated moderate – severe HCP and all 
received an EVD or VPS. Mild enhancement and no tuberculomas were reported on their admission 
scans; follow-up imaging was not done with contrast so the evolution of enhancement and 
tuberculomas could not be determined. Infarcts were visible in only 2 of these patients on admission: 
in the right basal ganglia in 1 patient and bilateral basal ganglia and left tempero-parietal region in the 
other. Global infarction involving all 7 vascular territories was observed in all of these patients by 
their last scan a median of 4 days (3-11 days) after admission. The remaining 3 patients who died 
underwent MRI and their data are reported with the overall MRI data. 
 







Infarcts overall on 
post-admission 
imaging 
Frontal lobe 1 4 4 8 
Temporal lobe  3 4 7 
Parietal lobe  2 4 5 
Occipital lobe  3 4 7 
Corpus callosum 1 4 4 7 
Basal ganglia 7 20 4 24 
Thalamus  3 4 6 
Cerebellum 1 2 4 5 
Brain stem  5 4 9 
Infra-tentorial  7 3 10 
Supra-tentorial  39 3 42 
Data presented as the number of reports of infarcts in each location, some patients were reported to have 
multiple lesions in multiple locations, Infarcts overall= combination of MRI findings and findings on the final 




Table 11.3: Vascular detail of infarcts on MRI 
Vessel Unilateral Bilateral Total 
MCA   23 
 Perforator 12 10  
 Branch 5 1  
 Major vessel 1   
ACA   5 
 Perforator    
 Branch  3  
 Major vessel  2  
PCA   3 
Vertebrobasilar   6 
Data presented as the number of reports of infarcts involving each cerebral vessel and its branches or 
perforators, patients frequently had combinations of vessels involved in infarction. Total = total number of 
patients with infarcts in that vascular territory 
 
Table 11.4: Infarcts overall by vessel 
 Admission CT Overall post-admission imaging 
a
 
 Unilateral Bilateral Total Unilateral Bilateral Total 
MCA 5 2 7 13 14 27 
ACA  1  3 6 9 
PCA    2 5 7 
Vertebrobasilar 1   1 9 10 
This table presents the frequency of infarcts in the 7 major vascular territories for admission CT scans and for 





Cerebral radiology features 
Figure 11.1: Hydrocephalus (HCP) 
 




MildHCP Moderate HCP SevereHCP 
visible temporal horns, rounding 
ofthe third ventricle (V3) 
all ventricles dilated, no 
transependymal fluid shift 
Dilated ventricles with 
periventricular luceny and loss of 
sulcal markings 
Admission CT scan 
demonstrating moderate 
HCP 
Follow-up CT scan after 
35 days demonstrating 




Figure 11.3: Basal meningeal enhancement 
 
Figure 11.4: Evolution of pre-contrast hyperdensity 
 
 
Post-contrast scans demonstrating enhancement in the basal 
cisterns with exudate surrounding the major vessels 
Admission pre-contrast CT scan 
demonstrating pre-contrast 
hyperdensity in the basal cistern 
CT scan after 11 days in the same 
patient demonstrating evolution of 
pre-contrast hyperdensity in a patient 
on full TB treatment 
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Small lacunar infarct in the 
right basa l ganglia on T2 
weighted MRJ 
Large vascular territory 
infarcts on T2 weighted MRI 
Multiple infarcts involving 
the basa l ganglia bilatera lly 
on T2 weighted MRI 
Global infarction on CT scan 
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Figure 11.6: Luxury perfusion in infarcted areas 
 
Figure 11.7: Parenchymal Tuberculoma 
 
Luxury perfusion observed in the 
infarcted basal ganglia 
Post-contrast MRI 
demonstrating a tuberculoma in 
the right cerebellum 
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Delayed tuberculoma development 
Delayed or ‘paradoxical’ tuberculoma development was defined as the progression of established 
tuberculomas or the occurrence of new tuberculomas on out-patient follow-up imaging despite 
treatment. These were observed in 4 of the 37 patients who survived till 6 months (10.8%). These 
were reported a median of 78 (47-106) days after admission and the initiation of anti-TB treatment. 
Two of these patients were asymptomatic and the lesions were discovered incidentally on routine 3 
month follow-up imaging, and 2 patients presented with signs of raised ICP and progressive HCP.  
Tuberculomas were mostly bilateral multiple tuberculomas (n=3) and their locations are detailed in 
Table 11.5. A TB abscess was observed in 1 of these patients, and all 4 scans demonstrated persistent 
basal enhancement. Images of late onset tuberculomas and evolution of enhancement are provided in 
Figures 11.8 and 11.9. 
Table 11.5: Tuberculoma location 
 Tuberculoma 
Admission CT 
Tuberculoma MRI Delayed 
Tuberculomas 
Frontal lobe 1 3 3 
Temporal lobe  4 1 
Parietal lobe  5  
Occipital lobe  5  
Corpus callosum  1  
Basal ganglia  3  
Thalamus  0  
Cisterns  6 4 
Cerebellum 2 11  
Brain stem  3  
Data presented as the number of reports of tuberculomas in each location on admission CT scans, MRI at 3 






Figure 11.8: Late onset tuberculomas 
 
Figure 11.9: Evolution of enhancement 
 
Admission CT scan 
demonstrating HCP and 
enhancement, no 
tuberculomas 




Multiple tuberculomas and a TB 
abscess observed 4 months after 
treatment initiation in the same 
patient with drug-susceptible TB 
MRl scan of the same 
patientl45 days after 
treatment initiation 
demonstrating progression 




MRAs were a late addition to the study protocol and were not performed in the first 10 patients. Of 
the remaining 34 patients, MRAs were performed in 29 patients (74.4%); 3 patients had died and in 2 
patients technical complications prevented imaging. MRA was normal in 13 patients (44.8%). 
Abnormalities in the remaining 16 patients involved predominantly the MCA (93.7%) singly or in 
combination with pathology in other vessels. The median number of vessels with pathology per 
patient was 2 (range 1-7). Abnormalities included vessel attenuation, irregular vessel calibre, vessel 
occlusion and absent vessels. Illustrations of MRA pathology are included in Figure 11.10. 
Table 11.6: Frequency of vascular pathology per vessel 
ICA MCA ACA PCA Pcomm 
Unilat Bilat Unilat Bilat Unilat Bilat Unilat Bilat Unilat Bilat 
1 1 5 10 3 4 0 0 0 3 
Data presented as the number of reports of pathology in each vessel. Unilat = unilateral, Bilat = bilateral 
 
Spinal imaging 
Spinal imaging was performed simultaneously with MRI brain scans at an average of 26 ±11 days 
post-admission. Spinal scans were conducted in 37 patients as 4 patients had died and 3 patients could 
not be scanned due to technical complications. Images from 4 of these 37 patients were excluded due 
to movement artefact (n=2), and patients waking before contrast could be administered (n=2). In the 
remaining 33 patients spinal disease was present in 25 children (75.8%), including spinal arachnoiditis 
in 24 patients (72%), spinal tuberculomas in 6 patients (18.2%) and intradural extramedullary plaque-
like collections of exudate in 3 patients (9%). There was no bony involvement. Spinal arachnoiditis 
involved enhancement of the cord (n=19, 79.2%) and of the nerve roots (n= 23, 95.8%). Exudate 
filled the thecal sac below the conus and/or caused clumping of the spinal nerve roots in 12 patients 
(50%). The severity of exudate in the spinal canal was mild in 12 patients (50 %), moderate in 6 
patients (25%) and severe in 6 patients (25 %). Among the 6 patients with spinal tuberculomas, 5 
patients had tuberculomas on the surface of the cord (83.3%) and 1 patient had an intramedullary 
tuberculoma (16.7%). Most of the patients with spinal disease were asymptomatic (n=23, 92%), 2 






Table 11.7: MR characteristics of the spine accompanying TBM (n=33) 
Feature Value Association with outcome 
Spinal disease overall 25 (75.8) p=0.31 
 Spinal arachnoiditis 24 (72.7) p=0.62 
 Severity  p=0.54 
 Mild 12 (50)  
 Moderate 6 (25)  
 Severe 6 (25)  
 Cord arachnoiditis 19 (79.1)  
 Nerve root arachnoiditis 23 (95.8)  
 Arachnoid nodules 4 (16.7)  
 Exudate in the thecal sac 7 (29.2)  
 Clumping of nerve roots 10 (41.7)  
 Spinal Tuberculoma 6 (18.2)  
 Single 3 (50)  
 Multiple 3 (50)  
Data are presented as number (percent) of patients reported to have the various forms of spinal pathology, the 
association with 6 month clinical outcome is reported   
 
Chest imaging 
CXRs were performed in 42 patients. Features suggestive of TB were documented in 22 patients 




Figure 11.10: MRA Abnormalities 
 
 
             
Nonna] MRA 
Focal stricture of the right 
MCA 
Absent left lCA" attenuated 
left MCN and bilateral ACA' 
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Figure 11.12: Spinal disease 
 
 
          





















Normal thecal sac 














1. Associations between radiological features 
No significant relationships were demonstrated between radiology features; only the difference in the 
incidence of tuberculomas and infarcts approached significance (p=0.06) in that infarcts were 
reported less frequently in patients with tuberculomas, and tuberculomas were reported less frequently 
in patients with infarcts. Pre-contrast basal hyperdensity was 100% specific in detecting post-contrast 
enhancement; however, it was only 64% sensitive. Abnormalities on MRA were not associated with 
infarcts. 
2. Association with admission, patient and laboratory characteristics 
Whether HCP was communicating or non-communicating was not significantly related to any patient 
or clinical features. The severity of HCP score was not associated with opening pressure (p=0.48). 
Neither HCP severity nor infarcts were related to MRC staging on admission (p=0.23 and p=0.43 
respectively) or a history of seizures (p=0.24 and p=0.31 respectively). Patients with spinal 
arachnoiditis were 4.3 times more likely to fail LP (p=0.04), the severity of spinal arachnoiditis was 
significantly associated with failed LP (p=0.002) and all patients who failed LP had moderate-severe 
spinal arachnoiditis. Patients with spinal arachnoiditis more commonly experienced a deterioration in 
ICP after it appeared to have normalised (p=0.03), this was not replicated for cerebral enhancement 
(p=0.9). A miliary pattern on CXR was not associated with age; however, having a suggestive CXR 
was associated with older age (p=0.03). Overall radiology features did not differ in patients with HIV 
co-infection.  
Only spinal arachnoiditis and cranial tuberculomas demonstrated significant associations with CSF 
chemistry. Lumbar CSF protein was higher in patients with more severe spinal arachnoiditis (p=0.03). 
Significant associations with tuberculomas were as follows: lumbar CSF polymorphonuclear cell 
counts were significantly higher in patients with tuberculomas (p=0.04), ventricular CSF lymphocytes 
were lower (p=0.03) and ventricular protein was lower (p=0.04). The differential between lumbar and 
ventricular CSF did not reach significance in the relationship with radiological variables. 
3. Association with outcome 
Mortality - Tuberculomas were more common in patients who survived (p=0.01), whereas infarcts 
trended towards being more common in patients who died (p=0.08). In particular, death was 
significantly associated with multiple (p=0.03), bilateral (p=0.006), and large infarcts (p<0.0001) – 
all patients who died had global infarcts, some patients who survived had lacunar infarcts. The 
number of vascular territories involved in infarction was positively associated with death (p<0.001); 
however, vascular pathology on MRA was not (p=0.41). 
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Six month outcome - Mild admission basal enhancement (p=0.05) and a higher frequency of 
tuberculomas (p=0.04) were associated with good outcomes. Infarcts were significantly associated 
with poor outcome (p=0.01) and no children who made a full recovery had infarcts while all children 
with a poor outcome had evidence of infarction. Bilateral (p<0.001), multiple (p=0.003) and large 
infarcts (p<0.001) involving multiple vascular territories (p<0.001) were predictive of poor outcome, 
but this relationship was not found for vascular pathology on MRA (p=0.44). Neither miliary TB 
(p=0.41) nor a suggestive chest x-ray (p=0.8) were significantly associated with clinical outcome. 
Neurodevelopmental outcome - Infarct presence and severity were not associated with 
neurodevelopmental deficit on any of the sub-scales or the GQ.  
4. Association with biomarkers 
 
Admission CT scan - Univariate analysis with admission CT scan features demonstrated that HCP 
severity was significantly associated with lumbar S100B (p=0.05), GFAP (p=0.01) and the initial 
concentration of combined neuromarkers (Z-Neuro Initial, p=0.01), where higher concentrations were 
observed with more severe HCP. Admission lumbar CSF cytokine concentrations were not associated 
with admission radiology, except for the following: IFN-  concentrations trended towards being 
higher in patients with more severe HCP (p=0.06); ventricular TNF-α and IFN-  concentrations were 
more elevated in patients with mild enhancement (p=0.05 and p=0.04 respectively) or no infarcts on 
their admission scans (p=0.03 and p=0.01 respectively). 
 
Table 11.8: Association between neuromarkers and admission radiology  
Admission CT S100B NSE GFAP Z-Neuro 
 LP V LP V LP V LP V 
HCP severity  x x x    x 
Basal enhancement x x x x x x x x 
Enhancement 
severity 
x x x x x x x x 
Tuberculoma (n=3) x - x - p=0.06 - x x 
Infarcts (n=3) x x x x x x x x 
This table demonstrates the association between neuromarkers (in the lumbar and ventricular CSF) and 
radiology features. The relationship between ventricular neuromarkers and tuberculomas could not be 
investigated as no patients with ventricular samples had tuberculomas. LP = lumbar CSF, V = ventricular CSF, 





Radiology overall –Neuromarkers  
Lumbar CSF - Analysis with radiology features overall (admission and in-hospital follow-up imaging) 
demonstrated that highest GFAP in lumbar CSF samples was positively associated with the severity 
of HCP (p=0.02) and highest S100B trended towards a positive association (p=0.06). However, the 
highest neuromarker concentrations were not predictive of opening pressure (p>0.05). No significant 
associations were demonstrated with failed medical treatment or ICP deterioration. Highest GFAP 
was significantly associated with the presence of infarcts (p=0.05), whereas highest S100B (p=0.9) 
and NSE (p=0.8) were not. The extent of infarction as measured by their size, whether they were 
unilateral or bilateral, singular or multiple was significantly associated with highest concentrations of 
GFAP and NSE (p –values in Appendix 14). The number of vessels demonstrating pathology on 
MRA was positively correlated with highest S100B (p=0.05).The overall incidence of tuberculomas 
did not have a relationship with neuromarker levels, however, highest GFAP was positively 
associated with multiple and bilateral tuberculomas (p=0.04 and p=0.05 respectively). No 
relationship was observed between highest neuromarker concentrations and spinal disease (p>0.05). 
Ventricular CSF - Highest ventricular CSF NSE was positively associated with bilateral infarction 
(p=0.001) and highest S100B approached significance in association with infarcts (p=0.07). Highest 
NSE was positively associated with infarct size (p=0.003) and highest GFAP approached significance 
(p=0.06); highest S100B was positively correlated with the number of vessels with pathology on 
MRA (p=0.04). 
Biomarker trend - ΔNSE (p=0.03), ΔGFAP (p=0.01) and Z-NeuroΔ (p=0.02) were positively 
associated with infarcts. Infarct size and number (unilateral or bilateral) were significantly associated 
with larger ΔNSE, ΔGFAP, Z-NeuroΔ as well as ΔS100B (p-values in Appendix 13). Larger ΔNSE 
trended towards significance in the relationship with vascular abnormalities recorded on MRA 
(p=0.07). ΔGFAP was negatively associated with multiple bilateral tuberculomas (p=0.03). No 
association was demonstrated between biomarker trend and spinal disease or HCP on admission.  
The associations between biomarker concentrations and radiological features are tabulated in Table 




Table 11.9: Association between neuromarkers and overall radiology 
 S100B  NSE  GFAP  Z-NeuroΔ 
 Highest Δ Highest Δ Highest Δ  
 LP V  LP V  LP V   
HCP severity p=0.06 x x x x x  x x x 
Infarcts x x x x x   x   
 Uni/bilat x p=0.07    p=0.08  x p=0.06 p=0.06 
 Single/multi x x p=0.08   x  x x p=0.08 
 Size x x      p=0.06   
MRA 
pathology 
x x x x x p=0.07 x x x x 
Tuberculoma x x x x x x x x x x 
 Uni/bilat x x x x x x  x  x 
 Single/multi x x x x x x  x  x 
Spinal disease x x x x x x x x x x 
 Arachnoiditis x x x x x x x x x x 
 Tuberculoma x x x x x x x x x x 
LP = lumbar CSF, V = ventricular CSF, Δ = absolute change from week 2-admission, Uni= unilateral, bilat = 
bilateral, multi = multiple,= p<0.05, x = p>0.05 – p-values detailed in Appendix 12 
 
Inflammatory markers – parenchymal and spinal tuberculomas were positively associated with highest 
lumbar CSF IL-12p40 (p=0.04), IP-10 (p=0.001) and MCP-1 (p=0.02). Infarcts and infarct severity 
were positively associated with highest TNF-α, MIP-1α, IL-6 and IL-8 concentrations in lumbar and 
ventricular CSF. IL-12p40 was negatively associated with vascular abnormalities on MRA and MCP-
1 was negatively associated with infarcts. ICP deterioration was associated with the highest 
concentrations of IFN-  (p=0.02), TNF-α (p=0.03), MCP-1 (p=0.05) and IL-10 (p=0.02) in lumbar 
CSF. Z-InflamΔ was not significantly associated with any of the cranial or spinal radiology features 
but demonstrated a positive relationship with CXRs suggestive of TB (p=0.03). A summary of 














IL-12p40 p=0.04 p=0.02   
IP-10 p=0.001 p=0.03   
MCP-1 p=0.02 p=0.05   
TNF-α   p=0.05 
p=0.02 
 





IL-6   p=0.05 
p=0.01 
 
IL-8   p=0.02  
This table presents the significant relationships which emerged from analysis of the association between all 
inflammatory markers and all radiological features. Non-significant relationships are not shown due to the large 
number of associations between 14 cytokines (in lumbar and ventricular CSF) and multiple radiological 




CHAPTER 11: THE RADIOLOGICAL FEATURES OF THE BRAIN 
AND SPINAL CORD IN PAEDIATRIC TBM 
Discussion 
 
This cohort of TBM patients demonstrated the typical radiology features suggestive of TBM including 
HCP, basal leptomeningeal enhancement, infarcts and tuberculomas. Novel descriptions of MRA and 
spinal pathology for the study cohort provided insight into the pathology of TBM in the cerebral 
vessels and the extension of disease in the spinal canal.  
Radiology findings 
Enhancement and exudates: As expected, enhancement involved the basal cisterns and was diffuse 
in most cases 
45,64,114,117,158
.  Pre-contrast hyperdensity appeared to be a reliable indicator of moderate-
severe enhancement as suggested by other paediatric TBM studies 
153
, but cases with mild post-
contrast enhancement may not be detected, and therefore, contrast-enhanced scans are still optimal as 
part of the presumptive diagnosis. This is especially important in the early phases of disease when 
mild enhancement likely represents the initial stages of the inflammatory response (as demonstrated 
by higher concentrations of ventricular pro-inflammatory cytokines TNF-α and IFN- ) and the risk of 
death is low.  
Infarction - Infarcts were rarely observed on the admission CT scan and DWI approximately 3 weeks 
after admission demonstrated that most infarcts were already more than 2 weeks old. This suggests 
that progression to infarction likely occurs within the first couple of weeks after admission and/or that 
early CT scans may not reveal the developing infarcts. It is clear in some cases, though, that a 
pathological process is ongoing even after the initiation of anti-TB treatment and steroids. This 
appears to be the case even though there is a relatively quick decrease in the inflammatory mediators. 
This is evident in the progression to infarction, the late development of tuberculomas, and the rise in 
neuromarkers in some patients. For patients with a fatal aggressive disease process, infarcts 
progressed rapidly to involve all 7 major vascular territories within the first 10 days, even when no 
infarcts were visible on the admission scan. Presumably, the consequences of the vascular pathology 
continue despite the decrease in inflammation. Small lacunar infarcts occurred frequently in patients 
who made good recoveries; however, multiple or large infarcts involving both hemispheres were 
prognostic of a poor clinical outcome. Infarcts developed at locations throughout the brain, including 
the brain stem and cerebellum; however, similar to other studies the MCA territory was most affected 
49,64,114,169,178
. This largely involved its perforators into the basal ganglia, and likely reflects the 
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predilection of the inflammatory exudate to collect in the Sylvian fissure 
21
. The predominance of 
vascular pathology in the MCA vessel seen on MRA mirrored the predominance of infarcts in the 
MCA territories suggesting that ischemia due to vasculopathy plays an important role in infarct 
development in TBM. However, the absence of a statistical association between MRA vessel 
pathology and infarction may be due to several reasons. Firstly, it is possible that vascular pathology, 
like vasospasm, occurred early within the first few weeks when infarction seems to have taken place, 
and resolved by the time of MRA. Secondly, this suggests that infarction is not only the result 
vasculitis, but may also have been the result of further disease processes that lead to brain tissue 
injury, including the contribution of increased ICP, direct damage from bacterial toxins, damage due 
to cytokine release of oxygen free radicals, the loss of pressure autoregulation as a result of 
inflammation, uncoupling of CBF and cerebral metabolism (discussed in Chapter 4).  
Tuberculomas Few tuberculomas were identified on admission CT scans. This may be due to the 
relatively poor sensitivity of CT scans in detecting small lesions; however, lesions may also develop 
late, despite a drug-sensitive microbe 
49,114,137,183
. Tuberculomas were spread throughout the brain, 
evenly distributed between the supra-tentorial and infra-tentorial compartments, and frequently 
occurred in the cisterns. Tuberculomas and infarcts were negatively correlated, in that tuberculomas 
arose more frequently in patients without infarcts, and infarcts were recorded more frequently in 
children without tuberculomas. Furthermore, tuberculomas were predictive of survival and infarcts 
were predictive of death. This suggests that the underlying pathophysiological processes in these 
children may have been different and possibly that processes leading to tuberculoma development 
may be protective against those leading to infarction. Associations with inflammatory markers 
revealed that elevations in IL-12p40, IP-10 and MCP-1 were significantly associated with 
tuberculomas (both parenchymal and spinal) but that MCP-1 was negatively associated with infarcts 
and IL-12p40 was negatively associated with vascular pathology on MRA. It is tempting to suggest 
that these cytokines may lead to the recruitment of monocytes and T-cells to the CNS which are able 
to limit the infection by containing it in a granuloma, but with such a limited sample size and so little 
information interpretation is speculation at best and further exploration would be necessary.  A higher 
concentration of CSF polymorphonuclear cells were observed in lumbar CSF, however,  these were 
results from admission LPs and the temporal resolution in their association with tuberculomas 3 or 
more weeks later is questionable. The delayed or ‘paradoxical’ development of tuberculomas after 
treatment initiation was observed in 11% of this cohort. This may be the result of a hypersensitivity 
reaction to bacillary debris released in response to the bactericidal effects of TB medication 
24,183
 or 
could represent an immune reconstitution response in immunosuppressed patients, of which this study 
enrolled very few. Unfortunately, the sample size of patients who developed delayed onset or 
progressive tuberculomas was too small to meaningful examine their relationship with neuro- and 
inflammatory markers and no conclusive comment can be made as to whether patterns in these 
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biomarkers could predict delayed tuberculoma development. The temporal resolution of the 
relationship would, however, be tenuous as biomarker measurements ceased by week 3 and delayed 
tuberculomas developed approximately 11 weeks after admission. Long term follow up imaging 
demonstrated tuberculoma resolution in all patients. 
Spinal cord and spinal SAS - To our knowledge, this is the first study to prospectively describe 
spinal disease associated with TBM in a large, exclusively paediatric, cohort. Spinal arachnoiditis was 
present in over 70% of these patients and ranged from a mild coating of the cord or roots to an 
exudate-filled thecal sac. The vast majority of these children had no symptoms or signs pointing to 
spinal involvement. In many cases the radiological findings were mild; however, several cases 
demonstrated gross pathology, including extramedullary plaques with compression of the spinal cord 
and complete or near-complete obliteration of the SAS in the region of the cauda equina. There are 
several potential clinical implications of these findings: First, the severity of the disease has a bearing 
on how successful LP and/or AEG procedures are likely to be, and provides a reason for why some of 
these fail. Obtaining an LP result is an important part of the diagnosis and management of the 
condition. AEGs are important in our protocol to differentiate between CHCP and NCHCP because 
none of the non-dynamic tests are reliable in making this distinction 
64,112. A ‘negative’ result due to 
arachnoid lesions or exudate preventing the air from travelling up the spinal canal may be 
misinterpreted as NCHP and lead to an avoidable VPS. 
Second, most of these patients were asymptomatic and the spinal cord pathology would not have been 
detected without a dedicated MR study. In our clinical experience, patients have presented on 
occasion with clinically significant neurological deterioration after TBM due to spinal cord 
involvement that was not diagnosed at the time of their TBM treatment. Although most children in 
this current series who had spinal pathology were asymptomatic, one patient with severe spinal 
arachnoiditis complained of pain and numbness in his legs. During his hospital stay this was attributed 
to the neuropathic side effects of ethambutol as his neurological exam was normal; however, these 
symptoms persisted into his 3 month follow-up. Given his MRI appearance, it is more likely that his 
symptoms were due to spinal cord and root involvement. Another patient with progressive spinal 
disease had a sensory deficit in a radicular distribution over the thorax. This study’s findings of few 
spinal-related neurological symptoms may underestimate the true incidence of symptoms as clinical 
neurological examination was likely suboptimal, especially if patients were young and/or had a 
depressed level of consciousness, and the lack of mobility was attributed to a generally ill state. 
Third, the understanding of the TBM disease process and of the treatment response (for example, 
cellular count changes and CSF drug levels) is often based on lumbar CSF results, with the 
presumption that this reflects basal cerebral subarachnoid disease. However, from the findings of the 
present study, it is suggested that the lumbar CSF results may as much reflect spinal cord and spinal 
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subarachnoid disease as they do cerebral subarachnoid disease. Additionally, there is a possibility of a 
relative block to CSF flow, as is well-described with spinal cord tumours in Froin’s syndrome 447. In 
this case, high protein values may reflect the relative absence of free flowing CSF in the rostrocaudal 
direction, rather than the severity of cerebral subarachnoid disease. This possibility is demonstrated 
clearly in the image of severe cauda equina arachnoiditis in Figure 11.12. The contribution of the 
spinal cord and subarachnoid inflammation and the lack of CSF flow in the cauda equina region may 
be part of the reason that there is little association between high protein values and outcome 
demonstrated in Chapter 9. Similarly, whether drug levels determined from lumbar CSF samples are 
reliable in the face of a large degree of exudate in the thecal sac, can be questioned. Elevated levels of 
lumbar CSF protein were positively associated with the severity of spinal arachnoiditis, suggesting 
that very elevated lumbar CSF concentrations of protein may raise the suspicion of spinal 
arachnoiditis when imaging is not available, as should an inability to obtain CSF from a LP.  
Associations with patient and admission variables 
The HCP severity score and CSF opening pressures were not significantly associated; this suggests 
that our interpretation of the degree of HCP is not predictive of the ICP, as was similarly 
demonstrated by Schoeman et al 
64,448
. Factors that may contribute to this discrepancy include non-
communication between the ventricular and lumbar CSF space as well as spinal arachnoiditis 
blocking CSF flow in the spinal canal. More importantly though, it most likely reflects the limitations 
of our radiological criteria in predicting ICP. This emphasizes the importance of actual ICP 
measurement in patient management. No association was shown between infarcts on admission and 
MRC staging; likely because so few children had evidence of infarction on admission CT scans. 
Although this may be due to the delayed appearance of infarcts and the lack of sensitivity of CT scan 
to detect early infarction, it is likely that neurological findings are also the result of other phenomena, 
including raised ICP, cerebral oedema, hyponatremia, seizures, and cranial nerve arachnoiditis. Many 
of these are potentially reversible, and so likely account for the early improvement in the clinical state 
in some patients. The severity of HCP was not significantly associated with MRC admission staging, 
which reflects the poor correlation between radiological criteria and ICP, but also the role of other 
contributors to raised ICP, including cytotoxic and vasogenic oedema, seizures, hyponatremia and the 
loss of pressure autoregulation in addition to HCP. Similarly, the absence of an association between 
seizure history and the radiological features of HCP, infarcts and tuberculomas may also be attributed 
to the fact that seizures may be brought on by multiple factors singly or in combination. Therefore, 
signs and symptoms are likely a combination of various processes occurring simultaneously rather 
than due to one single factor. HCP severity and infarction were not significantly associated with 
symptom duration. This may be influenced by the subjectivity of parental history reporting (as 
discussed in Chapter 9), but may also indicate that the temporal disease profile of TBM is 
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heterogenous across patients; aggressive disease may be associated with severe pathology rapidly, or 
a protracted disease course may be associated with severe disease due to the build-up of pathology 
over time. The heterogeneity in responses to TBM may be influenced by genetic vulnerability, and 
further research into the transcriptome of TBM may elucidate the underlying factors responsible for 
varied disease manifestations across patients  Although miliary TB has been recorded more frequently 
in younger children suggesting a weaker immune system and a predisposition to TB dissemination, 
this was not observed in this cohort and may be due to the small sample size of children who had 
miliary patterns on their CXR. It is uncertain why older children were found to have CXRs more 
suggestive of TB, especially as the risk of progressing from infection to disease is higher in younger 
children 
449
. However, a normal CXR does not exclude pTB 
450
 and therefore the prevalence of 
respiratory disease in younger children may have been underestimated.  
Failed medical treatment was not associated with the severity of basal or spinal exudate; however, 
ICP deterioration occurred more frequently in patients with spinal arachnoiditis. It is possible that this 
was as a result of opening pressures appearing lower than was actually the case due to the presence of 
adhesions blocking the flow of CSF in the spinal canal, or the limited CSF release during LP in 
patients who had severe arachnoiditis. ICP deterioration was significantly associated with elevated 
pro-inflammatory cytokine levels in the lumbar CSF which may represent an aggressive inflammatory 
response contributing to or as a result of the exudate and arachnoid lesions. Analysis comparing 
radiology features between HIV+ and HIV- children could not be meaningfully conducted due to the 
small sample size of co-infected children. 
Association with neuromarkers 
The severity of HCP on admission was associated with elevated concentrations of GFAP, and to a 
lesser extent, S100B. This suggests that these 2 neuromarkers may be elevated in response to injury 
induced by the pressure of expanding ventricles on the ventricular ependyma and peri-ventricular 
white matter, often accompanied by opposing pressure from brain oedema as has been suggested in 
the literature 
442,443
. Alternatively, elevated S100B and GFAP and severe HCP could represent a more 
injured brain, however, this would likely result in increased NSE concentrations as well. Elevated 
GFAP concentrations differentiated between patients with and without infarcts, and between patients 
with infarcts of varying severity. Additionally, GFAP was higher in patients with multiple 
tuberculomas, but the temporal profile of GFAP followed a downward trajectory in these patients. In 
combination, these findings suggest that GFAP is sensitive to brain damage as a result of various 
injurious processes and is sensitive to injury across the spectrum of severity. Elevated concentrations 
of S100B were associated with vascular pathology on MRA and an increasing S100B trend was 
significantly associated with multiple, large infarcts.  NSE was not elevated in patients with small 
lacunar infarcts but was significantly elevated in those with large infarcts. This suggests that S100B 
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and NSE may be markers of more severe neurological injury. Neuromarker concentrations were not 
associated with spinal disease; this may be due to the fact that the brain is the predominant source of 
these neuromarkers and, therefore, concentrations of S100B, NSE or GFAP released in response to 
spinal disease may be masked by larger concentrations of cerebral origin.  
Elevated concentrations of ventricular CSF IFN-  and TNF-α were associated with mild enhancement 
and an absence of infarcts on admission scan. This may denote patients at the early phases of the 
inflammatory disease process. Patients with CXRs suggestive of TB had increasing temporal 
combined CSF inflammatory marker profiles. It is possible that concurrent TB infection in a location 
additional to the brain is associated with an augmented immune response overall, that the immune 
response may be more prolific in those patients who develop pulmonary disease as well as cerebral 
disease, or that the temporal link between pulmonary infection and dissemination was shorter in these 
patients than in patients who may no longer have had signs of disease in their lungs. 
Limitations 
Due to differences in the sensitivity of CT and MRI in detecting pathology it was not possible to 
directly compare CT and MRI findings. Comment or analysis on the deterioration or progression of 
radiology features such as the severity of enhancement or HCP from admission to a MRI in week 3 or 
4 was, therefore, not possible. Additionally, the poorer sensitivity of CT relative to MRI may have 
underestimated the infarcts on admission. However, in resource limited settings where TBM is most 
likely to occur, MRI scanners are not likely to be standard of care and radiological evaluation most 
commonly relies on CT scanning.  
The timing of the MRI scan may have influenced our findings. MRI is not standard of care at our 
institution in the early management of TBM, in part because of resource-limitations, but also because 
this requires deep sedation or general anaesthesia. The timing of MRI scanning at 3 weeks was 
selected to allow sufficient time for evolving disease to manifest radiologically, and to maximise the 
detection of pathological consequences. MRAs could not be performed in patients who died early; 
therefore, the MRA data is skewed to patients who survived. This is true also for the other 
radiological findings. Arguably, more gross pathology may have been detected in the patients who 
died early. Data on the condition of cerebral vessels of patients undergoing fatally aggressive disease 
processes may have added greater insight to the link between infarction and vessel pathology. This is 
a group about which we require more information to inform possible interventions to interrupt this 
aggressive course. Similarly, data on spinal pathology was limited to patients who survived and may 
not represent the most severe form of TBM disease. However, these data still demonstrate the high 
frequency of spinal and MRA pathology and future studies involving imaging at earlier time intervals 
after admission may add further insight into the evolution of these disease processes.  
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Serum and CSF sampling was limited to the early weeks after hospitalisation; however, sampling of 
patients who returned with delayed tuberculoma development would have added insight into the 
relationship between these lesions and neuro- and inflammatory markers, and contributed to the 
understanding of the immunology or tissue injury surrounding this phenomenon of ‘paradoxical’ 
tuberculomas. 
The p-values of associations reported for radiology and clinical characteristics, outcome and 
neuromarkers were not corrected for multiple testing which would have substantially reduced the 
number of significant associations. However, this was an exploratory investigation which aimed 
largely to build pilot data on the association between biomarkers and radiology and develop 











CHAPTER 12 SUMMARY 
Monitoring brain oxygenation in TBM 
 
This chapter aimed to examine the potential utility of brain oxygenation monitors in detecting 
compromised brain oxygenation and its response to interventions. 
Data obtained from invasive PbtO2 catheters and non-invasive NIRS monitors were descriptively 
analysed in terms of their temporal profile and their relationship with ICP, neuromarkers and 
outcome. The level of agreement between PbtO2 and NIRS data was assessed. 
Only a few patients were considered candidates for invasive monitoring with PbtO2, consequently 
data analysis was limited and is largely descriptive. PbtO2 monitoring was only performed in patients 
considered to be at high risk for ischaemia based on clinical or radiological findings; this likely 
introduced bias in patient selection. NIRS was more widely used as it is non-invasive; however, 
maintaining good sensor-scalp contact in mobile children is challenging and NIRS monitoring could 
not be performed in all patients; this too would have introduced some bias in patient selection.  
The main findings were as follows: 
1. PbtO2 and NIRS demonstrated that brain oxygenation is compromised in a sub-set of patients 
with TBM and episodes of compromise can be detected in real time 
2. Brain oxygenation as measured by PbtO2 was very sensitive to fluctuations in ICP, even 
within the normal range, presumably because of the already narrowed cerebral perfusion 
pressure in these patients. This suggests that a lower ICP threshold and continuous ICP 
control may be indicated to maximise perfusion of the injured brain.  
3. NIRS values below 50% were significantly associated with poor outcome, suggesting that this 
may be considered a threshold of compromised brain oxygenation for NIRS monitoring in 
TBM. However, it is likely that some inter-individual variability exists so the trend in 
oxygenation and its response to interventions may be as important to consider. 
4. Case illustrations demonstrated that PbtO2 and NIRS were sensitive to changes in brain 
oxygenation in response to interventions aimed at improving brain oxygenation. This suggests 
that there is potential to treat impaired brain oxygenation in TBM. 
5. There was a reasonable level of agreement between PbtO2 and NIRS data and the two 
monitors demonstrated similar temporal profiles. 
6. Neuromarkers were not associated with indices of brain oxygenation as measured by PbtO2 
and NIRS. The absence of an association may be due to the small sample, missing early 
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episodes of oxygenation, the multifactorial nature of outcome determinants, or the fact that 





CHAPTER 12: MONITORING BRAIN OXYGENATION IN TBM 
Methods 
 
Ischemia plays a pivotal role in the pathophysiology and poor outcome of TBM. It is precipitated by 
various factors, most importantly raised ICP and vascular pathology. However, at present there are no 
means to reliably diagnose or monitor ischaemia in these patients. Clinical examination does not 
reveal the aetiology of a depressed level of consciousness and neurological deficits. Repeat brain 
imaging illustrates the evolving nature of ischemia and brain infarction, but only once the damage is 
already irreversible. Recently, technological advances have enabled aspects of brain oxygenation and 
perfusion to be monitored in real-time. All of the available methods have limitations, but may offer 
some benefit in guiding treatment in patients at risk of ischaemia, although further research is required 
before monitoring is adopted widely.  
As part of this study, data from brain tissue oxygen tension (PbtO2) and near-infrared spectroscopy 
(NIRS) monitoring in this TBM cohort were gathered. PbtO2 is used routinely at RXH for severe 
traumatic brain injury, and more recently it has also been used for patients with severe TBM 
236
. In 
general, these monitors are indicated for patients with a severely depressed level of consciousness 
who are usually ventilated in the ICU. The invasive nature of these monitors limits their use to the 
most severely ill patients. Often patients at risk of ischaemia initially appear to be mildly affected, but 
develop infarction later. Consequently, by the time the monitor is inserted, it may be too late to 
intervene. Therefore, NIRS was investigated as a potential non-invasive monitor to detect 
compromised brain oxygenation in TBM. NIRS has been examined in several conditions but as yet 
not in TBM 
211,245,246,248,251
.  
Because the use of PbtO2 monitors is uncommon, we anticipated few patients and so the analysis was 
planned to be largely descriptive.  
Aim 
The study aimed to 
1. Describe the profile of PbtO2 and its relationship with ICP and outcome in a cohort of 
paediatric TBM patients with HCP  
2. Describe the profile of NIRS and its association with outcome in a cohort of paediatric TBM 
patients with HCP  
3. Compare  NIRS and PbtO2 data in patients who had both monitors 
4. Illustrate the potential utility of brain oxygenation monitoring in TBM 
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The EVD is considered the gold standard for measuring ICP. It is an inexpensive, accurate and 
reliable method of monitoring ICP 
451
. It is inserted through a burr hole in the skull and guided into 
the lateral ventricle. PbtO2 catheters (Licox, Integra Neurosciences) were considered for patients with 
Stage III TBM with a low level of consciousness, particularly if ICU admission and ventilation was 
required. PbtO2 catheters were inserted via a bolt to ensure correct positioning, except when the skull 
was deemed too thin in young patients. In these cases the catheter was tunnelled under skin and 
secured with sutures, no problems with the tunnelled catheters were experienced. The catheter was 
targeted for frontal white matter 2.5 cm below skin and approximately 2cm from the EVD. 
Appropriate placement in white matter was confirmed on follow-up CT brain scans. Informed consent 
was obtained from all parents before insertion of intracranial monitors. Monitors were removed when 
the patient was considered stable for > 48 hours or when the EVD was replaced with a VPS. 
Patient management 
The EVD was usually placed to drain at a height of 15 cmH2O/ 11mmHg above the external auditory 
meatus. In patients who had low PbtO2, and in very young patients, the height of the EVD was 
reduced. For monitoring, the EVD was clamped and the pressure transduced to the bedside monitor 
display.  PbtO2 values <20mmHg were considered compromised brain oxygenation 
198,212,230
. Low 
PbtO2 was managed by lowering ICP further, and optimising MAP, systemic oxygenation and 
ventilation settings. In general, interventions were tested against the PbtO2 response.   
Data Collection  
Data were collected using a computerised physiologic recording system, ICMPlus
® 
(University of 
Cambridge, U.K) which samples data at 50 Hz and provides a data point averaged over 10 seconds. 
Variables recorded included MAP, ICP, PbtO2 and systemic saturation where possible. Data on 
partial pressure of arterial oxygen (PaO2) were collected from arterial blood gases (ABGs) and hourly 
ventilator inspired fraction of oxygen (FiO2) from ICU charts.  
Non-invasive monitors 
Near-infrared spectroscopy (NIRS) sensors (left and right) were placed on the forehead of patients 
admitted to the ICU as well as group of patients admitted to the medical wards. Since we aimed to 
collect pilot data on NIRS a quota of NIRS sensors were assigned to the study and consecutive 
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patients were monitored until the study’s quota finished. Data were collected continuously by the 
monitor at a frequency of 1 data point every 30 seconds. 
NIRS monitors were used for research purposes and did not direct patient management. Nasal prong 
oxygen was encouraged for all TBM children and was used at the discretion of the treating clinician. 
Data Analysis 
The profile of PbtO2 and relationship with ICP and outcome 
Descriptive statistics - PbtO2 catheters were allowed to settle for 2 hours, and data during this 
time were excluded from analysis to avoid using potentially artefactual data from a stabilising 
catheter. Data from catheters that were poorly placed were excluded. Descriptive statistics were 
calculated for PbtO2 as well as for ICP, MAP, CPP (calculated as MAP-ICP), PaO2, inspired fraction 
of oxygen (FiO2) and systemic saturation (SaO2). Hourly data were used. These physiological 
variables were only available for patients managed in the ICU where continuous monitoring occurs. 
The full complement of data was not available for all patients as this was contingent upon the 
availability of monitors and recording computers. Patients managed in the Neurosurgical High care 
ward received neurological observations twice daily.  
Relationship between PbtO2 and ICP - The relationship between these 2 variables was 
examined by plotting the temporal profile of PbtO2 and ICP for each patient who had complete data 
for both variables using hourly data, and a spearman’s correlation was performed. Electronic data 
were examined for case illustrations of the nature of the relationship between ICP and PbtO2 in TBM.  
Outcome description - Due to the very small sample size (n=6) statistical analysis with 
outcome could not be performed; therefore, PbtO2 data for the two outcome groups were examined 
descriptively and included the lowest PbtO2 recorded for the duration of monitoring, the median 
PbtO2 (PbtO224) over the first 24 hours of monitoring (or part thereof) and the time spent below 
PbtO2 thresholds < 5, 10 and 20mmHg. To maximise the representation of PbtO2 less than critical 
thresholds, high frequency data were interrogated. Clinical outcome at 6 months (poor outcome 
[PCSP 4-6: severe disability- death] vs good outcome [PCPS 1-3: normal – mild/moderate disability]) 
was used as the outcome measure. 
The profile of NIRS and relationship with outcome 
Descriptive statistics and the temporal profile of NIRS data were calculated for the full cohort of 
patients monitored with NIRS for the left (L) and right (R) sensors. Data is recorded at a frequency of 
1 data point per 30 seconds. Descriptive statistics were calculated for the L and R sensors and for the 
combined average of L and R for the entire recording period. Treatment thresholds for NIRS have not 
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been established, but normal ranges are thought to be between 60-80% 
238,242,243
 and animal research 
has shown NIRS saturation (SO2) <35% to be associated with irreversible neurological deficits 
239
. 
Therefore, as part of exploratory analysis to assess the association between compromised NIRS and 
outcome, the amount of time spent below various thresholds was calculated. These thresholds 
included time <40% and <50%, as well as time spent less than the median SO2 for the monitoring 
period. As monitoring continued for up to 10 days, the median was considered a more representative 
baseline for the recoding period as a whole than initial recordings at the start of monitoring, and 
therefore deviation from this median was assessed. Time spent below the specified thresholds was 
calculated for each patient and examined in association with mortality and clinical outcome at 6 
months. NIRS data were also examined for illustrations of its utility as a monitor of ischemia and of 
the response in brain oxygenation to intervention. 
NIRS and PbtO2 monitors 
Data collected simultaneously from patients with both PbtO2 and NIRS catheters were combined such 
that data points were time-linked. PbtO2 is measured in mmHg and normally ranges from 20-40 
mmHg; NIRS is measured as percentage saturation and usually ranges between 50 and 100%. To 
accommodate for the difference in the distribution of the 2 data sets, PbtO2 and NIRS data were 
converted into standard scores: this was done for the PbtO2 and NIRS data sets separately and 
involved subtracting each score from the overall cohort mean and dividing by the cohort standard 
deviation, such that the mean became 0 and the standard deviation became 1. To examine whether 
NIRS data reflected PbtO2 data the standard scores of the 2 monitors were compared using the Bland-
Altman plot which enabled the degree of agreement between PbtO2 and NIRS data to be calculated 
by plotting the mean difference between PbtO2 and NIRS scores against the mean of both data sets 
combined 
452
. Two lines of agreement were plotted at the level of 2 standard deviations above and 
below the mean difference value as indicators of the extent to which scores vary about the mean 
difference and therefore the extent to which PbtO2 and NIRS data differ from each other. Variation 
within two standard deviations suggests adequate agreement between the two brain oxygenation 
monitors. The ideal mean difference would be 0. The temporal profiles of the PbtO2 and NIRS data 
were examined by constructing box-and-whisker plots to ascertain whether the 2 monitors reflected a 
similar trend in brain oxygenation. Finally, case illustrations were identified which reflected how 
PbtO2 and NIRS responded to fluctuations in ICP and MAP and in response to interventions. 
The association between neuromarkers and brain oxygenation monitors (PbtO2 and NIRS) 
The relationships between neuromarkers and data from PbtO2 and NIRS were examined as follows: 
the admission S100B, NSE and GFAP concentrations were analysed in association with the first 24 
hours of PbtO2 and NIRS monitoring; the change (Δ) in S100B, NSE and GFAP were examined in 
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association with the time spent <5, 10, 20mmHg for PbtO2, and <40%, <50% and less than the 







CHAPTER 12: MONITORING BRAIN OXYGENATION IN TBM 
Results 
 
The profile of PbtO2 and relationship with ICP and outcome 
Descriptives - Six patients were monitored with PbtO2 catheters; 5 were admitted to ICU where 
continuous physiological monitoring took place, and 1 patient was admitted to the Neurosurgical High 
Care ward. All 6 patients had an EVD; the transduced EVD signal for ICP could be exported into the 
monitoring computer for only 3 of the 5 patients in ICU due to technical reasons. Continuous MAP, 
hourly SaO2 and inspired fraction of oxygen FiO2, and partial pressure of oxygen (PaO2) from 
routine arterial blood gases were recorded in 5 ICU patients. The median time of PbtO2 monitoring 
for all patients was 5.5 (4-6) days. A summary of descriptive statistics for these variables calculated 
from hourly data is provided in Table 12.1. 















Median 20.6 9.15 83.55 71.74 100 23.7 40 
Minimum 2.48 2 56.71 48.71 88.66 8.9 21 
Maximum 97.69 24 126.2 120.3 100 64 100 
P25 12.1 6 74.09 63.73 98.5 15.5 30 
P75 30.94 12.64 88.97 76.68 100 30.25 60 
This table represents descriptive statistics for physiological variables recorded during PbtO2 monitoring in ICU 
patients. Statistics have been calculated on hourly data. P25 = 25
th




Relationship between PbtO2 and ICP – The temporal profile for ICP and PbtO2 for the 3 patients 
with both monitors are displayed in Figure 12.1. In patient 1 PbtO2 increased and ICP decreased over 
time; in Patient 2 the ICP increased as did the PbtO2, although to a lesser degree; and in Patient 3 both 
ICP and PbtO2 increased with a larger increase observed in PbtO2. 
A spearman’s correlation between ICP and PbtOβ demonstrated a positive relationship (r=0.44, 





Figure 12.1: Temporal profile of PbtO2 and ICP 
 
This figure illustrates the temporal profile of 3 patients who had both ICP and PbtO2 monitoring using box-and-




 percentile. ICP 
and PbtO2 demonstrated variable relationships across the 3 patients 
Figure 12.2: Scatterplot: ICP and PbtO2 
 
The scatterplot demonstrates a positive relationship between ICP and PbtO2 (both measures in mmHg) 
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Case illustrations for the relationship between ICP and PbtO2 extracted from high frequency data 
recordings:  
Figure 12.3: In this illustration the EVD was clamped in preparation for a VPS and the ICP increased; 
this was followed by an immediate decline in PbtO2. After the EVD was unclamped and ICP 
decreased the PbtO2 recovered.  
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Figure 12.4: The commonly used treatment threshold for ICP in conditions such as traumatic brain 
injury is 20mmHg/ 27cmH20. Differential thresholds for children are not reliably described and so 
20mmHg remains most commonly used 
228
. This recording suggests that in patients who already have 
a compromised baseline perfusion, most likely due to associated vasculitis, fluctuations of ICP even 
within the normal range may aggravate the poor tissue perfusion, presumably by narrowing an already 
reduced cerebral perfusion pressure. Unfortunately the electronic ICP trace was not available for this 
patient. 
 







PbtO2 and outcome – Of the 6 patients who underwent PbtO2 monitoring, 3 had good outcomes (2 
patients made a full clinical recovery with a PCPS score of 1, and 1 patient had mild disability with a 
PCPS score of 2), and 3 patients had poor outcomes (1 patient was severely disabled with a PCPS of 4 
and 2 were vegetative with a PCPS score of 5). The poor outcome group had the lowest recorded 
PbtO2 as well as lower median PbtO2 values within the first 24 hours of monitoring than patients with 
a good outcome, and spent more time below critical PbtO2 thresholds (<5, <10, <20 mmHg), even 
though the duration of monitoring was less. These findings are demonstrated in Figure 12.5 and 
Figure 12.6 and tabulated in Appendix 15. princip 
Figure 12.5: Median PbtO224 and the lowest PbtO2 for poor and good outcome groups 
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Figure 12.5 demonstrates 
the median PbtO2 
recorded within the first 
24 hours (PbtO2_24) and 
the lowest PbtO2 recorded 
for the duration of 
monitoring in 6 patients 
with poor and good 
outcomes. PbtO2 
represented in mmHg 
 
Figure 12.6 demonstrates 
the number of hours spent 
with PbtO2 less than 
critical thresholds (5, 10, 
20 mmHg) for 6 patients 





The profile of NIRS and relationship with outcome 
Twenty-one patients were monitored with NIRS, the median number of days of monitoring was 7 (3-
11). The median SO2 was 67% (58-84) for the left sensor, 67% (58-90) for the right sensor, and 66% 
(57.5-86) for the combined L and R. The L and R sensors were not found to be statistically different 
overall and therefore outcome analysis was conducted on data for the 2 sides combined. The time 
spent <50% was significantly associated with death and poor outcome (p=0.02 and p=0.002 
respectively), and time spent less than the overall median was significantly greater in patients who 
had a poor clinical outcome than in patients with a good outcome (p=0.01). Time spent <40% was not 
significantly associated with outcome, likely because of the small number of data points falling below 
40%. These associations with outcome are detailed in Table 12.2. 
Table 12.2: NIRS association with outcome 









<40%   p=0.19   p=0.1 
 Median 62.5 0.25  4 0  
 P25 0 0  0 0  
 P75 508 4.5  62.5 1  
< 50%   p=0.02   p=0.002 
 Median 832.5 23.25  602.5 8.5  
 P25 745.5 3.5  44.5 1  
 P75 1171 141.5  1171 21  
Median overall   p=0.12   p=0.01 
 Median 4066 3162  3970.75 2850  
 P25 3774.5 2501.5  3703 1878.5  
 P75 5291.5 3875.5  4121.5 3300.5  
Data are presented as the number of minutes spent below NIRS thresholds 
 
Figure 12.7: Time spent below critical thresholds of NIRS for mortality and clinical outcome 

























Case illustrations of NIRS recordings in TBM patients: 
Figure 12.8 depicts the last 12 hours in a patient who died by day 4 post admission. The NIRS trace 
demonstrated a marked decline from SO2 >60% to below 40% and did not recover. 
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Figure 12.9 demonstrates an increase in the baseline of NIRS after an LP was performed in a patient 
with CHCP, and likely represents the improvement in CBF following the reduction in ICP. The 
patient underwent no other interventions during this time apart from the LP. 
Figure 12.9: NIRS improves after a lumbar puncture to treat raised ICP 
 
Figure 12.10 illustrates the improvement in the NIRS trace in a patient during the early hours of 
resuscitation during which MAP, haemoglobin and fluid status were optimised and electrolyte 
disturbances were corrected, suggesting an improvement in CBF and brain oxygenation. 
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Figure 12.11 illustrates the NIRS trace in a patient who suffered an aggressive disease process and 
died by day 10. The drop in the right trace on day 3 likely represents an ischaemic process which 
progressed to infarction in the right hemisphere as indicated on the CT on that same day (image 
included below). The reversal of the right and left trends seen on day 5 may have signified luxury 
perfusion in the infarcted right hemisphere and a progressive ischemic response in the left hemisphere 
indicated by the decline in the left NIRS trace. This pattern continued until day 7 when treatment was 
ceased and the patient died soon after. There were no problems with NIRS sensor contact in this 
patient 
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NIRS and PbtO2 monitors 
The Bland-Altman plot  (Figure 12.12) of standardised NIRS and PbtO2 scores demonstrated that the 
mean difference between these 2 brain oxygenation monitors was 0.024 (ideal is 0) and 6.07 % of the 
data points fell outside the limits of agreement; these data points mostly belonged to patients 5 and 7 
who both had increasing PbtO2 and NIRS over the duration of monitoring. A proportional increase in 
the data suggests that another factor is playing a role in the relationship between the PbtO2 and NIRS. 
This factor was likely time, as both variables increased with time after admission. This increasing 
temporal profile is depicted in Figure 12.13 and 12.14, which illustrate that PbtO2 and NIRS trends 
follow similar patterns across the duration of monitoring, although the variability of PbtO2 within 
patients was greater.  
 
Figure 12.12: Bland-Altman plot for PbtO2 and NIRS standardised scores 
 
This figure depicts the Bland-Altman plot testing the levels of agreement between PbtO2 and NIRS data in all 
patients who received both monitors  





311511 = 6 07% outside the limits of agreement 
Mean difference 0.044 
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Figure 12.13: Temporal profile of PbtO2 and NIRS for the monitored cohort overall  
 
This figure illustrates the temporal profile of PbtO2 and NIRS over the duration of monitoring for the cohort of 





 percentile. Both monitors demonstrated an increasing trend over time. 
Figure 12.4: Temporal profile of PbtO2 and NIRS per patient 
 
This figure demonstrates the temporal profile of PbtO2 and NIRS over the duration of monitoring for each 
individual patient who had both PbtO2 and NIRS monitoring. Box-and-whisker plots are used; boxes 




 percentile. Both monitors followed a 
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The similarity in the patterns of PbtO2 and NIRS were also observed within individual patients at 
selected time points. Figure 12.15 demonstrates how the trend in PbtO2 was mirrored by the trend in 
NIRS over a 7 hour time period. 
 
Figure 12.15: NIRS mirrors the trend in PbtO2 
 
 
This figure illustrates the parallel trends in PbtO2 and NIRS (left in blue and right in grey) over a 7 hour period. 

























Figure 12.16 illustrates how the 2 monitors followed a similar pattern of response to the dynamic 
relationship with other physiological variables which may influence brain oxygenation. Increases in 
MAP and ICP, likely due to suctioning or patient handling, resulted in immediate declines in both 
PbtO2 and NIRS.  
 
Figure 12.16: PbtO2 and NIRS in response to ICP and MAP 
 
 
This figure illustrates the parallel response in PbtO2 and NIRS (left in blue, right in grey) to increases in ICP 
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Figure 12.17 illustrates that both monitors responded positively to interventions targeted at increasing 
brain oxygenation, such as nasal prong oxygen. 
Figure 12.17: PbtO2 and NIRS both increase in response to nasal prong oxygen 
 
Additionally, PbtO2 and NIRS monitors also provided information on pathophysiological events that 
may be difficult to diagnose, such sub-clinical seizure activity as demonstrated by the cycling pattern 
of ICP, PbtO2 and NIRS demonstrated in Figure 12.18. These cycling episodes corresponded with 
twitching of the hand and were treated as sub-clinical seizures. 
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Association with neuromarkers 
No significant correlations were demonstrated between the indices of PbtO2 and NIRS and admission 







CHAPTER 12: MONITORING BRAIN OXYGENATION IN TBM 
Discussion 
 
Brain oxygenation monitors PbtO2 and NIRS demonstrated that brain oxygenation (as measured by 
these monitors) is compromised in TBM, and that low brain oxygenation can be detected in these 
patients in real time, is sensitive to raised ICP and responds to interventions. In individual patients 
there appears to be reasonable agreement in trends between the 2 monitors although the small patient 
numbers limited the analysis that could be done. Importantly, although these monitors may assist in 
detecting reduced oxygenation of the brain and provide insight into TBM, whether using these 
monitors to guide treatment improves outcomes awaits more evidence.    
Temporal profile 
Overall both PbtO2 and NIRS demonstrated the lowest readings on admission or day 1, followed by 
an increase thereafter (likely due to treatment), except in patients who suffered poor outcomes and in 
whom low PbtO2 and NIRS values were recorded on day 5 or 6. This suggests that TBM patients are 
at high risk of ischemia early in the first week after admission and the window of opportunity to 
intervene is likely greatest in this acute phase. This parallels the radiology findings which suggested 
that ischemia progressed to infarction within the first couple of weeks such that infarcts not visible on 
admission were already established by the 3 week MRI scan.  
PbtO2 and ICP 
An important factor contributing to compromised CBF and brain oxygenation in this early phase of 
disease is raised ICP, often due to HCP in these patients. This was demonstrated in the case 
illustrations depicted in Figures 12.3 and 12.4 where elevations in ICP, even within the normal range 
and over short time periods, resulted in an immediate and marked decrease in the PbtO2. This 
relationship was likely more pronounced due to the fact that baseline PbtO2 was already 
compromised in these patients; probably as a result of ischemia caused by direct vascular 
involvement. This suggests that in TBM patients the likely poor baseline brain oxygenation is 
particularly sensitive to increases in ICP. Possibly, a lower ICP treatment threshold and careful 
continuous ICP control may be indicated to maximise perfusion in the already compromised brain.   
Overall, the relationship between ICP and PbtO2 was not well demonstrated by the correlation 
between these two variables and in some instances their temporal profiles were increasing in concert 
whereas ICP is expected to have a negative relationship with PbtO2. This is likely due to a number of 
factors; first, PbtO2 may be influenced by a number of variables independently of ICP, especially in 
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these children in whom HCP was treated. The most important of these factors would be ischaemia 
resulting from vasospasm or vascular occlusion in response to basal exudate coating the vessels in the 
Circle of Willis. Second, a third factor may negatively or positively affect both ICP and PbtO2 
simultaneously. This does not preclude that the change in ICP will in turn have its own effect on 
PbtO2, but emphasizes that it is not the only factor causing a decrease in PbtO2. Third, both raised 
ICP and low PbtO2 may reflect injury severity. The more injured the brain, the greater the 
perturbation in cerebral physiology. This is associated with not only a greater likelihood of ICP and 
oxygenation problems, but also a stronger probability of other complications, like impaired pressure 
autoregulation and vascular reactivity, poor cerebral perfusion and disturbed metabolic function. 
Fourth, an increase in both ICP and PbtO2 may be precipitated by phenomena such as increased 
blood pressure when pressure autoregulation is impaired or hyperaemia which may occur in patients 
who suffered infarction leading to luxury perfusion in the infarcted territories. The absence of viable 
tissue to consume the oxygen provided would lead to an increase in PbtO2 as it measures oxygen 
tension and not utilisation, and the increased cerebral blood volume may precipitate an increase in 
ICP. Brain pathophysiology is also likely to be dynamic in these patients and therefore relationships 
between physiological variables may vary from day to day, and from patient to patient. This 
heterogeneity would be masked when data is pooled for analysis. The absence of an association 
observed between CPP (measured once weekly) and outcome in a TBM study by Nourse et al 
453
 may 
similarly have been due to the dynamic nature of brain physiology in the context of disease. However, 
despite the potential for variability in the relationship between ICP and PbtO2 it is clear that raised 
ICP may have a negative impact on PbtO2 in individual patients and at individual time points; 
therefore, ICP control remains an important component of TBM management. 
NIRS 
NIRS demonstrated episodes of low brain oxygenation and was responsive to changes in brain 
oxygenation levels due to pathology and intervention. Differences in the recordings from the right and 
left sensors appeared to provide additional information about interhemispheric brain oxygenation and 
pathology as they were occurring. A drop in the NIRS trace was likely associated with ischaemia, but 
the monitor was also sensitive to post-ischaemic changes such as luxury perfusion following 
infarction, indicated by a rise in the NIRS trend, demonstrated in Figure 12.11. This suggests that the 
interpretation of the NIRS readings are best made in the context of the recording as a whole and in 
conjunction with clinical and radiological indicators of injury; an elevated NIRS recording in a patient 
who has demonstrated compromised levels of NIRS and has clinical or radiological signs of severe 
disease does not necessarily suggest healthy brain oxygenation and may indicate hyperaemia in 




PbtO2 and NIRS in relation to outcome and intervention 
For patients with poor outcomes the frequency of both low PbtO2 and NIRS was more common than 
in patients with good outcomes. While this could not be statistically tested for PbtO2 due to the small 
sample size, the descriptive picture is still valuable in providing insight into the prevalence and 
potential consequences of compromised brain oxygenation in TBM. NIRS values <50% were 
predictive of poor outcomes in these children and this provides some indication of what may be 
considered compromised NIRS in TBM patients undergoing long term monitoring. NIRS was 
sensitive to fatally declining brain oxygenation and offered a visibly appreciable picture of 
deterioration leading to death in real-time; CT brain scans confirming the extent of infarction were 
often only conducted several hours later.  
The case illustrations demonstrated that PbtO2 and NIRS were sensitive to changes in brain 
oxygenation in response to changes in ICP and MAP and also in response to interventions. This adds 
insight into the dynamic relationship between intracranial and systemic physiological variables in 
TBM and may aid in tailoring patient management (such as targeting an optimal MAP or controlling 
the threshold of ICP) such that brain oxygenation may be optimised. Additionally, the response in 
PbtO2 and NIRS to interventions, some as simple as nasal prong oxygen, is promising and suggests 
that there may be potential simple methods to treat impaired oxygenation of the brain and mitigate its 
damaging effects on the brain; however, this would require formal study. 
PbtO2 and NIRS 
The data suggest that these two monitors demonstrate an acceptable degree of agreement and reflect 
similar patterns for brain oxygenation over time. NIRS may however be less sensitive than PbtO2 and 
more prone to error introduced by difficulties around sensor contact. The absolute values of NIRS 
require further investigation and thresholds indicative of injury and injury severity are unclear. This 
monitor is frequently used in the operative environment for short term monitoring where deviation 
from an established baseline in response to a surgical intervention (usually cardiac surgery) is 
measured as an indicator of compromised CBF 
246,247
. The pathology of a chronic illness like TBM 
has unique requirements from a brain oxygenation monitor including sensitivity to the effect of 
intracranial pathological on brain oxygenation, stability of signal for the duration of monitoring and 
clear treatment thresholds. NIRS demonstrated potential as a non-invasive monitor in TBM but 
further study into its long term utility, sensitivity to brain injury and critical thresholds are required. 
PbtO2, NIRS and neuromarkers 
The absence of an association between brain oxygenation monitors and neuromarkers may be due to a 
number of factors. Firstly, the sample size was small and limited analysis. Secondly, brain oxygen 
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monitors and neuromarkers are measuring different processes; neuromarker concentrations provide an 
index of tissue damage that has occurred, while brain oxygenation monitors provide a moving index 
of dynamic brain perfusion, perturbations in which may or may not lead to actual tissue injury. 
Thirdly, brain monitoring data and biomarker data were not time-linked; in a study in TBI a 
significant negative correlation was found between serum S100B concentrations and NIRS readings 6 
hours prior to sample collection 
242
. However, in this study CSF or serum samples were taken 
immediately after admission before the initiation of treatment, usually many hours before PbtO2 or 
NIRS monitoring were begun. Additionally, HCP treatment with EVDs or LPs would have 
commenced by the time brain monitoring was set up and the reduction in ICP would likely have lead 
to improved cerebral perfusion relative to admission when biomarker samples were taken. Fourthly, 
episodes of low brain oxygenation (in the case of PbtO2) during the time of monitoring would have 
been treated thereby limiting the impending tissue injury. 
Limitations 
PbtO2 monitoring was only performed in patients who were at high risk of ischaemia based on 
clinical and radiological findings. Therefore, the relationship with PbtO2 and outcome would have 
been biased by patient selection. Although the NIRS was non-invasive and could be used in all 
patients, this was not always feasible in children who were active and mobile (discussed further 
below), and therefore, there was likely some selection bias in this group as well.   
No monitoring modality is without its limitations nor does it present the full picture. Although PbtO2 
appears to be a useful tool for monitoring an aspect of brain oxygenation, it is not a precise measure 
of the adequacy of brain oxygenation and not a monitor of ischaemia per se as it is sensitive to several 
other variables, especially arterial PaO2 
454
. Positron emission tomography (PET) scanning is the gold 
standard for measuring brain perfusion, but it can only be done as a ‘snapshot’ study at one point in 
time, and continuous monitors are required in the clinical setting. Although PbtO2 is a focal monitor 
and is not placed in the region of the brain most affected by TBM, there is data to suggest that when 
placed in uninjured white matter PbtO2 provides an approximation of global brain saturation 
224,237
. 
Furthermore, the infarcts in this cohort were distributed throughout the brain and episodes of vascular 
pathology were reported to occur in all of the major cerebral vessels (Chapter 11), suggesting that 
ischemic processes are not limited to a single domain. Arguably, the process is global, even though 
the eventual infarct is focal; this may represent a vulnerability of certain vessels and territories to an 
ischaemic process. Raised ICP due to unresolved HCP is also likely to cause diffuse rather than focal 
ischaemia.  
Similarly, the near-infrared beam of NIRS interrogates only the frontal lobes and only superficially. 
The light signals may be affected by skull thickness, CSF and ambient light, and the relative 
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contributions of the venous, arterial and capillary compartments remains unclear (Chapter 4). Long 
term NIRS monitoring is also compromised by the technical limitations of the monitor probes. The 
sensors easily peeled off in response to perspiration, patient handling and patients pulling at them. 
Their design is not conducive to long term monitoring in children who are awake as the discomfort 
created by the sensors on the forehead awkwardly connecting to the bedside monitor increased the 
desire to pull them off, and made patient mobility difficult. Consequently, frequent disconnections or 
poor sensor contact compromised the reliability of the monitor and it performed better in patients with 
a depressed level of consciousness. This limits its utility in TBM patients who are on the milder 
spectrum of disease but still at risk of ischaemia. However, it may be argued that children with mild 








CHAPTER 13: SUMMARY AND CONCLUSION 
 
TBM is a frequent and potentially devastating disease in children from high TB prevalence areas. The 
disease remains challenging to diagnose and treatment is often delayed, increasing the risk of poor 
outcome. Currently clinical tools lack the sensitivity and specificity to assess injury severity on 
admission and radiological examination only illustrates injury once it is irreversible. Identifying 
patients at greatest risk of poor outcomes and predicting outcome can, therefore, be challenging. 
Reliable markers of neurological injury may offer clinicians the tools to assess injury severity, 
prognosticate, anticipate deterioration and direct treatment, and could serve as surrogate markers to 
evaluate the efficacy of novel interventions.  
This study aimed to examine three candidate markers of neurological injury (S100B, NSE and GFAP) 
together with a panel of inflammatory markers in the CSF and serum of paediatric patients with TBM 
in terms of their concentrations relative to controls, their temporal profile, their association with 
clinical, radiological and physiological indicators of injury severity, and their association with clinical 
and neurodevelopmental outcome. 
The main findings of this study in 44 paediatric TBM patients with HCP are summarised as follows: 
1. This cohort of patients with HCP represented the more severe spectrum of TBM admission to 
RXH. The mortality rate was 16% and 36% of patients were left with disability. All patients 
demonstrated neurodevelopmental deficits and the impact of TBM on development was likely 
multidimensional comprising the organic injury, as well as environmental, social and 
educational limitations imposed by prolonged treatment. 
2. Neuro- and inflammatory markers were elevated in the lumbar and ventricular CSF of TBM 
cases relative to controls on admission and for up to 3 weeks, however, serum concentrations 
were not. This suggests that CSF S100B, NSE and GFAP are indicators of TBM-induced 
injury and that the immune response in TBM is compartmentalised to the brain. 
3. CSF neuromarker concentrations were highest within the first week and declined thereafter, 
likely due to treatment, except in patients who died. Inflammatory markers demonstrated an 
early downward trajectory over time, suggesting that the inflammatory response was 
subsiding.  
4. Neuromarker concentrations were higher in the ventricular than lumbar CSF ngand 
inflammatory concentrations were higher in lumbar than ventricular CSF, likely reflect the 
cerebral origin of neuromarkers and the largely subarachnoid location of inflammation 
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5. Neuromarkers were poorly associated with patient and admission clinical characteristics 
suggesting that they provide information about brain injury that is not reflected in the history 
and clinical examination. 
6. Elevated neuromarker concentrations within the first week and overall were prognostic of 
poor outcome. The strongest predictor of outcome was an increasing trend in neuromarker 
concentrations over time.  
7. PCA combining all 3 neuromarkers over time demonstrated that concentrations continued to 
increase in patients who died, while combined inflammatory concentrations decreased. This 
suggests that it is not the ongoing immune response which is responsible for the progressive 
brain injury associated with TBM, but rather the secondary pathological processes that are 
initiated by the inflammatory process. 
8. Neuromarkers were not predictive of neurodevelopmental deficits, likely because they reflect 
the quantitative rather than the qualitative aspects of brain injury.  
9. GFAP was elevated in response to brain injury induced by HCP and raised ICP, tuberculomas 
and infarcts across the spectrum of injury severity. S100B was elevated in response to HCP 
and severe tissue injury, and small increases over time were strongly predictive of poor 
outcome suggesting that it is sensitive to deterioration. NSE was elevated in response to 
severe neurological injury and was prognostic of survivor outcome on admission.  
10. Inflammatory markers were poorly associated with clinical and radiological outcome. 
11. Novel descriptions of radiology in TBM included spinal pathology (arachnoiditis and 
tuberculomas) in 75% of patients, and attenuation/occlusion of the major cerebral vessels 
(particularly the MCA) in 55% of patients on MRA. 
12. Brain oxygenation monitors (PbtO2 and NIRS) demonstrated that brain oxygenation was 
compromised in TBM, sensitive to fluctuations in ICP, even within the normal range, and 
responsive to interventions.  
 
This project found that biomarkers of neurological tissue injury S100B, NSE and GFAP were elevated 
in TBM and associated with outcome. This suggests that these neuromarkers could be used to assess 
injury severity, to track disease course and prognosticate, and that they could be useful as surrogate 
end points in assessing the efficacy of novel interventions. The results demonstrated that the 
inflammatory process in TBM declines after the initiation of treatment, but that it likely sets up a 
cascade of secondary injury mechanisms that continue to perpetuate brain tissue injury. The 
radiological findings suggest that every child with TBM should have spinal imaging performed and 
that caution must be exercised when interpreting lumbar CSF results as they may not be reflective of 
the condition inside the cranium. Low brain oxygenation can be detected with brain oxygenation 
monitors in TBM and can respond to intervention. 
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Recommendations for future work 
This study’s findings demonstrated that S100B, NSE and GFAP are indicators of cerebral injury in 
response to pathology associated with TBM (whether it be injury due to ischaemia, raised ICP and 
HCP, or other mechanisms), and are prognostic of poor outcome. Further work in larger patient 
cohorts are recommended to validate and expand on the findings of this pilot project, including 
investigating other potential biomarkers of neurological injury. Research on the clinical value that 
neuromarkers may have to prognosticate and potentially to help guide therapeutic interventions would 
be an area for further research. The identification of high risk patients may allow for more aggressive 
targeted interventions. The feasibility of neuromarker testing as part of clinical routine would also 
need to be examined. 
S100B, NSE and GFAP were not well represented in the serum. While all TBM patients will 
eventually undergo a LP, identifying a marker of intracranial injury that is detectable in the serum 
during the early phase of injury when TBM may not yet be suspected, would be beneficial in raising 
the suspicion of meningitis early and hastening diagnosis and treatment initiation, especially because 
the symptoms are often non-specific.   
The panel of inflammatory markers selected offered limited insight into the immunology of the 
disease and were not associated with outcome. The temporal course of the disease is an important 
determinant of the immunological profile as measured by immune mediators such as cytokines and 
chemokines. However, the timing of infection and injury is not clear in TBM and there appears to be 
heterogeneity in the disease course between patients. Patients often present late and so the peak of the 
inflammatory response may have been missed. The later clinical deterioration, therefore, may be less 
associated with ongoing inflammation and more with secondary cerebral events set in motion by that 
inflammatory response. However, many questions still exist, so further characterization of the host 
response is important and research into the host transcriptomic response to TBM may offer insight 
into the immunology underlying TBM and generate biomarkers for diagnosis and treatment efficacy. 
The radiological findings of spinal disease accompanying TBM have important clinical implications 
in terms of diagnosis, management of HCP and lumbar CSF investigation for chemistry, drug assays 
and biomarker investigation. Therefore, establishing the prevalence of spinal disease in children with 
TBM in a larger sample size is important and may inform patient management. The recognition of the 
extent of spinal disease accompanying TBM, as well as the ependymal involvement, suggests further 
research on the pathophysiology of TBM and spread of disease through the central nervous system is 
warranted. Cerebrovascular pathology on MRA was surprisingly not associated with infarcts on 3 
week MRI. It may be that early pathology, including vasospasm, was missed. Therefore, earlier 
imaging may provide greater insight into the evolution of infarcts. However, other mechanisms may 
also contribute to the development of infarcts. The immunology of tuberculomas in TBM may be 
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valuable to examine further, especially in light of the fact that they were negatively associated with 
infarction. For these many reasons, we would recommend that MRI be part of the routine 
management of TBM in children. With the growing concerns about CT-induced radiation effects in 
children, it would seem safer and of greater value for MRI to be the imaging of choice in paediatric 
TBM, preferably on admission and at follow-up where needed. Given the frequency of intradural 
spinal pathology, the addition of spinal imaging would be ideal. The role of MRA still needs to be 
better defined.   
Brain oxygenation monitoring results suggested that PbtO2 is often compromised and is sensitive to 
changes in ICP in TBM, even within an apparently normal range. This may reflect the already 
narrowed cerebral perfusion pressure due to vasculitis. Further work into clarifying critical thresholds 
of ICP and blood pressure management in patients with TBM could be important in directing ICP 
management so as to maximise cerebral perfusion. These data also suggested that ischaemia or 
compromised brain oxygen is detectable in real time, and further research into the utility of routine 
brain oxygenation monitoring in TBM may yield worthwhile benefits to patient care. Similarly, 
investigation into interventions for poor brain oxygenation and their effect on patient outcome may be 
important steps to improving management of TBM. NIRS provided valuable insights, but further 
research into critical thresholds, instability of the signal and the practical issues of sensor and monitor 
design for long term monitoring in awake patients would need to be addressed.  
Microdialysis monitoring has potential to provide further insight into the inflammatory mileu and 
extent of brain tissue death by enabling the sampling and analysis of fluid derived from the cerebral 
extracellular space. There is further potential to conduct metabolic analysis, as well as drug recovery 
testing which may be particularly useful in a condition like TBM where brain injury continues in spite 
of full antibiotic and steroid treatment and better therapeutic options are urgently needed. 
In conclusion, although it is widely known that Christiaan Barnard performed the first heart transplant 
in Cape Town 47 years ago, it is less well known that prior to this his MD thesis was, in fact, on 
TBM. His discussion on the poor outcomes of TBM was sobering and remains as true today as it was 
so many years ago. Much work has been done by excellent and dedicated researchers in an attempt to 
make progress in changing the outcomes of this disease, but the challenges still loom largely, in part 
because the brain is notoriously difficult to study. However, with the recent advances in technology 
and laboratory technique and the potential that these have created to open new windows of insight 
into the brain, there is hope and promise that the years to come will witness greater progress in 
understanding and treating this disease that currently devastates so many. 
 
 
Appendix 1: TBM case definition criteria 
Case definition: TBM Diagnosis (adapted from Marais et al (2010) 
69– Table 2) 
Required criteria 
Symptoms and signs of meningitis including 1 or more of the following:  
headache, irritability, vomiting, fever, neck stiffness, convulsions, focal neurological deficits or 
altered consciousness, or lethargy.  
Definite TB 
Required criteria PLUS culture-positive CSF for TB or acid-fast bacilli visualised in CSF 
Probable TBM  
Required criteria PLUS a total diagnostic score of ≥10 points (when cerebral imaging is not available) 
or ≥ 12 points (when cerebral imaging is available) plus exclusion of alternative diagnoses.  
Possible TBM 
Required criteria PLUS a total diagnostic score of  6-9 points (when cerebral imaging is not available) 
or 6-11 points (when cerebral imaging is available) plus exclusion of alternative diagnoses.  
Not TBM 
Alternative diagnosis established, without a definitive diagnosis of TBM or other convincing signs of 
dual disease. 
Different categories  Diagnostic 
score 
A) Clinical criteria                                Maximum 
category 
score=6 
Symptom duration >5 days 4 
Systemic symptoms suggestive of TB (1 or more of the following): Weight loss/ 
failure to thrive (in children), night sweats, persistent cough >2 weeks 
2 
History of recent (within past year) close contact with pulmonary TB, positive TST 
or IGRA 
2 
Focal neurological deficit (excluding cranial nerve palsies) 1 
Cranial nerve palsy 1 
Altered consciousness 1 
B) Cerebrospinal fluid (CSF) criteria   Maximum 
category 
score=4 
Clear appearance  1 
Cells: 10- 500/µl 1 
Lymphocytic predominance (>50%) 1 
Protein >1 g/l 1 
CSF: plasma glucose ratio <50% and/or absolute glucose concentration <2.2mmol/L 1 




Basal meningeal enhancement 2 
Tuberculoma 2 
Infarct 1 
Pre-contrast basal hyperdensity 2 
D) Evidence of TB elsewhere         Maximum 
category 
score=4 
CXR suggestive of active TB 
Signs of TB = 2; Miliary TB = 4 
2 or 4 
CT/ MRI/ ultrasound evidence for TB outside the CNS 2 
Acid-fast bacilli identified or M.tb cultured from another source i.e. sputum, lymph 
node, gastric washing, urine, blood culture 
4 
Positive commercial sputum M.tb NAAT 4 
E) Exclusion of alternative diagnoses 
An alternative diagnosis must be confirmed microbiologically (by stain, culture or 
NAAT when appropriate), serologically (e.g. syphilis), or histopathologically (e.g. 
lymphoma). The list of alternative diagnoses that should be considered, dependent 




1. Pyogenic bacterial meningitis  
2. Cryptococcal meningitis  
3. Syphilitic meningitis  
4. Viral meningo-encephalitis  
5. Cerebral malaria 
6.  Parasitic/eosinophilic meningitis ( Angiostrongylus cantonesis, 
Gnathostoma spinigerum, toxocariasis, cysticercosis) 
7. Cerebral toxoplasmosis and bacterial brain abscess (space-occupying lesion 
on cerebral imaging) 
8.  Malignancy (e.g. lymphoma)   
TB: tuberculosis, M.tb: Mycobacterium tuberculosis, TST: tuberculin skin test, IGRA: Interferon–gamma 
release assay, NAAT: nucleic acid amplification test, CXR: chest radiograph, CT: computed tomography, MRI: 
magnetic resonance imaging, M.tb: Mycobacterium tuberculosis. 
*The individual points for each criterion (1,2 or 4 points) were determined by consensus, considering its 
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Appendix 3: Institutional Protocol for the Management of Hydrocephalus in TBM 




Patient clinically compromised/ 
acute deterioration of 
consciousness? 
Proceed to lumbar AEG with 
measurement of opening pressure 
Hydrocephalus No Hydrocephalus 
Suspected TBM 
Emergency 
insertion of EVD 
Yes 
No 
SXR: Air in the basal 
cisterns only 
SXR: Air in the 
ventricles 
Trial of medical 
treatment (see text) 
Surgery: ETV or VPS 






functioning ETV or 
VPS 
Head CT scan at 1 
and 3 weeks (+/- 
later CT). Repeated 
LPs to monitor 
pressure 
HCP resolves on CT; LP 
opening pressure 
normalizes 
HCP fails to resolve or increases, 
opening pressure fails to normalise 
VPS 
Head CT scan 
Proceed to diagnostic LP if 
considered safe 
Inform neurosurgeon before proceeding 
Likely CommHC 
Likely Non-CommHC 
SXR: No air visible –
consider repeat or clinical 
decision without AEG  
Refer to neurosurgeon 

Appendix 4: Paediatric Cerebral Performance Category Scale (PCPS) – Fiser et al (1992)419
I 
Pediatric Cerebral Performance Category Scale 
Overview: The Pediatric Cerebral Performance Category Scale was described by Fiser and can be used t, 
summarize the level of neurologic function seen in a pediatric patient. 
Clinical Features I Category Score 
• normal at age appropriate level I 1 • school age child attends regular school classroom 
• conscious alert and able to interact at an age mild disability 2 
appropriate level 
• school age child attending regular school classroom 
but grade perhaps not appropriate for age 
• may have a mild neurologic deficit 
• conscious moderate 3 
disability 
• sufficient cerebral function for age-appropriate 
independent activities of daily life 
• school age child attending special education 
classroom 
• may have learning deficit 
• conscious severe 4 
disability 
• dependent on others for daily support because of 
impaired brain function 
• any degree of coma without any of the criteria for coma or 5 
brain death vegetative 
state 
• unawareness even if awake in appearance without 
interaction with the environment 
• cerebral unresponsiveness 
• no evidence of cortical function and not aroused by 
verbal stimuli 
• possibly some reflexive responses spontaneous eye 
opening and/or sleep-wake cycles 
• apnea OR brain death 6 
• areflexia OR 
• electroencephalographic (EEG) silence 

Appendix 5: Griffiths Mental Scales-Extended Version
RECORD BOOK 
for use with the 
REVISED EXTENDED GRIFFITHS SCALES OF MENTAL 
DEVELOPMENT 
for testing babies and young children 
from birth to the eighth year 
Name: ____________ Gender: MIF ______ _ 
Address: 
_____ Telephone: ______________ _ 
Examiner: _______________________ _ 
Date of Assessment _____ year _____ Month _ ____ Day 
Date of Birth _____ year _____ Month _____ Day 
Chronological Age _____ year _____ ¥ onth _____ Day 
Age at Testing: _____ Months _____ Days 
_____ Months 
© Association for Research in Infant and Child Development (ARICD) 




Birth weight: Type of Deli very: 
Gestation: wks 
Position in family: Age of siblings: 
Relevant medical history: 
Relevant social/family history: 
Reason for referral: Referral source: 
Vision assessed: YeslNo Hearing assessed: YeslNo 







Summary of Clinical ObservationslTest Behaviour: 
3 
SUMMARY OF TEST RESULTS (Date of test: ___ ) 
Profile 
MA Credits in Months Summary in Months 
Subscales: A 8 C D E F Subscales A to F 
Months 
YEARS • 
I I '" items nassed X12; 
175 
* 
II II .. , items gassed X 12; 
101 
III 
!II ... items gassed ; 
3 
IV 
IV . . . items nassed ; 
3 
V 
V ... items gassed ; 
3 
VI 
VI ... items gassed ; 
3 
VII 
VII ... items [lassed ; 
3 
VIII 
VIII .. , items [lassed ; 
3 
Extra Extra 








CA (months) ; 
Raw Sub-
Quotients RawGQ ; 










Note: The Raw General Quotient or GQ is obtained by taking the average of all the six Sub·Quotients. 


















Likes pushing pram, toy, horse etc. 
Stands alone 




when talked to 
two or more recognizable 
, e.g. pleasure, fear, sadness, 
at 
adult who tries playfully to take 
movements 
reaction to situation, e.g., at table, 
to be fed 
cup or spoon play 
small children other than 
IN, um,,,, Credit: Year 1-8 
Items = . . 
FIRST 
C 
HEARING & LANGUAGE 
(babbles) to persons 
4 different sounds 




definitely to sing 
objects (2) 
Credit: Year J-C 
5 
YEAR 
YEAR I D E 
Months of 
EYE & HAND CO-ORDINATION PERFORMANCE NOTES AND COMMENTS Age 
; moving light with eye~ I Reflex grasp of ; finger I 
ILooks at bell-ring or toy 2 Reacts to .pap~r~hvS i Cal 2 
Looks steadily at bell -ring held still 3 : arm 3 
; moving hell _, ;n. 14 Hand goes to mouth R 4 
; moving bell -ring vertically 5 Holds rod 5 
s from one object to another 16 Plays with own fi ngers R 6 
moving bell-ring in a circle 7 ~.eacts to P~~:~d turni ng .7 
objects pulled along by string 18 Resists I of rod 8 
I Grasps ring when gi ven 19 Looks at yellow box on table 9 
Visually new environment II cube put in hand and holds it 110 
; for ring and grasps ' II Shows interest in box III 
2 :arries ring to mouth 12 Drops first cube for second 112 
rJnt('hf>" at dangling ring , 13 ~e';:'~:I~oi;:~:~ I" 
i iring ,14 Takes cube or toy from table 114 
3 
Hands explore table surface 15 IHolds two cubes 11 5 
4 Plays with ring - , h,k;no. banging etc. 16 ; cube ortoy 116 
; for and picks up string 117 IGrasps box 117 
L()<)k~ for fallen obiect 18 I Passcs tov or cube from hand to hand 18 
Strikes one object with another 19 I Reacts to paper: : 19 
5 
14. Reaches for and takes 
,eo" , ring by means of string 20 vr"n;", lwo objects at once 20 
,<U '-'U '-' '3 examiner scribble 21 l ~e;~~~:°J:;:e--'~ears , ;21 
6 
r and thumb partly 'p' 22 ILifts cup over toy 22 
7 




, in motor car R Lifts lid off box 25 
8 Likes ho ldmg lIttle toys Fmds toy under cup 26 
9 " "uws objects (record how child throws) Tries to take cubes out of box 27 
Thumb opposition 28 Holds th ird cube " 28 
10 Can hold pencil as if to mark on papcr 29 Clicks two bri cks together (in . 29 
TX2 
I I 
Can point with index finger 30 Mnninul:-!Ie:" box, lid and both cubes 30 
Plays pull ing ri ng or toy by string 31 both cubes from box 3 1 
12 
Uses pencil on paper a little 32 Unwraps and fi nds toy or cube 32 
for one hand R 33 ' . board TX21 
Plays pushing little cars along E-;:~ 00," ~," 'rom ,", 
Can hold four cubes in hands at once IPuts 2 bricks back into any I box when 35 
[ todo so 
Months Credit; Year I-A . Credit: Year J-B 
Items = Items = ". 




A B C 
Months of LOCOMOTOR PERSONAL-SOCIAL HEARING & LANGUAGE 
Age 




Walks alone 37 IPUIS small objects in and out of cup in 137 IUses 5 words 137 
Iplay 
Kneels on floor or chair ITrics to help dressing - arms into coat 138 Identifies objects (3) 138 
. _R 
14 
Stoops l ~b:,~S simple requests - "give me the R 139 IUses 6 or 7 words 139 
Trots aboul wcll ICan hold open cup for, 
R 
140 IEnjoys picture book 140 
15 
Can walk backwards ITries to lum ) or handle 
R 
141 objects (4) ,4 1 
Climbs to stand on a chai r 42 IShows shoes 142 Uses 9 words 142 
16 
Climbs stairs . up and down R 43 IUses spoon himself: Spills some R ; objeets (I) 143 
, 
I~~g babbled sentences 1# , Walks ; pull ing toy on string 44 ILikes adult to show book 144 some words 
Iclea~ 
17 Can seat se lf at table 145 IParts of doll 's body (I) hands, hair, fee t, 145 Names objects (2) I~ 
leyes, nose and mouth 
18 Walks upstairs 146 - ind icates when wet or dirty Uses 12 words 146 
Runs I Uses spoon well IUses 20+ words 147 
19 
Can kick a ball (tennis balJ size) cup well half full 148 objects (5 or 6) 48 
20 
Goes atone on stai rs ~ Can open a door 149 Uses word '"'VI II 149 
2 1 Walks up and down stairs 150 ICan lake un ",uos and socks 150 ; objects (7) 50 
22 Jumps of doll 's body (2) hands, hair, feet, 15 I IListens to stories 51 
23 nose and mouth 
24 
Can jump off a step Parts of doll's body (3) 152 I Names objects (3) ~S2 
!~;f:n~ff one,step . . bolh feet· "5' IHelps actively to dress or undress 
R 
153 ; objects (8) 53 
Walks upstairs - one fool on each step jParts of doll's body (4) hands, hair, feet, 154 INames objects (4) 54 
- adult • leyes, nose and mouth 
lPuts awa~~~~s~o so"J' ; when 155 INames objects (5) 55 
R 
IAsks fo r .lhin~s" at table by name - at least 156 IUses sentences of 4+ syll ables Sfi 
Itwo articles of food or drink R 
I Begins to cooperate in play with other 157 
. R 
IAt table uses spoon and fork together 
Iw;,hnn' help • R 
158 
IMonths Credit: ; Credit: Year lI -B Credit: Year lI-C 
Items = .. . Items = .. Items = .... 
( 1 19)x 12 .. . ( 123)x 12 ... ( 121)x12 .... 
























EYE & HAND CO-ORDINATION 
lid, box or brick upon 
more 
IUlnstfucu-,e play with boxes or other 
one 
stroke 
I"'U'"'''' Credit: Year 
to 
Hems = . 
/19)x 12 . 
RESULTS 
RAW AGE SUB- and 
SCORE EQUIVALENT GENERAL 








/ 19) x I 
OBJECTS 
IDENTIFIED NAMED 
A Bowel control complete 
Is this child usually quite bowel·continent 
reliable as regards this function, except for an 
occasional mishap? 
Bladder control by day 
Is this child usually reliably dry by day in 
regard to bladder function, but not necessarily 
at night? 
YES/NO 
Credit Year II 










YEAR 1II away toys when encouraged to do so 12 objects in box 
, ' I 
YEAR IV 
YEAR V 
Can ride a tricycle or other pedal toy 
Can cross both feet and both knees 
D(C); 
D; TX2 
hop on one fool : 3+ steps 
run fast ou t of doors 
with small household tasks on 
credit : YEAR []J - B 
undo buttons 
undress self 
1"" 00'", own hands and face, with some 
put on socks and shoes, unaided 
dress and undress self 
,1M.anages topcoat, cardjgan or raincoat 
toes, knees straight .~ ~:-l ~;:~~:~ own teeth, without assistance 
Item CV.6: Materi als (2+) 
1. What is a table made of? 
2. What is a window made of? 
3. What is a house made of? 
fetch item in a shop on request 
fas ten shoe buckles 
Items 
x2 
Itrd it rei rfll( J ('I \' 0 I f' 
R 
vocabulary (J 2) 
: Administer item after item FIVA) 
IDelines by usc (2+) 
6+ objects in large picture 
two or more descriptive wordsI'll 
weH in sentences of 6+ syllables 
credit: YEAR 1II - C 
Items 
X2 
six or more colours ), to 
Repeats one six-syllable sentence 
Compreh,ension (2+ items) 
Uses 2+ personal pronouns correctly ';/2.. 
Names J 2 objects in large picture 
Picture vocabulary (18+) 
Items 
X2 
Administer item after item FIVA) 
Opp<>sites (2) 
Repeats one ten - syllable sentence 
Picture description: One or more 
R L-"--I desc,·i pti ve sentences 
IMateri" ls (2+) (See below) 
Items == 
X2= 
Items CIV.2, CVI.5: Names Colours 











& FIFTH YEARS 
D 




PRACfICAL REASO ING 
Builds a tower of 8+ bricks ; board: 50 sec Knows 'aennv' or 'monev' 
D(C); TX2 I TX2(C) I " - , 
D -;- board : 50 sec TX2(C) IzIRe"eats I digit (8; 2; 7) 
--::- 9 bricks to box and RUIS the lid r-3 two insets for size 
DrC) .' Ion: 50 sec Itl' 1'1 TX2(C) 
,m oaus 6 beads . -4 screw toy ·r t 2 digits (1-6; 5-3; 9-4) 
n T' I (I' D(C) D(C); TX2[.. 
I Copie~a circle. Stage I -5 i J:lr board : 40 sec I.:;. Knows 'big' and ' little ' 
p tlyV\ I \1Vt: TX2(C) I J 
F0J:.~ 11 ~;c~0~;n .) square in half D(C) ~I S;'-hole board: 40 sec _ TX2(C) ~IP"'li1Tuna.ry, counting to 4+ 
Copies a borizontal stroke 
IHa.nd les scissors: Tries to cut 




Items =1.... Items = .... 
X2= X2= 
A to F 
Items =1 .... ~ 
X2= 3=_. 
1 by colour: Al l 12 I two towers for height 
D(C\_ pieces c-
ICoDies a cross: Stage I 2 ''' - Prt board: 60 sec 2 Compares two lines for length 
·2 \\I-\U DUl.\fI'\Q 1\(1\ 1" \N (I" I ' I X.;_L (,L~' I'--' 
IOra:vs a person: Sta$e r' 1--3 ~~il~; bridge with 3 boxes: Inferio r n f r' , , "l Can count 4 bricks correctly 
tIH.U t 7/~ \tCllUrU "'uu"' ~,~, ' J 
. Can cut a square into two fa irl y 4 VU I -"',-:!UQ'''''' board: 20 sec -:;- Visual memory (3) 
I ~q ual halves D(C) f-
IFolds a 1O.2cm (4in .) square twice 5 1Retums 9 bricks to box and puts the lid r;- Compares two weigh ts I .. 
D(C) on: 35 secT ,X:Z(C) L' ":J' I J 
ICopies a ladder: Stage f r- Six·hole board: 20 sec Knows right from wrong (r"u r-
q t, \ Ur'o.S 6 I XL(L) 6 "Is it right or wrong to hurt someone?" I 6 
.... "Is it right or wrong to lie to someone?" 
'moaus I I + beads 
IMonths Credit: YEAR IV-D Credit: YEAR IV -E Months Credit: YEAR IV-F YEAR IV 
A to F 
-=1 I~= -'I~ 
X2= X2=. X2. 3= .... 
I Cop~~" squar~: .Slage I 1 '0 No. 2: 50 sec I ICan count 10 bncks correclly I 
' Dra{~1f~' ~ "~J,.l~1?'-<. \ q li D; PIC) _ TX2_ 
: ~ tsge I ~ Train under bridge successfully 2 Knows number of fingers on each hand 2 
r D(C) _ _ 
Copie~ ; rde: Stage II ~ 3 inl:r No. 2: 40 sec 3 I Can take out the mIddle bnck 3 
I gocct D; PIC) _ _ 
,moaus I I beadsto colour patlem D(C) 14 "'. No.5: 50 sec 4 4 d'g'ts (3-7-2-9; 5-8- 1-6; 4 
'- D; P(C) _ P _ 
Copies 6+ letters 5 Builds 'gate' to model, using 3 boxes and 5 ICan count 15 bricks correctly 5 
_Ii~ ~ ~ 
~ci""u." . Can strip edge of paper Eleven·hole board: 40 sec '''Which costs more?" :(C) 
D(C) 6 IXL(L) 6 . ~ bicycle or a ball? (practice example) 6 
" watch or an ;, .0 Ina. I ) 
; Credit: YEAR V-D Months Credit: YEAR V-E ,Months Credit: YEAR V-F YEAR V 
, AmP 
-. I~= ... I~= I~ 
X2. X 2= X2= 3 = 
'1)/ UO/ dO I -t 9:>/ UO/d6/ID Wl/ L D/ ~ Q)/IJO/3D I")S / !JO/I!; 9J/ !S/ dO 115 
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bounce and calch a tennis ball 
hopskip, recognisable 
L) It '1'1;>11"11 c'rw 1 
(r!ft 
I Marcnes in time to tambourine 
throw a tennis ball up and catch it 
D(C); 
IHollSCOlch II lieU L 
for 20+ seconds 
Hopskips some distance in an open area 
D(C); 
Hopscotch III ~ c.tJ 3 
Rides a bicycle (2 wheeler) with skill 
X 2 A~ 
10 
a special playmate 
get a drink of water from the tap or 
without assistance R 
wash and dry own hands and face, 
without any assistance 
choose own clothes 
Knows address 
)/2 pj\'1J -\ h . .lI'1 of 
YEAR VI-B 
without assistance 
lay a table completely, with some 
dress and undress completely, 
help 
one special school friend 
cred; t: YEAR vn - B 
tie own shoe· laces 
shampoo hair, without any 
tie a double bow·knot 
credit: YEAR VIII - B 
SEVENTH 
(4+ items) 




Picture Description: 3 descriptive 
sentences 
Repeats one sixteen-syllable sentence 
Months cred it : YEAR VB - C 
Picture Description: 4 or more descriptive 
Compreh,ens;on (6+ ;tems) 
Dim"en"es (4) 
Uses 6+ personal pronouns correctly 
IOpp,,,;tes (3) 
cred;t: YEAR VIII - C 
& EIGHTH YEARS 
EYE&HANO 
a cross: Stage II + 
a triangle: Stage II 
No..! , 4<> 
. YEAR VII-O 
Extra items:+ X 2 
Item FY1.4: "Which goes 
11 
r-::-1P,mem-rnaling No.3: 50 sec 
IK,otums 9 bricks to box and puts the lid 
20 sec 
lPattern-nnaking No.4: 50 sec 
with 3 boxes: 
Wc>ur-sqllan" board: 7 sec 
Credit: YEAR VI-E 
No.3: 40 sec 
IPattern- maling No. 2: 25 sec 
!pattern-noaking No.3: 30 sec 
Palltern-nnak;ngNo. 3: 25 sec 
Pattenl-rrJalcmgNo. 5: 20 sec 
WI""',"- making No.4: 20 sec 






1. A big dog running or a puppy (baby dog) running? 
2. A bird flying or an aeroplane? 
3. A car or a bicycle? 
say six of the seven days of the week 
costs more?" P(C) 
or a ball? (Practice example) 
Arrangement I : Bird on nest 
q~l rl 1\(1 1\\ ri"d 
Knows right and left (6+) 
I. Right hand" 5. Left hand 
2. Left ear" 6. Righi ear 
3. Right foot X 7. Left foot 
4. Right eyeX 8. Left eye 
Arrangement fi: Pouring a drink 
'long' and 'shorl' 
of the week: (2+) 
day comes after Tuesday?" 
day comes before Saturday?" 
comes after 
Credit: YEAR VII-F 
'heavy' and 'light' 
'high' and 'low' 
I Repeats 5 digits (6- 1-3-8-4 ; 5-9-2-7-1; 














































1. Full Verbatim Report: Record everything the child says. 
2. Objects named (nouns) N = 
(Items CIlIA, CV.I) 
3. Descriptive words used (adjectives. adverbs) N = 
(Items CIII.5, CVII1.2) 
4. Personal pronouns and possessive pronouns N = 
(Items ClV.6, CVIII.6) 
5. Descriptive sentences of 6 or more syllables N = 
(Items CV.5, CVII.5, CVIII.3) 







I. Six or more syllables (Item ClII.6) 
2. Ten or more syllables (Item CVI.2) 
REPETITION OF SENTENCES 
a) Six syllable sentences (Item ClV.3). One correct sentence scores as a pass. 
"J have a little cat." 
II "My kitty caught a mouse." 
III ''The mouse had a long tail." 
b) Repeats 10 syllables (Item CV.4). ) One correct sentence scores as a pass. 
"My dog is a very good friend to me." 
ii "I take my dog when I go for a walk." 
c) Repeats a sentence of 16 syllables (Item CVlI.6). One correct sentence scores as a pass. 
"It will be my birthday next week, Mummy will give me a party." 
ii "The children were playing a game in the park and then they went home." 
COMPREHENSION: (Item ClV.4, CVI.l, CVIII.4) 
I. "What should you do if you feel tired?" 
2. " What should you do if you are cold?" 
oIl11/b 
3. " What is the thing to do if it is raining and you have to go out?" 
4. "What should you do if you are going somewhere and you missed the bllS?" 
S. " What do you do if you feel lonely?" 
6. " What is the best thing to do if you are on your way to school, and you find its getting late?" 
7. " What would you do if you were lost?" 
ell]; 14 
OPPOSITES: (Items CV.3, CVIIl.8) 
I. "A boy is big, a baby is _______ ?" 
2. "Coal is black, snow is _______ 7" 
3. "A lion is fierce, a lamb _______ 7" 
SIMILARITIES: 
I/J/:!J 
(Items CV1.4, CVII.2, CVII.4) 
" How are the moon and the stars the same?" (PRACTICE EXAMPLE) 
1. "How are a bird and an aeroplane the same?" 
2. " How are a car and a bus the same?" 
3. " How are a door and a window the same?" 
4. "How are a pen and pencil (or crayon) the same?" 
DIFFERENCES: 
d/3/LJ Ir; 
(Item CVI.6, CVII.3, CVIIl.5, CVIIl.7) 
" How are a fly and a bee different?" (pRACTICE EXAMPLE) 
I. "How are the morning and night different?" 
2. " How are a fish and a dog different?" 
3. "How are salt and sugar different?" 
4. "How are a triangle and a square different?" 
5. "How are winning and losing different?" 
MA Credits in Months 



























Summary in Months 
Subscales A to F 
Months 
I ... items nassed X 12: 
175 
" ... items Qassed X 12 = 101 
1II ... items nassed : 
3 
IV ... items gassed : 
3 
V ... items gassed : 
3 
VI ... items Qassed : 
3 
VII .. items gassed : 
3 
Vill. . i terns gassed : 
3 
Extra 
. items gassed : 
3 
Total MA (months) : 
CA (months) : 
RawGQ : 





Note : The Raw General Quotient or GQ is obtained by taking the average of all the six Sub-Quotients. 












Young Child's Attempt at Drawing 
Items 01.21,29,32; DII.39, 44, 49 
• 
Horizontal Stroke 
Items DIL54; OIII.2 

Appendix 6: TBM patients not eligible for study enrolment 
This cohort of 30 patients had a median age of 4.3 years (6 months-12 years). Most patients presented 
with Stage I TBM (n= 14, 46.7%). HIV co-infection was recorded in 4 (13.3%) of the 28 patients who 
were tested. The culture positivity yield was 33.3% (n=10), 2 patients were drug resistant (6.7% - 1 
had INH resistance, and 1 had INH and rifampicin resistance) and 2 patients (6.7%) had confirmed 
TB cultured from sputum. Three patients (10%) died during their hospital stay.  Demographic, 
admission clinical and laboratory characteristics for the excluded patients are tabulated below. 
Admission demographic and clinical characteristics for ineligible patients 
Demographic characteristics Value 
Age 4.3 (0.5-12) years 
 0-2 years 9 (30) 
 3- 5 years 7 (23.33) 
 >5 years 14 (46.67) 
Gender: male/female  15/15 
Admission characteristics  
Admission MRC Staging   
 1 14 (46.7) 
 2a/2b 5 (16.7)/ 5 (16.7) 
 3 6 (20) 
Vaccination (n= 21) 17 (81) 
TST (n= 20) 13 (65) 
HIV infection (n= 28) 4 (13.3) 
HIV exposure  6 (21.4) 
Diagnostics  
Positive CSF TB culture  10 (33.33) 
Confirmed TB in other specimens  2 (6.67) 
In-hospital mortality 3 (10) 
CSF chemistry  
Glucose (mmol/l) 2.55 (0.8-5.0) 
Abnormal (< 2.3) 11 (36.67) 
Chloride (mmol/l)  112 (95-126) 
Abnormal (< 120) 19 (63.33) 
Protein g/l 
a
 0.77 (0.1-9.28) 
Abnormal (> 0.45/ >0.8) 26 (86.67) 
Polymorphonuclear Cells (/cu mm) 5.5 (0-365) 
Lymphocytes (/cu mm) 93 (1-560) 
Total white cell count 117.5 (1-700) 
Abnormal (> 10) 28 (93.33) 
Lymphocyte predominance  
>50% 25 (83.33) 
>90% 14 (46.67) 
Values reported as median and range, number (percent), CSF chemistry reported for admission LP, 
a 
Protein 
reference ranges are age dependent: >1 year and <1 year respectively 
Imaging findings 
Admission CT brain scans demonstrated HCP in 9 patients (30%), basal meningeal enhancement in 
16 patients (64% - 5 patients did not have a contrast enhanced scan), pre-contrast hyperdensity in 4 
patients (13.3%), tuberculomas in 3 patients (10%) and infarcts in 3 patients (10%). CXRs were 








It is often useful to measure data in terms of its principal components rather than on a normal x-y 
axis. So what are principal components then? They’re the underlying structure in the data. They 
are the directions where there is the most variance, the directions where the data is most spread 
out. This is easiest to explain by way of example. Here’s some triangles in the shape of an oval: 
 
Imagine that the triangles are points of data. To find the direction where there is most variance, 
find the straight line where the data is most spread out when projected onto it. A vertical straight 
line with the points projected on to it will look like this: 
 
The data isn’t very spread out here, therefore it doesn’t have a large variance. It is probably not 
the principal component. 
A horizontal line are with lines projected on will look like this: 
 
On this line the data is way more spread out, it has a large variance. In fact there isn’t a straight 
line you can draw that has a larger variance than a horizontal one. A horizontal line is therefore 
the principal component in this example. 
Luckily we can use maths to find the principal component rather than drawing lines and unevenly 
shaped triangles. This is where eigenvectors and eigenvalues come in. 
Eigenvectors and Eigenvalues 
When we get a set of data points, like the triangles above, we can deconstruct the set into 
eigenvectors and eigenvalues. Eigenvectors and values exist in pairs: every eigenvector has a 
corresponding eigenvalue. An eigenvector is a direction, in the example above the eigenvector 
was the direction of the line (vertical, horizontal, 45 degrees etc.) . An eigenvalue is a number, 
telling you how much variance there is in the data in that direction, in the example above the 
eigenvalue is a number telling us how spread out the data is on the line. The eigenvector with the 
highest eigenvalue is therefore the principal component. 
Okay, so even though in the last example I could point my line in any direction, it turns out there 
are not many eigenvectors/values in a data set. In fact the amount of eigenvectors/values that 
exist equals the number of dimensions the data set has. Say i’m measuring age and hours on the 
internet. there are 2 variables, it’s a 2 dimensional data set, therefore there are 2 
eigenvectors/values. If i’m measuring age, hours on internet and hours on mobile phone there’s 3 
variables, 3-D data set, so 3 eigenvectors/values. The reason for this is that eigenvectors put the 
data into a new set of dimensions, and these new dimensions have to be equal to the original 
amount of dimensions. This sounds complicated, but again an example should make it clear. 
Here’s a graph with the oval: 
 
At the moment the oval is on an x-y axis. x could be age and y hours on the internet. These are 
the two dimensions that my data set is currently being measured in. Now remember that the 
principal component of the oval was a line splitting it longways: 
 
It turns out the other eigenvector (remember there are only two of them as it’s a 2-D problem) is 
perpendicular to the principal component. As we said, the eigenvectors have to be able to span 
the whole x-y area, in order to do this (most effectively), the two directions need to be orthogonal 
(i.e. 90 degrees) to one another. This why the x and y axis are orthogonal to each other in the 
first place. It would be really awkward if the y axis was at 45 degrees to the x axis. So the second 
eigenvector would look like this: 
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Appendix 9: GEE coefficients for biomarker concentrations according to sample type 
Sample type S100B NSE GFAP 
Rostro-caudal gradient overall     
 Coef CI Coef CI Coef CI 
Vent CSF 2.2 1.47-2.93 13.55 5.99-21.1 91.18 71.22-111.14 
Serum -1.59 1.22-2.38 -7.19 -12.83- -1.54 -21.59 -36.07- -7.11 
Patients with spinal arachnoiditis     
Vent CSF 1.18 0.46-2.33 8.9 -1.9-19.9 87.74 56.48-119 
Coef = GEE coefficient – coefficients represent number of μg/L by which ventricular CSF (vent CSF) is greater 
(positive coefficient) than lumbar CSF concentrations, and the number of μg/L by which serum is less than 
lumbar CSF concentrations (negative coefficient). All coefficients were p < 0.05 except for NSE in patients with 
spinal arachnoiditis – lumbar and ventricular CSF were no longer significantly different in those patients. The 















Appendix 10: Correlation matrix: Neuro- and inflammatory markers 
 
S100 NSE GFAP GRO IL-1ra IL-12p40 IP-10 MCP-1 MIP1-α TNF-α VEGF IFN-  IL-10 IL-1  IL-6 IL-8 RANTES 
S100 1.00 
                NSE 0.62 1.00 
               p-value 0.00 
                GFAP -0.12 -0.18 1.00 
              p-value 0.53 0.33 
               GRO 0.06 0.03 0.36 1.00 
             p-value 0.74 0.86 0.05 
              IL-1ra 0.38 0.56 -0.05 -0.01 1.00 
            p-value 0.04 0.00 0.77 0.94 
             IL-12p40 0.30 0.26 0.20 0.23 0.65 1.00 
  
 
        p-value 0.11 0.17 0.28 0.22 0.00 
            IP-10 0.30 0.23 -0.02 -0.12 0.29 0.25 1.00 
          p-value 0.11 0.22 0.94 0.53 0.12 0.19 
           MCP-1 0.03 0.22 -0.24 -0.43 0.33 0.02 0.23 1.00 
         p-value 0.87 0.25 0.20 0.02 0.08 0.92 0.22 
          MIP1-α 0.01 0.14 0.30 0.19 0.08 0.07 0.05 0.08 1.00 
        p-value 0.95 0.45 0.10 0.33 0.69 0.70 0.80 0.67 
         TNF-α 0.24 0.53 0.13 0.16 0.65 0.57 0.32 0.24 0.27 1.00 
       p-value 0.20 0.00 0.48 0.41 0.00 0.00 0.08 0.21 0.14 
        VEGF 0.34 0.55 0.14 0.26 0.58 0.54 0.13 -0.04 0.41 0.39 1.00 
      p-value 0.06 0.00 0.47 0.16 0.00 0.00 0.51 0.84 0.02 0.03 
       IFN-  0.06 0.17 -0.03 -0.23 0.36 0.45 0.58 0.31 -0.07 0.49 0.28 1.00 
     p-value 0.74 0.36 0.87 0.23 0.05 0.01 0.00 0.10 0.69 0.01 0.13 
      IL-10 0.24 0.35 0.06 0.12 0.30 0.60 0.26 -0.10 0.11 0.39 0.44 0.40 1.00 
    p-value 0.20 0.06 0.74 0.52 0.10 0.00 0.17 0.60 0.58 0.04 0.02 0.03 
     IL-1  0.18 0.11 -0.21 0.05 0.40 0.48 0.04 -0.09 -0.26 0.50 -0.05 0.24 0.31 1.00 
   p-value 0.35 0.57 0.28 0.80 0.03 0.01 0.84 0.64 0.16 0.00 0.78 0.20 0.10 
    IL-6 0.37 0.15 -0.23 -0.05 0.25 0.28 0.59 0.38 -0.19 0.13 0.03 0.61 0.18 0.18 1.00 
  p-value 0.04 0.44 0.23 0.80 0.19 0.13 0.00 0.04 0.31 0.49 0.89 0.00 0.33 0.34 
   IL-8 0.15 0.22 0.05 -0.06 0.34 0.14 0.31 0.22 0.00 0.20 0.14 0.39 0.21 -0.09 0.39 1.00 
 p-value 0.44 0.24 0.81 0.74 0.07 0.46 0.09 0.24 0.99 0.29 0.44 0.03 0.26 0.62 0.03 
  RANTES 0.22 0.29 0.02 0.29 0.23 0.10 0.05 -0.04 0.09 0.18 0.56 0.10 0.08 -0.21 -0.02 0.08 1.00 
p-value 0.23 0.12 0.92 0.13 0.21 0.59 0.79 0.81 0.63 0.33 0.00 0.59 0.66 0.26 0.91 0.66 
 This matrix demonstrates the correlation coefficients and p-values for correlations between neuro- and inflammatory markers, significant correlations marked in red 
Appendix 11: Summary of neuromarker univariate outcome analysis p-values 
  Mortality Outcome Morbidity 
    3 month 6 months 
S100B      
Lumbar Initial 0.42 0.15 0.03* 0.26 
Ventricular   0.02* 0.01* 0.08 0.18 
Lumbar Highest in week 1 0.19 0.04* 0.03* 0.18 
Ventricular   0.03* 0.01* 0.08 0.18 
Lumbar Highest overall 0.13 0.03* 0.04* 0.2 
Ventricular   0.02* 0.06 0.65 0.8 
Lumbar Absolute Δ <0.001 0.02 0.79 0.6 
NSE      
Lumbar Initial 0.18 0.07 0.03* 0.02* 
Ventricular   0.01* 0.01* 0.28 0.32 
Lumbar Highest in week 1 0.18 0.08 0.05* 0.02* 
Ventricular   0.003* 0.01* 0.3 0.18 
Lumbar Highest overall 0.01* 0.01* 0.04* 0.02* 
Ventricular   0.01* 0.01* 0.13 0.44 
Lumbar Absolute Δ 0.01 0.02 0.24 0.14 
GFAP      
Lumbar Initial 0.53 0.59 0.06 0.09 
Ventricular   0.23 0.27 0.96 0.9 
Lumbar Highest in week 1 0.07 0.12 0.07 0.09 
Ventricular   0.08 0.14 0.98 0.95 
Lumbar Highest overall 0.01* 0.07 0.02* 0.06 
Ventricular   0.09 0.33 0.92 0.96 




Appendix 12: ROC curves: Analysis neuromarkers and mortality 
 
ROC S100B and Mortality 
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Appendix 13: p-values for the association between neuromarkers and admission radiology  
Admission CT S100B NSE GFAP Z-Neuro 
 LP V LP V LP V LP V 
HCP severity 0.05* 0.56 0.22 0.93 0.01* 0.05* 0.01* 0.6 
Basal enhancement 0.63 0.29 0.89 0.55 0.94 0.23 0.68 0.29 
Enhancement 
severity 
0.37 0.26 0.26 0.38 0.54 0.23 0.61 0.2 
Tuberculoma (n=3) 0.27 x 0.29 x 0.06 x 0.09 x 
Infarcts (n=3) 0.4 0.65 0.33 0.24 0.64 0.55 0.61 0.24 
The relationship between ventricular neuromarkers and tuberculomas could not be investigated as no patients 




Appendix 14: p-values for the relationship between overall radiology features and 
neuromarker concentrations 
 S100B  NSE  GFAP  Z-NeuroΔ 
 Highest Δ Highest Δ Highest Δ  
 LP V  LP V  LP V   
HCP severity 0.06 0.4 0.44 0.24 0.5 0.55 0.02* 0.53 0.63 0.66 
Infarcts 0.9 0.39 0.12 0.8 0.62 0.03* 0.05* 0.14 0.01* 0.02* 
 Uni/bilat 0.1 0.07 0.04* 0.02* 0.01* 0.08 0.01* 0.18 0.06 0.06 
 Single/multi 0.09 0.46 0.08 0.002* 0.02* 0.09 0.02* 0.28 0.18 0.08 
 Size 0.37 0.17 0.02* 0.02* 0.003* 0.03* 0.002* 0.06 0.01* 0.01* 
MRA pathology 0.87 0.22 0.19 0.83 0.39 0.07 0.62 0.84 0.67 0.17 
Tuberculoma  0.09 0.29 0.1 0.94 0.27 0.17 0.6 0.7 0.1 0.19 
 Uni/bilat 0.85 0.12 0.84 0.1 0.83 0.77 0.05* 0.1 0.03* 0.49 
 Single/multi 0.76 0.13 0.69 1 0.66 0.82 0.04* 0.2 0.02* 0.3 
Spinal disease 0.67 0.13 1 0.26 0.59 0.56 0.28 0.82 0.95 0.51 
 Arachnoiditis  0.96 0.08 0.53 0.24 0.64 0.73 0.59 0.78 0.57 0.89 





Appendix 15: Prevalence of compromised PbtO2 values between outcome groups
Pt No Outcome PbtO224 Lowest 
PbtO2 
T<5 T<10 T<20 Days 
1 0 5.43 1.29 2556 5831 22179 4 
2 0 3.93 1.78 5436 18326 23072 4 
3 0 6.77 1.27 2813 8850 18130 6 
4 1 23.05 4.49 86 578 5540 6 
5 1 4.66 3.97 252 3064 12078 6 
6 1 17.30 7.38 0 1010 14485 5 
This table demonstrates the median PbtO2 recorded within the first 24 hours (PbtO2 24), the lowest PbtO2 
recorded during the monitoring period, and the time spent with PbtO2 <5mmHg, < 10mmHg and < 20mmHg for 
patients with poor (0) and good outcomes (1). The duration of monitoring is also included.  
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